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Summary
Asthma is a public health challenge in Wales. In order and improve its outcomes
and reduce its burden, reliable evidence on disease epidemiology is needed. In
this thesis, I describe the development of a platform for asthma surveillance and
research in Wales using routinely collected electronic health record (EHR) data in
the Secure Anonymised Information Linkage (SAIL) Databank.
To inform the development of operational definitions for asthma and its outcomes,
I examine the contemporary approaches to defining asthma and assessing its out-
comes using EHR data, and describe significant variations and suboptimal report-
ing on these approaches. I highlight the need for valid, standardised methods to
study asthma, and emphasise the increasing demand for improved reporting to
support research transparency and reproducibility.
Acknowledging the infeasibility of reference standards to define asthma in SAIL, I
describe the development of latent class model to identify asthma patients in this
databank. I assess the performance of this model in relation to other objective and
self-reported measures of asthma.
I also describe other methodological aspects of the development of the Wales
Asthma Observatory, including asthma data profiling and identification of impor-
tant data gaps.
To demonstrate the Observatory’s utility for health policy and service planning, I
highlight the variations in asthma epidemiology in Wales across age groups, gen-
der, and socioeconomic deprivation levels. I found that asthma patients living in
the most deprived areas had higher healthcare utilisation for asthma, indicating
worse disease control, than those in the least deprived areas.
Finally, I reflect on the experience of developing the Wales Asthma Observatory,
recognising its strengths and limitations, and identify opportunities and challenges
of maximising the use of routine data towards a learning health system for asthma
in Wales.
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Chapter 1
Introduction
Opportunities for better understanding of asthma
through routine health data
Asthma is a public health challenge in Wales. In order to reduce asthma burden
and improve its outcomes, reliable population-based evidence on the disease epi-
demiology is needed. In this chapter, I present an overview of asthma, its public
health burden, and endeavours to understand its epidemiology in Wales. Then, I
present an overview of routinely collected health data, and highlight their unique
potentials for better understanding of asthma. I then introduce my thesis aim
of developing the Wales Asthma Observatory, based on routinely collected data,
as a platform for asthma surveillance and research. I then describe the thesis
objectives, including exploring the practices and challenges of studying asthma
using routinely collected data, description of the Observatory’s methodology, and
demonstration of its utility for health policy using inequalities in asthma outcomes
as an example. I conclude with describing the thesis structure.
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1.1 Overview of asthma
Asthma is a chronic respiratory disorder typically characterised by cough, dysp-
noea, chest tightness, and wheeze [1]. The clinical manifestations of asthma often
exhibit a recurring and remitting pattern and a variable intensity over time [1].
The disease severity varies widely among patients, ranging from mild intermit-
tent symptoms to a severe persistent disease. Patients with any level of asthma
severity may develop exacerbations—temporary periods of acute or sub-acute de-
terioration in symptom control that can be life-threatening [2].
1.1. Overview of asthma 5
1.1.1 Asthma subtypes
Asthma is increasingly considered heterogeneous rather than a single disease.
There is growing evidence that “asthma” should be regarded as an umbrella term
comprising distinct phenotypes with diﬀerent clinical presentations potentially ex-
plained by distinct endotypes with diﬀerent pathophysiological mechanisms [3–
5]. The aetiology of asthma is thought to vary between phenotypes, with a wide
range of potential risk factors related to the host, genetics, and the environment
[6]. Asthma can also be classified based on other criteria such as triggerability
by allergens into allergic and non-allergic, and age of onset into early- and late-
onset disease [7]. In addition, other recognised phenotypes include infectious,
aspirin-induced, occupational, exercise-induced, and obese asthma [8].
The heterogeneous nature of asthma contributes to the challenges of diagnosis,
treatment, and developing epidemiological definitions as discussed later in Chap-
ter 2 and Chapter 3 (Section 3.1.1).
1.1.2 Pathophysiology
Asthma signs and symptoms result from complex underlying pathophysiology in
the airways that involves chronic inflammation, remodelling, hyperresponsive-
ness, and obstruction.
Airway inflammation
Airway inflammation results from an abnormal immune reaction to mostly exoge-
nous stimuli (e.g., pollen, viruses, and bacteria). Type 2 T-helper cells are a major
player in this immune reaction, which involves recruitment and activation of sev-
eral other types of immune cells in the airway mucosa, including eosinophils, mast
cells, basophils, neutrophils, monocytes, and macrophages [9].
Eosinophils have a unique role in asthma pathogenesis, and they are increased
in number in the airway, sputum, and blood. They produce chemical mediators
such as leukotrienes which cause airway smooth muscle contraction, recruitment
of inflammatory cells, and an increase in mucus production [10].
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Mast cells are increased in the airway mucosa and smooth muscle, and release
histamine, leukotrienes, cytokines, chemokines, and growth factors, which target
the smooth muscle, vessels, mucous glands, and sensory nerves [11].
Bradykinin, a natural vasoactive peptide and a by-product of the inflammatory
process, causes bronchoconstriction and cough [12].
Airway remodelling
Chronic inflammation in the airways leads to several irreversible structural changes
in the airways. These include airway wall thickening, hyperplasia and hypertrophy
in the epithelium, mucous glands and smooth muscle cells, submucosal collagen
deposition and basal membrane thickening, and neovascularisation and increased
sizes of vessels [9, 13]. Airway remodelling leads to irreversible narrowing of the
airways and contributes to the decline in the reversibility of airway obstruction
[9, 11].
Airway hyperresponsiveness
Airway hyperresponsiveness (AHR) is a measure of variable airflow limitation. It
represents the exaggerated response of airway smooth muscle to inhaled stimuli
leading to bronchoconstriction, which causes a decline in airflow. This response
may occur due to nerve stimulation, mast cell mediated events, or direct eﬀects of
stimuli on the airway smooth muscle [9, 13]. Several factors may contribute to de-
velopment of AHR, including eosinophilic airway inflammation, airway epithelial
damage, airway remodelling, and increased contractility of airway smooth muscle
[14].
Airway obstruction
Airway obstruction in asthma results from a combination of several factors, such
as increased airway thickness (due to smooth muscle cell hypertrophy and hy-
perplasia, and mucosal oedema), exaggerated bronchoconstriction, and excessive
mucous secretion and plugs in the airway lumen [15]. Airway obstruction leads
to dyspnoea, chest tightness, wheeze and a variable decline in lung function. Re-
versible airway obstruction is characteristic of asthma, but reversibility tends to
1.1. Overview of asthma 7
decline over time with the development of fixed obstruction due to airway remod-
elling. The variable nature of obstruction has been attributed to AHR [13].
1.1.3 Diagnosis
Asthma diagnosis is mainly clinical, although reasonably certain diagnosis often
requires a combination of careful medical history taking, clinical examination,
and objective tests [16]. The clinical definition of asthma by the British Thoracic
Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) guidelines re-
quires at least two of the main symptoms (cough, dyspnoea, chest tightness, and
wheeze) in addition to evidence of variable airflow obstruction [16]. With high
clinical suspicion of asthma, trial treatment with bronchodilators can be initiated;
a good response to this treatment, assessed with objective testing, allows confir-
mation of asthma diagnosis [16]. An intermediate probability of asthma, based on
medical history and clinical examination, warrants testing for airway obstruction
(variability and hyperresponsiveness) and airway inflammation [16]. Diﬀerential
diagnoses include an extensive list of disorders that can masquerade as asthma
such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, vocal cord
dysfunction, rhinitis, chronic cough syndrome, and gastro-oesophageal reflex [16–
18].
1.1.3.1 Patient medical history and clinical examination
Medical history is useful to establish whether symptoms, their onset, patterns
(e.g., episodic), and triggerability (e.g., association with known stimuli) are com-
patible with asthma. It may help to identify risk factors of asthma (e.g., atopy
or a family history of asthma), assess disease severity, and to rule out alternative
conditions.
On examination, the patient may show breathlessness (e.g., inability to complete
sentences) and tachypnoea. Chest auscultation may reveal widespread expiratory
wheeze, while chest percussion may reveal hyperresonance [13]. Non-pulmonary
atopic findings such as atopic dermatitis and allergic rhinitis support the diagno-
sis of asthma. In moderate and severe disease, the use of accessory respiratory
muscles, intercostal retractions, and pulsus paradoxus may be observed. Physi-
cal examination is useful to detect signs suggestive of alternative diagnoses (e.g.,
unilateral wheeze, focal lung abnormalities, and finger clubbing) [16].
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1.1.3.2 Diagnostic testing
The diagnostic tests in asthma allow investigating airway inflammation and re-
sponsiveness, establishing variability and reversibility of airflow obstruction, and
ruling out alternative diagnoses that mimic asthma. However, they can be nega-
tive during the asymptomatic periods of the disease and are therefore insuﬃcient
alone to establish or rule out asthma diagnosis [1, 16]. Table 1.1 shows measures
of performance of tests used in asthma diagnosis.
Lung function tests
Lung function tests include spirometry, plethysmography, peak flowmeasurement,
and diﬀusion capacity assessment.
A spirometer is a device that measures inspired and expired air volumes. The
forced vital capacity (FVC) and the forced expiratory volume in the first second
(FEV1) are central to the assessment of airflow limitation. Following a full inspi-
ration, the FVC represents the maximum possible volume of exhaled air whereas
FEV1 represents only the volume of exhaled air in the first second. Both measures
decrease in airflow limitation in asthma, but FEV1 usually decreases to a larger
extent than FVC. The ratio of the measured to predicted FEV1 often remains above
80% in mild disease and declines below 60% in untreated severe disease [19]. The
lower limit of normal FEV1/FVC ratio ranges between 85% to 70% depending on
age [16, 20]. Lower values for the respective age group are considered positive
for airflow obstruction and are often present in moderate and severe asthma [16].
However, these airflow limitation criteria alone, are neither sensitive nor specific
to asthma. More than half of patients with normal FEV1/FVC will have asthma [16,
21]. FEV1 is often normal in children with persistent disease and may fall in other
respiratory diseases [22]. Therefore, a normal spirometry test performed when
the patient is not symptomatic does not rule out asthma diagnosis. Furthermore,
a single measurement of FEV1 correlates poorly with asthma severity as classified
by symptoms and medications [23].
Reversibility to bronchodilators (also known as bronchodilator response) is the
improvement in airflow following acute treatment with a beta-agonist bronchodila-
tor. A positive test is defined as a 12% or more improvement, which should be at
least 200 mL, in FEV1 over the baseline [24]. However, these criteria may be
1.1. Overview of asthma 9
Table 1.1: Measures of performance of asthma tests. This table is adapted from [16]. The reference
tests were (spirometry and (bronchodilator reversibility or a challenge test]) with or without ‘typical
history of attacks’, diurnal variation, physician diagnosis, documented history of wheeze on at least two
occasions, and variability in FEV1 over time or during exercise testing.
Test Description Age
group
Sensitivity
(%)
Specificity
(%)
Positive
predictive
value (%)
Negative
predictive
value (%)
Spirometry FEV1/FVC < 70% adults 23–47 31–100 45–100 18–73
children 52 73 75 49
Bronchodilator reversibility Improvement in FEV1
of >12% (and >200 ml
in adults)
adults 17–69 55–81 53–82 22–68
children 50 86
Challenge
tests
Methacholine PC(20)
value of 68 mg/ml
adults 51–100 39–100 60–100 46–100
children 47–86 36–97 20 94
Mannitol: 635 mg
cumulative dose
causing a decrease in
FEV1 of >15%
adults 65 75 80 49
children 63 81
Exercise adults 26–80 100 100 0
children 69–72 69–72 90–99 5–73
Peak flow, mean variability
over 2-4 weeks
>20% adults 46 80 97 10
>15% adults 3-5 98-99 60-67 60
>15% (>3 days/week) adults 20 97 82 64
>12.3% children 50 72 48 74
Fractional exhaled nitric
oxide
>40 parts per billion adults 43–88 60–92 54–95 65–93
>35 parts per billion school
children
57 87 90 49
Blood eosinophils >4.15% adults 15–36 39–100 39–100 27–65
>4% children 55–62 67–84 56–69 73
Immunoglobulin E Any allergen-specific
IgE > 0.35 kU/l
adults 54–93 67–73 5–14 95–99
Total IgE >100 kU/l adults 57 78 5 99
Skin prick test Wheal >3 mm adults 61–62 63–69 14–81 39–96
children 44–79 56–92 65–92 36–79
falsely negative in many asthma patients, especially in those on treatment [15]. In
addition, reversibility to bronchodilators may occur in some patients with COPD
[25].
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Peak flow (also known as peak expiratory flow rate, PEFR) is the maximum rate of
expiratory flow during a short and maximally forceful expiratory eﬀort following a
full inspiration. It can bemeasured by the patient using a portable peak flowmeter
at home. Daily recording of peak flow is useful to demonstrate variability of airway
obstruction. Ideally, the patient is asked to make at least two recordings (during
the day and the night). A seven-day average of the diurnal diﬀerences of more
than 20% is considered positive for variability in airflow obstruction [16]. How-
ever, while this criterion has high specificity and positive predictive value (PPV), it
has low sensitivity and negative predictive value (NPV), which means it produces a
high rate of false negative results [16]. Peak flow is also useful for asthmamonitor-
ing [16]. Limitations of peak flow measurement, compared to spirometry, include
the dependency on the patient’s eﬀort and diﬃculty of controlling measurement
quality [26].
Diﬀusion capacity of the lung (DL), the ability to transfer gas (such as carbon
monoxide) from air to alveolar vessels, is usually normal or increased in asthma
[11, 27].
Whole-body plethysmography may show an increase in airway resistance, total
capacity of the lung, and residual volume; however, it is rarely needed in asthma
[11].
Airway responsiveness testing
The exaggerated response of airways (i.e. AHR) in asthma, which is an indicator of
airflow obstruction variability, can be investigated using bronchoconstrictor stim-
uli. These stimuli can be direct (such as methacholine or histamine) or indirect
(e.g., mannitol or exercise) [13, 16]. A decline in FEV1 of 20% or more is con-
sidered a positive result [16]. However, this test is not suitable for patients with
significant decline in lung function [16].
Exhaled Nitric Oxide
Nitric oxide (NO) is produced by several types of cells in the airway, including
eosinophils, during inflammation. The fractional exhaled nitric oxide (FeNO) can
be therefore used as a biomarker of airway inflammation in asthma. It can be
helpful in the diagnosis, disease categorisation (eosinophilic vs. non-eosinophilic),
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and determining the responsiveness to, and adjustment of, corticosteroid treat-
ment [28]. The diagnostic accuracy measures of FeNO range between 43-95%,
depending on the studies [16].
Skin prick testing
Skin prick tests help determine whether the patient is allergic to a common al-
lergen (e.g., house dust mite). The test involves introducing a small amount of
an allergen into the superficial epidermis. A weal with diameter of 3 millimetres
or more suggests the patient has specific immunoglobulin E (IgE) antibodies for
the used allergen [29]. Skin prick tests can help diﬀerentiate between allergic
and non-allergic asthma. However, due to its mediocre sensitivity and specificity
to asthma diagnosis, it cannot be used to establish or rule out the disease on its
own [16]. The current National Institute for Health and Care Excellence (NICE)
guidelines on asthma (NG80) recommends that skin prick testing should not be
oﬀered for the purpose of establishing the diagnosis but rather to identify triggers
after a formal asthma diagnosis is made [30].
Blood tests
A blood eosinophil count of more than 4% is suggestive to atopy. However, this
threshold, alone, has a poor predictive value for asthma diagnosis [16]. It is worth
noting that marked blood eosinophilia suggests alternative diagnoses (e.g., para-
sitic infestation or familial eosinophilia) [16].
Serum IgE can be helpful in asthma diagnosis. In adults, a serum level > 0.35 kU/l
of specific IgE antibodies to seasonal and perennial allergens, or total serum IgE
> 100 kU/I, indicates an atopic state. However, these thresholds have a very low
PPV, i.e. positive results poorly predict asthma [30]. In contrast, normal serum
level of IgE substantially reduces the probability of asthma in adults with an NPV
of 95-99% [16].
The current NICE guidelines on asthma, however, recommends that blood eosinophil
count and total and specific IgE tests should not be oﬀered for the purpose of
establishing asthma diagnosis [30].
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Imaging
Chest X-ray is usually normal in asthma, but it may show lung hyperinflation in
severe disease and pneumothorax in exacerbations and it is useful to exclude al-
ternative diagnoses [11].
1.1.4 Management
Asthma cannot be medically cured. Therefore, asthma management aims to ad-
equately control symptoms and maintain normal activity levels (i.e. minimise
asthma impairment) and minimise the risk of asthma exacerbations with the least
possible treatment adverse eﬀects [1, 16].
Asthma management involves key clinical concepts [2, 19]. Asthma control is the
extent to which symptoms are suﬃciently eliminated or reduced through treat-
ment to an acceptable target. Complete asthma control is defined as the absence
of symptoms, activity limitation, need for rescue medication, and asthma attacks,
with normal lung function and minimal side eﬀects of treatment [16].
Responsiveness to treatment is the ease with which disease control is achieved.
Impairment refers to symptom severity and the resultant functional limitation.
Risk is the probability of future exacerbations, chronic morbidity, and adverse ef-
fects of medications. Lastly, asthma severity is a complex concept composed of the
following components: level of control including level of impairment and exacerba-
tions in the last 12 months, level of current prescribed treatment, responsiveness
to treatment, and risk.
Management guidelines have been developed globally [1] and nationally [19, 31].
In the United Kingdom, the national guidelines recommend measures for primary
and secondary prevention, pharmacological management, in addition to guided
self-management [16].
Disease self-management is important in asthma and requires an adequate level
of patient education. Asthma self-management includes eﬀective trigger avoid-
ance, adherence to treatment, appropriate inhaler technique, regular monitoring
of peak flow, and following up the personalised action plan [13].
Most patients with asthma can be treated in primary care [32]. However, patients
with more severe disease (e.g., requiring ‘high-dose therapies’ or oral steroids),
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treatment-refractory disease, comorbidities, and/or risk of exacerbations need to
be referred to specialist care to review the diagnosis and management plan [13,
16].
1.1.4.1 Pharmacological treatments
Asthma therapies can be categorised clinically into:
• Quick relief medications (rescuers), which include bronchodilators, namely
short acting beta agonists, magnesium, and short-acting muscarinic receptor
antagonists (in asthma attacks), and provide quick reversal of airway obstruc-
tion;
• Controller medications (preventers), which provide long-term symptom con-
trol. These include anti-inflammatory medications (inhaled and oral corticos-
teroids, leukotriene receptor antagonists, and anti-immunoglobulin E anti-
bodies) and long-acting bronchodilators (long-acting beta adrenoceptor ago-
nists, theophyllines, and long-acting muscarinic antagonists).
Pharmacological categories of therapies
Beta 2 adrenergic agonists
Beta 2 adrenergic agonists act by increasing intracellular cyclic adenosinemonophos-
phate (cAMP) in airway smooth muscle cells. This inhibits contractility, decreases
airway hyperresponsiveness, and improves lung function [11].
Inhaled short acting beta agonists (SABAs), such as salbutamol and terbutaline,
have a quick onset on action (< 5 minutes) [33]. They are the main choice in
relieving acute symptoms in asthma [16].
Long-acting beta adrenoceptor agonists (LABAs) have a slower onset of action
(~5-30 minutes after inhalation) and their eﬀects last longer (12 hours or more)
[33]. They are usually used as additional controllers in combination with inhaled
corticosteroids (ICSs), when the latter are not suﬃcient to control the symptoms
and/or to reduce the side eﬀects of ICS [16]. Examples of LABAs include salme-
terol, formoterol, olodaterol, vilanterol, and indacaterol.
Side eﬀects of β2 adrenergic agonists may include muscle tremor, palpitations, and
a mild decrease in serum potassium [33].
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Anticholinergics
Muscarinic receptors antagonists inhibit cholinergic nerve-induced bronchocon-
striction and mucus secretion [11]. Tiotropium, a long-acting muscarinic antago-
nist (LAMA), can be used as an additional controller if ICS and LABA combinations
are not suﬃcient to control the symptoms [16]. Nebulised ipratropium, a short-
acting muscarinic antagonist (SAMA), can be used along with a nebulised beta-2
agonist in severe acute asthma attacks to improve bronchodilation and accelerate
recovery [16]. Side eﬀects may include dry mouth, dizziness, cough, arrhythmias
and, in the elderly, urinary retention and glaucoma [33].
Theophyllines
Theophyllines inhibit the metabolism of cAMP, which increase its activation of
beta-adrenoreceptors, leading to relaxation of airway smooth muscles [11]. How-
ever, their narrow therapeutic window requires measuring their plasma concen-
tration to adjust the dose. Side eﬀects may include nausea, tachycardia, arrhyth-
mias, and seizures [33].
Corticosteroids
Inhaled corticosteroids are the most eﬀective controllers of asthma [16]. ICSs
suppress airway inflammation mainly by suppressing the activation of the genes
that produces the inflammatory mediators. They decrease the number and activity
of inflammatory cells, particularly T lymphocytes, eosinophils, and mast cells, that
are responsible for airway inflammation [11]. This improves the disease control
by improving lung function, controlling airway hyperresponsiveness, and reducing
asthma symptoms. Examples of ICSs include beclometasone, fluticasone, budes-
onide, mometasone, and ciclesonide [33]. Adverse eﬀects may include oropha-
ryngeal candidiasis, hoarseness, and, at high doses, adrenal suppression and in-
creased bone turnover [33, 34].
Systemic corticosteroids, typically as oral prednisolone, are usually used as short
courses to treat asthma exacerbations [16]. They can be also used as long-term
treatment in patients with severe asthma that is uncontrolled with a high-dose
ICS, a LABA, a leukotriene receptor antagonist, and theophylline [16, 33].
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The dose of long-term corticosteroids in asthma should be carefully reviewed to
ensure adequate disease control with the least possible side eﬀects [16], which
may include diabetes, cataracts, glaucoma, and osteoporosis.
Leukotriene receptor antagonists
Leukotriene receptor antagonists (LTRAs), or antileukotrienes, block either the
synthesis of leukotrienes or their binding to leukotriene receptors, which sup-
presses bronchoconstriction, microvascular leakage, and eosinophilic inflamma-
tion [11, 13]. Examples of LTRAs include montelukast and zafirlukast [33]. LTRAs
can cause modestly improve symptoms in exercise-induced asthma and in asthma
patients with concomitant rhinitis [13, 15]. Common side eﬀects include headache
and gastrointestinal disturbances [33].
Biologic targeted therapy
Omalizumab is a monoclonal antibody that binds to circulating IgE and blocks
its interaction with mast cells and basophils [11]. It is given as a subcutaneous
injection [33]. Other biologic agents include mepolizumab and reslizumab, which
are given by subcutaneous injection and intravenous infusion, respectively. These
medications are very expensive and are reserved for patients with a distinct pheno-
type who fulfil NICE criteria; for omalizumab, patients with severe allergic asthma
who have frequent exacerbations despite high doses of corticosteroids [16].
Side eﬀects of omalizumab may include hypersensitivity reactions, leading to ur-
ticaria, hypotension, syncope, bronchospasm, and/or angioedema [33]. Rarely,
eosinophilic granulomatosis with polyangiitis (EGPA, also known as Churg-Strauss
syndrome)may occur due to corticosteroid withdrawal [35]. EGPAmaymanifest as
hypereosinophilia, worsening pulmonary symptoms, vasculitic rash, eosinophilic
myocarditis, and/or peripheral neuropathy [33].
Cromones
Cromones, such as cromolyn and nedocromil, inhibit mast cells and sensory nerve
activation [11]. They have some benefits in adults and children aged > 5 years,
and can be used in the control of exercised induced asthma [16]. They are listed
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as alternate initial controller therapies for mild asthma in national and interna-
tional guidelines, although ICSs are the preferred agents. Side eﬀects are rare
and include bronchospasm, cough, headache, eosinophilic pneumonia, rhinitis,
and throat irritation [33].
Magnesium sulphate
Intravenous magnesium sulphate causes relaxation of airway smooth muscle and
can be used in patients with acute severe asthma attacks who had no good initial
response to inhaled bronchodilators [16].
Immunosuppressants
Immunosuppressants such as methotrexate may be initiated by specialists in pa-
tients with severe asthma to achieve disease control and reduce oral steroids, but
there is no strong evidence base for their use [16, 33].
Treatment approach
The pharmacological management of asthma should follow a step-wise approach
starting with the step most appropriate to the presenting disease severity. The
2016 BTS/SIGN guidelines on asthma management recommended the following
treatment steps [16]:
For suspected asthma, monitored initiation of low-dose ICS treatment (very-low
to low dose in children) is recommended.
For confirmed asthma:
• Regular preventer: Low-dose ICS (very low dose in children). In children <
5 years, LTRA inhalers can used instead of ICS.
• Initial add-on therapy: Add LABA to ICS, normally as a combination inhaler.
In children < 5 years, use LTRA with very low dose ICS.
• Additional add-on therapy: If no response to LABA, stop LABA, and increase
ICS dose (to medium dose in adults, and low dose in children). If LABA addi-
tion was helpful but insuﬃcient, continue LABA, but increase ICS (to medium
dose in adults, and low dose in children) or try LTRA (in adults and children),
theophylline or LAMA (in adults).
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• High-dose therapies: Try increasing ICS (to high-dose in adults, and medium
dose in children); adding a fourth drug (in adults: LTRA, theophylline, LAMA,
or an oral beta-2 agonist; in children: theophylline).
• Continuous or frequent use of oral corticosteroids: Use daily corticosteroid
tablet in the lowest dose that provides adequate disease control, maintain
high-dose ICS (medium dose in children), and consider steroid-sparing ther-
apies.
Regardless of the treatment step, patients with symptomatic asthma should use a
SABA inhaler as required.
The most recent BTS/SIGN guidelines emphasise the importance of supported
self-management, with all those with asthma being oﬀered education for self-
management which includes a written personalised asthma action plan in addition
to regular review by health care professionals [16].
Treatment should be reviewed every three months until adequate disease control
is achieved. Stepping up the treatment is warranted if the disease is not satisfac-
torily controlled with the current step (e.g., when more than two SABA inhalers
are needed per week).
However, stepping up the treatment may expose the patient to increased side
eﬀects. Therefore, it should only be done after ruling out suboptimal adherence
with existing therapies, poor inhaler technique, and exposure to avoidable or mod-
ifiable triggering factors [16].
1.2 Asthma is a public health challenge
Asthma is a worldwide public health problem aﬀecting more than 300 million peo-
ple worldwide [36]. The International Study of Asthma and Allergies in Childhood
(ISAAC) was an important project for estimating and comparing asthma preva-
lence among children in 98 countries around the world [37]. The prevalence of
clinical asthma varies between countries, ranging from around 1% in Indonesia
to more than 10% in North and South America, Australia, and the United King-
dom [38]. In many countries, asthma prevalence seems to be increasing, and the
worldwide trends do not seem to be decreasing [39].
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Although mortality from asthma is relatively low, it represents only the tip of an
iceberg of a wide range of adverse outcomes and a significant public health burden
of the disease. The disease is associated with expensive health care utilisation,
increased morbidity, reduced quality of life, and wider societal impact such as
school and work absenteeism [40–42]. The annual cost of asthma in the United
Kingdom (UK) in 2011 has been estimated as £1.1 billion pounds (approximately
US$1.8 billion) [43]. Significant financial costs of asthma care are mainly driven
by medication use, exacerbations, and hospitalisations [41, 43, 44]. The costs are
particularly high for patients with severe refractory asthma [45]. Furthermore, 15
million disability-adjusted life years (DALYs) per year worldwide were attributed
to asthma [38]. Due to its high burden, asthma has increasingly received consid-
erable attention by health policy makers and researchers [46].
1.3 Asthma epidemiology in Wales
The United Kingdom has one of the highest asthma prevalences in the world across
all age groups [38, 43, 47–49]. According to Asthma UK, there were estimated 5.4
million asthma patients in the UK in 2015, of whom 314,000 are in Wales [50]. The
mortality rate from asthma in the UK is among the highest across Europe [51].
Asthma epidemiology in Wales has been studied over the recent decades, mainly
by means of cross-sectional health surveys and, to a lesser extent, using prospec-
tive cohort studies and routinely collected health data.
Health surveys are descriptive investigations of systematically collected health
determinants [52], and they are usually used for cross-sectional analyses. Health
surveys have been important tools to investigate asthma epidemiology in Wales.
The Welsh Health Survey (WHS) has been conducted in 1995, 1998, and annually
since 2003 before it ceased in 2015 [53]. In 2014, the WHS estimated the preva-
lence of patient-reported currently treated asthma in children and adults as 9%
and 10%, respectively [54, 55].
The WHS had limitations for studying asthma epidemiology. Self-report has been
prone to recall bias. In addition, sampling might not suﬃciently represent the
entire population since it was limited to people living in private households and
excluded the homeless, older people, some migrant workers, and special popula-
tions (e.g., armed forces and prisoners) as well as those living in care institutions
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Figure 1.1: Trends of self-reported (in blue and red) and GP-reported (in orange) treated asthma in
Wales between 1995 and 2015 according to the WHS [53] and the QOF [59], respectively.
and others due to language barriers [43, 56]. Being an annual study, the WHS
had a limited value in providing timely disease insights. The diﬀerences in the
asthma-related questions asked by the WHS and health surveys in the other UK
countries hinder the comparability of self-reported asthma prevalence across the
UK [43].
Electronic health record (EHR) data have been also used to estimate asthma epi-
demiology. Primary care data from a sample of Welsh general practitioner (GP)
practices, covering around 1% of population in Wales, have been used by the
Weekly Returns Service (WRS) of the Royal College of General Practitioners. How-
ever, the WRS reports did not produce separate asthma statistics for Wales [57].
Since April 2004, primary care data frommore (and later all) GP practices inWales
have been used to produce clinical performance indicators as part of the Quality
of Outcomes Framework (QOF) [58]. According to the QOF indicator of treated
asthma (ASTHMA1 or AST001) the prevalence of patients with asthma diagnosis who
received asthma treatment in the last 12 months, ranged from 6.4% in 2008–09
to 7.1% in 2015–16 [59]. These estimates were notably lower than the prevalence
of patient-reported GP-diagnosed and treated asthma as estimated by the Welsh
Health Surveys (see Figure 1.1).
A recent UK-wide analysis showed that Wales had a slightly higher asthma preva-
lence than the other member counties [43]. The annual prevalences of patient-
reported doctor-diagnosed-and-treated andGP-reported-diagnosed-and-treated asthma
in the fiscal year 2011–2012 were 9.8% and 6.9% in Wales compared to UK-wide
estimates of 9.2% and 6.8%, respectively. That study demonstrated that asthma
burden in Wales was high with estimated £74.7 million pounds being spent on
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asthma care by the Welsh public sector in the fiscal year 2011-2012 [43]. This
overall cost included £40.5 million on community prescribing, £9.7 million on GP
and practice nurse consultations and out-of-hour calls, £3.3 million on accident
and emergency (A&E) visits and ambulance trips, £8.4 million on hospitalisations,
and £12.8 million on Disability Living Allowance.
1.4 Asthma burden can be reduced
Despite its high prevalence, asthma burden can be reduced by identifying mod-
ified risk factors of adverse outcomes, and improving allocation of health care
resources [60, 61].
An investigation into asthma deaths in Wales between 1994–1996 [62] found that
factors other than disease severity, such as inadequate treatment and patient fac-
tors, were identified in 70% of cases. The inquiry concluded that some of deaths
that were attributed to asthma were preventable, and disease morbidity could be
reduced.
The National Review of Asthma Deaths (NRAD), a UK-wide inquiry of the circum-
stances of deaths due to asthma, found that potentially modifiable risk factors
played a significant role in the disease hospitalisation and mortality [51]. The
NRAD report identified avoidable risk factor in two thirds of the reviewed asthma
deaths. Adverse asthma outcomes can be avoided or ameliorated with early diag-
nosis, improved care, disease monitoring, patient education, personalised asthma
action plan, and self-management [51, 63–65]. Exacerbations can be predicted
using disease biomarkers and patient medical history [66–70].
Prevention of adverse outcomes can be boosted through better understanding of
the disease epidemiology, trends, wider determinants, endotypes and phenotypes,
and patterns of natural disease history. Systematic learning from health care data
at the population level is crucial for improving asthma care and prevention of
adverse outcomes. Eﬀective surveillance for asthma requires a stream of real-
time or near real-time data on asthma outcomes at the national level.
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1.5 Routinely collected data: an overview
Documentation of health and care events is an integral part of health care. It
serves a variety of purposes including supporting the delivery and continuity of
care as well as administrative, financial, and legal purposes [71]. However, be-
yond these uses, large volumes of health data accumulate over time, and can be
also useful for further purposes. Routinely collected data (RCD) are data that
are regularly collected without a priori specific purpose into central repositories
where they can be made available for secondary uses [72]. These data are usually
collected in coded forms. Clinical coding systems helps standardising the docu-
mentation of clinical information and facilitates the identification of patients with
a specific clinical profile. Table 1.2 shows examples of clinical coding systems used
in the UK.
Common types of RCD include data on primary and secondary care (EHR data),
laboratory tests, medication dispensing, medical insurance claims, vital events
(e.g., births and deaths), social care, and education.
Examples of RCD uses include policy and service planning and evaluation [77],
epidemiological studies, health surveillance, health technology assessment [78],
comparative eﬀectiveness research, and health economic analysis [43, 79].
Compared with traditional sources of health data, such as questionnaire surveys,
medical record review, RCD have several advantages for research and surveil-
lance. RCD are usually available in large volumes, and at relatively low costs [80].
Table 1.2: Main clinical coding systems in the United Kingdom.
Coding Scheme Description
International Classification of
Diseases, 10th Revision
(ICD-10) [73]
Produced and maintained by the World Health Organisation (WHO); aimed for inter-
national comparability of mortality andmorbidity; used to classify health encounters
based on diagnosis and health conditions for statistical and administrative purposes;
Read Codes [74] The standard medical terminology for coding clinical information in the UK general
practice.
Systematized Nomenclature of
Medicine - Clinical Terms
(SNOMED-CT) [75]
A comprehensive medical terminology for documentation of variety of information
types in clinical practice.
Office of Population Censuses
and Surveys Classification of
Interventions and Procedures
(OPCS-4) [76]
Maintained by NHS Digital; used to code operations, procedures and interventions in
UK secondary care.
British National Formulary
(BNF) [33]
The reference book of coded medication and prescribing in the UK.
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Many RCD sources cover entire populations, enabling generalisability of studies,
reliable epidemiological estimates, and studying rare conditions [81, 82]. The
contents of many RCD resources are rich and comprehensive enough to answer a
wide range of research questions. Person-level record linkage of two or more RCD
sources for the same population allows further research opportunities [83]. RCD
are observational, objective data that are often recorded by qualified professionals
rather than patients. They are therefore less prone to biases of self-report such
as recall, learning, responses biases [84, 85]. Studies using RCD are not prone
to experimenter bias since collection of data is independent from their secondary
uses. The often-longitudinal nature of RCD allows conducting inexpensive, com-
plex time series analyses. RCD reflect health, morbidity, and health care in the real
world rather than in idealised or artificial conditions such as in clinical trials [81].
Therefore, they have been used in the various phases of clinical trials including
patient follow-up and evaluation of real-world safety and eﬀectiveness drugs [86,
87].
Nevertheless, being originally collected for other purposes, RCD usually have lim-
itations for use in research. While clinical codes facilitate data standardisation,
they do not cover all aspects of health and care. Important non-coded narrative
data are usually missing from RCD. Incomplete, inaccurate, incorrect, and incon-
sistent capture and coding of data is a common concern about RCD [88–93]. Con-
founding is an important issue in RCD-based studies, and missing residual con-
founders limits causality inference [94, 95]. Users of RCD should consider their
provenance and the circumstances under which they are collected. For instance,
with incentivised documentation of care (e.g., QOF), some data items are better
recorded than others [93].
With the increasing use and quality of RCD, they have been recognised as key
sources of data in the strategic plans of several health research agencies, councils,
institutes, and funders across the UK [96–98].
1.6 Routinely collected data can improve our un-
derstanding of asthma
Asthma is an exemplar of health problems in which RCD can be eﬀectively used for
surveillance and support health policy and research. Depending on their content,
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RCD data can provide information on asthma symptoms, diagnosis, laboratory
tests, disease severity, disease control, treatments, monitoring, exacerbations,
healthcare utilisation, and care quality [99–105].
Asthma-related RCD have been increasingly used to study diﬀerent clinical and
epidemiological aspects of the disease. These include incidence, prevalence, and
burden and trends of asthma and its outcomes [43, 83, 106–109], risk factors
[110–114], and disease prediction [66, 68, 70, 115, 116].
RCD can be also useful inform management, prevention, and compare eﬀective-
ness of interventions [117–119].
RCD have been used in several countries to create disease registries and platforms
for asthma surveillance and research [120–122]. In the next section, I present an
overview of those projects.
1.7 Disease registries and observatories
1.7.1 Disease registries
A disease registry is a database that systematically tracks outcomes of interest for
patients who have a particular health condition and live in a defined geographic
area.
Disease registries are usually set up to support health policy, service planning
and/or research [123]. They have been widely used in epidemiological studies and
allowed assessment of disease outcomes and understanding the natural history of
chronic diseases [124]. Some disease registries can be also used to support health
care of individual patients [125].
In the UK, notable examples of asthma registries are the BTS Diﬃcult Asthma Reg-
istry [126], its successor the UK Severe Asthma Registry,1 and the UK Paediatric
Diﬃcult Asthma Network Registry.2
Traditionally, disease registries have relied on active, purpose-specific data col-
lection. However, the growing number of EHR databases have provided inexpen-
sive, rich, alternative sources of data. EHR-derived data are usually available
in large volumes, and contain real-world data on patient care. These data have
1https://cl2.n3-dendrite.com/csp/asthma/frontpages/index.html
2http://rs2.e-dendrite.com/csp/paedasthma/frontpages/index.html
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been increasingly used in registries of long-term conditions such as chronic kidney
disease [127], cancer [128], cardiovascular disease [129], and multiple sclerosis
[130].
1.7.2 Health and disease observatories
Health observatories are projects often run by public health or academic institu-
tions to monitor health status of the population.
There is no consensus on the definition of a health observatory [131, 132]. The
term ‘observatory’ means that, unlike health authorities, health observatories ob-
serve and analyse health phenomena while ‘standing back’ from them [133]. This
observational nature distinguishes health observatories from state-operated health
surveillance systems [131–133]. They often combine academic rigour with the
high quality of public health professional practice [132]. However, compared to
academic research projects, observatories often seek to provide more timely an-
swers to public health questions, supporting health service planners and policy
makers’ continuous need for up-to-date evidence [132].
Common core functions of health observatories include:
• highlighting health problems requiring attention and measuring their preva-
lences and burdens,
• conducting health surveillance3 on those problems,
• producing actionable insights,
• evaluating service delivery, and
• forecasting the population health [132]
In undertaking these functions, health observatories need to identify the various
sources of data that could be used to assess health problems, such as routinely
collected data sets and disease registries [43]. They can also identify important
gaps in data sources, and often seek to link diﬀerent data sources for better un-
derstanding of health problems [43, 132, 134].
Health observatories often target several health problems [131, 132]. However,
some are dedicated to specific public health problems, such as health inequality,
or specific diseases, such as asthma.
3Health surveillance is the systematic, continuous analysis, interpretation, and feedback of data
related to specific health problems in a population [52]
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Several asthma-specific observatories and surveillance systems have been estab-
lished around the world. In the UK, the Surveillance of Work-related and Occupa-
tional Respiratory Disease (SWORD) system, maintained data about workers with
occupational asthma [135]. It used systematic, voluntary reporting from special-
ists of data about suspected new cases including demographics, occupation, and
suspected causal agents. A similar system, the Observatoire National de Asthmes
Professionnels, was established in France to monitor occupational asthma [136].
It was based on clinical, diagnostic and profession-related data about workers with
occupational asthma, which were voluntarily reported by physicians using ques-
tionnaires. In Canada, the Ontario Asthma Surveillance Information System (OA-
SIS) is based on a cumulative cohort of asthma patients in Ontario [134]. OASIS is
based on health administrative data of physician billing, emergency department
visits, and hospital admissions. It aims to monitor changes in asthma epidemiol-
ogy, management, and health service use as well as variations in clinical practice
and disease burden. In the United States (US), the Population-Based Eﬀectiveness
in Asthma and Lung Diseases (PEAL) Network is an asthma registry with wide
research, surveillance, and public health applications [137]. The PEAL Network
uses data of computerised medical billing and claims as well as pharmacy and
laboratory data. Claim data for emergency department visits and hospitalisations
have been also widely used for asthma surveillance elsewhere [105, 107, 120, 121,
138, 139].
1.8 An asthma observatory for Wales: opportuni-
ties, challenges, and solutions
Given the high asthma burden in Wales, the motivation of this doctoral project
was the pressing need for a reliable tool to monitor and study the disease and its
outcomes.
In the UK, including Wales, asthma is mainly managed in primary care. Primary
and secondary care data have been routinely collected with high-to-complete ge-
ographical coverage across Wales. These data, as well as various other health
data source, are maintained and linked in the Secure Anonymised Information
Linkage (SAIL) databank at Swansea University [140, 141]. With the high asthma
prevalence in Wales, large volumes of rich, representative, real-world, longitudi-
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nal observational data on asthma patients are available in the SAIL Databank. This
data-intensive environment provides a unique opportunity to develop an observa-
tory for asthma in Wales.
Developing an observatory for asthma exploits the merits of RCD but is hindered
by their limitations. Algorithms to identify patients with asthma and assess asthma
outcomes using RCD data are essential in the observatory development. However,
for a heterogeneous disease such as asthma, identifying cases and assessment of
outcomes using RCD was a key challenge, and valid case definitions were needed.
However, there were neither gold standards for the clinical definitions of asthma
and its outcomes, nor consensus on their definitions using RCD.
With the above challenges, data-driven approaches can be employed to uncover
patterns generated by the disease in the population. Populations health data
‘speak for themselves’. Their patterns, however, need to be carefully interpreted
in the light of clinical and epidemiological knowledge and hypotheses, as well as
data provenance and quality [142]. Using proper design and interpretation, data-
driven approaches, such as mixture models (e.g., latent class analysis (LCA), can
be employed to identify asthma patients in a population.
1.9 Thesis aims, research questions, and objectives
The aims of this thesis are to describe the methodology and development of the
Wales Asthma Observatory4 as a platform for asthma surveillance and research
in Wales, and to demonstrate its utility for health policy. Throughout the thesis, I
will refer to the Wales Asthma Observatory as the Observatory.
The thesis includes a systematic scoping review of approaches to define and assess
asthma using RCD and their reporting quality. A particular focus of the thesis is
the identification of asthma patients in Wales using RCD in the light of the absence
of gold standard and inherent limitations of RCD.
Research questions
Throughout the thesis I will answer the following research questions:
4http://www.wales-asthma-observatory.uk/
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1. What are the contemporary approaches and practices of identifying asthma
patients and assessing asthma outcomes using RCD? How well have these
approaches and their validity been described? (Chapter 2)
2. Can a latent class model based on recorded primary care data identify clin-
ically meaningful asthma-related groups? How does this model compare
with commonly used doctor-reported and self-reported measures to identify
asthma patients? (Chapter 3)
3. How well have asthma-related primary care events been recorded in Wales?
(Chapter 4)
4. Do asthma patients across the socioeconomic scale in Wales have equal dis-
ease outcomes? (Chapter 5)
Objectives
To address the research questions, I pursued the following objectives:
1. To review the current practices of studying asthma using routinely collected
data (Chapter 2). This is performed through a systematic scoping review of
the recent asthma literature with the following objectives:
a. To survey the algorithms used to define asthma and assess asthma out-
comes using routinely collected EHR data;
b. To explore the practices of the reporting on the validity of those algo-
rithms;
c. To assess the clarity of reporting on the implementation of these algo-
rithms and other methodological aspects related to the use of RCD.
2. To discuss the challenges of identifying asthma patients using RCD (Chapter 2
and Chapter 3).
3. To develop a data-driven reference identification for asthma in Wales based
on routinely collected data (Chapter 3). This includes:
a. Development of a mixture model, namely latent class model, to identify
patients with both ever and current asthma.
b. Evaluating the concordance of this model with other routine data-based
case definitions as well as with self-reported measures.
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4. To describe the purpose, context, and methodology used in the Observatory
development, as well as data quality (Chapter 4). This will include the follow-
ing sub-objectives:
a. To describe the purposes of the Observatory as a data-intensive platform
for asthma surveillance and research.
b. To describe the logistics, technical infrastructure, and RCD databases
based on which the Observatory was founded.
c. To define the Observatory’s source population and the case definitions
used to identifying asthma patients.
d. To describe the Observatory’s data structure and the available variables.
e. To describe the approach used to improve eﬃciency and reproducibility
of data interrogation.
f. To assess the quality of selected asthma-related primary care events in
the Observatory.
5. To demonstrate the Observatory’s utility for health policy by investigating
inequalities in asthma outcomes (Chapter 5). This includes:
a. Investigate the variations in asthma-related outcomes across the depri-
vation groups in Wales, using a count regression model adjusted for age
group and gender.
b. To interpret the model in the light of previous studies and strengths and
limitations of routinely collected data used.
c. To reflect on the implications of the findings on health policy in Wales.
6. To reflect on the work presented in Chapters 2, 3, 4, and 5, identify main
strengths and weaknesses of the Observatory, interpret the findings with re-
lated literature, discuss the opportunities and challenges to maximise the
potentials of asthma data, and outline further research directions.
1.10 Thesis structure
The rest of the thesis is organised as follows:
In Chapter 2, I present a systematic scoping review of the diﬀerent approaches
of defining asthma and assessing its key outcomes, and the clarity of reporting
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on their implementation and validity. The review reveals wide variations in these
approaches, and highlights the challenges of developing uniformRCD-basedmeth-
ods to study asthma. This systematic scoping review was published in a leading
respiratory journal [102].
In Chapter 3, I present an overview to approaches to develop valid methods to
identify asthma patients using RCD. Recognising asthma heterogeneity, data lim-
itations, and informed by the findings of the previous chapter, I justify using a
data-driven approach to identify asthma patients. I describe a latent class model
based on primary care data as a data-driven identification model for asthma in the
Observatory. I also derived a reusable classification algorithm base on the latent
class model. I compared the algorithm’s performance with commonly used asthma
case definitions based on objective and self-reported data.
In Chapter 4, I describe the Observatory’s context, purpose, data structure, case
definitions, variables, information governance, and approaches to improve eﬃ-
ciency and reproducibility of the Observatory interrogation. I also examine the
quality of asthma-related primary care data and discuss their implications on the
Observatory utilisation.
In Chapter 5, I demonstrate the Observatory’s utility for health policy by examin-
ing the inequality gaps in asthma outcomes across the socioeconomic spectrum in
Wales.
Finally, in Chapter 6 I reflect on the work presented in this chapter, present with
the thesis’s original contributions, and discuss the Observatory’s strength and
weaknesses in the wider context of asthma and RCD research. I explore oppor-
tunities and challenges towards maximising the value of RCD to improve asthma
outcomes. I then propose future research directions and developments to improve
the Observatory’s methodology and content.
Chapter 2
Defining asthma and
assessing asthma outcomes
using electronic health
record data: a systematic
scoping review
Same conditions, diﬀerent definitions
This chapter is based on the following published paper:
Al SallakhMA, Vasileiou E, Rodgers SE, Lyons RA, Sheikh A, and Davies GA. Defin-
ing asthma and assessing asthma outcomes using electronic health record data:
a systematic scoping review. Eur Respir J 49 (6 2017) 1 (see Appendix A.2).
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In this doctoral project, I used routine data to create a registry and observatory
for asthma in Wales. However, the heterogeneous nature of asthma and the lim-
itations of routinely collected EHR data impose challenges on how these data
could be used for this purpose. In addition, there is currently no consensus on
approaches to defining asthma or assessing asthma outcomes using electronic
health record (EHR)-derived data.
To inform the methodology of identifying of asthma patients and assessing the
outcomes in this project, described in Chapter 3, in this chapter, I present a sys-
tematic scoping review of how routinely collected EHR data have been used in the
recent international asthma literature.
I systematically searched for asthma-related articles published between 1-1-2014
and 31-12-2015. From the eligible studies, I extracted the algorithms used to
identify asthma patients and assess severity, control and exacerbations from us-
ing diﬀerent types of EHR-derived data sources. I also investigated how authors
justified the validity of these algorithms, and how they reported on the aspects
related to the use of EHR-derived data in their studies.
From 113 eligible articles, I found significant heterogeneity in the algorithms used
to define asthma (n = 66 diﬀerent algorithms), severity (n = 18), control (n = 9),
and exacerbations (n = 24). For the majority of algorithms (n = 106), validity
was not justified. In the remaining cases, approaches ranged from using algo-
rithms validated in the same databases, to using non-validated algorithms that
were based on clinical judgement or clinical guidelines. The implementation of
these algorithms was sub-optimally described overall.
Although EHR-derived data are now widely used to study asthma, the approaches
being used are significantly varied and are often underdescribed, rendering it
diﬃcult to assess the validity of studies and compare their findings. Given the
substantial growth in this body of literature, it is crucial that scientific consensus
is reached on the underlying definitions and algorithms.
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2.1 Introduction
Methods to define and assess asthma are key to the development of the Wales
Asthma Observatory. To inform the development of Observatory, it was important
to survey the contemporary methods to define and assess asthma using routinely
collected electronic health record (EHR) data. This would provide insights into
the diﬀerent approaches and the challenges to define the disease from these data.
Asthma is in clinical practice a diagnosis based on the patient’s history, exami-
nation and objective tests [143]. Typically, the diagnosis is made initially based
on signs and symptoms such as wheezing, shortness of breath, tightness of chest,
or cough that often follow characteristic fluctuating patterns and triggerability.
Confirmation of diagnosis requires demonstrating variable expiratory obstruction
of airflows over time [1]. However, asthma is not a single clinical entity. Instead,
it is increasingly considered to represent a heterogeneous group of disorders with
diﬀerent phenotypes and endotypes [5]. In addition, several other diseases may
masquerade as asthma leading to misdiagnosis [143]. Subsequently, the clinical
definitions of asthma and its key outcomes, including asthma severity, control, and
attacks/exacerbations have been the subject of vigorous debate with no consensus
yet reached on a gold standard for diagnosis [2, 144–148].
The uncertainty in the clinical definition of asthma has significant implications
for research. Particular challenges arise in the context of epidemiological studies
where groups of populations rather than individual patients are compared, and
in which validated, standardised, operational case definitions are needed [149,
150]. Various types of health data have been used in these studies. Traditionally,
these data were often self-reported or collected by investigators specifically for
the purpose of research. In addition, these studies have been increasingly con-
ducted using data derived from EHR such as health administrative data, health
insurance data, primary care data, dispensing data, and disease registries. These
data usually have the advantages of being inexpensive, objective, read-world data,
and are usually available in large volumes. However, they have inherent limita-
tions such as incorrect, inconsistent, or missing recording of health care events,
resulting in many key clinical variables being missing or of low quality [82, 151]
(see Section 1.5).
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The limitations of routinely collected EHR data add a further layer of complexity
and challenges to the use of these data in asthma research. Investigators often
resort to indirectly assess low-quality variables using surrogate variables of higher
quality or algorithms based on those surrogate variables. Although the face va-
lidity is important, formal validation of these algorithms is critical to ensure re-
producibility of findings of studies conducted using routinely collected EHR data
[152]. With the increasing and widespread use of EHR data in asthma literature, it
is however unclear to which extent algorithms to define and assess asthma using
these data have been supported by suﬃcient evidence of validly.
Clear reporting of methodology in studies conducted using routinely collected
data (RCD) is critical not only for scientific transparency and understandability
by their consumers (e.g., researchers, service providers, policy makers), but also
for reproducibility and comparability of research findings as well as for evidence
synthesis and meta-analysis. Guidelines to improve the reporting of observational
studies have been available for several years [153]. However, adherence to these
guidelines has been suboptimal [154, 155]. Furthermore, a recent assessment
found that the reporting of studies conducted using routinely collected health data
was often inadequate [156]. Until recently there were no clear guidelines on how
to report specific methodological aspects related to the use of EHR-derived data
in research. The REporting of studies Conducted using Observational Routinely-
collected health Data (RECORD) Statement [157], published in September 2015,
was an extension to the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) Statement which argues authors to completely and
clearly communicate, in addition to the main methodology, important aspects re-
lated to the use of routinely collected health data in their study. To my knowledge,
there was no existing assessment of the clarity of reporting on the use of EHR data
in the recent asthma literature.
To assess the approaches and practices of using routinely collected EHR data in
asthma research, I systematically interrogated the recent EHR-based asthma lit-
erature with the following objectives:
• To describe the diﬀerent methods of defining asthma and assessing disease
severity, control and exacerbations in EHR-based studies;
• To assess the clarity of reporting on the implementation and validity of these
methods.
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2.2 Methods: a systematic scoping review
I conducted a systematic scoping review based on Arksey andO’Malley’s five-stage
framework [158]. This methodology included identifying the research question,
identifying relevant studies through literature search, selection of eligible stud-
ies, data charting and collating, and summarising and reporting the results. The
research questions were:
• How were asthma and its key outcomes defined using EHR data in the recent
literature?
• How did authors report on the validity of their EHR-based algorithms?
• How clearly was the reporting on the implementation of these algorithms and
other EHR-related methods?
2.2.1 Identifying the research questions
Since this framework is intended for exploratory review, research questions could
be iteratively developed during the review process. The primary research question
behind this scoping review is:
• How has asthma and its key outcomes been defined using RCD in the recent
literature?
In addition, while reviewing the literature, two other related research questions
emerged to address validation of case definitions and the clarity of reporting of
methodological aspects related to routinely collected EHR data:
• How did authors report on the validity of their RCD-based case definitions?
• More generally, how clear were the RCD-related methods reported?
2.2.2 Identifying relevant studies: literature search strategy
I searched PubMed using a broad query (Table A.1.1) to retrieve asthma studies
that used EHR-derived data and were published between January 1, 2014 and
December 31, 2015. The search query was iteratively improved by adding many
variations and equivalents of the keywords “EHR” and “routinely collected data”
as well as named data sources found in the literature. Only articles written in
English were included.
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2.2.3 Study selection
I excluded non-relevant articles by reviewing titles and abstracts, referring to the
full-text when needed. I included only articles where asthma was a main find-
ing. For the purpose of this review, I limited the concept of EHR-derived data
to coded, objective, individual-level data that were generated as a by-product of
routine health care. Therefore, I excluded studies in which only text-based med-
ical records were used, the coded nature of EHR-derived data was unclear, the
used data were aggregated, or no asthma-specific variables were measured from
EHR-derived data. For example, if the only variables measured from routine data
for asthma patients were related to co-morbidities or birth weight the study was
excluded.
2.2.4 Data extraction, charting and synthesis
From each of the eligible articles, I extracted and summarised information from
the full text and online supplements, including basic bibliography, setting (coun-
try) and design; names and types of EHR-derived data sources used; algorithms to
identify asthma patients, assess disease severity, control, exacerbation; and how
authors reported on algorithm validity. In this context, I referred to ‘validation’
as any attempt to assess the algorithm’s concurrent1 or construct validity.2 I used
the RECORD Statement’s 13-items checklist [157] to assess the completeness and
clarity of reporting of methodological aspects related the use of EHR-derived data
in the study. I investigated whether in each study authors provided detailed in-
formation on how they identified asthma populations and assessed asthma out-
comes. Ideally, the checklist requires authors to provide detailed description of
the algorithms used, including complete lists of clinical codes and any validation
performed previously or in the same study. In addition, information about the
data sources used should be provided, including their content and validity, their
catchment areas, level of access to them by authors (i.e. whether they had access
to the whole or part of the dataset), explanation of any record-linkage performed,
and in which date range the data used in the study were originally recorded. Au-
thors should also explain how they prepared and cleaned the data for the purpose
1Concurrent (criterion) validity is the extent to which the algorithm agrees with a concurrent mea-
sure, the validity of which to establish the diagnosis was previously assessed.
2Construct validity is the extent to which the algorithm accurately measures the real disease state.
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of their study (e.g., how they processed inconsistent and invalid values). Also,
they should ideally publish the programming source codes used for data extrac-
tion, preparation, and analysis. To enable the readers critically evaluate the valid-
ity of studies, authors should adequately communicate any implications of using
EHR-derived data sources in their studies to assess a complex condition such as
asthma. Table A.1.2 describes the data extraction and charting tool used in this re-
view. Article screening and data extraction were performed independently by two
researchers (myself and Eleftheria Vasileiou3) with my first supervisor, Gwyneth
Davies, arbitrating.
2.2.5 Collating, summarising and reporting the results
I summarised the general characteristics of the reviewed articles including the
country to which the study source population belonged, study design, and types
of routine data sources used in the study (e.g., health insurance claims, primary
or secondary care, or pharmacy dispensing data). I highlighted the clinical labels
used in asthma algorithms as they appeared in the studies. I also identified the
approaches used in these algorithms which aimed at improving their accuracy.
I also summarised the practices of justifying the validity of algorithms (e.g., by
citing a previous validation of the same algorithm in the same population) as well
as aspects related to the use of EHR data.
2.3 Results
2.3.1 Characteristics of studies and data sources
I included 113 articles in the review. Figure 2.1 shows the study selection pro-
cess. Most studies were conducted in the United States (US), Taiwan, and Canada
(Table A.1.3), and employed longitudinal designs (Table A.1.4). The most com-
monly used data types were health insurance claims followed by medical record
repositories and dispensing databases (Table A.1.5).
3A PhD student at Asthma UK Centre for Applied Research, University of Edinburgh.
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287 records identified
through database searching
287 records screened
139 of full-text articles
assessed for eligibility
105 studies included
in qualitative synthesis
148 of records excluded
34 of full-text articles excluded
Figure 2.1: Flowchart for study selection in this scoping review.
2.3.2 Defining asthma
2.3.2.1 Various diagnostic labels of asthma
I identified 66 diﬀerent algorithms to define asthma under seven diagnostic labels
(Table A.1.6).
‘Persistent asthma’ was defined over 12 and 24 months using the US Healthcare
Eﬀectiveness Data and Information Set (HEDIS) criteria [159], which involved as-
sessing for any of the following asthma-related events: (1) emergency department
(ED) visit, (2) hospitalisation, (3) outpatient visit and two asthma prescriptions, or
(4) four asthma prescriptions [160–163]; by HEDIS criteria except “four asthma
prescriptions” [164]; and by any asthma encounter (hospitalisation or ED visit) or
using oral corticosteroids (OCS) for three or more days [165].
‘Current asthma’ was defined by any asthma encounter in the last three years
[166].
‘Current general practitioner (GP)-reported and diagnosed asthma’was defined as
any asthma encounter in the last 12 months, and ‘current GP-reported, diagnosed
and treated asthma’ as the same plus any asthma prescription in the same period
[167].
Patients with treated asthma were otherwise required to have at least three dis-
pensing events of asthma treatments in three diﬀerent quarters of the year [168].
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‘Acute asthma’ was defined using any asthma diagnosis codes in ED or inpatient
data [169].
In the remaining studies, the label ‘asthma’ was defined using various algorithms,
some of which were similar to those of the aforementioned more specific labels.
The intervals over which asthma diagnostic/management and prescription codes
where queried were specified in 31 and 8 studies, respectively. The positions of
diagnostic codes in the encounter (i.e. primary or secondary) were specified in 37
studies.
I identified five approaches in these algorithms: requiring diagnostic/management
events, prescription events, or both (Table A.1.7).
2.3.2.2 Approaches to restrict study domain
To reduce the risk of misclassification, some studies applied additional non-asthma
selection criteria which weremeant to exclude individuals who are unlikely to have
asthma. These criteria were based on restricting the study population based on
age and co-morbidities.
Age restriction
In 12 studies Table A.1.8, age restriction was applied to asthma definitions as
an indirect way of excluding those with co-morbidities that are common at age
extremes and to acknowledge the uncertainty of asthma diagnosis in these ages.
The minimum age limits at were 2 (n = 4), 3 (n = 2), 5 (n = 1) and 12 (n = 1),
while the maximum age limits were 40, 55 and 60 (n = 1 for each).
Excluding patients with specific co-morbidities
Eighteen studies (Table A.1.9) applied additional criteria to exclude asthma pa-
tients who also had other conditions, most commonly cystic fibrosis and chronic
obstructive pulmonary disease (COPD). The list also includes “smoker over the age
of 60” as a proxy for COPD diagnosis. The complete list is shown in Table A.1.9.
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2.3.3 Assessing asthma severity
Eighteen studies used 20 diﬀerent algorithms to assess asthma severity (Table A.1.10),
as binary (i.e. severe vs. non-severe asthma) [160, 168, 170–183] or ordinal vari-
ables (mild, moderate, and severe asthma [184]; or low, moderate, and high-risk
asthma [185]). The algorithms were based on one or more of the following asthma-
related variables: number and/or dosage of prescriptions—namely short acting
beta agonist (SABA), inhaled corticosteroid (ICS), OCS, and leukotriene receptor
antagonist (LTRA)—and number of hospitalisations, ED and outpatient visits. Al-
most all algorithms (17) used prescriptions (either alone or with other variables),
while one algorithm was based only on hospitalisations and ED visits [181]. The
intervals over which asthma severity was assessed were three [174], six [183],
12 [160, 168, 173, 175–177, 179, 181, 182, 184, 185], 24 months [178, 180], or
unclear [171, 172].
2.3.4 Assessing asthma control
Nine studies assessed asthma control using 11 algorithms, in 9 of which the in-
terval was 12 months, in one 1-3 months, and in the remaining study this was
unclear (Table A.1.12). Uncontrolled asthma was defined by a minimum number/-
dose of SABA prescriptions [175, 176, 184, 186, 187]; any or short-course OCS
prescriptions [175, 176, 186–189]; any hospitalisation or ED visit with either di-
agnosis of asthma [172, 175, 176, 186–188, 190] or — in already diagnosed asthma
patients — diagnosis of status asthmaticus, pneumonia, dyspnoea, or respiratory
insuﬃciency [175]; unscheduled outpatient visits for asthma or lower respiratory
tract infections (LRTI) [176]; and GP consultations for LRTI requiring antibiotics
in asthma patients [176]. Asthma impairment was defined based on the required
SABA use, namely an average of more than two salbutamol puﬀs per day [176].
One study assessed asthma control based on number of OCS and SABA prescrip-
tions per year (without giving any further details about the actual algorithm) [186].
2.3.5 Defining exacerbations
Twenty-four studies defined exacerbations using EHR-derived data (Table A.1.11),
as a dichotomous variable (absent vs. present) [161, 162, 168, 172, 175–177,
180, 182–184, 187–189, 191–199], or stratified into absent, moderate and severe
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[200]. Oral corticosteroid prescriptions were used as a marker for exacerbations
in 17 studies, either alone [168, 175, 176, 180, 184, 187, 192, 193, 198] or with
a concurrent asthma encounter (e.g., a GP, outpatient, or ED visit, or hospitalisa-
tion within five or seven days) [161, 162, 177, 182, 183, 191, 197, 199]. In one
study, exacerbations were defined by a minimum of six SABA prescriptions per
year [192]. Other definitions included an outpatient code of ‘asthma exacerba-
tion’ [197], asthma hospitalisation [168, 175, 177, 180, 182, 184, 188, 189, 191,
193, 195, 196, 198–200], asthma ED visit [161, 175–177, 180, 182, 183, 188, 189,
191, 193, 196–199], or hospitalisation with diagnosis of status asthmaticus, or
— in already diagnosed asthma patients — diagnosis of pneumonia, dyspnoea, or
respiratory insuﬃciency [175].
2.3.6 Clarity of reporting
Overall, the reporting of methodological aspects of using EHR-derived data was
suboptimal. The majority of studies presented no information on the algorithms’
validity. Among studies that reported on the validity, I identified 10 practices of
reporting or on or justifying the validity of algorithms (Table 2.1): (1) perform-
ing validation or concordance analysis in the same study against other measures
based on diﬀerent data sources (e.g., medical record review or patient-reported
measures); (2) referring to previous validation of similar algorithms in the same or
(3) diﬀerent databases; (4) referring to previous validation of similar algorithms
for diﬀerent diseases in the same or (5) diﬀerent database (6); using algorithms
‘consistent’ with previous studies in the same or (7) diﬀerent databases; (8) using
nationally developed algorithms; (9) using algorithms based on clinical guidelines;
(10) and relying on previous validation of the database content. Some studies did
not provide clear algorithms for asthma severity or control, but only referred to
their components [168, 180, 182, 183, 186].
Of the 113 reviewed studies, 40 studies used record-linkage, of which 17 men-
tioned it in the abstract, and 28 provided at least some explanation in the full
text. The geographical region, time frame of data, and types or names of the data
sources were mentioned in 83, 91, and 104 abstracts, respectively. Eighty-three
studies reported their extent of access to the data sources. The intervals over
which the algorithms were applied were often not reported. One hundred and
eleven studies touched on the implications of using EHR data to study asthma. Of
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Table 2.1: Practices of reporting or justifying the validity of algorithms to define and assess asthma
using EHR-derived data.
Algorithm validity was justified by Number of algorithms
Identifying
asthma
patients
Assessing
severity
Assessing
control
Defining ex-
acerbation
Total per
category
Validation of the same algorithm in the same
database
14 1 1 1 17
Validation of the same algorithm in different
database(s)
2 6 3 2 13
Validation of other diseases’ algorithms in the
same database
2 0 0 0 2
Validation of other diseases’ algorithms in differ-
ent database(s)
1 0 0 0 1
Being consistent with similar studies in the same
database
1 0 1 0 2
Being consistent with similar studies in different
database(s)
1 0 0 1 2
Validation or concordance analysis in the same
study
4 0 0 0 4
Being based on nationally developed algorithms 3 0 0 2 5
Relying on the validity of database coding 5 0 0 0 5
Being based on clinical guidelines 0 3 0 0 3
Not justified 76 8 4 18 106
these, 64 and 63 studies discussed the risk of misclassification bias and unmea-
sured confounding, respectively. Six studies acknowledged the possible changes
over time in data quality and coding practices and the entailing changes in case
definition eligibility and accuracy. Five studies explained their data cleansing pro-
cedures. Finally, no study shared the programming codes of data preparation and
analysis.
2.4 Discussion
2.4.1 Statement of main findings
There is a considerable international activity in using EHR-derived data to study a
variety of asthma populations and outcomes. This systematic analysis of the con-
temporaneous asthma literature provides a high-level view on how asthma and its
main outcomes have been defined using routinely collected EHR data. Importantly,
I found wide variations in the approaches used with limited attention being paid
to the validity of the underlying algorithms used and suboptimal reporting on the
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methodology. This poses a major challenge to the interpretation and reproducibil-
ity of this important, emerging body of research inquiry.
2.4.2 Strengths and limitations
To my knowledge, this is the first systematic exercise to investigate the quality of
reporting on EHR-based studies, especially the validity of measures, in the con-
text of asthma. In undertaking this work, I used robust approaches which involved
two people independently selecting studies and undertaking data extraction. The
findings of wide variations and suboptimal reporting of methods and their validity
may also apply to other chronic diseases. This review had no geographic limits,
but it was confined to assessing the recent literature. Examining the most recent
asthma literature is most likely to provide meaningful insights on current prac-
tices. Finding studies conducted using routinely collected EHR data in the litera-
ture was challenging as there was no standardised method to do this. A dedicated
Medical Subject Headings (MeSH) term for “routinely collected health data” in
MEDLINE database was previously suggested [201]. However, I believe my broad
search query, including a long list of synonyms routinely collected health data
and clinical codes for asthma diagnosis reasonably increased the search recall.
In few studies, it was a challenge to separate criteria used to define asthma from
the study-specific inclusion and exclusion criteria. A limitation was that I did not
systematically check whether the references provided by a study to support the
claimed validity of algorithms in question actually provided suﬃcient evidence of
validity. For example, slight diﬀerences might exist between the algorithms used
in a given study and those validated by previous studies.
2.4.3 Interpretation in the light of previous studies
Although EHR-derived data are convenient resources for research, they are orig-
inally collected for other purposes, and usually suﬀer from missing or incorrect
data and potential biases [82, 151, 202]. Asthma-related EHR data potentially
suﬀer from significant levels of uncertainty due to a set of factors. Some of these
factors are inherent to asthma as a heterogeneous disease with fluctuating and
variable natural history. Other factors include the wide variability in health care
provision, and in the practices of documentation and coding of clinical data. In
addition, EHR systems usually fail to capture complete and accurate clinical in-
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formation at the point of care due to design limitations and ineﬃcient use of these
systems by clinicians to document clinical data [203, 204]. Altogether, these fac-
tors create high levels of variability and inconsistency in the information recorded
on asthma patients, even those with similar clinical profiles. Furthermore, many
EHR-derived databases often lack important variables, such as lung function, in-
dication of dispensed medications, adherence to treatment, and lifestyle, which
are vital for identifying and assessing asthma patients.
The aforementioned issues impose challenges on the interpretation of asthma-
related health events in EHR-derived data and their use to identify and assess
asthma patients. These issues are further discussed in Section 3.1.1. In this
review, asthma diagnosis codes were commonly used solely for identification of
asthma patient. However, these codes may be recorded after a trial or wrong
diagnosis, and do not capture undiagnosed patients [205]. In addition, although
an asthma diagnosis code may be recorded during any asthma-related health en-
counter, it does not necessarily imply an active or treated disease. More complex
approaches for asthma patient identification included the requirement of medica-
tion codes in addition to an asthma code either to identify treated patients or to in-
crease the specificity of “any asthma” case definition. Patients with “any asthma”
were also ascertained by only medication codes where only dispensing data were
available. However, this approach could exclude patients with active disease who
did not receive prescriptions. In addition, it could incorrectly include non-asthma
patients since some asthma medications, such as SABA and oral corticosteroids,
could be prescribed in other conditions.
These challenges are however not insurmountable. In this analysis, I found sev-
eral approaches, in addition to asthma-related criteria, which were intended to
improve the specificity of algorithms such as age limitation, exclusion by comor-
bidities, and diagnosis position restriction. I was able to distinguish these ap-
proaches from study-specific patient selection criteria. Age restriction was driven
by the uncertainty of asthma diagnosis in age extremes. In early childhood the
clinical diagnosis of asthma is diﬃcult to establish, while in the elderly COPD
may be misdiagnosed as asthma [206]. Excluding patients, who already satisfied
asthma criteria, but who also had other specific co-morbidities was a common
practice. In the absence of data on respiratory symptoms, lung function, and lab-
oratory tests, excluding adult “asthma” patients who also had COPD diagnosis
and/or smoking history reflects the assumption that they were unlikely to have
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asthma, and was assumed to increase the specificity of asthma case definitions.
However, although misdiagnosis between the asthma and COPD is common, they
may coexist in what is known as asthma-COPD overlap syndrome (ACOS) [207],
although whether this should be considered a distinct third entity is under active
debate [208–211]. Many other respiratory conditions can mimic asthma. Unless
excluding asthma cases with co-morbidities is required by the study’s scope, it
may introduce risk of diagnostic purity bias [212] which compromises the study’s
external validity.
Ultimately, validity of the EHR-based algorithms should be assessed. Ideally, these
algorithms should be validated in the databases in which they are intended to be
used. However, this was often not the case. Instead, using algorithms with only
reasonable face validity based on clinical guidelines or clinical judgement is a very
common practice in EHR-based studies [213, 214]. These approaches implicitly
assume that clinical codes in the database accurately represent the patient’s ac-
tual health care events [213], which is a questionable assumption. It is worth
noting that the validity of algorithms is not necessarily portable across datasets
or populations [215]. This means that a case-finding algorithm that performs well
in a dataset may be inaccurate if used in another dataset. Populations may diﬀer
in demographics, health parameters, and health care. EHR-derived datasets, even
those with the same type of healthcare data, may diﬀer in their content and quality.
In this review, however, I found that it is common for algorithms of asthma and
its outcomes to be re-used in other populations without re-validation in the target
datasets. I believe this problem is underappreciated and deserves more attention.
Reproducibility and replicability are crucial issues in medical research and re-
quire complete, clear, and transparent reporting of methods. Under-reporting on
the implementation details and the validity of methods compromises transparency
and reproducibility. It has been previously found that in EHR-based studies, full
lists of clinical codes were often not reported [216, 217]. A recent, large-scale
reproducibility exercise identified similar challenges due to suboptimal reporting
of EHR-based studies, particularly sharing code lists and algorithms [218]. Under-
reporting of a study methodology means that the time and resources invested in
conducting that study is wasted [219].
For complex clinical variables such as asthma and its outcomes, the lack of stan-
dardisation of the clinical definitions and the wide variability in the EHR-based
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algorithms undermine the validity and replicability of studies [152]. The signifi-
cant methodological heterogeneity I found in the EHR-based asthma assessment
algorithms reflects, in addition to the content diﬀerences between the databases
used, the lack of consensus on the clinical definitions in the first place despite
continuous standardisation eﬀorts [2, 146, 220, 221]. The focus of this work was
to examine asthma algorithms and their validity specifically in the context of EHR-
derived data, but this highlights the fundamental need to reach consensus on clin-
ical asthma definitions and the appropriate validation of asthma diagnosis. For
example, there is still an active debate on whether lung function is essential to
establish asthma diagnosis [147, 148]. A recent study also found significant vari-
ation in algorithms to assess asthma severity from health insurance data [222].
Unjustified inter-study variation in the operational definitions of the same clinical
concepts creates challenges for comparability [121], meta-analysis and evidence
synthesis. These issues have been raised for asthma [223] and other allergic
conditions such as peanut allergy [224, 225] and anaphylaxis [226], where wide
variations in findings were potentially attributed to inconsistent case definitions.
The findings in this chapter are likely to be applicable to a wide range of chronic
conditions when defined and assessed using EHRs.
2.4.4 Implications for policy, practice and research
This review sheds light on the opportunities oﬀered by the increasingly ubiquitous
EHRs, but also highlights considerable heterogeneity and suboptimal reporting of
EHR-based asthma assessment algorithms and the implications of these practices
on comparability and reproducibility of studies.
Developing reliable algorithms to identify asthma patients and assess asthma out-
comes using EHR data is a non-trivial challenge. Standardising asthma algorithms
used in research, where possible, is a crucial need. However, this may be imprac-
tical since databases usually diﬀer in their content, validity may not hold across
diﬀerent populations [215], and no best practice currently exists [222]. Similar
challenges arise when comparing asthma epidemiology between multiple popula-
tions [227], as the availability and quality of data may diﬀer across those popu-
lations and a single case definition may not work for all of them. These method-
ological issues, in addition to suboptimal reporting, should be considered when
interpreting and synthesising evidence from geographically dispersed studies.
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With the accelerating availability of EHR-derived data and their rapidly growing
use to study asthma, I believe the global asthma research community needs to
pay more attention to the methodological issues related to the use of these data in
asthma research. I believe that consideration needs to be given to convening an
international task force to work on the harmonisation of those algorithms under
uniform and consistent clinical labels, while considering the diﬀerences between
populations and databases. In addition, validation of these algorithms in the re-
spective populations should be given a high priority [215]. Furthermore, to allow
more accurate assessment of asthma from EHR-derived data, eﬀorts are needed to
improve the capture and coding of asthma-related data at the point of care [228]
which requires more eﬃcient EHR systems [203, 204]. In addition, emerging
data sources such as patient-generated data and wearables need to be harnessed
[229]. Finally, to improve the clarity of reporting on EHR-related methodological
aspects, I strongly advocate the adoption of the RECORD Statement as an exten-
sion of the STROBE Statement by authors, journal editors, and peer reviewers
[156, 157]. Optimal reporting should include complete code lists, detailed algo-
rithms and validity assessment. Implications of using EHR-derived data to study
a complex condition such as asthma should be clearly communicated to enable
judgement of internal and external validity.
2.5 Conclusion
This systematic scoping review showed considerable international interest in ex-
ploiting EHR-derived data to study asthma. Asthma diagnosis, exacerbation, sever-
ity and control, have been assessed from diﬀerent types of EHR-derived data using
various approaches. However, there were considerable variations and inconsis-
tency in these approaches. These variations were compounded by sub-optimal
reporting of methods, their validity, and other aspects concerning the use of EHR-
derived data for research. Reusing algorithms of asthma outcomes in new pop-
ulations without re-validation, and relying only on clinical judgement and face
validity were common practices. These issues make it diﬃcult to assess the repro-
ducibility of research and perform evidence synthesis and meta-analyses. Given
the substantial investments taking place in EHRs globally, the number of EHR-
based asthma studies is likely to grow substantially in the coming years. Unless
addressed, these issues will aggravate the reproducibility problem and increase
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the avoidable waste in this important body of research. It is therefore important
that the asthma-interested research community works to place it on a solid foot-
ing in order to ensure the quality and reproducibility of this work. Improving the
reporting of these aspects using standardised guidelines such as the RECORD
Statement would improve the rigour, transparency and reproducibility of asthma
research.
The findings in this chapter will inform the discussion on the challenges of defining
asthma using routine collected EHR data in Chapter 3. In that chapter, I will
explore and demonstrate the usefulness of using data-driven methods, instead of
manually developed algorithms, to identify asthma patients.
Chapter 3
Identifying asthma patients
in Wales
Defining a complex condition using real-world data
In this chapter, I discuss the challenges of developing accurate case definitions for
asthma. I then highlight the common methods used in validating asthma defini-
tions from a variety of data sources. In the absence of a gold standard for asthma
definition, latent class analysis (LCA) can be used to identify hidden clusters in a
population using the observed data. I describe the development of an LCA model
to identify patients with asthma, particularly those with currently treated asthma,
using routinely collected primary care data in the Secure Anonymised Information
Linkage Databank in Wales. Based on this model, I trained a classification algo-
rithm to identify asthma patients that can be used in this Databank and similar
data settings.
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3.1 Introduction
In the light of the literature review findings presented in Chapter 2, I further
discuss the challenges of defining and assessing asthma using routinely collected
data (RCD) considering asthma heterogeneity, data limitations, and the absence of
a gold standard to define asthma. I then justify the use of data-driven approaches
to identify people with ever and current asthma in the Wales Asthma Observatory.
3.1.1 Challenges of developing accurate case definitions
Developing case definitions is an essential step in the development of disease ob-
servatories and registries [137] and is crucial to the interpretation of epidemiolog-
ical estimates and research findings [213]. However, particular challenges exist
when identifying patients with a complex disease such as asthma. In addition,
many disease registries increasingly use electronic health record (EHR)-derived
data, which adds particular challenges related to the limitations of these data [102,
151, 202]. I summarise these challenges below:
3.1.1.1 Asthma is a heterogeneous condition
Asthma is not a single disease entity; there is increasing recognition that the dis-
ease is an umbrella of heterogeneous sub-entities at the molecular, pathological
and clinical levels (i.e. endotypes and phenotypes) [4, 5, 230]. This means that
patients who are diagnosed with ‘asthma’ do not all have the same underlying
disease process. Furthermore, the natural course of asthma exhibits variability
within and between patients, who also diﬀer in their response to treatment. There-
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fore, it is practically diﬃcult to find a single, precise clinical definition of asthma
that everyone agrees upon [2, 144–148].
3.1.1.2 Variations and changes in clinical coding practice
EHR-based case definitions for asthma are often based on recorded events related
to patients’ health, such as diagnosis, physician’s visits, and prescriptions. How-
ever, physicians diﬀer in their diagnostic skills and prescribing behaviour [231]. In
addition, their practices are subject to changes by the continuous evolution of clin-
ical guidelines, which can potentially aﬀect clinical coding practices [109], as well
as by incentives and resources. Variations in clinical practice mean that there is
variation in the recorded data, even for clinically similar asthma patients. Further
variations in the recorded data may result from diﬀerences in the documentation
and coding of clinical data between physicians.
3.1.1.3 Limitations of EHR-derived data
Along the pathway of clinical data, from the point of care to central data reposito-
ries, several factors introduce error, uncertainty, and information loss into these
data [102, 151, 202, 232]. EHRs usually capture both unstructured and structured
data that are collected during clinical encounters. At the data entry stage, how-
ever, incorrect, invalid, or inaccurate data may be recorded due to both human and
computer related factors. Due to design limitations of EHR systems [203, 204], not
all clinical data are recorded and/or coded by physicians [228, 233]. In addition,
clinical coding aims to reduce the detailed data captured during the encounter
into few clinical codes on diagnosis, clinical findings, disease management events,
and prescriptions. However, the commonly used clinical coding systems usually
have limited granularity compared to the captured narrative data. These coding
systems, while facilitating standardised coding [233], fail to codify all the details
that are in the patient record. These non-codified data are important for secondary
uses. Furthermore, in practice, clinical coding is a barrier to data recording [233],
and physicians use only few of the available codes and under-utilise the granular-
ity of coding schemes [228]. Finally, there is an increasing trend to link routinely
collected health data from diﬀerent sources, thereby introducing a further threat
to data quality. Record-linkage can potentially introduce errors and biases to data
analyses [234].
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3.1.2 Validity assessment of asthma case definitions is needed
Due to the aforementioned challenges to define asthma, a single epidemiologi-
cal case definition for asthma using routinely collected EHR data does not exist.
At the same time, these challenges highlight the need to assess the validity of
case definitions and clinical variables measured using these data [213, 235, 236].
Validity assessment has a particular importance in the development of disease
registries and observatories as well as research databases since the validity and
interpretation of epidemiological estimates and research findings depend on ac-
curate patient identification and characterisation [236]. Reporting guidelines pro-
mote complete and transparent reporting on the methods and their validity. The
REporting of studies Conducted using Observational Routinely-collected health
Data (RECORD) Statement [157], which is an extension of the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) Statement [153],
argues that authors of studies conducted using routine data should clarify whether
the variable definitions used in their study have been validated. A comprehensive
check-list of diagnostic values [201] has been proposed to be used in the reporting
of validation studies including cross-tabulation, sensitivity, specificity, accuracy,
positive and negative predictive values (PPV and NPV), likelihood ratios (LRs),
Cohen’s kappa, receiver operating characteristic (ROC) curve including the area
under the curve (AUC), and case prevalence along with 95% confidence intervals
when applicable. Several approaches to validity assessment are discussed in this
section.
3.1.2.1 Approaches for validation of routine data-based case definitions
In epidemiological studies, validity of case definitions can be assessed using a vari-
ety of methods. A recent systematic review identified various methods to validate
asthma diagnosis in EHRs [237]. These included manual review of the narrative
medical records, medication data, and questionnaire data. Since a gold standard
is usually unavailable or inaccessible, acceptable reference standards are used.
A reference standard can be simple or composed of multiple reference measures,
in which case it is called a composite reference standard [238]. When used, a
composite reference standard is thought to have a discriminatory property that is
greater than those of each of its components alone [238].
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When no accepted reference standard can is available, the researcher can per-
form concordance analysis or latent variable modelling. Concordance analysis
evaluates the agreement between a case definition and independent measures,
usually derived from other data sources [217, 236, 238]. In this method, neither
the case definition under assessment, nor the independent measure, are assumed
to represent the ground truth (i.e. the real disease status as confirmed by clinical
diagnosis and/or laboratory tests). Instead, the level of agreement between the
two identification methods can provide insights into the reliability and meaning
of each method. Alternatively, labelled classes in a well-specified latent variable
model can be used to train a case identification algorithm which can be used as
an ‘internal reference’ within a particular dataset [238].
In other approaches, aggregate data are used to compare rates or distributions
of two case definitions [217, 236]. These approaches can be used when the re-
searchers have no access to individual level data necessary to test one of the
compared case definitions, but instead have access to aggregate results.
Practically, the choice of appropriate validation methods therefore depends on the
available data sources, and the availability of a gold or reference standard, as well
as the research questions and design.
Manual review of medical records
While routinely collected EHR data are usually coded, the source medical records,
whether paper-based or computerised, usually contain more detailed data, includ-
ing narrative clinical notes, about patient care. Point-of-care data are a good ref-
erence for validating case definitions because they contain more detailed data
about patient care before being coded. For this purpose, medical records for a
sample of individuals in a specified cohort are reviewed to confirm whether they
had a confirmed asthma diagnosis at a certain point of time. Often, researchers
send questionnaires to physicians [239, 240], nurses [241], or an expert panel to
review patient records [242]. Clinical examination and/or laboratory tests such
as lung function tests on the validation sample could be sometimes repeated to
confirm or rule out the diagnosis. Ideally, the reviewer should be blind to the
clinical codes to avoid confirmation bias [239, 241].
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Analysis of concordance with dispensing data
Individual-level pharmacy dispensing datasets usually contain valuable informa-
tion on asthma treatment. Analysis of concordance can be performed between
case definitions based on dispensing data and other case definitions based on
diﬀerent data sources such as hospitalisation records, questionnaires filled by
general practitioners (GPs), and self-administered questionnaires [237, 240, 243,
244].
A limitation of dispensing data is that they often lack information on diagnosis.
Not all asthma medications are specific to asthma, and therefore it is diﬃcult to
ascertain whether an ‘asthma medication’ was actually prescribed to treat asthma
or another co-morbidity. For example, inhaled corticosteroid (ICS) (in combination
with bronchodilators) can be also prescribed for chronic obstructive pulmonary
disease (COPD), and oral corticosteroids are indicated to a wide range of non-
respiratory conditions. It is therefore diﬃcult to accurately find asthma patients
solely from dispensing data [245, 246].
Self-reported asthma measures
Self-reported data about asthma are commonly used in research. Questions about
having asthma symptoms, severity of asthma symptoms, ’ever asthma’, ‘current
treated asthma’, and/or using specific asthma medications are commonly included
in national health surveys and asthma questionnaires [54, 247, 248]. Self-reported
asthma measures have been used as a reference to assess the validity of asthma
codes in primary care records [249] and in analysis of agreement with billing and
health insurance data [250, 251].
Self-reported data have unique advantages and disadvantages. They represent
patients’ experience and understanding of their own health conditions which are
not always appreciated by physicians [252]. However, some patients do not have
clear understanding of their health status. For example, some asthma patients
may believe they have asthma while in fact they have been diagnosed with COPD
or hay fever. Self-perception of health status can be influenced by variety of other
factors such as educational attainment and employment [253]. Self-reported data
are usually prone to recall bias, i.e. patients with more health problems are often
more likely to report previous exposures or health events. I found that, using
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the Welsh Health Survey (WHS), patient-reported currently treated asthma had
suboptimal concordance with the ‘ever-diagnosed currently treated asthma’ as-
certained from general practice data [254].1 For these reasons, patient-reported
doctor-diagnosed asthma should not be considered as a ‘gold standard’ case defi-
nition for asthma [255].
Where no accepted reference standard exists
The above approaches to obtain reference standards for validation of routine data-
based case definitions can be expensive, time-consuming, and/or labour-intensive.
Where accepted reference standards based on independent data sources are un-
available or unfeasible, other approaches can be followed. For example, case def-
initions can be developed based on medical knowledge, clinical guidelines, and/or
relevant literature, as well as knowledge of data recording and coding practices
(see Section 2.3 for examples from the systemic scoping review in Chapter 2).
These approaches often assume the completeness and accuracy of data recordings
and may rely on heuristic techniques assumed to improve accuracy. For example,
a researcher may decide to exclude from a case definition people in whom the
diagnosis may not be ‘certain’; e.g., those with diﬀerential diagnoses or particular
morbidities (see Chapter 2).
A diﬀerent approach to follow in the absence of accepted reference standards is
to use data-driven methods, such as latent class analysis (LCA). Such methods
use computational techniques to understand the hidden population structure in
relation to specific observed characteristics [256]. In order to ensure meaningful
findings, these methods should be performed in the light of the established knowl-
edge about the disease pathophysiology, clinical course, and epidemiology as well
as about data provenance and quality [142].
3.1.3 Latent class analysis: An overview
In the absence of accepted referenced standards for asthma case definitions, it is
possible to identify asthma patients from RCD by examining the recorded events
related to asthma. Examples of such variables include the following dichotomous
variables:
1I presented this analysis in the British Thoracic SocietyWinterMeeting 2016; the poster is available
in the Appendix B.1.
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• ‘ever diagnosed with asthma’
• ‘had GP attendances related to asthma in the last year’, and
• ‘received inhaled steroids in the last year’.
Each of these events alone may not be sensitive or specific to the ‘true status’
of asthma. However, analysing the patterns of correlation between them these
events can help identify people groups that are likely to have the disease. Using
cross-tabulation, the existing patterns of correlation between these variables can
be identified along with their frequencies; these patterns of correlation represent
diﬀerent patient profiles. By examining these profiles, it is possible to assign, to
patients, meaningful clinical labels that explain their patterns of observed charac-
teristics. For example, if the pattern suggests asthma, it will be assigned the label
‘asthma’, otherwise it will be labelled as ‘none’ or ‘no asthma’. In reality, diﬀerent
profiles may have the same clinical label, possibly each with diﬀerent certainty.
Eventually, these label-sharing patterns are merged together in common groups,
some of which represent patients with the disease.
The aforementioned exercise allows us to understand the population distribution
and facilitate the process of identifying patients based on their observed data pat-
terns. However, with a high number of observed variables and their levels (i.e.
high-dimensional data), this exercise becomes extremely complex and impracti-
cal. This is a typical problem where computational clustering methods, such as
LCA, can be used. LCA can be useful in analysing and understanding complex
patterns in high-dimensional data.
3.1.3.1 Concept and assumptions
LCA is a finite mixture modelling method, i.e. a method that models a mixture
of sub-groups in a population. It aims to cluster a population into sub-groups
related to a set of observed variables [257, 258]. LCA assumes that the patterns
of correlation in these observed variables within the population can be explained
by, in addition to measurement errors, a hidden categorical variable, called a la-
tent variable, which has a pre-defined number of levels (Figure 3.1). The latent
variable partitions the population into sub-groups called latent classes. These
latent classes are qualitatively distinct although they are fuzzy in nature as in-
dividuals have probabilistic memberships in these classes (see Section 3.1.3.4:
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“Membership probabilities” below). In this chapter, the latent variable represents
a patient’s disease state at a given point of time.
V1 V2 V3Observedvariables
Latent
variable
error error error
Figure 3.1: Visual representation of a latent class model. The model assumes that the observed vari-
ables are influenced by the categorical latent variable as well as measurement and random errors.
LCA is a non-parametric model which requires categorical (including dichoto-
mous) or ordinal observed variables. Therefore, by using these types of data,
assumptions about the normality, linearity, or homogeneity of data are avoided.
LCA aims to identify latent classes that explains the whole correlation between
variables at the population level; that is, it assumes that any associations between
the observed variables are assumed to be solely due to the influence of the latent
variable. Therefore, in a perfect latent class model, the observed variables are
independent of each other within each class [257, p. 44]. For example, inside the
latent class of “asthma”, the presence of diagnosis codes does not per se influence
the probability of presence of prescription codes. This assumption is called the
‘local independence’ or ‘conditional independence’ and is important in latent class
modelling, although it may not hold in a large sample.
3.1.3.2 Model specification
The construction of a simple latent class model starts with the hypothesis that
certain structure exists in a population. Then a set of observed variables are cho-
sen, which could be dichotomous or categorical. Ordinal variables can be used
in the modelling but they are treated as categorical. Interval variables need to
be transformed into these types of variables. The observed variables should be
chosen on the basis of having strong relevance to the hypothesised population
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structure. More specifically, they should have high discriminatory power to dis-
tinguish between some of the hypothesised sub-groups in the population.
An empirical study has shown that adding a larger number of highly discriminat-
ing observed variables to the model had beneficial eﬀects on the model estimation
[259]. However, a larger number of observed variables may increase the possibil-
ity of sparseness in their contingency table, especially with a relatively small sam-
ple size. To avoid sparseness, larger sample sizes, when available, are preferred
[259].
3.1.3.3 Parameter estimation
The parameters estimated by LCA include the following:
• Probabilities for any random individual to be in each latent class, i.e. preva-
lences of the latent classes.
• Probabilities of observing each level of each observed variable in each latent
class—also known as item-response probabilities.
The model parameters are estimated using the expectation-maximisation (EM)
algorithm, sometimes along with the Newton-Raphson algorithm [260], both of
which iteratively search for maximum–likelihood parameter values for which the
data are more likely to be observed [261]. The algorithm starts the iterations
with random values for the estimated parameters and estimates the expected cell
counts in the contingency table of the observed variables. Depending on how ex-
pected cell counts fit the observed ones, the model parameters are then improved
in order to maximise the log-likelihood function. In each iteration, if the increase
in the log-likelihood for the current solution is less than a pre-defined value, the
maximum log-likelihood is considered to have been found and the current solu-
tion is chosen as the ‘best solution’ [257, 260]. In ideal conditions, the algorithm
converges to find a best solution among all possible solutions, called the ‘global
maximum solution’. However, sometimes the algorithm converges to a ‘local max-
imum’ solution that is optimal only among neighbouring solutions and not among
all possible solutions. This problem is more likely to happen when the number of
latent classes is too high. To avoid local maxima, it is advised to repeat the estima-
tion algorithm with diﬀerent starting values so that a local maximum model is not
selected by the estimation algorithm as the best solution [260]. Practically, the
number of iterations is usually limited by a maximum limit, e.g. 1000 iterations,
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determined by the researcher. If the expatiation-maximisation algorithm reaches
this limit before convergence, no best solution is selected.
3.1.3.4 Membership probabilities
Based on observed characteristics, individuals are assigned posterior probabilities
of their membership in each of the latent classes [257, p. 67].
Thus, since each individual may belong to more than one latent class, the iden-
tified latent classes have in principle a fuzzy nature rather than being mutually
exclusive. However, usually, each individual is eventually assigned to the latent
class of maximum membership probability [262]. Each of the identified latent
classes may contain more than one patient profile. In other words, individuals in
each latent class may have diﬀerent, but usually similar, observed characteristics.
Item-response probabilities in each latent class represent the averaged observed
characteristics in that class.
3.1.3.5 Model homogeneity and separation
The aim of LCA is to identify ‘distinct’ and ‘homogeneous’ latent groups in the
population. However, since each latent class may include mixed patient profiles,
especially in a model with high complexity, the best solution is that which max-
imises the within-class similarities and the between-classes diﬀerences.
Class homogeneity is the degree of similarity between individuals in a given latent
class. It can be evaluated by examining the item-response probabilities within that
latent class independently of the other latent classes. In that latent class, if most of
the item-response probabilities are high or low (i.e. close to 1 or 0), which means
that either there is a single prevalent patient profile (i.e. with a prevalence close
to 1) or that the patient profiles in that class are highly similar to each other, then
this latent class is said to be highly homogeneous. Otherwise, if most of the item-
response probabilities are marginal (i.e. close to 0.5), which indicates there is no
single prevalent patient profile, then this class is said to have low homogeneity.
Latent class separation is the degree to which the individuals in each latent class
are diﬀerent from the individuals in the other latent classes. Class separation
can be evaluated by comparing the item-response probabilities between the la-
tent classes. In a model with high latent class separation, each latent class has
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item-response probabilities that are clearly distinct from those in the other latent
classes.
A latent class model with a high class separation necessarily implies a high degree
of homogeneity within each latent class. However, a latent class model with a high
degree of homogeneity within latent classes does not necessarily imply a high
degree of separation between latent class.
A useful latent class model will identify highly-diﬀerentiated, well-separated, and
likely more interpretable latent classes. One way to improve homogeneity and
separation is to choose observed variables with high discriminating power, i.e.
thought to be strongly related, both conceptually and quantitatively, to the latent
variable in question. However, a latent class model that has a good fit to the data
may otherwise have poor class separation and thus poor interpretability.
3.1.3.6 Model assessment and selection
In LCA, the number of latent classes is pre-specified by the researchers based
on their hypothesis and assumptions about the population structure. However,
the actual data may fit lower or higher number of classes than assumed by the
researchers. Therefore, they often repeat the modelling with diﬀerent numbers of
classes and compare them in terms of model diagnostics (to assess the absolute
and relative fit of the models) and clinical plausibility.
Absolute model fit
The absolute fit of a latent class model considers its fit to the data regardless
of its competing models. Since a latent class model is based on a contingency
table of its observed variables, the absolute model fit can be assessed using this
contingency table. Therefore, Pearson’s chi-square test can be performed to test
the null hypothesis that the observed counts of patient profiles in the contingency
table can be produced by the estimated latent class model [257]. The likelihood
ratio chi-squared statistic, G2, is a variant of Pearson’s chi-square test. In both
tests, the expected counts of patient profiles, as estimated based on the model
parameters, are compared to the observed counts of patient profile. The degree
of freedom is the total number of observed patterns minus the number of esti-
mated parameters minus 1. The test statistic is then compared to the reference
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chi-square distribution to obtain a p-value representing the probability that the
observed data can be produced by the estimated latent class model under the null
hypothesis.
However, both Pearson’s chi-square and the likelihood ratio chi-squared tests are
not appropriate when sparseness exists in the contingency table of the observed
variables, i.e. when the contingency table contains too many cells with small or
zero counts. This happens in latent class models with small sample sizes and/or
large number of variables. In addition, in modelling using larger samples, both
tests are likely to produce smaller p-values, i.e. indicating weaker evidence of
absolute model fit.
Relative model fit
The Akaike information criterion (AIC) [263] and the Schwarz’s Information Cri-
terion (often called the Bayesian information criterion, BIC) [264, 265] are two
information criteria each of which provide an estimate of the information lost when
a given statistical model is fitted to given data. They seek a balance between the
model’s goodness of fit and its parsimony. A model’s parsimony is the opposite of
complexity, and is represented by the number of estimated parameters, or simply
by the number of latent classes. Thus, AIC and BIC are also called ‘parsimony
indices’, as they prefer models with fewer number of estimated latent classes. To
obtain the desired balance, AIC imposes a penalty on G2 based on the number
of parameters, while BIC imposes a larger penalty based on both the number of
estimated parameters and the sample size.
AIC and BIC can be used to measure which one of the competing latent class mod-
els, diﬀering by number and characteristics of classes, best fits a given dataset.
The model with the lowest value represents a more optimal balance between
model fit and parsimony and is preferred over its competitors. Due to the dif-
ference in imposed penalty, AIC and BIC may not agree on the ‘optimal model’
they suggest.
However, they do not provide a meaningful absolute measure of quality for a la-
tent class model independently of the other competing models. This means that a
competing model with the best AIC and/or BIC may still have poor absolute fit to
the data.
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Model interpretability
Although the best-fit model based on the above model selection methods is often
chosen by researchers, it does not always contain a clinically meaningful struc-
ture. For example, variables with lower clinical relevance to the clustering exer-
cise (e.g., have clinically lower discriminatory power) may be used by the best-fit
model in the generation of latent classes more than other more clinically relevant
variables. In such cases, researchers use domain knowledge to decide whether
the best-fit model is clinically and/or biologically plausible. Otherwise, the re-
searchers may need to re-specify the model, i.e. revise the choice of observed
variables and their levels.
3.1.3.7 Model interpretation
The interpretation of an LCA model is based mainly on its estimated parameters.
The item-response probabilities can be used to describe the latent classes and
assign meaningful labels to them [257, p. 29]. For example, a class in which
individuals have high probabilities (e.g., 0.8 or more) of both of ‘having asthma
diagnosis’ and ‘receiving asthma prescriptions in the last year’ can be assigned
the label of ‘doctor diagnosed currently treated asthma’.
If the number of classes in the best fit-model is higher than that expected by the
researcher, i.e. the clustering is deeper than desired, then the researcher may
choose to keep this model but manually combine similar classes to form fewer but
larger ‘super classes’ representing the desired clinical clustering.
If the model is not clinically interpretable, then the researcher may need to choose
a diﬀerent competing model, or even decide to re-specify the model by modifying
the observed variables.
Model interpretation particularly depends on the relevance of input variables and
the quality of data. The careful choice of both input variables and number of
classes (the latter is partly determined by the expected clusters as based on the
predictor variables) are critical for clinically meaningful clustering. Even though,
meaningful interpretation of the resultant classes could be diﬃcult; e.g., classes
may not correspond with the commonly recognised clinical definitions of the dis-
ease sub-groups.
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A latent class may contain individuals who do not match the clinical description
assigned to the latent class as a whole. For example, the ‘no-asthma’ class, based
on the model design (i.e. choice of predictor variables) may include people who
can be classified by experts as people with asthma. Similarly, the ‘asthma’ class
may include people who have conditions other than asthma, e.g., COPD, but share
some of the common characteristics of asthma patients (receipt of bronchodila-
tors). Therefore, LCA is usually considered exploratory rather than confirmatory.
3.1.4 Using latent class analysis to identify asthma patients
in the Wales Asthma Observatory
The development of the Wales Asthma Observatory requires reliable case defini-
tions for asthma. The Observatory is based on data in the Secure Anonymised
Information Linkage (SAIL) Databank. Case identification algorithms for ‘ever
asthma’ and ‘currently treated asthma’ based on diagnosis and prescription events
have been validated in other datasets [102]. However, they may not necessarily
retain their validity in the SAIL Databank. Assessing their validity against com-
plete patient records is time-consuming, labour-intensive and expensive, render-
ing it unfeasible in this doctoral project. Data on self-reported ‘currently treated
asthma’ were available in the results of the WHSs for the years 2013 and 2014
which were record-linked to the SAIL Databank. However, these data only con-
tained responses to a simple question for ‘currently treated asthma’, without spec-
ifying a time-frame for such status. Therefore, this self-reported variable cannot
be considered an accepted reference for ‘currently treated asthma’.
In the absence of a feasible, accepted reference standard for asthma, LCA is an
appropriatemethod to identify asthma patients in the SAIL Databank. This method
fits the nature of both asthma and routine data held in the SAIL Databank.
Clinically, the presence of asthma is not a binary status, and the certainty of physi-
cian’s diagnosis is not always perfect. In practice, asthma diagnosis could be
classified into ‘absent’, ‘possible’, ‘likely’, or ‘confirmed asthma’. Therefore, the
uncertainty of asthma diagnosis can be represented probabilistically, which cor-
responds to the fuzzy approach followed by LCA to assign class memberships for
individuals in a population.
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Asthma-related observed characteristics that can be derived from the SAIL Data-
bank can be dichotomous (e.g., ‘ever asthma diagnosis’), polytomous (e.g., ’age
group at asthma diagnosis’), and continuous data (e.g., ’number of ICS prescrip-
tions in the last year’). However, for the purpose of detecting asthma patients
from such data, continuous data can be transformed into categorical (dichoto-
mous and/or polytomous) data using appropriate cut-oﬀs, e.g., ‘no prescriptions’
vs. ‘one or more prescriptions’. This fits well with the types of observed variables
required in LCA, namely, categorical (or ordinal) variables.
Despite guidelines on diagnosis, asthma could be clinically confused with a variety
of conditions, especially COPD. Distinguishing asthma fromCOPD can be challeng-
ing [266, 267]. Some patients exhibit features of both conditions in what has been
recognised as the asthma-COPD overlap syndrome (ACOS) [207]. Therefore, it is
worthwhile to consider the misdiagnosis and overlap between asthma and COPD
in latent class models that attempt to identify asthma patients.
The output of LCA in this chapter will include individuals’ class membership prob-
abilities and their assigned classes. While such results are useful to create a
reference identification for asthma in the SAIL Databank, it cannot be used for
this purpose elsewhere. In order to facilitate the re-use of the resulting reference
identification in data sources that are similar to the SAIL Databank, a classification
algorithm in the form of a decision tree can be trained from a dataset labelled by
the developed latent class model.
3.2 Objectives
In this chapter, I developed an identification model for asthma in the SAIL Data-
bank, and evaluated it against other widely used physician-reported and self-
reported case definitions. Specifically, the objectives were to:
• Develop a data-driven reference identification of asthma, particularly those
with currently treated asthma, using LCA of RCD in the SAIL Databank.
• Derive a classification algorithm for asthma that can be used in the SAIL
Databank and similar databases.
• Assess the agreement between the classification algorithm and the following
commonly used case definitions:
– GP-reported ever-diagnosed asthma
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– GP-reported currently treated asthma
– GP-reported ever-diagnosed, currently treated asthma
– Self-reported currently treated asthma.
– Self-reported currently treated COPD.
These case definitions are explained below in Section 3.3.5.1. This assess-
ment included analysis of concordance and calculating estimates of diagnos-
tic accuracy for those case definitions using the predictions by classification
algorithm as references and vice versa.
3.3 Methods
In a cross-sectional design, I used primary care data on asthma and COPD recorded
in or before 2014 for a sample of the Welsh population to find, using LCA, clinically
meaningful classes (i.e. clusters) related to the two conditions in that year. Based
on the chosen latent class model, I then derived a classification algorithm to iden-
tify patients with asthma, including those with currently treated asthma, as well
as those with COPD and ACOS in the primary care population. I compared that
classification algorithm with other case definitions for asthma and COPD based on
doctor-reported and patient-reported data.
Figure 3.2 illustrates the methodology followed in this chapter.
3.3.1 Data sources
I used individual-level demographic and primary care data from the SAIL Data-
bank. The SAIL Databank contains anonymised linked data datasets derived from
EHRs and several non-health datasets in Wales [140, 141]. I used the following
two datasets:
• The Welsh Demographic Service (WDS): The WDS contains de-identified de-
mographic and administrative information for National Health Services (NHS)
patients in Wales. I used this dataset to identify NHS patients who satisfied
the follow-up criteria described below.
• The GP dataset: The GP dataset contains de-identified health care events,
such as recorded diagnoses, clinical findings, prescriptions and monitoring
as well as other events codified in Read codes by GPs. I used the GP dataset as
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Figure 3.2: The methodology followed in Chapter 3. ACOS: asthma-COPD overlap syndrome; COPD:
chronic obstructive pulmonary disease; GP: General Practice; LCA: latent class analysis; WHS: Welsh
Health Survey.
.
a main data source in my analysis since in the United Kingdom (UK) asthma
is mainly treated in primary care [32]. At the time of data extraction and
analysis, themost recent extract of the GP dataset was in April 2016, covering
about 80% of GP surgeries in Wales, which voluntarily sent their data to the
SAIL Databank. I used the GP dataset to measure the observed variables
described below.
Since I only accessed anonymised health data within the SAIL Databank and did
not work with humans, no ethical approval was required. This doctoral project
was covered by approval of the SAIL Information Governance Review Panel (see
Appendix C.2).
3.3.2 Patient population
I defined the source population of the study as every individual who satisfied the
following criteria:
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• Registered in at least one GP practice that contributed its data to the SAIL
Databank at the time of the analysis.
• Had continuous GP registration during the analysis year, i.e. between 1-1-
2014 and 31-12-2014. To calculate GP registration periods for individuals,
I used an unpublished commonly used algorithm developed in-house by the
analyst team of the SAIL Databank. This algorithm takes into account periods
of registration with SAIL and non-SAIL participating practices as well as the
volumes of data contributed by each practice over time. The algorithm uses
that information to determine periods of continuous follow-up of patients in
the primary care dataset in the SAIL Databank.
• Did not die on or before 31-12-2014.
I did not apply age restrictions to the source population. The study sample was
randomly selected from the source population. The sampling was stratified by
general practices to improve their representativeness. I determined the sample
size for latent class modelling based on the available computational capacity in
the SAIL Gateway.
3.3.3 Latent class modelling
3.3.3.1 Observed variables
In this modelling, the observed variables were based on GP-recorded primary care
events related to asthma and COPD. The choice of these events and the dimensions
of the observed variables was determined based on their usefulness, from a clin-
ical perspective, for identifying and distinguishing between patients with asthma
and/or COPD. Including observed variables of both asthma and COPD in the same
latent class model allowed identification of patients with either or both conditions
(i.e. ACOS). These variables included events on disease-related diagnosis, GP vis-
its, prescriptions, and smoking. Events of GP visits and prescriptions were queried
over the analysis year, while the other events were queried over any time up to
the end of the analysis year. Most of the observed variables were transformed into
binary variables: ‘0’ for ‘no events found’ and ‘1’ for ’one or more events found’.
The ‘age at asthma diagnosis’ variable had three categories: ‘< 40 years’ and ‘40
or more’ as well as ’no diagnosis’. A full list of variables is shown in Table 3.1. The
lists of Read codes used in the variable definitions are available in Table B.2.1.
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Table 3.1: Observed variables used in the latent class model. Clinical codes are listed in Table B.2.1.
Variable Time interval for calculation Categories
Asthma related
Asthma diagnosis codes ever ever 0, 1+
Age at asthma first diagnosis codes, if any - < 40,≥ 40, no diagnosis
Asthma GP visits codes in the last 12 months last two years 0, 1+
COPD related
COPD diagnosis codes ever
ever 0, 1+
COPD GP visits codes in the last 12 months last two years 0, 1+
COPD-specific prescriptions codes** last two years 0, 1+
Prescriptions
ICS codes last two years 0, 1+
SABA codes last two years 0, 1+
LABA codes last two years 0, 1+
ICS+LABA codes last two years 0, 1+
OCS codes last two years 0, 1+
LTRA codes last two years 0, 1+
Others
Smoking history ever no, yes
Abbreviations: COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; GP = general practitioner; LTRA =
leukotriene receptor antagonists; LABA = long-acting β2 agonists; OCS = oral corticosteroids; SABA = short-acting β2 agonists.
** COPD-specific prescriptions include: glycopyrroniumbromide, indacaterol, olodaterol, anticholinergic bronchodilators (ipratropium
bromide, oxitropium bromide, tiotropium, aclidinium, umeclidinium), roflumilast, oxygen cylinders, and COPD rescue packs.
3.3.3.2 Number of classes and model selection
Theoretically, the expected number of latent classes is based on the observed vari-
ables used in the modelling. Since I included variables for both asthma and COPD,
the minimum number of latent classes that I expected was four classes consistent
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with the following labels: ‘asthma’, ‘COPD’, ’both’, and ‘none’. However, the in-
clusion of asthma-related current GP visits and prescriptions (i.e. in the last 12
months) in themodel was aimed at distinguishing groups of patients with currently
treated asthma from those with ever diagnosed asthma without current treatment.
Therefore, the number of expected classes could be increased to represent those
diﬀerent groups and possibly to also diﬀerentiate between patients with less and
more severe diseases.
I started the modelling for two latent classes and then iteratively increased the
numbers of latent classes. I aimed to select a model that satisfied both the follow-
ing criteria:
• The BIC was minimum (compared to the competing models) or became ‘sta-
bilised’ (e.g., using the elbow method, in which the researcher looks for an
“elbow” in the plot of the model’s BIC against the number of classes).
• The latent classes were clinically relevant.
In the selected model, I assigned to the identified classes clinical labels consistent
with ‘asthma’ (including currently treated asthma), ‘COPD’, ‘both’, and ‘none’
based on the estimated item-response probabilities in each latent class. I used
the class proportions as prevalence estimates of their corresponding labels in the
study population in 2014.
To simplify the model, I aimed to merge similar classes (e.g., classes of currently
treated asthma diﬀering in the probability of prescriptions) into super classes
(e.g., currently treated asthma).
3.3.3.3 Statistical tool
I performed the latent class modelling using the R package poLCA (version 1.4.1,
2014) [260].
3.3.4 Derivation of a classification algorithm
Based on the latent class model, which was developed for the year 2014, I de-
rived a classification algorithm which can be used to identify patients with asthma
(including currently treated asthma), COPD and ACOS as well as in similar pri-
mary care datasets. To do so, I performed recursive partitioning [268] using the
R package rpart (version 4.1-11, 2017) [269]. In this method, a decision tree is
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constructed using supervised learning from a labelled dataset, called the training
dataset. A decision tree is composed of nodes and branches. The nodes include
interior nodes, each of which splits the corresponding partition of the sample into
two parts based on a true/false question about one of the features, and final nodes
(i.e. leaves) representing the labels assigned to the corresponding branches.
The construction of a decision tree is stepwise. At each step, including that of
the root node (i.e. which corresponds to the whole training dataset), the dataset
is split into two subsets based on a true/false question about one of the features
(i.e. a predictor variable). Each split is intended to reduce the misclassification
in the resulting two children nodes compared to that in their parent node. Since
more than one feature can provide a reduction in misclassification, the feature
that maximises such reduction is chosen for the given split. Theoretically, while
the model fit may improve with further binary splits, a split may provide only small
improvement in the misclassification. Allowing such a split leads to overfitting
where the accuracy of the tree is high or perfect in the training dataset but low in
the validation dataset. To prevent overfitting, smaller improvements in the model
fit are panellised with higher costs. In addition, any split with improvement in the
model fit that is smaller than a control measure, called the complexity parameter,
is considered not worth pursuing. To determine the complexity parameter, rpart
fits a full tree from which it extracts all the possible sub-trees and performs on
each of which 10-fold cross-validation. It then shows the sub-trees for which the
complexity parameters are greater than a set threshold, usually 0.01 or as desired
by the researcher. It then determines the complexity parameter from the sub-tree
that has the lowest cross-validation error. The determined complexity parameter
can be then used to prune the full tree, giving a trimmed tree as a best solution,
representing the best possible balance between model complexity and cost.
I used the sample previously used for LCA to perform recursive partitioning. I
used the latent classes (after being merged into super classes as appropriate) as
labels and the observed variables, used in the LCA model, as features. I randomly
partitioned the sample into two subsets: a training subset (approximately 70%)
for the decision tree development, and a validation subset (approximately 30%)
to validate the developed decision tree. The two subsets were balanced in terms
of the proportions of labels. To validate the developed decision tree, I used it to
predict the labels in the validation dataset. Then, I calculated various diagnostic
measures for the model using the confusionMatrix function of the caret package
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(version 6.0.77, 2017) in R. These statistics included: classification accuracy (Acc,
the proportion of correct predictions in the validation dataset along with its 95%
confidence interval); the no information rate (NIR, also known as the no informa-
tion error rate; the proportion of the largest class, which gives an idea of how
useful the predictors were in predicting the classes compared with just predicting
them using class proportions); the p-value of Acc > NIR (a one-sided test to see
if the model accuracy is better than just predicting the most prevalent class); Co-
hen’s Kappa (for the agreement between the known labels and predictions); and
statistics by class including sensitivity, specificity, positive and negative predictive
values of class-specific prediction, class prevalence, detection rate (proportion of
detected class members relative to the whole sample), detection prevalence (the
prevalence of truly and falsely detected cases), and balanced accuracy ((sensitivity
+ specificity)/2).
3.3.5 Comparison of the classification algorithm with other
case definitions
I compared the classification algorithm described above with other case defini-
tions based on objective and self-reported data.
3.3.5.1 Case definition used for comparison
GP-reported ever-diagnosed asthma
The case definition ‘GP-reported ever-diagnosed asthma’ refers to patients who
had, on a given date, asthma diagnosed by GPs and recorded using one of a set of
Read codes indicating asthma diagnosis. To identify such patients in the SAIL’s
GP Dataset, I used the asthma diagnosis Read code set shown in Table B.2.1,
which were based on the Quality of Outcomes Framework (QOF)’s AST001 in-
dicator [270].
GP-reported currently treated asthma
The case definition ‘GP-reported currently treated asthma’ refers to patients who
were receiving asthma prescriptions on a given date. For the purpose of this the-
sis, this case definition was operationalised by identifying patients who had at
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least one asthma prescription during the last 12 months before the end of the
analysis year (i.e. between 1 January 2014, and 31 December 2014). The pre-
scription codes are shown in Table B.2.1 and were based on those used in the
AST001 indicator of the QOF [270].
GP-reported ever-diagnosed, currently treated asthma
The ‘GP-reported ever-diagnosed, currently treated asthma’ case definition re-
quires the patients to satisfy both the aforementioned case definitions. Thus, this
case definition is almost identical to the AST001 indicator (but without excluding
patients with ‘exception codes’).
Self-reported currently treated asthma
The ‘self-reported currently treated asthma’ case definition was based on theWHS
of 2014 [54]. The WHS 2014 collected self-reported information on a range of
health and health-related lifestyles from samples of the population of Wales. The
WHS 2014 results dataset was already linked to the SAIL Databank [271]. How-
ever, from that dataset, I only had access to the responses of participants who
were 16-year-old and above in 2014. Those participants consented to link their
responses to their medical records [272]. From this dataset, the only question
related to asthma, other than asthma symptoms, asked the participant whether
he or she was currently treated for a number of diseases including asthma. I used
responses to this question as a case definition for ‘self-reported currently treated
asthma’. I considered invalid responses as negative responses.
Self-reported currently treated COPD
In the WHS 2014, participants were asked whether they were currently treated
for chronic bronchitis and/or emphysema. I considered positive responses for any
of these two conditions as a case definition for ‘self-reported currently treated
COPD’. I treated invalid responses as negative responses.
3.3.5.2 Statistical analysis
I performed the comparisons between the classification algorithm and each of the
above-mentioned case definitions in the group of WHS 2014 participants whose
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responses where successfully linked to SAIL. I calculated sensitivity, specificity,
PPV, NPV, and Cohen’s kappa coeﬃcient for concordance of each of the above
case definitions against the classification algorithm labels as references and vice
versa.
3.4 Results
3.4.1 Sampling and sample characteristics
The size of source population was 2,303,819 which equated to approximately
74.5% of the mid-year estimate of 3,092,000 for the population of Wales in mid-
2014.2 The study sample included 50,000 individuals, 50.3% of whom were fe-
males. Figure 3.3 shows a histogram for the sample age at the beginning of the
year 2014.
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Figure 3.3: A histogram for the sample age at the beginning of year 2014.
2Based on: Time series: Wales population mid-year estimate. Oﬃce for National Statis-
tics. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationesti-
mates/timeseries/wapop/pop
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3.4.2 Summary of the competing latent class models
I started the latent class modelling for a one-class model and was able to increase
the number of classes up to 12. The item-response probabilities within the classes
of each of the 12 competing models are shown in diagrams in Appendix B.3.
According to the item-response probabilities, in the two-class model, people with
events related to asthma and/or COPD were aggregated in one class with a share
of 16.2%. In the three-class model, this class was split into two classes. One of
these classes had a share of 14.1% and seemed to include mostly asthma patients,
although it appeared highly heterogeneous, as indicated by the marginal proba-
bilities for the asthma GP visits and short acting beta agonist (SABA) vari-
ables. A very small proportion of people in this class showed characteristics sug-
gesting COPD. Another class in the two-class model, with a share of 2.4% appeared
to have significant marginal probabilities (i.e., close to 0.5) for events related to
COPD and prescriptions, suggesting high heterogeneity. A very small proportion
of people in this class had characteristics related to asthma.
With higher number of classes, themodels continued to reclassify people intomore
refined classes with higher homogeneity. In the four-class model, the asthma-
dominated class in the three-class model was further split into two classes both of
which had ‘asthma diagnosis ever’; one class with a share of 7% had also high prob-
abilities for asthma-related current GP visits and prescriptions, while the other
class had zero to very low probabilities of these events.
In the five-classmodel, there were one class (6.6%) for ever diagnosed asthmawith
no current treatment, another class (2.4%) appeared to be dominated by COPD
characteristics with some probability for asthma-related events, and one class
(84%) with no asthma or COPD characteristics. However, there were two almost-
similar classes (3.7% and 3.4%) for ever-diagnosed currently treated asthma; the
main diﬀerences between these two classes were that one had a very high prob-
ability for ICS and a very low probability for ICS-long-acting beta adrenoceptor
agonist (LABA), while the other class had the opposite situation: a very low prob-
ability for ICS and a very high probability for ICS-LABA.
In the six-class models, those two ‘ever-diagnosed currently treated asthma’ were
almost reunited into one class (6.9%). There was one highly homogeneous class
(1.4%) suggesting currently treated COPD, one class (6.2%) for ever diagnosed
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not currently treated asthma, and one class (1.0%) that showed high probabil-
ities for both current asthma and COPD events. However, there was one class
(2.2%) showing only variable probabilities for asthma prescription, with almost
no recorded diagnosis of asthma or COPD.
In the seven-class model, the only significant refinement on the previous model
was that a previously one large class with asthma or COPD characteristics become
split into two classes (51.4% and 30.9%) with low and high probabilities of smoking
history, respectively.
In the eight-class model, these two none-asthma none-COPD classes joined again.
The two treated asthma classes, previously observed in the five-classmodel, emerged
again, however, with diﬀerent prevalences; the class with ICS events and no ICS-LABA
combinations had a prevalence of 3.9%, while the class with ICS-LABA combina-
tions but with no sole ICS prescriptions had a prevalence of 2.7%. There was an
‘asthma and COPD’ class (0.9%) with high homogeneity; it showed high proba-
bilities for both asthma and COPD diagnosis, GP visits, and prescription events.
In this class, the probability of ‘smoking ever’ was very high (90.9%). However,
the probability of having recent asthma-related GP-recorded events visits in the
last 12 months was marginal (43.0%). These item-response probabilities indicated
patients in this class potentially had ACOS. Other classes included one class (6.6%)
for ‘ever diagnosed asthma without current treatment’, one class (1.3%) for ‘ever
diagnosed currently treated’ COPD, one class (1.4%) with high probabilities for
each of SABA and ICS events and low probability for ‘ever smoking’, and one
class (1.0%) with low to marginal probabilities for asthma prescriptions but very
high probability for ‘ever smoking’.
Compared to the eight-class model, the significant refinements in the nine-class
model were a split of one of the ‘ever-diagnosed currently treated asthma’ classes
into two (2.5% and 1.3%) which, however, were reunited in the 10-class model.
The assignment of the sample individuals into the classes across the competing
models is shown in Figure 3.4, while model diagnostics for each of the competing
models are shown in Figure 3.5.
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Competing models
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Figure 3.4: An alluvial diagram showing assignment of the sample individuals across the produced com-
peting latent models. Each band represents a group of individuals sharing the same class in the last
competing model (the 12-class model), and demonstrates how they were assigned to classes across
the other competing models.
3.4.3 Model selection
Based on the model diagnostics diagram (Figure 3.5), the AIC, BIC, and G2 diag-
nostics for the models with one to 12 classes declined significantly between the
one-class model and the four-class model. Then, these three diagnostics continued
to decline slightly until they stabilised at the eight-class and nine-class models.
The Chi-square static declined abruptly between the one-class and the two-class
models before it appeared to visually stabilise across the competing models. The
nine-class model had the lowest BIC value, while the other diagnostics, AIC, Chi-
square, and G2, had their lowest values at the 12-class model. However, the de-
cline in the BIC value between the eight-class model and the nine-class model
was very small and negligible, indicating very little improvement in the informa-
tion gain. In addition, as described in Section 3.4.2, the structures of these two
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Figure 3.5: Diagnostics for the competing latent class models. For each diagnostic, the class with the
minimum value was marked with a large dot. AIC = Akaike information criterion; BIC = Bayesian infor-
mation criterion; Chisq = Pearson Chi-square goodness of fit statistic; Gsq = G-squared.
classes were very similar, with the eight-class model showing clinically meaningful
classes. Therefore, the eight-class model appeared to be a good solution, among
the other competing models, that reasonably fit with the purpose of this latent
class modelling of identifying patients with asthma, including those with currently
treated asthma.
3.4.4 Model interpretation: Characterising and labelling the
identified classes of the best-fit model
Figure 3.6 shows the classes of the eight-class model along with their prevalences,
item-response probabilities, and assigned labels.
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Figure 3.6: Class prevalences and item-response probabilities of the eight-class model. The left-most
column shows the names and levels of the observed variables. The small bar-plot above each latent
class demonstrates class separation: it shows the average probabilities, within each class, of member-
ship in all the latent classes.
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The eight-class latent class model which I chose as a solution consisted of the
following classes:3
1. ‘Ever diagnosed asthma without current treatment’: This class has a
prevalence of 6.6%. All the individuals in this class had asthma diagnosis
events, recorded in 88% of the class members before the age of the 40. Only
5.0% and 6.9% of the class members had asthma-related events and SABA
prescriptions in 2014. 41.0% of the class members ever smoked on or before
2014.
2. ‘No asthma or COPD diagnosis, modestly currently treated, with ever
smoking’: The prevalence of this class was 1.0%. Its individuals had no
asthma diagnosis events recorded by the end of 2014, although 2.4% of them
had non-diagnosis asthma-related GP events (excluding prescriptions) recorded
in 2014. However, 50.0% of people in this class had at least one SABA pre-
scription, and 19.5% had ICS-LABA combination prescriptions, and 30.6%
had prescriptions for oral steroids in 2014. In addition, 11% of the class mem-
bers had recorded COPD diagnosis, although only 1.8% had COPD-related
GP visits in 2014, and 11.8% had prescriptions usually prescribed for COPD.
Smoking related events were found for 78.9% of the class members. The
average age of the class members in 2014 was 61.7 years with a standard
deviation of 18.6 years. The marginal item-response probabilities in this class
suggests it includes heterogeneous sub-groups of individuals some of which
might be COPD patients, while others were smokers without symptoms of
COPD. For this class, I suggested the label ‘possible/at risk of COPD’.
3. ‘Neither asthma/COPD’ (or ‘none’): This class, having a prevalence of
82.2%, had almost zero item-response probabilities for all the observed vari-
ables except for ‘smoking ever’ which had 37.8% probability.
4. ‘Ever-diagnosed currently treated asthma; ICS without LABA’: This
class had a prevalence of 3.9% and showed 100% probability for asthma di-
agnosis events recorded before the age of 40 for 73.2% of the class members.
74.6% of the class members had recorded asthma-related GP events in 2014
and had high probabilities for ICS (75.8%) and SABA (93.9%) prescriptions
and 15.6% probability for oral corticosteroids (OCS) prescriptions. 43.3%
3The numbers associated with the classes were merely numerical labels as appeared in the output
of the latent class modelling, and did not imply any order.
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of individuals in this class had recorded smoking-related events. This class
included people from all age groups (mean = 39.5; standard deviation (SD)
= 22.2).
5. ‘Currently treated; no recorded asthma or COPD diagnosis; with mod-
est smoking ever’: This class with 1.4% prevalence was similar to the class
#2 described above, as it had no recorded asthma diagnosis. However, it had
zero-probability for COPD diagnosis events, very high probability (89.9%) for
SABA prescriptions in 2014, and 41.8% for ICS prescriptions in that year.
The class members had 24.5% probability for OCS prescriptions, and 29.8%
probability of ‘smoking ever’. Based on these characteristics, I assumed this
class included asthma patients with no recorded diagnosis.
6. ‘ACOS’: This class with 0.9% prevalence showed almost total probabilities
for asthma and COPD diagnosis events. For 75.3% of the class members,
the earliest recorded diagnosis of asthma was before the age of 40. While
43.5% of the class members had asthma related events in 2014, 74.3% had
COPD-related events in that year, and 70.2% had prescriptions specific to
COPD in the same year. The class members had a very low probability for
ICS prescriptions (11.0%), but very high probabilities for SABA (91.4%) and
ICS-LABA combination prescriptions (81.7%) in 2014. Almost half of the class
members (49.7%) had oral steroids in 2014 indicating severe and/or uncon-
trolled symptoms.
7. ‘Ever-diagnosed currently-treated COPD’: This class had a prevalence of
1.3% and showed 100% probability for COPD diagnosis events, high proba-
bilities for COPD-related GP events (74.3%) and COPD-specific prescriptions
(70.2%). The vast majority of people in this class (96.5%) had recorded smok-
ing history. There was also a high probability for SABA prescriptions (81.2%),
but a marginal probability for ICS-LABA combination prescriptions (54.4%),
and a 31.7% probability for oral steroids in 2014. The class showed very low
probabilities for ICS-alone (9.0%) and LABA-alone (8.8%) prescriptions.
8. ‘Ever-diagnosed currently treated asthma; ICS with LABA’: This class
had a prevalence of 2.7%. It was closely related to the class #4 described
above. All its members had asthma diagnosis events, recorded under the age
of 40 for 60.2% of patients. 74.0% of the class members had asthma-related
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Figure 3.7: Visualisation of the eight-class latent class model using principal component analysis.
ACOS: asthma-COPD overlap syndrome; COPD: chronic obstructive pulmonary disease; GP: general
practitioner; ICS: inhaled corticosteroid; LABA: long-acting beta adrenoceptor agonist; SABA: short act-
ing beta agonist.
GP events in 2014. Almost half of people in this class (53.2%) had recorded
smoking events.
Figure 3.7 visualises the classes in the eight-class model using principal compo-
nent analysis (PCA). The distances and overlaps between the latent classes were
consistent with their clinical interpretation overall.
3.4.5 Class merging
Since I was interested in identifying patients with active asthma, I merged the
classes 4, 5, and 8 into a single super class labelled “currently treated asthma”.
Most patients (82.5%) in that super class had recorded asthma diagnosis (Class
4 and 8); the remaining patients (Class 5, 17.5%) had no recorded diagnosis of
asthma or COPD but had a very high probability of using SABA inhalers, a marginal
probability (≈42%) of using ICS inhalers, and a low probability (≈30%) of smok-
ing history. Although some of those patients might have received those inhalers
without actually having asthma, I kept them in the super class of ‘currently treated
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Table 3.2: The latent classes and their prevalences before and after merging.
Before merging After merging
1. Ever diagnosed asthma without current treatment
(6.6%)
No change
2. possible COPD (1.0%): No asthma or COPD
diagnosis, modestly currently treated, with ever
smoking
No change
3. ‘None’ (82.2%): None-asthma none-COPD’ No change
4. Ever-diagnosed currently treated asthma; ICS without
LABA (3.9%)
Currently treated asthma (8.0%)5. No asthma or COPD diagnosis; currently treated, with
modest smoking ever (1.4%)
8. Ever-diagnosed currently treated asthma; ICS with
LABA (2.7%)
6. Asthma-COPD overlap syndrome (0.9%) No change
7. Ever-diagnosed currently-treated COPD (1.3%) No change
ICS: inhaled corticosteroid; LABA: long-acting beta adrenoceptor agonist; COPD: chronic obstructive pulmonary disease.
asthma’. Table 3.2 shows the classes and their prevalences before and after merg-
ing. I later used the labels of the resulting simpler six-class structure in the train-
ing of a classification algorithm (see Section 3.4.6 below).
3.4.6 Derivation of classification algorithm
A decision tree with 11 splits (and 12 leaves) was trained using recursive partition-
ing. The R package rpart performed 10-fold cross-validation to select the optimal
size of the decision tree. The results of this cross-validation are shown in Table 3.3
and Figure 3.8.
Table 3.3: Results of 10-fold cross-validation for the recursive partitioning model, showing the cross-
validation error for each sub-tree.
Complexity
parameter Number of splits Relative error
Cross-validation
error rate
Cross-validation
standard
deviation
1 0.39935 0 1.00000 1.00000 0.01193
2 0.31750 1 0.60065 0.60065 0.00961
3 0.07331 2 0.28315 0.28315 0.00679
4 0.04409 3 0.20984 0.20984 0.00588
5 0.03589 4 0.16576 0.16576 0.00525
6 0.02324 5 0.12987 0.12987 0.00466
7 0.01162 6 0.10663 0.10663 0.00423
8 0.01025 7 0.09501 0.09501 0.00400
9 0.01003 8 0.08476 0.08630 0.00381
10 0.01000 11 0.05468 0.07536 0.00357
Root node error: 5,852/35,004 = 0.16718
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Figure 3.8: Visualisation of the 10-fold cross-validation results of the recursive partitioning. The hori-
zontal dotted line was drawn at 1 standard deviation above the minimal cross-validation error. The tree
with 12 leaves (11 splits) had the lowest cross-validation error and was therefore the desired tree. cp:
complexity parameter.
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In these results, the tree with 11 splits had the minimum cross-validation error
rate (0.075). The complexity parameter of this tree, 0.01, was used to further
prune the full tree in an attempt to remove splits, if any, that caused over-fitting.
The final pruned tree is shown in Figure 3.9.
asthma 
diagnosis
codes ever > 0
COPD diagnosis code > 0
ICS > 0
ICS-LABA > 0
1.49%
0.64%
0.21%
83.55%
ICS > 00.43%
ICA-LABA > 0
6.21%
0.20%
SABA > 0
4.48%
COPD diagnosis codes ever > 0
asthma GP visits
in the last year > 0
ICS > 0
ICS-LABA > 0
0.82%
0.65%
0.59%
0.75%
yes no
currently
treated
asthma
currently
treated
asthma
currently
treated
asthma
currently
treated
asthma
currently
treated
asthma
currently
treated
asthma
ever diagnosed
asthma without
current treatment
ever diagnosed
asthma without
current treatment
ACOS
COPD
possible/
at risk of
COPD
none
Figure 3.9: A decision tree representation of the classification algorithm. At each node, the left branch
is followed when the condition is true. The width of branches is proportionate to the number of indi-
viduals in the derivation sample who followed these branches relative to the size of the entire sample.
The final nodes, i.e. leaves, represent the labels to be assigned for new cases. ACOS: asthma-COPD
overlap syndrome; COPD: chronic obstructive pulmonary disease; GP: general practitioner; ICS: inhaled
corticosteroid; LABA: long-acting beta adrenoceptor agonist; SABA: short acting beta agonist.
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This final tree represented the classification algorithm that could be used to clas-
sify individuals in new samples into the following six categories:
• ‘currently treated asthma’
• ‘ever diagnosed asthma without current treatment’
• ‘possible/at risk of COPD’
• ‘COPD’
• ‘ACOS’
• ‘none’
The actual variables that were chosen by recursive partitioning for the construc-
tion of this tree were:
• “having asthma diagnosis events ever”
• “having asthma related GP visit in the last 12 months”
• “having COPD diagnosis events ever”
• “having SABA prescriptions in the last 12 months”
• “having ICS prescriptions in the last 12 months”
• “having ICS-LABA combination prescriptions in the last 12 months”
Table 3.4 shows a confusion matrix and statistics for the cross-classification of
the decision tree predictions against the labels used in the training. Overall, the
predictive performance of the classification algorithm was very high, which meant
it could be used to accurately classify new populations based on the latent class
model that I described earlier in this chapter. An exception was that the algo-
rithm had a low sensitivity to identify people with ‘possible/at risk of COPD’ as it
misclassified 56% of them into the ‘none’ class.
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Table 3.4: Confusion matrix and statistics for the cross-classification of the predicted classifications
against the LCA-based labels in the validation dataset. These statistics reflected how well the classifi-
cation algorithm represented the latent class model.
Confusion matrix
Predicted
ACOS
Ever
diagnosed
asthma
without
current
treatment
Currently
treated
asthma
Possi-
ble/at risk
of COPD
COPD None
LCA-based labels
ACOS 116 6 10 0 0 0
Ever diagnosed asthma
without current treatment <5* 1,004 0 0 0 0
Currently treated asthma 9 8 1,035 10 <5* 37
Possible/at risk of COPD 0 0 0 26 <5* 36
COPD 0 0 0 <5* 199 0
None 0 <5* 11 0 25 12,455
* Values masked to comply with the SAIL Databank policy on small numbers.
Overall statistics
Accuracy 0.9893 (95% confidence interval (CI): 0.9875, 0.9909)
No Information Error Rate
0.8354 (i.e. if we just assigned all individuals into the
largest class ‘none’, we would be correct in 83.5% of
cases)
p-value of a one-sided test that “the Accuracy is higher
than the No Information Error Rate” < 2.2
-16
Cohen’s Kappa 0.9635
Class-specific statistics
ACOS
Ever
diagnosed
asthma
without
current
treatment
Currently
treated
asthma
Possi-
ble/at risk
of COPD
COPD None
Sensitivity 0.921 0.984 0.980 0.684 0.873 0.994
Specificity 0.999 1.000 0.995 0.997 1.000 0.985
Positive Predictive Value 0.879 0.999 0.940 0.406 0.990 0.997
Negative Predictive Value 0.999 0.999 0.998 0.999 0.998 0.971
Prevalence 0.008 0.068 0.070 0.003 0.015 0.835
Detection Rate 0.008 0.067 0.069 0.002 0.013 0.831
Detection Prevalence 0.009 0.067 0.073 0.004 0.013 0.833
Balanced Accuracy 0.960 0.992 0.988 0.841 0.936 0.989
ACOS: asthma-COPD overlap syndrome; COPD: chronic obstructive pulmonary disease; CI: confidence interval; LCA: latent class
analysis.
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3.4.7 Comparing the classification algorithm with other case
identification methods
Comparisons between the classification algorithm and the case definitions de-
scribed in Section 3.3.5.1 are shown in Table 3.5.
The following two comparisons had the highest Cohen’s kappa value:
• The ‘QOF indicator of asthma (AST001)’ and the algorithm’s definition of ‘cur-
rently treated asthma’ had a kappa value of 86.5%.
• ‘Asthma diagnosis code’ and the union of algorithm’s definitions of ‘ever di-
agnosed asthma without current treatment’ and ’currently treated asthma’
(i.e. ‘any asthma’) had a kappa value of 94.5%.
However, the self-reported definition of currently treated asthma had lower agree-
ments with the algorithm classification, with kappa values of 61.5% and 56.4% for
the concordance with the algorithm’s definitions of ‘currently treated asthma’ and
‘any asthma’, respectively. Interestingly, the self-reported definition of currently
treated asthma has a level of non-random agreement, although very low (kappa =
12.2), with the algorithm’s definition of ‘ever diagnosed asthma without current
treatment’. Finally, the algorithm’s definition of currently treated COPD had poor
disagreement with the self-reported definition of currently treated COPD (kappa
= 28.3).
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3.5 Discussion
3.5.1 Summary and interpretation of the findings
In this chapter, I described the development of a latent class model to identify
patients with ‘asthma’ (including those currently treated asthma and those with
ever diagnosed asthma without current treatment), COPD, and both conditions in
Wales in 2014. Based on this model, I trained a classification tree which can be
used to classify new samples into the above labels.
I performed the latent class modelling for 1-12 classes on a random sample of
the Welsh population. Based on model diagnostics and clinical interpretability, I
chose the eight-class model as the optimal clustering in relation to the observed
variables used in the modelling. The eight-class model succeeded in clustering the
population into distinct, homogeneous classes. There was one large class (82.2%)
characterised by the absence of almost all asthma and COPD related events, ex-
cept having a modest probability of smoking history. There were also four classes
consistent with asthma: one ever-diagnosed currently treated, two ever-diagnosed
currently treated, and a smaller class with no diagnosis but with current asthma
prescriptions. Only one small class had distinctive characteristics of COPD with
a prevalence of 1.3%; almost all people this class had positive smoking history.
Interestingly, the overlap between asthma and COPD was clearly represented in
a distinct, homogeneous class with a prevalence of 0.9%. One class showed low
to marginal probabilities for asthma prescriptions with very low probabilities for
COPD diagnosis and prescriptions.
Followingmodel interpretation, I merged classes consistent with ‘currently treated
asthma’, simplifying the clustering model into six labelled groups. I then used
these labelled groups along with all the observed variables, which were used in
the latent class modelling, to train a classification algorithm. The best classifica-
tion algorithm was a decision tree with 11 splits and 12 final nodes. This algo-
rithm is transferable and therefore can be used in new samples in the GP dataset
in the SAIL Databank and could be also tested in similar external datasets. The
‘currently treated asthma’ label predicted by the classification algorithm included
all patients with current asthma prescriptions. This label had a high agreement
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with the QOF definition of ever diagnosed currently treated asthma (the AST001
indicator). The union of the algorithm’s definitions of ‘currently treated asthma’
and ‘ever diagnosed asthmawithout current treatment’ had a very high agreement
with having an asthma diagnosis code ever. There was a suboptimal agreement be-
tween the algorithm’s definition of ‘currently treated asthma’ and the WHS-based
definition of ‘self-reported currently treated asthma’. This can be potentially ex-
plained by the possibility that some respondents thought they had asthma while
they did not, while some respondents may have not received asthma prescrip-
tions in the last 12 months or ever. In addition, the WHS did not specify a time
frame when asking the respondents whether they were “currently” treated for
asthma. Accordingly, respondents might have understood the word “currently” as
time frames diﬀerent from the 12-month interval traditionally used by researchers.
These explanations were supported by the analysis I presented in Appendix B.1, in
which I found discordance between the WHS definition of self-reported currently
treated asthma and GP-reported asthma diagnosis and prescriptions, including
the interval over which prescriptions were queried.
3.5.2 Strengths and limitations
3.5.2.1 Strengths
Latent class analysis can reveal asthma epidemiology in routine data
In the absence of an accepted reference standard for identifying asthma patients,
mixture modelling methods such as LCA allow identifying likely patients using the
available observed data. Since asthma in the UK is mainly managed in primary
care, I performed the LCA based on the informed assumption that asthma epidemi-
ology was reflected in primary care EHR data. LCA follows a top-down approach,
unlike the bottom-up approach used in cluster analysis. The latter assesses the
similarities between individuals in order to form clusters. LCA, however, utilises
the distributions of the observed characteristics to identify distinct latent groups,
and then assesses the membership probabilities of each individual into these hy-
pothesised groups. Those probabilistic class memberships fit with the nature of
asthma as a probabilistic rather than a binary condition. The identified latent
classes reflected the heterogeneous nature of asthma as a condition with varying
severity which overlapped with COPD. By computationally uncovering the popula-
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tion structure in relation to asthma and COPD related variables, LCA identified the
likely patient groups, some of which could be otherwise overlooked in the manual
researcher-led development of case definitions.
Asthma and COPD were included in the same model
The inclusion of both asthma and COPD data in the same model is a particular
strength. It allowed the exploration of the overlap between the two diseases in
EHR-derived data. it makes the model useful for researchers who, for example,
want to study a subset of asthma or COPD patients who also have characteristics
of the other disease (i.e. ACOS), or those who have one disease without the other.
Derivation of a transferable classification algorithm
A remarkable strength in this chapter is the derivation of a classification algorithm
based on the best-fit LCA model. Since the LCA model was performed on a sample
of 50,000 individuals and not on the entire population in the SAIL Databank, its
output cannot be directly used to identify asthma patients from outside this sam-
ple. To overcome this limitation, I derived a classification algorithm that can be
used on diﬀerent samples and by other researchers in the SAIL Databank. This
transferable classification algorithm can be also tested in other similar primary
care databases. This algorithm could be used to produce more accurate estimates
of the disease prevalence compared to methods based on patient-reported data
from national health surveys and those based on the Quality of Outcomes Frame-
work’s AST001 indicator.
3.5.2.2 Limitations
The analysis in this chapter has some limitations.
Limitations related to EHR-derived data
The latent class modelling described in this chapter was based on relatively lim-
ited data that were usually insuﬃcient to establish diagnosis at the point of care.
Much of the information that were usually available to GPs to establish asthma
and COPD diagnoses were not available in the primary care dataset of the SAIL
Databank. This was mostly due to poor recording and/or coding at the point of
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care. Those low-quality data included, for example, lung function tests. Since the
quality of observed variables was essential for a well-specified latent class model,
I constructed these observed variables only using events that were thought to
be of reasonable quality in the SAIL Databank. Such events included diagnosis,
disease-related GP visits, prescriptions, and smoking history.
Despite using those observed variables which were known to be well coded in the
GP dataset in the SAIL Databank, the imperfect quality of these variables could
have still aﬀected the latent class modelling. In interpreting the chosen model,
I took into account the nature and limitations of EHR-derived data such as the
possibility of missing or incorrect coding as well as record-linkage errors. For ex-
ample, Class 5 (Figure 3.6) was characterised by current prescriptions suggesting
active asthma but with no recorded diagnosis events; I assumed that patients in
this class were possibly being treated for asthma as they had a low probability of
ever smoking.
The clinical meanings of the latent classes were based on surrogate variables, such
as GP diagnosis codes, visits, and prescriptions as well as smoking history, rather
than on more direct disease markers such as clinical and laboratory findings. Nev-
ertheless, I hypothesised that LCA of these surrogate variables can reasonably
distinguish between patients with asthma, COPD, and ACOS. This provided an op-
portunity to assess how clustering based on these surrogate variables will perform
compared with that based on asthma and COPD biomarkers [7, 273–279].
Asthma-COPD overlap syndrome was treated as a separate class
In the merging of the latent classes and the derivation of the classification al-
gorithm, I treated ACOS as a separate label rather than merging it with asthma
and/or COPD groups. This approach was in-line with the view that ACOS is a third
condition, a view which was, however, subject to active debate [210, 211, 280].
Limitations of latent class analysis
Although latent class analysis was an appropriate clustering method that fit with
asthma heterogeneity, it had some particular limitations.
The specification of the observed variables, model selection and interpretation
all involved significant levels of subjectivity. Model interpretation and usefulness
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both depend largely on the choice and configuration of the observed variables,
which thus needs careful consideration. Therefore, assessing the derived classi-
fication algorithm against other GP- and self-reported measures was needed and
provided useful information to assess its meaning.
The population structure identified by LCA may not exactly represent the clinical
epidemiology of asthma and COPD. It has been shown that the patient groups iden-
tified using such unsupervised statistical learning techniques may partly reflect
artefact from the analysis method including transformation and encoding of the
observed variables [281]. Therefore, an important future work is to compare this
LCA model performance with full patient record data and/or clinical assessment
for a population sample.
The classification algorithm was not a superior reference
Given limitations related to data quality and provenance as well as LCA, the clas-
sification algorithm derived in this chapter was not intended to be a superior ref-
erence against which other asthma case definitions, could be assessed. Arguably,
no easily implementable, gold standard operational definition for asthma exists.
3.5.3 Comparison with related works
LCA has been widely used on asthma-related data. While some studies used LCA
to mainly identify asthma cases [282], the more common use was to uncover phe-
notypes of asthma and related wheezing and atopic disorders [274, 277, 283].
The study by Prosser et al. [282] was closely related to the aim I pursued in this
chapter. However, the main aim of that study was to identify only patients with
treated asthma. It used slightly diﬀerent configuration of the observed variables
derived from health insurance claims and hospital discharge data. Themodel diag-
nostics favoured the two-class model, which estimated the prevalence of treated
asthma in British Columbia in 2001 as 9.9%. In my analysis, however, I aimed
to identify treated and untreated cases of asthma, which had the prevalences of
8.0% and 6.6%, respectively, and a combined prevalence of 14.5%. In addition, the
authors of that study did not take into consideration COPD-related data in their
model specification. Conversely, I included events related to COPD as observed
variables in order to allow the model to distinguish between asthma and COPD
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patients (and to identify those with ACOS). I also used the age at asthma diagno-
sis (before vs. after the age of 40) in order to improve distinction between asthma
and COPD patients and to improve the overall interpretation of the model.
Another LCA-based studywas based on questionnaire data about respiratory symp-
toms of 4,000 children aged 8-12 years [277]. The authors used 11 questions from
the International Study of Asthma and Allergies in Childhood (ISAAC) question-
naire. They assessed their LCA model using objective asthma markers such as
allergic sensitisation and bronchial hyper-responsiveness. They identified seven
latent classes labelled as ‘no respiratory symptoms’ (with prevalence of 59.4%),
‘cough during colds’ (19.1%), ‘chronic cough and phlegm’ (5.3%), ‘nocturnal breath-
lessness’ (4.9%), ‘wheeze only with colds’ (4.8%), ‘wheeze without colds, with
cough’ (4.5%), and ‘wheeze without colds, without cough’ (2.1%). These classes
were overall diﬀerent from those I identified in this chapter. The authors reported
that asthma diagnosis was highly reported by the parents in the ‘wheeze’ and ‘noc-
turnal breathlessness’ classes, leading to an 8.5% prevalence for parent-reported
doctor diagnosis of asthma. In my LCAmodel, however, the classes consistent with
‘asthma’ (including every diagnosed asthma and currently treated asthma) had an
aggregated prevalence of 14.5%. In my modelling, I did not use objective disease
markers to specify or validate the model since these data were under-recorded
in the SAIL’s GP dataset (see Chapter 4). Finally, that study was performed on
children only, whereas my latent class modelling was based on data from all age
groups. For future work, however, it would be worthwhile to perform a separate
latent class modelling for each age group, or using age group as a covariate for
the model in order to control its eﬀect on the identified latent structure.
3.5.4 Future directions
Future developments of the latent class model described in this chapter include
refinement of the observed variables and exploring new predictor variables from
primary and secondary care data.
In addition, Wales-wide pathology data are expected to be linked to the SAIL Data-
bank in 2018. These data include important asthma-related data such as periph-
eral eosinophil count and immunoglobulin E (IgE) levels. Such data linkage would
provide an opportunity to explore asthma phenotypes in Wales in a greater depth.
3.6. Conclusion 103
Patients with asthma exhibit diﬀerent profiles in terms of the disease natural his-
tory and progression. These temporal profiles may be related to clinically recog-
nised phenotypes and underlying endotypes. A longitudinal extension of LCA,
latent transition analysis (LTA), would allow modelling the temporal profiles of
asthma natural history in Wales. That extended analysis would provide better
understanding of the disease’s changing epidemiology, and help inform service
planning, resource allocation, and support more personalised disease manage-
ment.
3.6 Conclusion
Accurate case definitions are critical to the development of the Wales Asthma Ob-
servatory.4 However, due to various sources of uncertainty in asthma-related rou-
tine data, clear identification of asthma patients using these data is challenging.
In the absence of a reliable reference standard, I used LCA of recorded primary
care events in the SAIL Databank to identify clusters of likely patients with asthma
and/or COPD. The model diagnostics and interpretability favoured the eight-class
model which included four classes for asthma (diﬀering by recorded asthma diag-
nosis and prescriptions), one for COPD, one for asthma-COPD overlap syndrome,
one with scarce prescriptions probabilities, and one with no asthma or COPD re-
lated events.
Based on the latent class model, and after merging three classes of currently
treated asthma, I derived a classification algorithm which could be used to clas-
sify new samples into six clinical labels: ever diagnosed asthma without treat-
ment, currently treated asthma, COPD, ACOS, possible/at risk of COPD, and none.
I assessed the classification algorithm against other objective and self-reported
case definitions. The classification algorithm can be also used or tested by other
researchers in similar primary care data sources.
The unsupervised machine learning approach used in this chapter relied on the
assumption that despite the challenges to define asthma from RCD, these data
reflected the disease clinical epidemiology. By computationally uncovering the
population structure, LCA identifies all the likely patient groups that could be
overlooked in the manual researcher-led development of case definitions. There-
4http://www.wales-asthma-observatory.uk/
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fore, the developed LCA model could produce more reliable estimates for asthma
prevalence using RCD.
Specifying the LCA model using asthma and COPD observed variables allowed
identifying patients with one or both disease. This approach concurs with the
current interest to understand the asthma-COPD overlap and allows defining this
controversial clinical entity using RCD.
The LCA-based method to identify asthma patients from RCD that I developed
in this chapter will be one of a set of asthma case definitions available in the
Observatory as described in Chapter 4.
Chapter 4
Development of the Wales
Asthma Observatory
Purpose, design, and data quality
A main output of this doctoral project is to establish the foundations of the Wales
Asthma Observatory based on a national asthma registry using the Secure Anony-
mous Information Linkage (SAIL) Databank. In this chapter, I discuss the purpose
of the Wales Asthma Observatory as a platform for asthma research and surveil-
lance, and its wider context in the United Kingdom and worldwide.
I describe the design of the Observatory and the underlying asthma registry, in-
cluding source population, structure, content, technical logistics, and approaches
to support reproducibility. I then identify important data gaps in asthma related
events in the primary care database. Afterwards, I discuss the strengths and limi-
tations of the Observatory, including the wide coverage, implications of data gaps
and anonymisation, and specific challenges of assessing asthma outcomes using
the SAIL Databank. I then present recommendations for better capture of asthma
routine data in the SAIL Databank. I conclude by proposing further developments
to the Observatory.
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4.1 Introduction
Amain output of this doctoral project was to establish the foundations of the Wales
Asthma Observatory (http://www.wales-asthma-observatory.uk/) as a platform for
asthma research and surveillance. In this chapter, I describe the Observatory’s
purpose, context, design and methodology. In addition, due to the known data
quality issues in electronic health record (EHR) data [284, 285], I present quality
assessment of selected asthma-related variables in routinely collected, primary
care data in Wales. I then discuss the strengths and limitations of the Observatory
as well as challenges related to asthma and routinely collected data (RCD). I also
propose further developments to the Observatory, and suggest recommendations
to improve the quality of asthma RCD.
4.2 Purpose and context
The Observatory is intended to be used as a research platform for supporting a
wide range of cross-sectional and longitudinal asthma studies. It can be used
as a surveillance tool, producing disease insights at both local and national lev-
els in Wales. The Observatory includes a regularly updated, cumulative e-cohort
(described in the next section), which enables near real-time disease monitoring,
tracking, and forecasting. The linkage to area-based deprivation indices enables
investigations into the inequalities in asthma care across Wales, as demonstrated
in Chapter 5.
The Wales Asthma Observatory is closely aligned with the UK Asthma Observatory
(UKAO), a UK-wide platform led by the Asthma UK Centre for Applied Research
(AUKCAR) [286]. Data from the four UK countries feed into the UKAO [287]. These
currently include person-level and aggregate data about primary and secondary
care, community medication dispensing, ambulance services, and national health
surveys [43].
In the wider context, the Wales Asthma Observatory will support the AUKCAR’s
research endeavours towards promoting better asthma control, maximising treat-
ment benefits, and reducing exacerbations and adverse outcomes.
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The Observatory can play a vital role in the endeavours to bridge the gap between
evidence and practice. The concept of learning health systems (LHS) has been
developed over the past decade to address the crucial need to improve the re-
use of health data to make continuous improvements of health care delivery [288,
289]. An LHS is a healthcare system that continuously ‘learns’ from care delivery.
It requires an integrated, seamless cyclical process of collecting data generated as
a by-product of care delivery, using these data to create new knowledge, and use
the created knowledge to inform decision making and performance of everyday
care delivery [290–293]. With plans for piloting an LHS for asthma in Wales, the
Wales Asthma Observatory can be a building block in the foundations of such a
vital system.
4.3 Methods
The Observatory includes a national asthma registry in Wales. I built the reg-
istry from routinely collected de-identified health data in the Secure Anonymised
Information Linkage (SAIL) Databank. This registry represents a cumulative, na-
tionwide cohort of asthma patients based on the dynamic population of Wales. It
is intended to include all previous (remitted or deceased) cases of asthma in the
country as well as existing and new incident cases. The cohort was assembled
using variety of case definitions, mostly based on the systematic scoping review
in Chapter 2, and included essential asthma outcomes such as disease severity,
exacerbations, and death due to asthma as well as asthma remission.
Figure 4.1 illustrates the general process of compiling the Observatory.
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WHS WIMD
Figure 4.1: Compilation of the Wales Asthma Observatory. WDS: Welsh Demographic Service; OPD:
Outpatient Dataset; WLGP: Welsh Longitudinal General Practice; PEDW: Patient Episode Database for
Wales; EDDS: Emergency Department Data Set; ADDE: Annual District Death Extract.
In this section, I describe:
• the ethical and information governance requirements of the Observatory de-
velopment;
• the technical environment in which the Observatory was developed;
• data sources used, including content, coverage, and data quality indicators
(in addition, I consider in-depth the quality of recording of selected asthma-
specific Read codes in Section 4.5);
• the source population;
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• case definitions used to identify people with asthma;
• the Observatory’s data structure and variables;
• output dissemination plan;
• approaches to support research reproducibility; and
• data sharing and requirements to access the Observatory.
4.3.1 Ethics and information governance
The development of the Wales Asthma Observatory was approved by the SAIL
Information Governance Review Panel (IGRP), which acts as a data guardian (see
Appendix C.2 for the approval letter).
Typically, an application to access SAIL data in a research project starts with a
scoping discussion in which a SAIL analyst discusses with the applicants the suit-
ability of their research projects and the required datasets. In the second stage,
the applicants are required to complete a detailed application including a research
proposal (objectives, methods, data required from SAIL datasets, and time peri-
ods and geographical and demographical distributions of data). The application
is submitted to the IGRP which assesses the project’s suitability and compliance
with SAIL’s information governance policy, and may raise issues and questions
based on the application. After these questions are resolved and the IGRP is sat-
isfied with the project, it sends a letter of approval to the applicants. Following
approval, and before the applicants can start accessing SAIL data, they need to
demonstrate appropriate information governance knowledge and skills by under-
taking an accepted training course.1 In addition, users are required to sign the
SAIL’s Data Access Agreement which details operational and information gover-
nance rules. Detailed information about the application process can be found on
the SAIL Databank website.2
An approval from a research ethics committee was not required for the Observa-
tory development since it only used de-identified data, which was consistent with
the current National Health Services (NHS) Health Research Authority guidance
[294].
1Examples of accepted training course are the “Research, GDPR (General Data Protection Regula-
tion) and confidentiality Quiz”, which is run by the Medical Research Council, and the “Safe User
of Research data Environments (SURE) Training” course, which is run by the Oﬃce for National
Statistics (ONS) , the UK Data Service, and the Administrative Data Research Network (ADRN).
More details are regularly published on the SAIL Databank website: https://saildatabank.com/
application-process/following-approval/
2https://saildatabank.com/application-process/
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4.3.2 Logistics and technical environment: the SAIL Data-
bank
I developed the Observatory using data from the SAIL Databank.3 The SAIL Data-
bank is a repository of de-identified, linked health datasets inWales. Data providers
include general practices, hospitals, and the Oﬃce for National Statistics (ONS).
The Observatory was developed within the SAIL Gateway. The SAIL Gateway is a
privacy-protecting safe haven for anonymised person-level data [295]. Approved
users can access data through a secure remote access system.
Data in the SAIL Databank are organised in database schemas, which are log-
ical structures that group database elements such as tables, views, and proce-
dures. I currently maintain the Observatory data in a dedicated SAIL schema
(SAILW0317V), the content of which is described below in Section 4.3.5. These
data can be interrogated using the Structured Query Language (SQL). I used the
SQL and R programming languages to extract data from SAIL and to organise the
Observatory schema.
4.3.3 Data used in the Observatory
4.3.3.1 Data sources
I used the following SAIL datasets in the development of the Wales Asthma Obser-
vatory. Table 4.1 summarises the coverage and content of these datasets, while
Table C.1.1 (in the Appendix) shows their data fields and Table C.1.2 and Fig-
ure C.1.1 show the frequency of events and unique patients in each dataset by
calendar year. Each of these datasets cover all of Wales, except the Welsh Lon-
gitudinal General Practice (WLGP) dataset which currently covers about 80% of
general practices. New extracts of these datasets are regularly received by the
SAIL Databank every few months to over a year.
Welsh Demographic Service dataset
The Welsh Demographic Service (WDS) contains de-identified demographic and
administrative data about people who use the NHS in Wales. These data include
3https://saildatabank.com/
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gender, week of birth (defined by date of the firstMonday after birth), date of death
(for dead people), registration history at general practices, and Lower Layer Super
Output Areas (LSOAs) of residence as reported by the individual upon registration.
The WDS data has been recorded since 1992 and covers all of Wales. The most
recent extract of the WDS in SAIL was created in April 2018 and included data of
a cumulative population of ~5.3 million people.
The NHS is a free to use service. However, the WDS normally does not capture
persons who do not use the NHS. Those may include healthy people (particularly
young men for whom there is no health screening), disengaged people who do not
use the NHS unless in emergencies, some prisoners, and those who used private
GPs [296].
Welsh Longitudinal General Practice dataset
The Welsh Longitudinal General Practice (WLGP) Dataset contains de-identified
health care events, such as recorded diagnoses, clinical findings, prescriptions
and monitoring as well as other events. Data are collected by GPs during patient
visits and are then coded into Read codes by GPs or clinical coders. The most
recent extract of the GP dataset was created in April 2018, covering about 80%
of GP surgeries in Wales, and including data for a cumulative population of about
four million people. This dataset is of paramount importance for the Observatory
since in the UK asthma is mainly treated in primary care [32].
The dataset has 99.58% matching with the WDS. The WLGP dataset shows in-
creased recording of primary care events since the introduction of the Quality of
Outcomes Framework (QOF) in 2004-2005 (see Table C.1.2). However, the lack
of standardised coding practices leads to variations and inconsistencies in data
recording. In Section 4.5, I consider the quality of recording of selected asthma-
specific Read codes.
Emergency Department Dataset for Wales
The Emergency Department Data Set (EDDS) was created in 2009 and captures
visits to accident & emergency (A&E) departments as well as minor injury units
(MIUs) in NHS hospitals across Wales. The most recent extract of the EDDS was
created in April 2018 and included data on a cumulative population of about 2.5
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million people. Data collected during each A&E attendance include investigations
performed, diagnosis made, anatomical areas involved, treatment provided, as
well as other administrative data related to the attendance. Diagnosis is coded
using a three-digit alphanumeric code chosen from a list of 83 possible codes rep-
resenting broad diagnostic categories. In addition, to the primary diagnosis, there
are further five positions to record additional or secondary diagnoses. Due to the
nature of emergency attendances, recorded diagnoses may be uncertain or un-
confirmed. Practices of recording and coding of data vary between the diﬀerent
A&E departments and MIUs. The EDDS currently receives data on all emergency
attendances in Wales. However, in the earlier years (2008-2011), some A&E de-
partments were not able to submit their data to the EDDS, and therefore data in
that period may be incomplete (see Table C.1.2). Therefore, caution should be
exercised when using this dataset for epidemiological and research analyses.
Patient Episode Database for Wales
The Patient Episode Database for Wales (PEDW) dataset was created in 1991 and
includes records for all planned and emergency inpatient admissions in addition to
day case admissions to all NHSWales hospitals as well asmost admissions ofWelsh
residents to hospitals in England. The most recent extract of the PEDW dataset
was created in May 2018 and included data on a cumulative population of about
3.3 million people. Recorded data are captured during the inpatient episode and
includes admission diagnosis, procedures and operations performed, as well as
length of stay (LOS), Healthcare Resource Group (HRG), and other administrative
data. Admission diagnosis is recorded using ICD-10. In addition to a mandatory
primary diagnosis code for a hospital episode, the database allows recording of 1-
13 secondary diagnosis codes. The PEDW is generally considered to be high qual-
ity [297, 298]. However, it is mainly an administrative database which was created
as a tool to track hospital financial activity rather than for epidemiological and
research purposes. The database also suﬀers from between-hospital variations
in practices of coding admission diagnosis in the available 14 diagnosis positions
[297]. Further discussion about the quality of the PEDW is in Section 5.5.4.1.
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Outpatient Dataset
TheOutpatient Dataset (OPD) includes data on outpatient appointments in all NHS
hospitals in Wales. These data include attendance date, specialities of care and
the treating physician, and site of treatment. In addition, fields for diagnosis and
procedures performed in outpatient settings are available, but data on these items
are poorly recorded. The most recent extract of the OPDwas created in June 2018,
including data for about 3.2 million people since 2004 across all of Wales.
Annual District Death Extract
The Annual District Death Extract (ADDE) dataset is produced and maintained
by the ONS and is linked to the SAIL Databank. This dataset contains mortality
data since 1996 including up to eight causes of death from Medical Certificates of
Cause of Death (MCCD) certified by amedical practitioner or a coroner.4 Causes of
death are automatically or manually coded in ICD-10 from the MCCD. I used it to
ascertain whether death was recorded as due to or related to asthma in deceased
asthma patients.
Welsh Health Survey
The Welsh Health Survey (WHS) has been conducted in 1995, 1998, and annually
since 2003 before it ceased in 2015 [53]. It collected self-reported information on
a range of health and health-related lifestyles from samples of the population of
Wales. The WHS 2013 and 2014 results datasets for respondents aged 16-year-
old and above are already linked to the SAIL Databank [271]. Those participants
consented to link their responses to their medical records [272]. The only question
related to asthma, other than asthma symptoms, asked the participant whether he
or she was currently treated for a number of diseases including asthma. I used
responses to this question as a case definition for ‘self-reported currently treated
asthma’. I considered invalid responses as negative responses.
4Mortality Statistics: Metadata, July 2015, Oﬃce for National Statistics (link).
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Welsh Index of Multiple Deprivation
The Welsh Index of Multiple Deprivation (WIMD) is the oﬃcial tool to assess the
level of multiple deprivation in small areas in Wales. It consists of the following
weighted eight domains: Income, Employment, Health, Education, Geographical
Access to Services, Housing, Physical Environment, and Community Safety. I dis-
cuss the WIMD index in depth in Section 5.1.3.2.
4.3.3.2 Data anonymisation and linkage
Data 
Provider NWIS SAIL Databank
NHS Number
Name
Address
Date of Birth
Healthcare
data
ALF
Join Key
ALF
Join Key
ALF 
(encrypted)
Join Key 
(encrypted)
ALF 
(encrypted)
Healthcare
data
Join Key
Healthcare
data
Join Key 
(encrypted)
Healthcare
data
UsersAuthorised 
SAIL analysts
NobodyAuthorised 
NWIS staff
Sensitive data
Access to 
data
Content 
of data
Data 
holder
Temporary encrypted 
identifiers
Doubly encrypted 
identifiers
Data provider
Figure 4.2: Split-file approach to data anonymisation by a trusted third party (adapted from Ford et al.
[141]). ALF: Anonymised Linking Field; NWIS:National Health ServicesWales Informatics Service; SAIL:
Secure Anonymised Information Linkage.
Data anonymisation and linkage on the aforementioned data sources is performed
by the National Health Services Wales Informatics Service (NWIS), which acts as
a trusted third party (see Figure 4.2) [140, 141]. A data provider splits its data
in two files: File 1 which contains demographic data, and File 2 which contains
clinical data. The data provider assigns a join key for these two files. File 1 is
securely transferred to NWIS. Then, NWIS replaces the demographic data with
an Anonymised Linking Field (ALF), which is designed to be a unique identifier
across diﬀerent data providers. NWIS then creates File 3 which contains the ALF
as well as the data provider’s join key. Then, it sends this File 3 to the SAIL Data-
bank. Separately, the data provider sends File 2 to the SAIL Databank. In the
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Table 4.2: Case definitions used in the Wales Asthma Observatory. Clinical codes used in the GP-data-
based case definitions are listed in Appendix E
Case definition Description
Ever-diagnosed asthma One or more asthma diagnosis codes any time before a given date.
Ever-diagnosed and currently
treated asthma
One or more asthma diagnosis codes any time before a given date, and one or
more asthma prescription codes in the last 12 months; this case definition
corresponded to the Quality of Outcomes Framework indicator AST001
without considering exceptions.
Currently treated asthma One or more asthma prescription codes in the last 12 months.
Ever-treated asthma One or more asthma prescription codes any time before a given date.
Self-reported currently treated
asthma
Based on the Welsh Health Surveys; only available for a small number of
patients. The survey question on whether the participant was ‘currently being
treated for asthma’ did not specify a time frame. However, based on my own
analysis (see Appendix B.1) I used a period of 26 months ending with the end
of the survey year.
SAIL Databank, File 2 and File 3 are re-joined using the join key to produce a
de-identified dataset, containing encrypted ALF and clinical data, which can be
linked to datasets from other data providers.
4.3.4 Eligibility criteria
The Observatory aims to cover the entire dynamic population of Wales. Therefore,
I defined the source population as all individuals for whom records exist in the
WDS dataset.
Since the Observatory aims to include all potential and confirmed asthma patients
in Wales, I included in the Observatory people who met any of a set of case def-
initions for asthma, from the most inclusive to the most specific ones. Table 4.2
lists case definitions currently included in the Observatory. Each person in the
Observatory satisfies at least one case definition ever.
The use of these multiple case definitions of asthma allows capturing most pa-
tients, ranging from those with uncertain diagnosis to those with the more strictly
defined currently-treated asthma. This approach facilitates studying diverse sub-
groups of asthma patients diﬀering in diagnosis certainty and disease activity. It
also provides flexibility for researchers to choose the appropriate case definitions
for their studies. The use of broad case definitions to capture patients with any in-
dication of asthma was previously adopted by a similar project in the United States
(US), the Population-Based Eﬀectiveness in Asthma and Lung Diseases (PEAL)
Network [137].
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Each of the used case definition has its ownmeaning and uses in research. Nonethe-
less, I considered the ’ever GP-diagnosed currently-treated asthma’ the main case
definition of asthma in the Observatory as it reflects the active disease, which is
often an essential criterion in many asthma studies.
The case definitions in Table 4.2 can be represented as state variables, i.e. as-
sessed over time periods. I assessed the case definitions over patient-specific
periods (Figure 4.3) rather than fixed periods (e.g., start and end of year) for all
patients. This allowed an accurate start and end of disease states. For example,
the definition of “currently treated asthma” (“there was at least one asthma pre-
scription in the last 12 months”) is true for any given date within the state period
(see Figure 4.3).
Time
Asthma diagnosis events
Asthma prescription events
Ever diagnosed asthma
Ever treated asthma
Ever diagnosed currently
treated asthma *
Currently treated asthma *
* At least one prescription code
over the last 12 months
months
12
Death
Ev
en
ts
D
is
ea
se
 s
ta
te
s
Disease state
Event
months
12
months
12
Figure 4.3: Examples of the assessment of case definitions as disease states (state variables) in the
Wales Asthma Observatory. The diagram shows asthma diagnosis and prescription events for an imag-
inary patient in addition to four case definitions assessed over patient-specific time intervals based on
those events.
4.3.5 Registry structure and variables
Data for each person in the Observatory currently include demographics, which
asthma case definitions (“asthma states”) were satisfied over which periods, as
well as asthma-related outcomes and variables. These outcomes and variables
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include asthma treatment step, disease severity, and exacerbations, and periods
of follow-up based on GP registration history (see Table 4.3). Metadata about
the Observatory compilations and dataset versions used in each compilation are
stored in a separate database table (WAO_data_sources_versions).
Table 4.3: Data tables in the asthma registry
Name Description Fields
Demographics Basic demographic data ALF
WOB
DOD
Patient
follow-up
Periods of follow-up for patients based on GP registrations from
the WDS dataset. Those GP registration records were filtered
using an in-house algorithm (FNC.CLEAN_GP_REG, developed
by the SAIL Analytical Services Team) that excludes periods
over which some GP practices, despite being participating in
SAIL, did not send reasonably adequate amounts of data to
SAIL.
ALF
start date
end date
Asthma State Whether an individual satisfied a case definition of asthma over
a specific period or a calendar year. Examples of asthma case
definitions include “ever diagnosed asthma” and “currently
treated asthma” (see Table 4.2).
ALF
case definition/state
start date
end date
Treatment Step Treatment step from 1 to 5 based on the 2016 BTS/SIGN
asthma guidelines, in addition to ‘SABA as needed’, over a
period of up to six months.
ALF
start date
start end
treatment step
Asthma
Severity
Disease severity classified as intermittent, mild, moderate, or
severe based on prescriptions [299] over a period of up to six
months. Intermittent = SABA as needed;mild: low-dose ICS or
other low-intensity therapies;moderate: low/moderate-dose
ICS with LABA (or other additional therapies); severe:
high-intensity therapies (high-dose ICS with LABA, oral
corticosteroids, or other additional therapies.
ALF
start date
end date
asthma severity
Asthma
Exacerbation
Records for asthma exacerbation defined based on primary and
secondary care utilisation. An asthma exacerbation is defined
by short course of oral corticosteroids, asthma-related
emergency admission, or asthma-related hospitalisation, with
periods less than 4 weeks apart being merged into single
exacerbation period.
ALF
start date
end date
Asthma-related
death
Record of death in which asthma was an underlying cause of
death from the ONS’s ADDE dataset.
ALF
DOD
position of asthma code in death record
Data source
versions
Shows the available compilations of the Observatory and the
names and versions/extracts of SAIL datasets used in each
compilation (table name: WAO_data_sources_versions).
Observatory compilation number and
date (e.g., WAO_2_20181005) Source
data table name and version (e.g.,
SAILWLGPV.ALF_GP_EVENTS_
CLEANSED_20180820)
ALF: Anonymous Linking Field; BTS: British Thoracic Society; DOD: date of death; GP: general practitioner; LABA: long-acting beta
adrenoceptor agonist; SABA: short acting beta agonist; SIGN: Scottish Intercollegiate Guidelines Network; WOB: week of birth.
Additional data that could be added in the future include:
• Timeline of laboratory test results such as total immunoglobulin E (IgE),
blood eosinophil count, as well as lung function measurements.
• Asthma phenotypes (e.g., eosinophilic asthma, adult-onset asthma, asthma
with fixed airflow limitation, and poorly steroid-responsive asthma); pheno-
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types can be identified using clustering methods guided by the relevant lit-
erature [4, 5, 7].
• Environmental data including air pollution, housing quality, calculated for
small areas and linked through the Residential Anonymous Linking Fields
(RALF) [300].
• Patient reported outcome measures (PROMs), such as Asthma Control Ques-
tionnaire (ACQ) responses.
4.3.6 Dealing with missing and invalid data
In the Observatory compilation script, I excluded persons with an invalid ALF (i.e.
had a value of NULL). In addition, the Observatory includes periods of follow-up
based on GP registration history, which can be used for censoring in time-to-event
analyses.
Non-existence of a health event in an event-based dataset, such as most SAIL
datasets, does not imply non-occurrence of that event; it may rather due to non-
recording of such an event in categorical codes and may have been recorded in
narrative fields not available within SAIL. The nature of such event-based datasets
means that it was impossible to identify such unrecorded events. However, in
the Observatory development, the case definitions were based on events that are
assumed to be well recorded.
4.3.7 Updating the Observatory data
The Observatory data are based on the SAIL Databank. Data in the SAIL Databank
are not collected in real-time but are rather collected and updated with a variable
lag time ranging from few months to over a year. Subsequently, the Observatory
data are not real-time, but are intended to be updated following updates to any of
the source SAIL datasets.
The updating process can be performed using the same data extraction and pro-
gramming script used in the initial compilation of the dynamic cohort. For each
update, names of newer dataset extracts should be used as input in that script.
This process will create a new version of the Observatory, including an updated
patient cohort and variables (see Figure 4.1).
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4.3.8 Support for reproducible research
Reproducibility is important for epidemiological studies [157, 218]. It requires
full and clear documentation of the methods used, including algorithms to define
health variables and extract data as well as programming code used for analysis.
For studies using routine data, certain considerations are needed to address repro-
ducibility. In such studies, interpretation of findings largely depends on the clinical
codes and data extraction methods used to identify patients and define outcomes.
Therefore, these codes should be accessible and reusable by the wider research
community in order to support transparency, reproducibility, and comparability of
findings [102, 157, 301].
A key part of an EHR-based disease registry is a library of clinical code lists used
by studies. In the Wales Asthma Observatory, I developed a technical platform
where clinical code lists could be collaboratively maintained, shared, and reused
by researchers and analysts (see Figure C.3.1). Interrogation of routine databases
often involves repetitive programming tasks, such as manually constructing and
modifying complex database queries. These tasks generally require significant
time from an experienced data analyst. The above-mentioned platform enables
users to collaboratively develop and reuse study-specific data extraction proce-
dures. To minimise the need to write manual and repetitive queries, the platform
automates significant parts of data extraction from the Observatory and the GP
dataset. It automatically generates and executes the required SQL queries. Au-
tomating data extraction is aimed to support scalability, save significant time by
analysts, and reduce human error. In addition, the platform has a graphical user
interface which allows researchers with no programming skills to develop code to
subsequently interrogate the data.
At the time of writing, the platform is maintained inside the SAIL Gateway at the
address http://gpact.chi.swan.ac.uk. However, requirements are being dis-
cussed with the SAIL Databank team to make the query building platform avail-
able for the public outside the SAIL Gateway. A similar public repository of clinical
codes is being maintained by the University of Manchester [216].5 Compared to
that repository, the platform that I developed will enable public sharing not only
of clinical code lists, but also of data extraction procedures that are used inside
5http://ClinicalCodes.org
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the SAIL Gateway, but not the underlying patient level data. When the platform
will be publicly available, each code set and data extraction procedure will have a
permanent citable Internet address. This platform is intended to support research
transparency and reproducibility as stated in the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) [153] and the REporting of
studies Conducted using Observational Routinely collected health Data (RECORD)
statements [157].
Another threat to reproducibility is that the data sources used by the asthma reg-
istry are regularly updated. A new data extract (i.e. version) usually contains more
recent data captured since the previous extract. However, it is possible that a
new data extract also includes additional historical data not sent before from data
providers to SAIL. Reproducibility of analyses is not guaranteed if repeated using
diﬀerent extracts of data. To minimise this limitation, the registry data tables are
versioned based on the updates of the source dataset. This allows epidemiological
estimates to be reproduced using the same data used in the previous calculations.
4.3.9 Dissemination of the Observatory output
The Observatory can be used to perform epidemiological analyses on a regular
basis or on demand. Examples of these analyses include basic epidemiological
parameters for asthma such as disease incidence, life-time and annual disease
prevalences, incidence of exacerbations, emergency visits, hospitalisation, as well
as disease burden. In addition, prevalence of asthma phenotypes and temporal
profiles of disease activity can be explored.
Consumers of the Observatory output are intended to include several user groups
such as service planners and managers, policy makers, scientists and academics,
health care professionals, asthma patients, and other members of the public. It
is therefore important for the published output to consider the needs of this wide
spectrum of users. The Observatory output will be published on a dedicated pub-
lic website using appropriate format and state-of-the-art visualisation techniques.
Users will be able to subscribe with newsletters and alerts about output of their
interests. Dissemination will also utilise the infrastructure of AUKCAR as well as
Asthma UK’s dissemination channels, allowing wider reach to people with asthma.
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4.3.10 Data sharing and access to the Observatory
Since the Observatory is based on the SAIL Databank, researchers who wish to
access the Observatory need to seek approval from the SAIL’s IGRP (see 4.3.1).
The Observatory can be queried by approved SAIL projects and can be linked to
internal SAIL data (e.g., about other health conditions) or external data (e.g., for
a bespoke cohort) that are linked into SAIL.
4.4 Summary statistics
This section presents statistics from theObservatory describing the database records
of asthma case definitions, incidence and prevalence of selected case definitions,
and asthma-related health care utilisation.
Table 4.4 shows the all-time number of records and unique patients for each of
the case definitions defined in Table 4.2 based the most recent versions of SAIL
datasets. The current version of the Observatory data includes a cumulative cohort
of 541,159 patients with ever diagnosed asthma for whom there are 6,456,786.3
years of follow-up data available in the primary care dataset (WLGP, 2018-08-20
extract).
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Table 4.4: All-time number of records and unique patients for each of the case definitions. These
records belong to all patients in the WDS, WLGP, and WHS datasets, including living and deceased pa-
tients.
Case definition Number of records Number of unique
patients
Patient-years of
follow-up in SAIL*
Ever-diagnosed asthma 541,159 541,159 6,456,786.3
Ever-treated asthma 1,174,389 1,174,389 11,531,260.3
Currently treated asthma 2,220,979 1,175,621 5,518,568.2
Ever-diagnosed, currently treated
asthma
1,046,819 476,546 3,594,309.5
Self-reported currently treated
asthma (based on the WHS)
1,199 1,173 -
GP = general practitioner; WDS =Welsh Demographic Service (WDS); WHS =Welsh Health Survey (WHS); WLGP =Welsh Longitudinal
General Practice (WLGP). * Only available for case definitions based on the GP dataset (WLGP).
Using these records, Table 4.5 shows the period prevalences of asthma case defi-
nitions in the calendar year 2017 at national and health board levels.
In addition, cumulative incidences and period prevalences of the asthma case defi-
nitions between 2000 and 2017 are shown in Figure 4.4. For cumulative incidence
of each of the case definitions in each year, the denominator was the number
of people with continuous registration at GP practices and complete data in the
WLGP (extract 2018-08-20) in the respective year, excluding people who already
satisfied the case definition at the beginning of the year. The numerator included
people in the denominator who satisfied the case definition during the respective
year for the first time in their life. For period prevalence, I defined the denomina-
tor was the same used for incidence without excluding people with the condition
at the beginning of the year. The numerator was the number of people in the
denominator who satisfied the case definition for any period in that year.
Prevalences of lifetime and current asthma showed a steady although slow in-
crease between 2000 and 2017, except for the prevalence of lifetime asthma treat-
ment which showed a steeper increase from 15% to 30%. However, incidences of
asthma diagnosis asthma treatment showed an overall decreasing trend, starting
in 2000 at 7.4% and 18.8% for diagnosis and treatment, respectively, with a slight
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increase between up to 2002, before declining significantly between 2003 and
2006-2007 (which might be, in part, due to a change in the recording of asthma
diagnosis during that period), followed by stabilisation at 3.1-3.4% and 15.0-16.6%
for the incidence of diagnosis and treatment, respectively.
Figure 4.5 shows statistics about asthma-related primary and secondary care util-
isation by patients with GP diagnosed asthma patients who received at least one
asthma prescription in 2017. The figure shows percentages of those patients who
had specific asthma-related events including specific asthma prescriptions, A&E
events, and hospitalisations in the same year (2017).
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Figure 4.4: Cumulative incidences and period prevalences of asthma case definitions inWales between
2000 and 2017.
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Figure 4.5: Distributions of asthma-related primary and secondary care utilisation events by patients
with GP diagnosed asthma patients who received at least one asthma prescription in 2017.
Lastly, in the most recent extraction of the ADDE dataset, there were 3,180 peo-
ple for which asthma was recorded among the conditions related to death. Among
those people, 1,273 (40.0%) had no GP-recorded asthma diagnosis, 859 (27.0%)
had no GP-recorded asthma prescriptions ever, and 823 (25.9%) had neither diag-
nosis nor prescription records for asthma.
130 Chapter 4. Development of the Wales Asthma Observatory
4.5 Quality of asthma-related events in the
GP database
4.5.1 Background
Health care data are mainly event-based and are mostly captured in a narrative
format [302]. Clinical coding is often motivated by clinical and administrative
purposes. However, even when perfect, clinical coding often involves information
loss since coding schemes do not cover all aspects of health and health care. In
practice, both electronic capture and coding of patient data are suboptimal [285].
Examples of barriers include cost, training needs, ineﬃcient design and negative
attitudes to EHR systems as well as lengthy lists of codes to choose from [233,
302]. Subsequently, many healthcare events may not be captured or only partially
recorded or coded at the point of care. Since only coded data are usually routinely
collected, those healthcare events would be missing in central repositories.
For most primary care events, minimal event attributes include code and date.
This also applies to events involving measurement of health parameters such as
body mass index (BMI) and blood eosinophil count. For such measurement events,
a GP can use an informative code (e.g., 42K1.: Eosinophil count normal) to de-
scribe the measurement. Alternatively, he or she can use a declarative code (e.g.,
42K..: Eosinophil count) with the measurement value recorded in a separate
field.
The incidence of non-recording may diﬀer between diﬀerent types of events; for
example, while some primary care events are known to be well-recorded (e.g., di-
agnosis codes that are required for the QOF indicators), others are less frequently
coded, partially coded, or are even completely not coded [284]. Regarding events
for which numerical values are expected besides the codes, it is possible to di-
rectly calculate the frequency of missing or invalid values for the recorded codes.
However, where the code itself is absent, it is impossible to ascertain, at the indi-
vidual level, whether the event did not happen at all or it was simply not coded.
Nonetheless, some insights into the levels of missingness of these events could be
potentially still obtained by calculating their recording frequency in the asthma
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population. This is particularly feasible for essential health care events that are
required by national guidelines (e.g., lung function testing to confirm diagnosis),
which are expected to be recorded for large proportions of patients.
To investigate the quality of recording of asthma-related events in the GP dataset
of the SAIL Databank, I examined the percentage frequency of recording for se-
lected asthma-related event codes and event values for a sub-cohort of the asthma
population.
4.5.2 Methods
I included in the sub-cohort all patients who had an asthma diagnosis Read code
between 1-1-2006 and 1-1-2012, with no “asthma resolved” in the four years fol-
lowing the diagnosis date. I did not included patients diagnosed before 1-1-2016
(one and nine months after the introduction of the QOF in April 2004) to ensure
adequate level of recording of GP data. The Read codes used for patient inclusion
are listed in Table C.4.1.
I chose the following six groups of asthma-related events: Triggers of asthma in
the patient, disease severity, steps undertaken by GPs to manage asthma control,
spirometry tests to assess lung function, serum eosinophil count, and level of to-
tal IgE. The Read code definitions of these events are shown in Table C.4.3. For
each event group, I calculated the proportion of patients in the sub-cohort who
had at least one code over their follow-up period. For the first three groups, the
follow-up period was four years from the diagnosis date. This was an appropriate
period to allow equal follow-up for all patients in the cohort within the date range
of the available GP data at the time of data extraction. For the events of lung
function, eosinophil count, and total IgE, the follow-up period was similar except
that it also included three months before the diagnosis date. This was because
these diagnostic procedures could have been performed before the diagnosis was
confirmed and recorded.
I also examined the recorded values for 54 Read codes for lung function testing
(see Table 4.7). I calculated the percentage of missing values and inspected the
distributions of the recorded values. Usually, event values only include numerical
data. For values represented as percentage, there was no percent sign (%) and
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therefore theywere not directly distinguishable from other data formats. Nonethe-
less, the intended values can be often easily inferred from the event description.
4.5.3 Results
The sub-cohort included 127,303 asthma patients, 55.1% of whom were females.
4.5.3.1 Recording of event groups
Table 4.6 shows percentages of patients with at least one recording of key asthma-
related GP events over the follow-up period. 81.6% of the patients had at least
one event code for lung function testing. In addition, 52.5% of the patients had
at least one event code for serum eosinophil count. However, for the other event
groups, the proportion were smaller: 9.7% for asthma control steps, 4.8% for
asthma triggers, 1.8% for asthma severity, and 1.2% for total serum IgE.
Table 4.6: Percentages of patients with at least one recording of key asthma-related GP events over
specified periods from diagnosis.
GP Event % of patients (95% confidence interval)
Asthma triggers * 4.8 (4.7, 4.9)
Asthma severity * 1.8 (1.8, 1.9)
Asthma control steps * 9.7 (9.6, 9.9)
Lung function test ** 81.6 (81.4, 81.8)
Serum eosinophil count ** 52.5 (52.2, 52.7)
Serum total IgE ** 1.2 (1.1, 1.2)
GP = general practitioner; IgE = immunoglobulin E.
* In the four years after diagnosis date.
** From three months before to four years after diagnosis date.
4.5.3.2 Quality of values of lung function events
For the recorded lung function events, values were missing in 11.4% of these
events. The lowest proportion of missingness was for predicted peak expiratory
flow rate (PEFR) using the 13826 European Standard6 (0.3% [95% confidence
interval (CI): 0.2-0.4%]), while the highest proportion was for percentage of pre-
dicted vital capacity (93.5% [81.1-98.3%]). Results for the rest of the codes are
shown in Table 4.7).
Figure C.5.1 includes visualisation of lung function event values using beanplots
[304] which show distribution density and makes it easy to spot anomalies in data
6This standard specifies the requirements for peak expiratory flow meters which is designed to be
used to evaluate lung function in humans with spontaneous breathing [303].
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Table 4.7: Percentages of missing values for lung function event codes.
Event
code
Event description Number of
all events
Number of
events with
missing values
Percentage of events
with missing values
Percent-
age
95%
confidence
interval
3395. Peak exp. flow rate:
PEFR/PFR
320,621 5,869 1.8 (1.8-1.9)
339A. PFR - before bronchodilation 45,657 750 1.6 (1.5-1.8)
339H. Predicted peak flow 35,741 127 0.4 (0.3-0.4)
339p. Predict PEFR using
EN13826 std
25,121 73 0.3 (0.2-0.4)
339g. Serial peak expiratory flow
rate
23,325 2,371 10.2 (9.8-10.6)
339M. FEV1/FVC ratio 19,962 361 1.8 (1.6-2.0)
339R. FEV1/FVC percent 18,974 1,503 7.9 (7.5-8.3)
339S. Percent predicted FEV1 14,866 1,920 12.9 (12.4-13.5)
339o. PEFR using EN 13826 device 14,206 112 0.8 (0.7-1.0)
339B. PFR - after bronchodilation 13,140 437 3.3 (3.0-3.7)
339P. Expected FEV1 7,186 55 0.8 (0.6-1.0)
339C. PFR - expected 6,436 144 2.2 (1.9-2.6)
339D. PFR - best ever 6,284 65 1.0 (0.8-1.3)
339Q. Expected FVC 5,086 31 0.6 (0.4-0.9)
339i. FVC/Expected FVC percent 4,735 1,655 35.0 (33.6-36.3)
339b. FEV1 after bronchodilation 3,843 148 3.9 (3.3-4.5)
339n. Serial PEFR abnormal 3,570 2,349 65.8 (64.2-67.4)
339N. Expected FEV1/FVC ratio 3,212 105 3.3 (2.7-4.0)
745D4 Post bronchodilator
spirometry
3,137 2,668 85.0 (83.7-86.3)
339a. FEV1 before bronchodilation 2,680 114 4.3 (3.5-5.1)
339E. PFR >80% of predicted 2,405 1,174 48.8 (46.8-50.8)
339m. FEV1/FVC ratio after
bronchodilator
2,344 74 3.2 (2.5-4)
339T. FEV1/FVC > 70% of
predicted
1,811 810 44.7 (42.4-47.1)
339V. Recorded/predicted PEFR
ratio
1,392 <5 <0.4 *
339d. PEFR post steroids 1,307 338 25.9 (23.5-28.3)
339c. PEFR pre steroids 1,262 169 13.4 (11.6-15.4)
339F. PFR 60-80% of predicted 1,171 553 47.2 (44.3-50.1)
339l. FEV1/FVC ratio before
bronchodilator
1,083 59 5.4 (4.2-7.0)
66Yc. Num consecutive days
<80% PEFR
956 83 8.7 (7.0-10.7)
339U. FEV1/FVC < 70% of
predicted
838 314 37.5 (34.2-40.9)
339u. Peak inspiratory flow rate 799 642 80.4 (77.4-83)
33950 Diurnal variation of PEFR 753 302 40.1 (36.6-43.7)
339G. PFR <60% of predicted 640 251 39.2 (35.4-43.1)
339O1 FEV1/vital capacity ratio 344 7 2.0 (0.9-4.3)
339L. Expected peak flow rate x
80%
329 <5 <1.5 *
339I. Expected peak flow rate x
50%
327 <5 <1.5 *
339K. Expected peak flow rate x
30%
325 <5 <1.5 *
339O0 FEV1 reversibility 170 7 4.1 (1.8-8.6)
339X. Percentage of best ever
PEFR
162 <5 <3.1
339Y. Percentage of PEFR
variability
155 23 14.8 (9.8-21.6)
339r. FEV1/VC percent 118 86 72.9 (63.8-80.5)
339f. FEV1 post steroids 69 <5 <7.2 *
339S0 Percentage predicted FEV1
after bronchodilation
69 8 11.6 (5.5-22.1)
339e. FEV1 pre steroids 48 <5 <10.4 *
* Value masked to comply with the SAIL Databank’s disclosure policy.
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Table 4.7: Percentages of missing values for lung function event codes. (cont’d)
Event
code
Event description Number of
all events
Number of
events with
missing values
Percentage of events
with missing values
Percent-
age
95%
confidence
interval
339t. Percentage of predicted VC 46 43 93.5 (81.1-98.3)
339Z. Respiratory flow rates NOS 39 27 69.2 (52.3-82.5)
339s. FVC before bronchodilation 34 16 47.1 (30.2-64.6)
339k. FEV1/FVC ratio post steroids 21 <5 <23.8 *
339J. Optimal peak flow rate 21 <5 <23.8 *
339W. Worst peak flow rate 12 <5 <41.7 *
33972 FEV1 after change of
bronchodilator
7 <5 <71.4 *
339j. FEV1/FVC ratio pre steroids 5 <5 * *
33951 PEFR after exercise <5 <5 * *
* Value masked to comply with the SAIL Databank’s disclosure policy.
and multimodal distributions. For most of the lung function testing events, the
distribution of the recorded values appeared to be consistent with the expected
units and ranges. For example, event values such as the forced expiratory volume
in the first second (FEV1) and expected forced vital capacity (FVC) appeared to
be recorded mostly in litres as expected, but with few apparent percentage val-
ues. For event values that were expected to be recorded as percentages, most
of the values appeared to be percentages, with few values, for some event types,
recorded as simple ratios. Examples included percent predicted FEV1, percent of
actual to expected FVC, FEV1/FVC ratios, FEV1/vital capacity (VC) ratio, record-
ed/predicted PEFR ratio, and percentage of best ever PEFR. FEV1 reversibility
had a large peak between 1 and 10, with a small peak at 100. Post-bronchodilator
spirometry (745D4) values distributed mostly between 200 and 500, likely rep-
resenting the change in FEV1 in millilitres from before and after bronchodilator
administration.
4.5.4 Interpretation
Based on the above-studied asthma-related events, the recording of events and
their values varied widely between event groups. Events that document asthma
triggers, severity, and steps tomanage the disease control were occasionally recorded.
These events are important for asthma studies concerned in disease activity and
management. Blood eosinophil count is usually a part of the full blood count test
which can be performed for many indications other than asthma (e.g., for women
in pregnancy). Blood eosinophil count can be used to predict severe exacerbations
4.6. Discussion 135
and poor asthma control [305]. However, this test was only available in the GP
dataset for about half of the studied patients. Future developments in automatic
reporting of results may change this.
Lung function tests, particularly PEFR, were relatively better recorded. However,
codes for airway obstruction reversibility tests were underrecorded. They are ex-
amples of events for which numerical measurements are supposed to be recorded
along with the event code. However, this analysis demonstrated that the values
of these events showed variable levels of missingness and inconsistency. Bimodal
distributions were common among these event values. One apparent reason is the
diﬀerent ways test results were recorded by healthcare professionals. Many of the
values that were supposed to be recorded as either percentages or simple ratios
were recorded in both formats, one of which was often dominant. For events such
as FEV1 before bronchodilation, a possible explanation of the bimodal distribu-
tion is that GPs had diﬀerent understanding of the unit in which the event values
should be recorded (e.g., litres vs. percent or change). A longitudinal between-GP
practice analysis of these values could be helpful in evidencing these potential
explanations.
4.6 Discussion
4.6.1 Summary of the Observatory design and data quality
The Wales Asthma Observatory represents a regularly updated asthma registry.
It also oﬀers a platform for various types of asthma epidemiological research and
a surveillance tool to inform health policy and service planning. While traditional
disease registries use de novo data collection, the Observatory represents an un-
traditional approach to disease registry as it mainly uses RCD to identify and de-
scribe cases.
The Observatory included patients who satisfied one or more of multiple case
definitions for asthma, including the one developed in Chapter 3. Patients were
longitudinally characterised using a number of key asthma outcomes. Improving
eﬃciency and reproducibility of data extraction was considered in the Observatory
structure and user interface. The Observatory data are versioned, and the user
interface allows rapid, reproducible, reusable, and shareable data extraction.
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However, I demonstrated a traditional problem of using RCD: suboptimal quality
of data. There were various patterns of missingness and inconsistency in asthma
data in Wales. Many lung function tests were recorded without measurements.
When recorded, measurements of some tests were inconsistent.
4.6.2 Strengths and opportunities
The Wales Asthma Observatory project has several strengths. It relies on inexpen-
sive, sustainable, and regularly updated sources of routine data in the SAIL Data-
bank. The wide-to-complete national coverage of the SAIL datasets enables per-
forming representative, population-based studies with large number of patients.
This opportunity is usually not available through other traditional sources of data
such as national surveys and primary data collected by researchers. The avail-
ability of several case definitions to identify asthma patients provides researchers
with flexibility and ability to compare their findings with studies performed else-
where using various case definition. In addition, the Observatory benefits from a
collaborative platform to share clinical code lists and data extraction procedures
within research teams and, in the future, with the wider research community and
the public as well. This collaborative platform is intended to save analyst time,
to improve collaboration and sharing of methods, as well as to support research
documentation, reproducibility and transparency.
4.6.3 Challenges and limitations
4.6.3.1 Primary care-based case definition of asthma may exclude some
patients
The asthma case definitions used in the Observatory, including the inclusive and
strict ones, were based on primary care data only. This was justified as asthma in
the UK is managed mostly in primary care [32].
However, it is possible that some people with asthma may not be captured by the
primary care dataset (WLGP). The WLGP dataset currently covers only ~80% of
GP practices (see Section 4.3.3). This means that people with asthma who never
registered at those participating practices were not included in the Observatory.
In addition, it is possible that some people had presented with acute asthma symp-
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toms at A&E departments and/or were hospitalised for asthma without being cap-
tured by GP data-based case definitions of asthma used in the Observatory.
Therefore, the Observatory would benefit from using secondary care data in iden-
tifying asthma patients, which will be considered in future developments.
4.6.3.2 Inherent limitations of routine data
Limitations of routine data for use in research are discussed in Chapters 2 and
3. The use of these data in disease registries is challenged by a range of limita-
tions. For example, these data are usually collected for clinical and administra-
tive purposes in mind and therefore may not be readily appropriate for secondary
uses such as disease surveillance, service planning, or research. Despite the wide
use of standardised clinical coding schemes such as ICD-10 or Read codes, EHR-
derived data collected over many years often lack standardisation as the same
piece of clinical information may be recorded in diﬀerent forms [233, 306].
Case definitions are a core part of a disease registry or observatory. However, de-
veloping accurate case definitions based on routine data is challenging. Disease
registries that are built using active reporting of individual cases have the advan-
tage of individual-level assessment of eligibility, often using confirmed diagnosis
by clinicians. In contrast, a routine data-based disease registry is populated by
applying the same eligibility criteria en masse to all people in a large population
in a database [213], which can introduce high risk of misclassification. In addition,
it has been shown than methods to estimate asthma prevalence from routine data
may be inaccurate [307].
4.6.3.3 Traditional methods to define cases and outcomes may need re-
consideration
In Chapter 2, I found significant heterogeneity in the definitions of asthma and
asthma outcomes. There were variations, not only in the types of health events
used to assess the disease, but also in the time interval over which these health
events are queried. These query intervals should be chosen based on stability of
disease statuses over time [251]. Longer intervals may conceal important tempo-
ral variations of the measured disease status. Conversely, shorter intervals may in-
troduce unrealistic temporal variations. The case definitions currently supported
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by the Observatory use 12-month intervals. This has been traditionally the most
frequently used interval in research and for clinical and administrative purposes
(e.g., for the QOF). However, evidence is lacking about whether 12 months is the
best interval over which asthma activity, severity, and control are assessed. There-
fore, further studies are needed to choose the most appropriate and meaningful
interval for each of these variables.
4.6.3.4 Implications of the suboptimal quality of asthma-related routinely
collected data on asthma research
Data gaps undermine the ability of routinely collected EHR data to inform asthma
care [308] and support research. Significance and implications of data gaps are
specific to how data are used. For example, gaps in lung function data make it dif-
ficult to assess asthma severity, which could be alternatively assessed by asthma
medications [309]. Similarly, unavailability of medication dispensing data is a sig-
nificant limitation in adherence studies. In contrast, such gaps are unlikely to be
an issue in prevalence studies that rely on physician’s diagnosis codes.
Guidelines in the UK recommend performing airway obstruction reversibility tests
when asthma diagnosis is uncertain [16]. An essential objective part of the clin-
ical diagnosis of asthma is to confirm the airway obstruction reversibility, which
often strongly indicates an asthma diagnosis and rules out chronic obstructive pul-
monary disease (COPD). Reversibility data would allow identification of a patient
subgroup with very high certainty of asthma diagnosis. However, I found that
codes of these tests were under-recorded in the GP dataset. One explanation is
that a significant number of lung function tests were performed in secondary care
settings. A similar gap between the number of diagnosis codes and spirometry
codes were observed in Alberta, Canada [308].
The QOF, arguably, appeared to improve the recording of healthcare events that
are required by its quality indicators (see Table C.1.2). However, the asthma indi-
cators AST001 and AST002, for example, only require event codes to be recorded;
they do not assess the quality and completeness of recorded event measurements
per se [310].
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4.6.3.5 Primary care coding in the UK will change
The primary care data used in the Observatory are coded using Read codes. Read
codes are a clinical coding scheme which covers wide aspects of primary care
encounters. It is the main coding scheme used in primary care in the UK. How-
ever, GP practices in the UK are expected to transition from Read codes to Sys-
tematized Nomenclature of Medicine–Clinical Terms (SNOMED-CT) in 2018 [311].
Therefore, to ensure sustainability of the Observatory, themethods used to identify
patients and assess disease outcomes need to be modified to support SNOMED-CT
coding in due time.
4.6.3.6 Data security and implications of anonymisation
There are important considerations when using de-identified data, such as those
used in the Observatory. Despite replacing people’s identifiers in the SAIL Data-
bank with multiply encrypted unique identifiers (i.e. ALFs), re-identifiability of
patient data is possible unless additional steps are taken. For example, very small
groups of patients with rare combinations of characteristics related to their health
or health care usage may be re-identified if the data are presented in particular
formats. This may be an issue for less common events, such as hospital admissions
or day cases, or complex combinations of multiple broad criteria. For instance,
there could be fewer than five patients who were in a specific age group at a
specific date, lived in a small city, had asthma diagnosis made in a specific year,
and received a very high number of inhalers in a specific year; these combinations
may increase the risk of patient re-identifiability.
To avoid the risk re-identifiability of patients, all outputs from the Observatory
must conform to the SAIL information governance policy [295]. For outputs to
be available outside the Gateway, they must be first reviewed by senior analysts
who assess the output for re-identifiability risk and compliance with the approved
project proposals. In the output data, groups with frequencies smaller than a
certain limit, usually five, must be suppressed from reporting or aggregated with
other groups, and dates are aggregated into time periods.
Risk of patient re-identifiability can be high when person-level information from
diﬀerence sources is publicly available. However, SAIL controls all individual link-
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ages within the databank and does not export individual level data to avoid this
possibility.
Although the use of anonymised data in the Observatory protects patient identi-
ties, it places limits on how these data can be used. For example, a prediction
model can be developed within the anonymised registry using the power of multi-
ple, linked, large volume datasets. Within such an anonymised setting, individual
predictions for anonymous persons can be obtained. Due to anonymisation, how-
ever, it is impossible to link these predictions back to patient records at the point
of care, e.g., a GP surgery. Instead, to use that prediction model at the point
of care, ideally all predictor variables from other care settings (e.g., emergency,
inpatient, and/or outpatient care) that are used in the model development need to
be available at the point of care. However, this is often not feasible. A possible
workaround approach is to develop a prediction model, within the anonymised
registry, using only the types of data that will be available at the point of care.
Then, using sensitivity analysis, the performance of this prediction model can be
compared with a model that is based on all the data sources available in the reg-
istry.
4.6.4 Recommendations for better capture of asthma data
Based on the analysis of data quality that I presented earlier in this chapter, I rec-
ommend that eﬀort needs to bemade to ensure that better data on asthma care are
captured and recorded in EHRs. Wider standardisation of the ways health events
are recorded is particularly needed. This could be achieved though better clinical
coding training of healthcare professionals. Motivating GPs to improve coding
when their time is very short could be potentially achieved by demonstrating the
value of projects using complete coding (e.g., those already performed using the
SAIL Databank7). EHR systems should facilitate standardisation of clinical coding
by incorporating on-screen coding advice and better validation rules, which insure
the right data are recorded in the right place and in the expected format. Natural
language processing (NLP) techniques, which are increasingly implemented in
EHR systems to codify narrative data, should consider validity of the produced
coded data. Capture of more accurate and complete data at the point of care will
result in better value and utility of the asthma registry and the Observatory. Pro-
7Examples of studies that used the SAIL Databank can be found in the following links: https://sail-
databank.com/saildata/uses-for-sail-data/ and https://saildatabank.com/saildata/sail-publications/
4.6. Discussion 141
fessional societies representing primary and secondary care respiratory medicine
could be the most appropriate groups to lead eﬀorts to improve the quality of cap-
tured data. In addition, implication of data quality and the lack thereof on patient
care, service planning, and research needs to have more presence in venues of
continued professional education and research meetings to make clinicians more
data conscious. Furthermore, payment for performance schemes such as the QOF
need to consider the quality and completeness of the recorded data in addition to
their quantity [284] as added incentives.
4.6.5 Future development
Although the Wales Asthma Observatory benefits from rich sources of routine data
in the SAIL Databank, data about several aspects of healthcare are still missing.
These include clinical, laboratory, andmedication prescribing data from secondary
care, as well as community medication dispensing data. However, endeavours are
currently under way to link the all-Wales pathology data to the SAIL Databank as
well as to increase the depth of coding of clinical correspondences using NLP tech-
niques. Using these data in the Observatory would enable highly useful research
applications such as improving accuracy of asthma case definitions and disease
phenotyping. Environmental data including data on housing quality, pollution,
greenness, use of outdoor spaces, commuting routes, and modes of transport can
be also linked to the Observatory in order to answer questions about the eﬀect of
various environmental factors on asthma outcomes [300, 312, 313].
Emerging sources of data such as data from smart inhalers and wearable tech-
nologies, despite being currently of limited use, can be later used to enrich the
asthma registry with important variables about disease activity and medication
usage and adherence over time. Asthma-related PROMs can be of high signif-
icance to clinical care and research [314]. Future development of the asthma
registry can include developing platforms to collect asthma-related PROMs and
link them to asthma-related routine data. This will enable investigating the re-
lationship between doctor-reported and self-reported asthma outcomes and will
allow assessing the association of PROMs with each of health services utilisation
patterns, health care quality, and health care inequalities.
An LHS of asthma in Wales is needed to close the gap between evidence and
practice. By facilitating near real-time disease surveillance, the Wales Asthma
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Observatory can be a building block which would help this ambitious project to
materialise.
4.7 Conclusion
The Wales Asthma Observatory represents an untraditional approach to a disease
registry, and a platform for research and surveillance. In this chapter, I described
development of the Observatory, including purpose, source population, structure,
content, and technical logistics.
The quality of asthma related data in Wales is suboptimal. There were various
patterns of missingness and inconsistency in these data. Many lung function tests
were recorded without measurements. When recorded, measurements of some
tests were inconsistent. To improve the capture of asthma data, I proposed en-
hanced EHR data entry quality checks, data quality awareness training for health-
care professionals, and data quality based incentivisation of health care providers.
I described approaches to improve eﬃciency and reproducibility of studies that
will use the Observatory. I developed an easy-to-use user interface that supports
shareable, reusable, and scalable data extraction from the Observatory and the
GP dataset.
Further developments to the Observatory will provide linkage to additional RCD
sources and PROMs, and adaptation to the upcoming clinical coding system, SNOMED-
CT.
Chapter 5
Inequalities in asthma care
and outcomes in Wales
In the previous chapters, I have discussed the development of the Wales Asthma
Observatory. In this chapter, I demonstrate an example of utilising the Observatory
to inform health policy. Variations in asthma outcomes between population groups
have been widely reported worldwide. These inequalities can be assessed using
area-based deprivation indices. An important application of the Wales Asthma
Observatory in supporting health policy is to investigate whether inequalities in
asthma care and outcomes exist between socioeconomic groups. In this chapter,
I investigated the variations in the incidence of asthma-related healthcare utili-
sation in primary and secondary care among asthma patients in Wales across the
quintiles of theWelsh Index ofMultiple Deprivation. I found wide social gradient in
asthma where patients in the most deprived areas had remarkably more asthma-
related hospitalisations indicating poorer outcomes. I also discuss the implications
of these findings on health policy.
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5.1 Introduction
5.1.1 Asthma variations are common
The epidemiology of asthma and asthma outcomes exhibits variations around the
world. The International Study of Asthma and Allergies in Childhood (ISAAC)
revealed wide geographical variations in the prevalence of self-reported asthma
diagnosis. There were twenty-fold variations in the prevalence of self-reported
asthma between the study centres around the world [48, 315]. The variations
were not only seen between countries but also within countries and within cities
such asMexico City andNew York city [37]. In the United Kingdom (UK), moderate
variations have existed between its member countries in the prevalence and inci-
dence of asthma, based on self-reported and doctor-reported data [43]. However,
there were limited variations between UK metropolitan and non-metropolitan ar-
eas, with the latter having slightly higher prevalences [316].
Studying the variations in asthma epidemiology can potentially help understand
the aetiological factors and determinants of the disease. It has been suggested
that the geographical variations in asthma epidemiology result from complex inter-
action of numerous factors. The eﬀect of environmental determinants on asthma
has been extensively studied. Air pollution has been linked to asthma epidemiol-
ogy. There is contradictory evidence on whether air pollution is associated with
increased asthma incidence and prevalence [317, 318], with a suggestion that ad-
verse eﬀects of traﬃc-related air pollution tend to be close to major roads [318].
It is more evident, however, that air pollution increases the incidence of asthma
exacerbations among people who already have the disease [318, 319]. Climate has
been also suggested to influence the prevalence of asthma symptoms. Data from
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146 centres of the ISAAC study showed that in Western Europe the prevalence of
asthma symptoms in school children was positively associated with indoor humid-
ity, and negatively associated with temperature, outdoor humidity, and altitude
[320].
Socioeconomic determinants have been also found to influence asthma epidemi-
ology. In 1973, Mitchell et al. found that in Scotland, severe asthma was more of-
ten observed in children of semi-skilled and unskilled manual worker parents and
children of larger families [321]. A systematic review has found that lower socioe-
conomic status is associated with higher asthma prevalence [322]. In England, a
study in the early 1990s found that asthma hospital admissions rates were higher
in areas with high deprivation where most admissions came via Accidents and
Emergency departments rather than referrals from general practitioners (GPs)
[323]. Another study in Cardiﬀ found that hospital admission rates for asthma
were correlated with the level of social deprivation [324]. Those hospital admis-
sion rates were, however, not correlated with the prevalence of asthma or wheez-
ing but with the prevalence of chronic phlegm and the exposure to second-hand
smoke at home. Low socioeconomic status was associated with less treatment in
wheezy children [325] and poorer asthma control and persistent airway obstruc-
tion in adults [326].
Variations in asthma epidemiology, especially those ascribed to socioeconomic
factors, highlight inequalities in health and health care and represent important
challenges to health policy.
5.1.2 Inequality and inequity in health and health care
Health inequalities have been defined by the World Health Organisation [327] as:
“diﬀerences in health status or in the distribution of health determinants between
diﬀerent population groups”. Uneven distributions of health status and its de-
terminants may result from numerous factors creating advantages and disadvan-
tages that accumulate over the course of life [328]. The term health inequalities
is a descriptive term that is often used to describe those uneven distributions in
health status and determinants and that do not per se imply moral judgement
[329]. Some forms of health inequalities are practically unavoidable and do not
represent injustice. Examples include health disparities that result from biolog-
ical diﬀerences between population groups or external factors, such as natural
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environment, over which they usually do not have control. Arguably, individuals’
‘free choices’ may also contribute to health inequalities [327], although this is
debatable since individuals’ ‘free choices’ can be influenced by the environment
in which they live [330]. However, other disparities in health result from unneces-
sary, unfair, and unjust variations in health determinants, in which case they are
called health inequities [327, 331]. The concept of health inequity has attracted
hot debate and controversy [329], and since it is based on value judgement, it is not
easy to determine which health inequalities are universally inequitable. Braveman
et al. (2003) presented an operationalised definition of health equity: “Equity in
health is the absence of systematic disparities in health (or in the major social
determinants of health) between groups with diﬀerent levels of underlying social
advantage/disadvantage—that is, wealth, power, or prestige” [332].
In epidemiological studies, health inequalities are often assessed by comparing
health status and determinants between social groups in the population. In large
epidemiological studies, however, individual-level data on socioeconomic status
may not be available, and collecting these data from the study individuals is im-
practical. In these studies, area-based measures of socioeconomic status and de-
privation have been widely used to study health inequalities.
5.1.3 Area-based socioeconomic measures
5.1.3.1 Overview
The diﬀerent socioeconomic factors can have accumulating, interactive eﬀects on
the individual’s health over the course of life [328, 333]. Some of these factors,
such as income, employment, and educational attainment, act on the individual
level. On the other hand, factors related to the community and environment act
on the group and area levels and may have eﬀects on the person’s health status
independent from individual health determinants [334, 335]. To account for those
complex and interacting factors, area-based socioeconomic measures have been
developed, usually using census data, to provide ‘simple’ socioeconomic profiles
and ranks for geographic areas [336]. These measures can be based on a single or,
more commonly, multiple components representing diﬀerent socioeconomic fac-
tors [333]. Area-based socioeconomicmeasures have been widely used in epidemi-
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ological studies to assess the eﬀect of socioeconomic status on health, although
they are most commonly used as control variables and confounders [333].
In the UK, examples of area-based socioeconomic measures include:
• Townsend’s Index [337],
• Index of Multiple Deprivation (England) [338],
• the Scottish Index of Multiple Deprivation [339], and
• the Welsh Index of Multiple Deprivation [340].
5.1.3.2 The Welsh Index of Multiple Deprivation
TheWelsh Index ofMultiple Deprivation (WIMD) is the oﬃcial area-basedmeasure
of relative socioeconomic deprivation in Wales. The WIMD is based on socioeco-
nomic indicators that represent aggregate characteristics of residents in the area
and/or describe the area itself. TheWIMDwas commissioned by theWelsh Govern-
ment to create a measure to understand relative diﬀerences in deprivation, based
on several domains measured at a small area level across Wales. The WIMD was
designed a tool to inform the development of policies and allocation of funding so
that they target the most disadvantaged communities [341]. The WIMD index is
updated every few years, with versions released in the years 2000, 2005, 2008,
2011, and 2014.
The WIMD 2011 index is constructed from weighted sum of eight deprivation do-
mains, each is composed of several deprivation related indicators. According to
the WIMD 2011 Technical Report [342], those deprivation domains include the
following, ordered by weighting: Income, Employment, Health, Education, Ge-
ographical Access to Services, Housing, Physical Environment, and Community
Safety. I provide an overview for these deprivation domains including how they
were constructed.
1. Income domain This domain is based on the proportion of residents in a
given area with low income or those who claim income-related benefits, and
has a 23.5% weighting in the overall WIMD 2011 index.
2. Employment domain This domain represents the proportion of residents in
the working age in a given area who have employment-related deprivation
(i.e. receiving benefits related to employment). This domain has a 23.5%
weighting in the overall WIMD 2011 index.
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3. Health domain This domain captures the health-related deprivation, and is
constructed from four indicators including limiting long-term illness, death
rate in the area from all causes, incidence of cancer, and low birth weight.
This domain has a weighting of 14% in the overall WIMD 2011 index.
4. Education domain This domain reflects the deprivation relating to edu-
cational attainment in a given area among children and young residents as
well as the lack of educational qualifications and skills among adults. It is
constructed from average school scores of children, proportion of residents
not in higher education at the age of 18 or 19, proportion of residents aged
25 or above with no educational qualifications, and proportions of half day
absence among children in primary and secondary schools. This domain has
a weighting of 14% in the overall WIMD 2011 index.
5. Geographical Access to Services domain This domain captures the depri-
vation relating to inaccessibility of necessary services to each household in
a given area. Inaccessibility to a service is measured by the average time
needed to reach it using the shortest trips by bus and/or by walking. The ser-
vices include National Health Service dentists, food shops, GPs, Post Oﬃce,
primary and secondary schools, leisure centres, and transport nodes. This
domain has a weighting of 10% in the overall WIMD 2011 index.
6. Housing domain This domain represents the level of disadvantage due to
lack of adequate housing, and is constructed from indicators including pro-
portion of residents who lack central heating in their households, and pro-
portion of residents who live in overcrowded households. This domain has a
weighting of 5% in the overall WIMD 2011 index.
7. Physical Environment domain This domain represents the disadvantage
from environmental factors in a given area that can aﬀect the quality of life.
These factors include air quality and pollution, emissions, risk of flooding, and
distance to waste disposal and industrial sites. This domain has a weighting
of 5% in the overall WIMD 2011 index.
8. Community Safety domain This domain reflects the level of safety and pro-
tection from crimes in a given area. It is constructed from indicators includ-
ing the proportions of oﬀenders among adults and young people, numbers of
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burglaries, criminal damages, thefts, violent crimes, and fire incidents. This
domain has a weighting of 5% in the overall WIMD 2011 index.
The WIMD index is produced for all Lower Layer Super Output Areas (LSOAs)
in Wales. LSOAs were outlined by the Oﬃce for National Statistics of the UK
for census related purposes [343]. LSOAs vary widely in spatial size but they are
intended to have comparable population sizes; according to theWIMD 2011 index,
the average population in those small areas was ≈1,600 people in that year [341].
The WIMD index gives a rank from 1 (most deprived) to 1,896 (least deprived) to
the 1,896 LSOAs in Wales.
Themost deprived areas inWales are distributedmostly in the southern areas such
as Rhondda Cynon Taf, Blaenau Gwent, as well as the east and north of Swansea,
pockets in Newport, and the south and east of Cardiﬀ (Figure 5.1).
Limitations of the WIMD index
A relative ranking measure
WIMD is a ranking system in which areas are ordered according to their sum of
weighted deprivation scores. However, it does not quantify the level of depriva-
tion, and therefore it does not quantify the diﬀerences in deprivation between
areas [341]. That is, the WIMD index can tell that an area has a higher or lower
multiple deprivation than another area, but it does not tell by how much.
It describes areas, not residents
Being an area-based measure, the WIMD is intended to describe the relative mul-
tiple deprivation in the area as a whole based on average scores of individuals.
Therefore, it does not imply that all the residents have the same multiple depriva-
tion. For example, it is possible that diﬀerent residents in an area have diﬀerent
types and levels of deprivation. A consequence of this limitation is that not all
deprived individuals live in the most deprived areas, and not all least deprived
individuals live in the least deprived areas [341]. Rather, it is possible that a num-
ber of individuals with very low deprivation live in areas with overall high depri-
vation. This limitation mainly concerns the deprivation domains that are based on
individual-level data. However, it almost does not apply to the other deprivation
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Figure 5.1: Map ofWales showing ranks of the 2011Welsh Index ofMultiple Deprivation for Lower-level
Super Output Areas. Source: StatsWales, Welsh Government (https://statswales.gov.wales/
Download/File?fileId=91). © Crown Copyright and database right 2011.
domains that use data on the areas themselves, namely the Geographical Access
to Services, Physical Environment, and the Community Safety domains.
It is incomparable with indices in other UK countries
Other UK countries have their own multiple deprivation indices. However, it is
not possible to directly compare these indices with the WIMD index due to the
diﬀerences in the deprivation domains and the ways they are calculated [341].
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5.2 Aims and Objectives
Variations in asthma outcomes between socioeconomic groups represent a signifi-
cant challenge to health policy. While such variations were previously reported on
small, localised populations in Wales [324], a country-wide analysis is needed to
assess the scale of these inequalities. The aim in this chapter is to investigate the
variations of asthma outcomes across the socioeconomic deprivation spectrum in
Wales.
The objectives were as follows:
• To develop count regression models for asthma-related outcomes against the
WIMD index quintiles, adjusted for age group and gender. The count regres-
sion models will be performed in a cohort of ever-diagnosed asthma (regard-
less of current treatment) and in a cohort of ever-diagnosed currently-treated
asthma (‘current asthma’).
The asthma-related outcomes included the following:
– Asthma-related GP events: Any asthma-related visits to GPs
– Asthma routine reviews
– Asthma-related visits to Accident and Emergency departments
– Asthma-related hospital admissions
• To interpret the models in the light of previous studies and strengths and
limitations of the routinely collected data used.
• To reflect on the implications of the findings on health policy in Wales.
5.3 Methods
Using the Wales-wide Secure Anonymised Information Linkage (SAIL) Databank, I
accessed anonymised data on patients with a GP diagnosis of asthma in or before
2009 and continuous GP registration between 2010 and 2014 and linked those
data to the quintiles of the 2011 version of the WIMD. I define the follow-up period
as five calendar years from 2010-1-1 to 2014-12-31.
5.3.1 Data sources
In this analysis, I used the following datasets in the SAIL databank:
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• TheWelsh Demographic Service (WDS): TheWDS contained de-identified
demographic and administrative information for National Health Services
(NHS) patient in Wales.
• The WIMD 2011 dataset: I used the 2011 version of the WIMD index which
was the latest version available in the SAIL Databank. This dataset included
rank quintiles of the overall WIMD index for all small areas (i.e. LSOAs) in
Wales.
• The Welsh Longitudinal General Practice dataset: I described the Welsh
Longitudinal General Practice (WLGP) dataset in Section 3.3.1. I used the
“2018-08-20” version of the dataset.
• The Emergency Department Data Set (EDDS) for Wales: The EDDS
dataset was created in 2009 and captured visits to Accident & Emergency
(A&E) departments as well as minor injury units (MIUs) in NHS hospitals in
Wales. Recorded data for each attendance include investigations performed,
diagnosis made, anatomical areas involved, treatment provided, as well as
other administrative data related to the attendance. Diagnosis is coded us-
ing a three-digit code chosen from a list of 83 possible codes representing
broad diagnostic categories. In addition, to the primary diagnosis, there are
five further positions to record additional or secondary diagnoses. Due to
the nature of emergency attendances, recorded diagnoses may be uncertain
or unconfirmed. Practices of recording and coding of data vary between the
diﬀerent A&E departments and MIUs. The EDDS currently receives data on
all emergency attendances inWales. However, in the earlier years, some A&E
departments were not able to submit their data to the EDDS, and therefore
data in that period may be incomplete. Therefore, caution should be exer-
cised when using this dataset for epidemiological and research analyses.
• Patient Episode Database for Wales: The Patient Episode Database for
Wales (PEDW) database was created in 1991 and includes records for all
planned and emergency inpatient admissions in addition to day case admis-
sions to NHS Wales hospitals as well as most admissions of Welsh residents
to hospitals in England. Recorded data include admission diagnoses, pro-
cedures and operations performed during admissions, as well as length of
stay (LOS), Healthcare Resource Groups (HRGs), and other administrative
data. Admission diagnoses are recorded using the 10th revision of the In-
ternational Classification of Disease (ICD-10). In addition to a mandatory
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primary diagnosis code for a hospital episode, the database allows recording
of an additional subsidiary code and up to 12 secondary diagnosis codes.
The PEDW database is considered of a high quality.1 However, it is mainly
an administrative database which was created as a tool to track hospital fi-
nancial activity rather than for epidemiological or research purposes. The
database also suﬀers from between-hospital variations in practices of coding
of admission diagnosis in the available fourteen diagnosis positions.
5.3.2 The source population and study cohorts
The source population included people who met all the following criteria:
• Had records in the WDS dataset (version 2018-04-10).
• Had records in the WLGP dataset (version 2018-08-20).
• Lived at least to 2014-12-31.
• Were successfully linked to a valid WIMD 2011 ranking.
• Had continuous GP registration in the period between 2010-1-1 and 2014-12-
31, which includes the period over which the outcome events are queried in
addition to one year before it. To calculate GP registration periods for indi-
viduals, I used an unpublished algorithm developed in-house by the analyst
team of the SAIL Databank. I assessed the eﬀect of requiring continuous GP
registration in a sensitivity analysis in Section 5.4.2.4.
From the source population defined above, I created the following two cohorts:
• Cohort 1 included people with asthma diagnosis recorded before 2010-01-01.
• Cohort 2 was a sub-cohort of Cohort 1 in which people received at least one
asthma prescription in any year between 2010 and 2014 (i.e. the follow-up
period), in addition to having asthma diagnosis before 2010-01-01.
Asthma diagnosis was defined using the Read codes "H33%%", "H3120", "1O2..".
Asthma prescriptions were defined using the Read code sets in Appendix E.
5.3.3 Socioeconomic status
I linked each patient to the WIMD quintile of their area of residence during the
follow-up period of 2010-2014. Where a patient had more than one address during
1See http://www.publichealthwalesobservatory.wales.nhs.uk/PEDW
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the follow-up period, I selected the address with the longest duration within that
period. This WIMD quintile variable was coded with 1 (the most deprived) to 5
(the least deprived).
5.3.4 Outcome variables
The outcome variables were counts of asthma-related events in primary and sec-
ondary care in the period from 2010-1-1 to 2014-12-31. The code lists used in
the construction of these variables are shown in Appendix E. The following are
description of each of the outcome variables:
5.3.4.1 Number of asthma-related GP visits
For this analysis, I defined an ‘asthma-related GP visit’ by any Read code that
indicates an asthma-related contact with a GP. Where more than one relevant code
occurred on the same date, I treated them as a single visit.
5.3.4.2 Number of asthma reviews
An asthma review is a special, scheduled visit to GP, in which disease control is
assessed and management plan including prescriptions and self-management ad-
vice is reviewed. Asthma reviews are ideally arranged regularly on at least an
annual basis [16]. To identify asthma reviews from the GP dataset, I used a list of
codes for annual review, medication review, follow-up, monitoring by nurse, and
review using the Royal College of Physicians’ three questions [344].
5.3.4.3 Asthma-related emergency department visits
I identified asthma-related emergency department (ED) visits from the EDDS dataset
using the code 14A (“asthma”). I treated ED visits as asthma-related if it contained
this code in any of the primary or secondary diagnosis positions.
5.3.4.4 Asthma-related hospital admissions
I identified asthma-related hospital admissions from the PEDW dataset by looking
for episode records in which an ICD-10 code for asthma (J45) or status asthmaticus
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(J46) was in the primary diagnosis position or any of the remaining 13 secondary
diagnosis positions.
5.3.5 Statistical analysis
I performed the statistical analyses described below for each of the two study
cohorts.
5.3.5.1 Descriptive statistics
The descriptive statistics described the source population and the two asthma
cohorts. For the source population, I calculated statistics about age and gender
in addition to the prevalence of ever-diagnosed asthma at 2010-01-01 and the
prevalence of ever-diagnosed currently treated asthma over 2010.
For the two asthma cohorts, I calculated the distributions of specific characteris-
tics in relation to the WIMD quintiles. These characteristics included age, gender,
receiving specific types of asthma prescriptions over the follow-up period, and
the four outcomes variables (see above). In addition, I calculated asthma med-
ication ratio, which represents the ratio of controller to controller-and-rescuer
asthmamedications [345]. I included inhaled corticosteroids (ICSs) and ICS-LABA
(long-acting beta adrenoceptor agonist) combination inhalers as controller pre-
scriptions, and included short acting beta agonist (SABA) inhalers as the rescuer
medications. The formula was ICS + ICS_LABA
ICS + ICS_LABA+ SABA calculated over the five
follow-up years. In averaging the ratio, I excluded those who received none of
these three inhaler categories over that period.
5.3.5.2 Variation of age between deprivation quintiles
I used the Kruskal-Wallis rank sum test to test the diﬀerences in age distribution
between quintiles of the overall WIMD index.
5.3.5.3 Count regression
To test the eﬀect of multiple deprivation on each of the four outcome asthma vari-
ables, which were count variables, I developed a count regression model for each
of them. The independent variable was the quintile of the overall WIMD index. I
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tested the distribution of counts for each of the outcome variables and found that
their variances were larger than their means. In addition, there were excessive
numbers of patients with zero counts for each of the outcome variables. There-
fore, I used zero-inflated negative binomial (ZINB) regression, which allows for
over dispersion and models the excess in the zero counts.
A ZINB model assumes that count data are generated by two processes. One of
these is a Bernoulli process which determines whether an individual is theoret-
ically eligible to have a non-zero count [346]. Accordingly, there are individuals
who are not eligible to have non-zero counts and therefore should have no events.
In my study, those individuals were asthma patients in whom the disease was mild
or remitted and therefore they needed no visits to GPs. Those patients would also
have had no need for asthma-related ED visits or hospital admissions. Patients
with more severe but well-controlled disease would also have no asthma-related
ED visits or hospital admissions. On the other hand, for individuals who are el-
igible to have non-zero counts, the counts are assumed to be determined by a
negative binomial distribution which expects some individuals to have no events
and others to have one or more events. In my study, this applied to asthma patients
who had active disease and, depending on disease severity and control as well as
other non-asthma-related factors, might or might not need to have contact with
primary and/or secondary care. To model the above described two processes, a
ZINB model fits two regressions: a logistic regression to model the probability of
having non-zero count, and a negative binomial regression to model themagnitude
of counts.
In this chapter, I used ZINB regression models to model the counts of the above-
mentioned outcome variables in relation to the WIMD index quintile. I considered
the least deprived areas (i.e. the fifth quintile) the reference group. Therefore,
in the resulting model, the exponentiated coeﬃcients for each of the other four
quintiles (1 to 4) represented the incidence rate ratio (IRR) of the relevant events
for that quintile compared with the least deprived areas. I also calculated the
95% confidence intervals (CIs) for these IRRs. I adjusted the model for 5-year age
groups and gender.
I used the zeroinfl function from the R package pscl version 1.4.9 to perform
the zero-inflated negative binomial modelling [347].
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I examined the model fit with quantile-quantile (Q-Q) plots of the raw residuals as
well as with rootograms. Rootograms are graphical representation of both the ob-
served counts as bars, and the expected counts, which are predicted by the model,
as a curve [348]. The axis that represents the counts (i.e. usually the vertical axis)
has a square-root scale. By including both the predicted and observed values in
the same graph, a rootogram helped show the deviation of the predicted counts
from the observed counts. A hanging rootogram has the bars of observed counts
“hanged” on the curve of predicted counts. The deviations of the predicted counts
from the observed counts were shown as deviations from the horizontal axis, and
provided a visualisation of the goodness of fit of the model.
5.4 Results
5.4.1 Descriptive statistics of the source population and study
cohorts
Table 5.1 shows characteristics of the source population. A flowchart of case se-
lection for both asthma cohorts is shown in Figure 5.2.
Table 5.1: Characteristics of the source population in the year 2010 across the WIMD quintiles.
WIMD
1
WIMD
2
WIMD
3
WIMD
4
WIMD
5
no
valid
WIMD
All
Gender (% of females) 50.1 50.2 50.3 50.2 50.4 45.7 50.2
Age mean 36.7 38.9 40.7 41.3 41.9 45.6 39.9
SD (22.0) (22.2) (22.4) (22.5) (22.5) (21.8) (22.4)
Prevalence (%) of ever-diagnosed
asthma
12.0 11.4 11.0 10.9 11.0 9.6 11.2
Prevalence (%) of ever-diagnosed
asthma, currently treated asthma
7.4 7.0 6.8 6.6 6.5 6.2 6.8
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Had a record in the Welsh
Demographic Service
(version 2018-04-10)
5,292,125
Had a record in the Welsh
Longitudinal General Prac-
tice (version 2018-08-20)
4,114,646
Lived at least to 2014-12-31
3,397,973
Had valid registered
addresses between
2010-01-01 and 2014-12-31
to which WIMD 2011
could be linked
2,731,465
Had continuous GP registration be-
tween 2010-01-01 and 2014-12-31
1,940,377
Had asthma diagnosis
recorded before 2010-01-01
218,754
Cohort 1:
People with
ever-diagnosed asthma
Had at least one asthma pre-
scription in every calendar
year between 2010 and 2014
101,509
Cohort 2:
People with
ever-diagnosed
currently treated asthma
Figure 5.2: A flowchart of case selection.
The first cohort included 218,754 patients with ever-diagnosed asthma, while the
second cohort included 101,509 patients with ever-diagnosed currently treated
asthma. Table 5.2 shows basic characteristics of both cohorts.
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Table 5.2: Characteristics of the study cohorts: Cohort 1.
WIMD 1 WIMD 2 WIMD 3 WIMD 4 WIMD 5 All
Number of
patients
N 49,597 43,681 43,570 37,228 44,678 218,754
% 22.7 20.0 19.9 17.0 20.4 100.0
Gender % Females 53.6 52.5 51.8 51.2 50.5 52.0
Age mean 36.7 38.1 39.3 39.8 40.4 38.8
SD 20.1 20.4 20.7 20.7 20.6 20.5
median 33.9 35.9 37.4 38.1 39.2 37.0
IQR 19.8-51.5 20.7-53.7 21.6-55.4 22.2-56.0 22.8-56.1 21.3-54.4
Study outcomes
Asthma-related
GP visits
N 179,149 165,094 198,431 176,769 150,756 870,199
mean count 4.00 4.05 4.11 4.05 3.70 3.98
%with count≥ 1 68.6 69.0 69.3 68.8 67.3 68.6
Asthma reviews N 111,065 97,277 97,656 82,053 98,721 486,772
mean count 2.24 2.21 2.24 2.23 2.20 2.25
%with count≥ 1 62.4 63.1 63.3 63.0 62.6 62.9
Asthma related
A&E visits
N 1,011 848 808 702 621 3,990
mean count 0.020 0.019 0.019 0.019 0.014 0.018
%with count≥ 1 1.5 1.4 1.4 1.4 1.1 1.3
Asthma related
hospitalisations
N 2,390 1,568 1,351 1,037 980 7,326
mean count 0.048 0.036 0.031 0.028 0.022 0.033
%with count≥ 1 2.4 2.1 1.8 1.6 1.4 1.9
Prescriptions
SABA inhalers mean count 19.8 17.1 15.2 13.9 11.8 15.7
% with count≥ 1 71.8 71.4 71.1 70.6 69.6 70.9
ICS inhalers mean count 6.5 5.8 5.5 5.4 5.0 5.7
% with count≥ 1 38.4 38.0 37.8 38.6 37.8 38.1
ICS-LABA
combination
inhalers
mean count 11.7 10.8 10.0 9.1 8.2 10.0
% with count≥ 1 35.9 34.9 34.3 32.7 31.1 33.8
Asthma
medication ratio
mean 0.42 0.43 0.44 0.44 0.45 0.43
Theophylline mean count 0.7 0.6 0.5 0.4 0.3 0.5
% with count≥ 1 1.9 1.7 1.4 1.3 0.8 1.4
Leukotriene
receptor
antagonists
mean count 2.2 2.1 1.8 1.6 1.5 1.8
% with count≥ 1 8.4 8.0 7.6 7.0 6.6 7.6
Oral
corticosteroids
mean count 1.9 1.8 1.8 1.7 1.4 1.7
% with count≥ 1 31.8 30.6 30.7 29.7 26.6 29.9
% of patients
with≥ 1 asthma
prescriptions in
every N years of
the 5-year
follow-up period
0 years 28.5 28.6 28.4 28.9 30.0 28.9
1 year 6.0 6.1 6.2 6.2 6.5 6.2
2 years 5.4 5.5 5.6 5.8 5.7 5.6
3 years 5.5 5.5 5.6 5.7 5.9 5.6
4 years 5.1 5.1 5.3 5.7 5.7 5.4
5 years * 49.4 49.1 49.0 47.8 46.3 48.3
* Patients in this row represent Cohort 2 (patients with ever-diagnosed currently treated asthma).
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Table 5.2: Characteristics of the study cohorts (continued): Cohort 2.
WIMD 1 WIMD 2 WIMD 3 WIMD 4 WIMD 5 All
Number of
patients
N 19,760 23,574 20,657 20,471 17,047 101,509
% 19.5 23.2 20.3 20.2 16.8 100
Gender % Females 59.0 57.2 55.4 54.7 53.7 56.1
Age mean 45.1 46.3 47.0 47.6 47.6 46.6
SD 20.0 20.2 20.6 20.5 20.6 20.4
median 46.5 47.8 48.6 48.7 48.8 48.0
IQR 30.4-60.7 31.6-62.3 32.2-63.3 33.4-63.7 33.6-63.5 32.1-62.7
Study outcomes
Asthma-related
GP visits
N 155,206 137,387 138,218 114,315 125,401 670,527
mean count 6.58 6.65 6.75 6.71 6.35 6.61
%with count≥ 1 98.0 98.0 98.3 98.2 98.7 98.2
Asthma reviews N 90,765 79,034 78,574 65,497 78,302 392,172
mean count 3.9 3.8 3.8 3.8 4.0 3.9
% with count≥ 1 93.6 94.5 94.6 95.0 96.3 94.7
Asthma related
A&E visits
N 825 694 694 552 506 3,271
mean count 0.035 0.034 0.034 0.032 0.026 0.032
%with count≥ 1 2.4 2.3 2.4 2.3 1.9 2.3
Asthma related
hospitalisations
N 2,193 1,381 1,214 895 874 6,557
mean count 0.093 0.067 0.059 0.053 0.044 0.065
%with count≥ 1 4.3 3.8 3.3 3.0 2.6 3.4
Prescriptions
SABA inhalers mean count 38.1 33.0 29.3 27.3 23.7 30.7
% with count≥ 1 98.6 98.1 97.4 97.5 97.5 97.8
ICS inhalers mean count 12.2 10.9 10.4 10.4 9.9 10.8
% with count≥ 1 53.9 53.1 53.8 55.4 55.2 54.2
ICS-LABA
combination
inhalers
mean count 23.7 21.9 20.5 19.0 17.7 20.7
% with count≥ 1 64.9 63.5 62.3 60.3 59.3 62.2
Asthma
medication ratio
mean 0.48 0.50 0.52 0.52 0.54 0.51
Theophylline mean count 1.5 1.3 1.0 0.9 0.6 1.1
% with count≥ 1 3.8 3.5 2.9 2.7 1.8 3.0
Leukotriene
receptor
antagonists
mean count 4.5 4.3 3.6 3.4 3.2 3.8
% with count≥ 1 15.9 15.2 14.3 13.4 13.1 14.4
Oral
corticosteroids
mean count 3.5 3.3 3.2 3.1 2.5 3.1
% with count≥ 1 52.0 49.7 49.1 48.6 44.7 49.0
* All patients in this cohort had one or more prescriptions in every year between 2010-2014.
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Asthma prevalences in the source population across WIMD quintiles
The prevalence of ever-diagnosed asthma in the source population at the begin-
ning of 2010 was 11.2%, ranging from 10.9 in the next least deprived areas (WIMD
4) and 11.0 in the least deprived areas (WIMD 5) to 12.0% in the most deprived
areas (WIMD 1). The prevalence of ever-diagnosed, currently treated asthma dur-
ing the same year was 6.8%, ranging from 6.2 in the least deprived areas (WIMD
5) to 7.4% in the most deprived areas (WIMD 1).
Distribution of WIMD quintiles
In both cohorts, the quintiles of theWIMD rank had comparable shares (Table 5.2),
with the next least deprived quintile (WIMD 4) having the least proportion of in-
dividuals (17.0% and 16.8% in Cohorts 1 and 2) and the most deprived quintile
(WIMD 1) having the highest proportion (22.7% and 23.2% in Cohorts 1 and 2).
Distribution of gender
Females were 52.0% of Cohort 1 and 56.1% of Cohort 2. In both cohorts, the
more deprived areas had higher proportions of females —the gradient in Cohort
1 ranged from 50.5% in WIMD 5 areas to 53.6% in WIMD 1 areas and in Cohort 2
from 53.7% to 59.0% in those areas, respectively.
Distribution of age
Cohort 1 was younger than Cohort 2. The mean age in Cohort 1 was 38.8 years
with a standard deviation (SD) of 20.5, a median of 37.0, and an inter-quartile
range of 21.3-54.4 years. In Cohort 2, the mean age was 46.6 years (SD = 20.4),
and the median was 48.0 with an inter-quartile range of 32.1-62.7 years.
There were more young people in areas of higher deprivation. The mean age
ranged in Cohort 1 from 36.7 in the most deprived areas (WIMD 1) to 40.4 in
the least deprived areas (WIMD 5) and in Cohort 2 from 45.1 in WIMD 1 areas
to 47.6 in WIMD 5 areas. Kruskal-Wallis rank sum test confirmed the unequal
distribution of age ranks across the five deprivation groups in both cohorts (χ2 =
923.8 and 231.0 for Cohorts 1 and 2, with p-values < 0.0001). Figure 5.3 shows
the distribution of age for each of the WIMD quintiles.
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WIMD 1
WIMD 2
WIMD 3
WIMD 4
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1.2 19.8 33.9 51.5 97.9
1.1 20.7 35.9 53.7 99.5
1.0 21.6 37.4 55.4 100.8
1.3 22.2 38.1 56.0 99.5
0.6 22.8 39.2 56.1 97.4
Age
1.8 30.4 60.7 97.7
1.1 31.7 62.3 95.0
2.0 32.2 63.3 96.5
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Figure 5.3: Distribution of age across WIMD overall rank quintiles in the study cohorts. (a) Boxplots
showing the minimum, maximum, first and third quartiles, median (black lines), and mean (red dotted
lines) of age for each WIMD quintile. (b) Beanplots showing the density of age distribution for each
WIMD quintile. The large black dotted line represents the overall mean, and the smaller red dotted lines
represent the per WIMD quintile means.
Distribution of asthma prescriptions across the deprivation quintiles
In Cohort 1, the more aﬄuent areas had more patients with intermittent or no
asthma treatment over the five follow-up years (Table 5.2). Conversely, the higher
the deprivation, the higher the percentage of patients with continuous asthma
prescriptions.
In Cohort 2, where all patients received asthma prescriptions in each of the follow-
up years, there was a remarkable gradient of more prescriptions with higher de-
privation. For example, in the most deprived areas the average number of SABA
inhalers over five years per patient was 38.1 compared with 23.7 in the most af-
fluent areas, while the gap for ICS inhalers was 12.1 to 9.9, for ICS-LABA combi-
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nation inhalers was 23.7 to 17.7, and for oral corticosteroids (OCS) was 3.5 to 2.5,
respectively, between those areas. It is worth noting that the average controller
to controller-and-rescuer medication ratio in the most deprived areas (0.48) was
lower than that in the least deprived areas (0.54).
Percentages of patients with outcome events overall
68.6% and 62.9% of Cohort 1 patients had recorded asthma GP visits and asthma
reviews, respectively, in the 5-year follow-up period. In comparison, 98.2% and
94.7% of patients in Cohort 2 had no recorded asthma GP visits and asthma re-
views, respectively. In both cohorts, however, only very few patients had recorded
asthma-related A&E visits and hospital admissions (1.3% and 1.9% in Cohort 1,
and 2.3% and 3.4% in Cohort 2). Histograms of the outcome variable counts illus-
trate the skewed data in both cohorts (Figure 5.4).
Average number of outcome events overall
The average counts of outcome events over the five-year follow-up period were
significantly higher in Cohort 2 than in Cohort 1; on averages there were 4.0 and
6.6 asthma-related GP visits, 2.2 and 3.9 asthma reviews, 0.018 and 0.032 asthma-
related A&E visits, and 0.033 and 0.065 asthma-related hospital admissions in
Cohorts 1 and 2, respectively.
Average counts of outcome events in each WIMD quintile
Without adjustment to age group and gender, in Cohort 1, the most deprived areas
had on averagemore outcome events per patient than the least deprived areas (Ta-
ble 5.2): 4.00 vs. 3.70 asthma-related visits to GPs, 2.24 vs. 2.21 asthma reviews,
0.020 vs. 0.014 asthma-related visits to A&E, and 0.048 vs. 0.022 asthma-related
hospital admissions.
In Cohort 2, on average, the most deprived areas had also more asthma-related
visits to GPs (6.58 vs. 6.35), more asthma-related visits to A&E (0.035 vs. 0.026),
more asthma-related hospital admissions (0.093 vs. 0.044), but less asthma re-
views (3.85 vs. 3.96) per patient than the least deprived areas.
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Figure 5.4: Histograms of outcome event counts in the study cohorts.
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Figure 5.5: Average counts of the outcome events between 2010 and 2014 per WIMD rank quintiles in
Cohort 1 and Cohort 2.
Gradients
In both cohorts, despite the gap in asthma GP visits and reviews on the two sides
of the deprivation scale, there were no consistent gradients across the whole de-
privation scale (Figure 5.5). The three middle deprivation areas (WIMD 2, 3, and
4) had on average more asthma GP visits than both the most (WIMD 1) and least
deprivation (WIMD 5) areas, with the middle deprivation areas having the highest
averages in both cohorts. In contrast, for asthma reviews, the WIMD 2, 3 and 4
areas had smaller average counts than WIMD 1 and 5 areas in Cohort 2, with no
clear pattern in Cohort 1.
In both cohorts, although the average counts of asthma A&E visits decreased with
less deprivation, there was no gradient since the least deprived areas (WIMD 5)
had significantly smaller average counts than the other four more deprived areas.
Finally, there were clear gradients of more asthma hospitalisations with higher
deprivation in both cohorts.
5.4.2 Zero-inflated negative binomial regression (ZINB)mod-
els
The outputs of the four ZINB models for each study cohort are shown in Table 5.3.
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5.4.2.1 Incidence rate ratios of study outcomes across deprivation quin-
tiles
Following adjustments for age group and gender, I found statistically significant
diﬀerences in incidence rates of the outcome events between the WIMD quintiles.
For asthma-related GP visits, all the first four WIMD quintiles had statistically
significant IRRs compared to the fifth quintile. Over the five-year follow-up period,
there were 7.8% more predicted events per patient in the most deprived areas
(WIMD 1) than in the least deprived areas (WIMD 5), with predicted counts of 3.94
and 3.65, respectively. In Cohort 2, the diﬀerence in predicted events between the
WIMD 1 and 5 areas was smaller (3.6%), with predicted counts of 6.37 and 6.15
in those areas, respectively. The WIMD 2, 3, and 4 areas had slightly higher IRRs
than WIMD 1 areas in both cohorts.
For asthma reviews, the only statistically significant IRR at the 0.05 level in Cohort
1 was 1.037 (1.025-1.048) for WIMD 1; there were 3.7% more predicted events
in the least deprived areas (WIMD 1, 2.34 events) compared to the least deprived
areas (WIMD 5, 2.25). In Cohort 2, all the IRRs were statistically significant and
slightly less than 1, with an IRR of 0.99 (0.978-0.999) for the most deprived areas
compared to the least deprived areas (with predicted number of asthma reviews
of 3.81 and 3.86, respectively).
For asthma A&E visits, the IRRs for WIMD 1 to 4 areas in Cohort 1 were all sta-
tistically significant, ranging from 1.368 for the most deprived areas (WIMD 1)
to 1.298 for the middle deprivation areas (WIMD 3). There were 36.8% more
predicted asthma-related A&E visits in the most deprived areas than in the least
deprived areas (0.023 vs. 0.016 visits). In Cohort 2, the IRRs were slightly lower
than those in Cohort 1, ranging from 1.229 for the most deprived areas (WIMD
1) to 1.257 for the middle deprivation areas (WIMD 3). There were 22.9% more
predicted asthma-related A&E visits in the most deprived areas than in the least
deprived areas (0.043 vs. 0.035 visits).
In both cohorts, the clear gaps in the predicted asthma-related GP visits and A&E
visits were between the four more deprived quintiles (WIMD 1-4) together, which
showed relatively similar estimates, and the least deprived quintile (WIMD 5).
Lastly, a clear and steep social gradient existed for asthma-related hospital ad-
missions. In Cohort 1, in the most deprived areas, there were 123.2% more pre-
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Figure 5.6: Incidence rate ratios with 95% confidence intervals in both study cohorts for each of the
outcome variables in each of the deprivation quintiles relative to the least deprived quintile, controlled
for age group and gender.
dicted asthma-related hospital admissions than in the least deprived areas (0.074
vs 0.033 predicted asthma admissions, IRR = 2.232 [1.983-2.512]). The gap was
slightly smaller in Cohort 2, where there were 95.5% more predicted asthma-
related hospital admissions in the most deprived areas compared to the least de-
prived areas (0.139 vs. 0.071 predicted asthma admissions, IRR = 1.955 [1.718-
2.226]).
For Cohort 1, all p-values for the IRRs of the outcome variables were less than
0.0001, except those for in the asthma reviews model which were above 0.05. For
Cohort 2, most of the p-values were less than 0.001; the IRRs of asthma reviews
and A&E visits between WIMD 1 vs. WIMD 5 had p-values of 0.031 and 0.006,
respectively.
A visualisation of IRRs of the outcome variables for the WIMD rank quintiles is
shown in Figure 5.6.
5.4. Results 171
● ● ● ● ● ● ● ● ●
●
●
●
● ● ●
●
● ●
● ● ●
●
●
●●
●
●
●
●
●
● ●
● ● ● ●
●
●
● ● ● ●
● ● ●
● ●
●
p = 0.871
p = 0.149
p = 0.843
p = 0.085 p = 0.074 p = 0.133
p = 0.001 p = 0.002
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p = 0.566 p = 0.443
p < 0.001
p < 0.001 p < 0.001
  . 94
p = 0.023
p = 0.002
p = 0.287
p = 0.163
p < 0.001
p < 0.001
p = 0.202
p = 0.021
p = 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001 p < 0.001
p < 0.001
p < 0.001
p < 0.001 p = 0.005
p = 0.007
p < 0.001
p < 0.001
p < 0.001
p < 0.001 p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001 p < 0.001
p < 0.0010.0
0.3
0.6
0.9
1.2
1.0
Age Group
In
ci
de
nc
e 
R
at
e 
R
at
io
0-
4
5-
9
10
-1
4
15
-1
9
20
-3
4
35
-3
9
40
-6
4
65
-6
9
70
-7
4
75
-7
9
80
-8
4
85
-8
9
90
-1
19
●
●
●
●
●
● ● ● ●
●
●
●
●
●
●
●
●
●
● ● ●
●
●
●
●
●
● ● ● ●
● ●
●
● ● ●
●
●
● ● ●
●
● ● ●
● ●
●
p = 0.569
p = 0.001
p < 0.001
p < 0.001
p = 0.469
p < 0.001 p < 0.001
p < 0.001
p < 0.001
p = 0.304
p = 0.083
p = 0.005
p = 0.377
p < 0.001
p < 0.001
p < 0.001
p = 0.004
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p = 0.059
p = 0.027
p = 0.028
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001 p = 0.006
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
p < 0.001
Co
ho
rt 
1
Co
ho
rt 
2
●a
●a
●a
●a
Asthma GP Visits
Asthma Reviews
Asthma A&E Visits
Asthma Hospitalisations
Reference
0.0
0.3
0.6
0.9
1.2
1.0
In
ci
de
nc
e 
R
at
e 
R
at
io
Figure 5.7: Incidence rate ratios with 95% confidence intervals for each of the outcome variables in age
groups relative to the youngest age group (0-4 years), controlled for deprivation quintile and gender.
5.4.2.2 Incidence rate ratios of study outcomes for age groups and gender
IRRs of the outcome variables across age groups are shown in Figure 5.7.2
In both study cohorts, the variations of IRRs, relative to the reference age group 0-
4 years, between age groups were relatively small for asthma GP visits and asthma
reviews but were large for A&E visits and admissions.
2It is worth noting that since age was calculated at the beginning of the follow-up period, IRRs for
patients in a given age group covered their next five years of life; e.g., for patients in the 15-19 age
group, the IRRs covered periods starting at the age of 15 to 19 and ending at the age of 20 to 24,
depending on patient’s age at the beginning of the follow-up period.
172 Chapter 5. Inequalities in asthma care and outcomes in Wales
Table 5.3: Outputs of the zero-inflated negative binomial models. The values shown include the inci-
dence rate ratios and their 95% confidence intervals.
Cohort 1
Outcome Variable ~ WIMD Quintile + Age Group + Gender | 1
Outcome variables
Asthma-related
GP visits
Asthma reviews Asthma-related
A&E visits
Asthma-related
hospitalisations
IRR sig 95% CI IRR sig 95% CI IRR sig 95% CI IRR sig 95% CI
Deprivation Quintile
(reference level: WIMD 5)
WIMD1 1.078 *** 1.066-1.090 1.037 *** 1.025-1.048 1.368 *** 1.201-1.558 2.232 *** 1.983-2.512
WIMD2 1.082 *** 1.070-1.094 1.011 . 0.999-1.022 1.344 *** 1.175-1.537 1.722 *** 1.521-1.950
WIMD3 1.094 *** 1.082-1.107 1.010 . 0.998-1.022 1.298 *** 1.134-1.487 1.408 *** 1.241-1.597
WIMD4 1.083 *** 1.071-1.096 0.992 0.980-1.004 1.358 *** 1.181-1.563 1.357 *** 1.188-1.548
Age Group
(reference level: 0-4 years)
5-9 0.988 0.948-1.030 0.980 0.938-1.024 0.641 * 0.431-0.952 0.490 *** 0.334-0.720
10-14 0.932 *** 0.895-0.971 0.867 *** 0.830-0.905 0.367 *** 0.249-0.541 0.206 *** 0.142-0.301
15-19 0.810 *** 0.778-0.844 0.674 *** 0.645-0.704 0.274 *** 0.186-0.404 0.077 *** 0.053-0.113
20-34 0.888 *** 0.854-0.923 0.746 *** 0.716-0.778 0.255 *** 0.176-0.371 0.097 *** 0.068-0.140
35-39 1.015 0.975-1.057 0.938 ** 0.899-0.979 0.236 *** 0.159-0.350 0.113 *** 0.077-0.166
40-64 1.098 *** 1.057-1.142 1.137 *** 1.091-1.185 0.198 *** 0.136-0.287 0.147 *** 0.102-0.211
65-69 1.112 *** 1.068-1.159 1.295 *** 1.241-1.352 0.116 *** 0.075-0.180 0.098 *** 0.066-0.147
70-74 1.119 *** 1.074-1.166 1.324 *** 1.268-1.383 0.132 *** 0.085-0.207 0.121 *** 0.081-0.183
75-79 1.084 *** 1.039-1.131 1.263 *** 1.208-1.321 0.195 *** 0.124-0.307 0.142 *** 0.093-0.217
80-84 1.025 0.978-1.073 1.187 *** 1.131-1.246 0.145 *** 0.084-0.249 0.206 *** 0.130-0.327
85-89 0.952 . 0.900-1.007 1.058 . 0.998-1.122 0.111 *** 0.052-0.236 0.184 *** 0.103-0.326
90-119 0.855 ** 0.767-0.953 0.872 * 0.772-0.985 0.099 ** 0.019-0.508 0.057 *** 0.014-0.227
Gender
(reference level: male)
Female 1.042 *** 1.034-1.049 1.100 *** 1.092-1.109 1.708 *** 1.568-1.860 2.310 *** 2.132-2.503
Intercept 5.051 *** 4.857-5.252 2.994 *** 2.873-3.121 0.042 *** 0.029-0.061 0.088 *** 0.061-0.127
Log
likelihood
-520934.8 -415837.7 -17497.8 -24249.9
Significance codes: • p<0.1; ∗ p<0.05; ∗∗ p<0.01; ∗∗∗ p<0.001; IRR: incidence rate ratio.
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Table 5.3: Outputs of the zero-inflated negative binomialmodels (continued). The values shown include
the incidence rate ratios, statistical significance, and their 95% confidence intervals.
Cohort 2
Outcome Variable ~ WIMD Quintile + Age Group + Gender | 1
Outcome variables
Asthma-related
GP visits
Asthma reviews Asthma-related
A&E visits
Asthma-related
hospitalisations
IRR sig 95% CI IRR sig 95% CI IRR sig 95% CI IRR sig 95% CI
Deprivation Quintile
(reference level: WIMD 5)
WIMD1 1.036 *** 1.025-1.046 0.989 * 0.978-0.999 1.229 ** 1.060-1.424 1.955 *** 1.718-2.226
WIMD2 1.049 *** 1.038-1.060 0.975 *** 0.964-0.985 1.238 ** 1.063-1.442 1.489 *** 1.299-1.706
WIMD3 1.065 *** 1.054-1.076 0.977 *** 0.966-0.987 1.257 ** 1.079-1.464 1.267 *** 1.104-1.455
WIMD4 1.060 *** 1.048-1.071 0.975 *** 0.964-0.986 1.259 ** 1.072-1.478 1.238 ** 1.070-1.434
Age Group
(reference level: 0-4 years)
5-9 0.996 0.954-1.041 0.987 0.943-1.032 0.749 0.480-1.168 0.545 ** 0.350-0.849
10-14 1.032 0.989-1.077 0.983 0.940-1.027 0.595 * 0.383-0.923 0.335 *** 0.216-0.520
15-19 1.004 0.962-1.049 0.914 *** 0.874-0.956 0.471 ** 0.301-0.738 0.148 *** 0.094-0.234
20-34 0.965 . 0.926-1.005 0.867 *** 0.830-0.904 0.380 *** 0.250-0.579 0.134 *** 0.088-0.204
35-39 0.963 . 0.923-1.004 0.876 *** 0.839-0.915 0.228 *** 0.147-0.354 0.104 *** 0.067-0.160
40-64 0.969 0.931-1.009 0.973 0.933-1.014 0.150 *** 0.099-0.227 0.107 *** 0.071-0.162
65-69 0.933 ** 0.895-0.973 1.052 * 1.007-1.098 0.078 *** 0.048-0.125 0.058 *** 0.037-0.091
70-74 0.936 ** 0.897-0.976 1.072 ** 1.027-1.120 0.089 *** 0.055-0.144 0.073 *** 0.047-0.115
75-79 0.908 *** 0.870-0.949 1.025 0.980-1.072 0.137 *** 0.084-0.222 0.089 *** 0.056-0.142
80-84 0.867 *** 0.828-0.908 0.966 0.921-1.014 0.102 *** 0.057-0.181 0.121 *** 0.074-0.199
85-89 0.828 *** 0.784-0.874 0.871 *** 0.822-0.922 0.084 *** 0.039-0.184 0.116 *** 0.063-0.211
90-119 0.763 *** 0.689-0.845 0.718 *** 0.641-0.804 0.096 ** 0.019-0.489 0.015 *** 0.002-0.132
Gender
(reference level: male)
Female 1.031 *** 1.025-1.038 1.061 *** 1.054-1.069 1.597 *** 1.448-1.760 2.135 *** 1.954-2.334
Intercept 6.536 *** 6.275-6.808 4.068 *** 3.900-4.244 0.085 *** 0.056-0.129 0.208 *** 0.137-0.315
Log
likelihood
-267255.4 -218843.2 -12495.4 -18616.1
Significance codes: • p<0.1; ∗ p<0.05; ∗∗ p<0.01; ∗∗∗ p<0.001; IRR: incidence rate ratio.
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The IRRs patterns across age groups for asthma reviews, A&E visits, and admis-
sions were similar between the two cohorts, which, however, diﬀered in the pat-
terns of asthma GP visit IRRs.
In Cohort 1, the rates of asthma GP visits gradually decreased with age in the
youngest age groups with a minimum of 0.81 in the 15-19 group (relative to the
reference age group 0-4) year before increasing again towards a maximum of 1.12
in the 70-74 group and decreasing again to 0.85 in the 90-119 group. In contrast,
in Cohort 2 the estimates peaked at 1.03 in the 10-14 before decreasing slightly
and steadily with older age, reaching 0.76 for the age group 90-119.
In Cohort 1, asthma review IRRs pattern across age groups was similar to that of
asthma GP visits, although it had a higher magnitude of variation. In Cohort 2,
the pattern was similar to that in Cohort 1 but with less variation between age
groups.
For asthma-related A&E visits, there was a general gradient of decreasing IRRs
with older age in both cohorts. In Cohort 1, the gradient was steep in the younger
age groups, i.e. under 19-year old, before flattening between the age groups 15-18
and 35-39 years and decreasing slightly further in the older age groups. However,
in Cohort 2, the gradient was less steep in the younger groups and steadily de-
creased up to the 65-68 age group.
The two cohorts had almost similar patterns of asthma-related hospitalisation
IRRs, showing steeper, decreasing gradients with age in children, before stabilis-
ing at the 15-18 age group with slight fluctuations over the older groups.
Females had overall 4%more predicted asthma-related GP visits, 10%more asthma
reviews, 71% more asthma related A&E visits, and 131% more asthma-related
hospitalisations — p-values for gender diﬀerences were all less than 0.001.
5.4.2.3 Model fit
In both study cohorts, the quantile-quantile plots for the raw residuals for the four
ZINB models showed that the raw residuals overall followed a normal distribution
(Figure 5.8). However, while there was a little right skewness for the asthma-
related GP visit models, the right skewness was clearer in the models of the other
three outcome variables—asthma reviews, asthma-related A&E visits and asthma-
related hospitalisations—especially for hospitalisations.
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Figure 5.8: Quantile-quantile plot for the model residuals.
Rootograms showed an alternative visualisation of the model fit, focusing of the
deviation between the observed and predicted frequencies for the counts of the
outcome variables (Figure 5.9). The deviations between the observed and pre-
dicted frequencies were relatively small, indicating a good overall fit for each of
the four models in both cohorts.
5.4.2.4 Sensitivity analysis
The findings presented above in both cohorts were produced for patients with
complete GP registration in Wales between 2010 and 2014. However, among
297,976 and 111,253 patients with “ever-diagnosed asthma” and “ever-diagnosed
currently treated asthma over the follow-up period” in the source population,
79,222 (26.6%) and 9,744 (8.8%) patients, respectively, had incomplete GP regis-
tration over the five-year follow-up period.
By including those previously excluded patients to Cohort 1 and Cohort 2, the
overall patterns of IRRs across the WIMD quintiles did not change significantly
in both cohorts. Between the most and least deprived areas, most IRRs became
slightly higher than but still close to those in the original cohorts with complete GP
registrations. The IRRs of asthma GP visits, reviews, A&E visits and hospitalisa-
tions became 1.102 [1.090-1.114], 1.064 [1.052-1.075], 1.542 [1.377-1.726], and
2.254 [2.033-2.498] in the ever diagnosed asthma cohort (Cohort 1), and 1.032
[1.022-1.042], 0.987 [0.977-0.997], 1.242 [1.081-1.427], and 1.889 [1.671-2.135]
in the ever-diagnosed, currently-treated asthma cohort (Cohort 2), respectively.
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Figure 5.9: Rootograms illustrating the goodness of fit for the zero-inflated negative binomial models
for the four outcome variables in both study cohorts.
The sensitivity analysis confirmed that the observed diﬀerences in asthma-related
primary and secondary care utilisation between the most and the least deprived
areas existed regardless of the continuity of GP registrations.
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5.5 Discussion
5.5.1 Summary of findings
I identified patterns of variation in asthma-related healthcare utilisation across
the deprivation scale as well as between age and gender groups in Wales.
Compared to the least deprived areas, there were wide gaps in asthma-related ED
visits (36.8%) and hospital admissions (123.2%) in the most deprived areas despite
a small excess in asthma-related primary care use, including asthma reviews, in
these areas. However, these gaps were slightly smaller (22.9% and 95.5%, respec-
tively) among asthma patients with continuous asthma prescriptions throughout
the study period.
Therewas a gradient of increasing asthma-related hospital admissions by increased
deprivation. However, there were no consistent gradients for asthma-related GP
visits, reviews, and A&E department visits across the deprivation scale. Instead,
for asthma-related GP visits and A&E department visits, the contrast was between
the more aﬄuent areas, which had the lowest incidence rates, and the other more
deprived areas together, which had higher incidence rates.
Notably, there were also significant diﬀerences by gender in asthma-related health-
care utilisation. Although females with asthma had a modest excess in disease-
related primary care contacts including asthma reviews, they were far more likely
to attend A&E departments and to be admitted to hospitals due to asthma.
Age groups also showed wide variations in asthma-related healthcare utilisation.
Among patients who continuously received asthma treatments, asthma-related GP
visits decreased with older ages. However, asthma patients between the age of
10 and 35 were less likely to undergo asthma reviews compared to those in the
age groups between 40 and 85. Finally, younger patients were more likely to visit
A&E departments and to be admitted for asthma than older patients.
There was a remarkable gradient of more prescriptions but lower proportion of
asthma controller medications with higher deprivation.
The above findings were not aﬀected by whether patients were treated for asthma
throughout the follow-up period or by their continuity of GP registrations.
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5.5.2 Interpretation in the light of previous studies
5.5.2.1 Comparison with previous studies
The associations that I found between socioeconomic status and asthma outcomes
in Wales were consistent with other studies in Wales, England, and elsewhere.
Asthma outcomeswere shown to be associatedwith both area-based and individual-
level deprivation [349, 350].
Asthma severity has been widely linked to socioeconomic status, where severe
disease was found to be more prevalent in people with lower socioeconomic sta-
tus [351]. Lower socioeconomic status also increased the risk of poor asthma
control and the incidence of exacerbation, independent of disease severity [349,
352, 353]. Also, asthma patients with low socioeconomic groups, measuredmainly
through education level, had higher asthma morbidity, including higher incidence
of exacerbations [352] and worse asthma control independently from the disease
severity. One explanation of the poorer asthma control among patients with low
socioeconomic status is that this group has poorer medication adherence [354].
In my study, the prevalences of both ever-diagnosed asthma and ever-diagnosed,
currently treated asthma increased in the more deprived areas. Similar findings
were reported in England [350]. However, the poorer asthma outcomes asso-
ciated with higher deprivation were contrasted, in other studies, with the re-
ports of increased disease incidence with lower deprivation [324, 355]. In one
study, asthma-related hospitalisation rates were correlated with the prevalence of
chronic phlegm and indoor exposure of second-hand smoke but the variations of
these rates between socioeconomic groups were not explained by variations in the
prevalences of asthma or wheezing [324].
Another study, however, reported contradicting findings that no statistically sig-
nificant diﬀerence was found in the number of asthma exacerbations between pa-
tients in low and medium/high socioeconomic status groups [356]. That study
reported that the less deprived people had lower secondary care utilisation after
exacerbations, which might suggest they received better management and had
better self-management than the most deprived groups [356].
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5.5.2.2 WIMD mainly describes areas, and to a lesser extent, individuals
The Welsh Index of Multiple Deprivation is an area-based measure, i.e. an eco-
logical variable. Therefore, associations studied using the WIMD index may not
necessarily hold at the individual level [357, 358]. Essentially, the findings in this
chapter highlighted variations between small areas of diﬀerent deprivation ranks.
While deprivation indicators for a given small area represent the average levels of
disadvantage of persons living there, those persons may widely diﬀer in their own
characteristics. Therefore, depending on the extent of those variations, group-
level associations might not be valid for individuals who were far from the average
characteristics.
While the Income, Employment, Health, Education, and Housing domains of the
WIMD are constructed based on average scores of individuals living in a given
area, the other domains, i.e. Access to Services, Community Safety, Physical En-
vironment domains, are by definition roughly equal for all residents in that area.
Therefore, the findings in this chapter could be carefully extended to the individ-
ual level, i.e. asthma patients living in the most deprived areas had worse asthma
control despite having slightly more primary care contact.
5.5.2.3 Asthma-related emergency department visits and hospitalisations
usually indicate worse asthma severity and control
Asthma-related ED visits and hospital admissions have been widely used as proxy
measures for asthma severity, control, and exacerbations [102]. Asthma control is
the extent to which the disease symptoms and future risks are suﬃciently elimi-
nated or reduced through treatment to an acceptable target [1, 2, 16]. Suboptimal
asthma control may result from inadequate secondary and tertiary prevention for
asthma, such as inappropriate prescribing, inadequate asthma review, and sub-
optimal self-management and patient education. Accordingly, the findings in this
chapter suggest that asthma patients in the least deprived areas could have not
only more severe disease (i.e. requiring a higher level of medication to achieve
control) but also that disease control (i.e., achieving satisfactory symptom con-
trol) was poorer overall (e.g., due to inadequate treatment). The diﬀerence in the
average asthma medication ratio and asthma reviews between the least and the
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most deprived areas may partly explain the gap in asthma-related A&E visits and
admissions between those areas.
However, not all the asthma-related visits to A&E departments indicate real med-
ical emergencies or worsening in the disease control. Instead, in areas of higher
deprivation levels in particular, the higher number of such visits might not be
completely due to genuine need to visit these facilities. There are a wide range of
reasons why patients may bypass their GPs to visit A&E departments, i.e. using
A&E departments as primacy care facilities [359]. Inaccessibility to GP practices
and pharmacies, which were accounted for in the Access to Services domain of the
WIMD index, might play a role in the increased A&E visits in the more deprived
areas.
A study in the United States found that patients with insuﬃcient health literacy
made more return visits in 14 days to A&E departments than those with adequate
health literary [360]. Subsequently, inadequate health literacy in areas of higher
deprivation could be contributing to the higher asthma-related A&E visits found
in this chapter.
Overcrowded GP practices in the more deprived areas may also contribute to the
increased A&E visits in these areas. A recent report investigating the pressure on
general practices in the UK had found that general practices in areas with higher
levels of deprivations faced higher pressure than those in lower deprivation areas
[361]. In that report, residents of higher deprivation areas used health services
more likely and frequently than those in lower deprivation areas. In East London,
for a given age group after the third decade of age, areas with higher deprivation
had higher rates of GP consultations per patient compared to areas with lower
deprivation [362]. This suggests that the IRR of 1.31 in asthma A&E visits between
the most deprived and the least deprived areas may overestimate the diﬀerences
in asthma control between them.
5.5.2.4 Why did the most deprived asthma patients have more GP visits?
The small excess of 8% in primary care contacts in the most deprived groups com-
pared to the least deprived might be due to several factors. The intrinsic disease
severity might be contributing to this gap. It has been found that asthma patients
in the most deprived areas often had more severe disease than those in the least
derived areas [351, 355].
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The excess could be also, in part, due to poorer disease control in the most de-
prived areas, leading to higher use of primary and secondary care. Unscheduled
GP visits for asthma often indicate suboptimal disease control and/or exacerba-
tions. However, in the SAIL Databank, it was not possible to directly distinguish
between scheduled and unscheduled GP visits.
Another potential factor for the excess in asthma-related GP visits in the most de-
prived areas is lower health literacy. This might have hindered successful asthma
self-management, and reduced patient’s adherence to treatment and engagement
in decision making [363]. Asthma patients with lower levels of education were
found to use more short-acting bronchodilators and less controller medications,
leading to poorer asthma control [364]. Lower health literacy can therefore lead to
higher dependency on GPs and an increasing tendency to request appointments.
5.5.3 Study strengths
The main strength of this work was the use of objective real-world data at the in-
dividual patient level. The GP dataset extract that I used had a coverage of almost
80% of practices in Wales at the time of analysis. Through this dataset, I was able
to identify and study a very large proportion of all asthma patients living in Wales
between 2010 and 2014. In addition, I used an in-house developed algorithm that
identified patients with gaps of more than 30 days that might result from either de-
registration by the patient or the practice not sending data to the SAIL Databank.
By excluding those patients from the study population, I minimised the possibility
of missing GP events due to these reasons. However, it was possible that patients
with gaps in their GP registrations were less concerned about their health, which
could be due to inadequate health literacy which was in turn associated with lower
education attainment and worse health outcomes [365]—characteristics suggest-
ing higher deprivation levels. Alternatively, it was possible that those patients
could have had milder asthma, or simply did not reside in Wales for the whole
follow-up period. I demonstrated through a sensitivity analysis that the exclusion
of those patients led to only small reductions to the IRRs that did not alter the
conclusions.
Another strength is that the 2011 WIMD index incorporated a comprehensive
range of deprivation domains for small areas in Wales, representing a helpful tool
for multifaceted measurement of socioeconomic status.
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In Wales, the National Health Services provides free-of-charge medical services,
including prescriptions, to Welsh residents. This could be an advantage in this
study by avoiding possible bias that could have happened if those services where
paid for, completely or partly, by patients. Direct contributions to health care
costs required by patients, especially with low income, may lead to less healthcare
utilisation in order to avoid costs [366, 367]. For example, a study in the United
States (US) suggested that higher proportions of consumed out-of-pocket asthma
medication costs to household income were associated with higher exacerbation
risk in children [353].
5.5.4 Study limitations
5.5.4.1 Case definitions for asthma-related A&E visits and hospitalisa-
tions were not validated
To my knowledge, there are currently no validated algorithms that would have
allowed me to accurately identify asthma-related A&E visits and hospitalisations
in the corresponding datasets in the SAIL Databank. Data recording and coding
practices at inpatient and A&E departments may vary acrossWales [297, 368]. For
ED visits, the recorded diagnosis may not be final, and may not always correspond
to the reason of the visit [368]. In the PEDW dataset, hospital episodes had 14
available fields for recording admission diagnoses: one primary diagnosis, one
subsidiary diagnosis, and 12 secondary diagnoses [369].
In my analysis, asthma-related hospital admissions included any hospital episodes
in which asthma was recorded as an admission diagnosis in any of the 14 avail-
able diagnosis positions. However, this definition of asthma-related hospital ad-
mission may have overestimated the number of actual events. In some cases, it
was possible that asthma was recorded as a secondary indication for admission.
Alternatively, asthma could have been recorded despite not being a reason for ad-
mission (e.g., it was well controlled prior or during the admission, and did not need
specialist care hospital stay). Therefore, it is possible that some counted hospital
admissions in my analysis were not related to asthma and therefore should have
been excluded. Nonetheless, I assumed that the algorithm that I used to iden-
tify asthma-related hospitalisations equally inflated, if any, the estimated counts
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across the five WIMD rank quintiles and therefore would not significantly aﬀect
the estimated IRRs.
In contrast, querying asthma diagnosis codes from the first position only may ex-
clude relevant hospital episodes in which asthma was a main or a contributing
reason for admission. In the PEDW episode data, primary diagnosis field was
inconsistently used. Diagnosis codes were sometime found only following non-
diagnosis codes.3 This means that the actual main medical diagnosis was not
always recorded in the primary diagnosis field. Such a data quality issue was
addressed in a recent study were asthma-related hospital episodes in Wales were
identified using an asthma code being recorded in the first diagnosis position
after ignoring the aforementioned non-diagnosis codes [43]. In my own analy-
sis, I found that this approach increased the number of identified asthma-related
hospital episodes by about 64% compared with using the primary diagnosis field
only. Further work is needed to develop and validate accurate case definitions for
asthma-related A&E visits and hospitalisations, possibly using a machine learning
approach.
5.5.4.2 Possible residual confounders
Several variables that might have aﬀected both the deprivation level and asthma
outcomes were not included in the regression models presented in this Chapter.
These variables were not available or were sub-optimally coded in routine data.
For example, I did not adjust the regression models for smoking status. Nor did
I investigate the eﬀect of smoking status on the outcome variables. Cigarette
smoke is a known and strong trigger of asthma exacerbations among first-hand
or second-hand smoker asthma patients. A systematic review and meta-analysis
found that exposure to second-hand tobacco smoke among children with asthma
almost doubled the risk of hospitalisation for asthma exacerbation and worsened
pulmonary function [370].
Smoking was also shown to be positively associated with deprivation [371]. In
England, an analysis by the Oﬃce of National Statistics found a strong association
between the proportion of current smokers and the level of deprivation [372]. In
that analysis, people living in the areas at the highest deprivation quintile were
3Such codes include symptoms, signs, abnormal clinical or laboratory findings, medical, surgical
and allergy history, and other miscellaneous health-related statuses or events that exist in the R and
Z chapters of the ICD-10 classification.
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more than twice likely to smoke than those living in areas categorised as the lowest
deprivation quintile. Part of the eﬀect of the level of multiple deprivation on the
number of asthma-related ED visits and hospital admissions might be influenced
by diﬀerential smoking status.
On the other hand, smoking is a leading cause of premature death, and a risk factor
for numerous health problems, including cancer, low birth weight, and limiting
health conditions [373], all of which are part of the Health domain of the WIMD
index. Accordingly, smoking status might have, to some extent, confounded the
relationship betweenmultiple deprivation level and the four asthma-related events
that I studied. Therefore, if recorded in high quality, smoking status should have
been added to the regression models used in my analysis to reduce the potential
confounding bias.
Health literacy is also a potential confounder. The Institute of Medicine [374]
defined health literacy as “the degree to which individuals have the capacity to
obtain, process and understand basic health information and services needed to
make appropriate health decisions”. Health literacy aﬀects asthma outcomes both
directly and indirectly, though inadequate patient knowledge of asthma, subopti-
mal asthma self-management and improper use of inhalers [375, 376]. Health
literacy also aﬀects the WIMD through the Education domain [377]. However,
data on health literacy were not available in the routinely collected electronic
health record (EHR) data in the SAIL Databank.
5.5.4.3 WIMD overall index and asthma exacerbations: a possible circular
relationship
An important consideration when studying the associations between area-based
socioeconomic measures and health outcomes is when the former include a health
component.
The overall WIMD index includes the Health domain, which includes limiting long-
term illness, death rate in the area from all causes, incidence of cancer, and low
birth weight. Asthma mortality in Wales in 2011 was 1.8 per 100,000 population,
a small contribution to the all-cause crude death rate of 990 per 100,000 popu-
lation [378, 379]. However, asthma, especially when uncontrolled, is likely to be
a limiting condition with significant and profound eﬀects on patients’ quality of
life [380–382]. A recent survey of 4,650 asthma patients in the UK by Asthma UK
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found that 46.4% of the respondents reported sleep diﬃculties due to asthma, and
45.2% reported that asthma interfered with their daily activities [383]. Low birth
weight and other adverse perinatal outcomes, such as pre-term delivery and small
for gestational age infants, have been linked to the severity of maternal asthma
and/or asthma medications used by mothers during pregnancy [384–386].
Asthma could also aﬀect the Education domain of the WIMD index. Suboptimal
asthma control among children, as well as urgent or emergent asthma-related
healthcare utilisation, have been shown to be associated with school absenteeism
[387]. In addition, asthma could aﬀect the Employment domain of the WIMD index
by increasing job absenteeism and hindering job retention. A Danish study found
that people with current asthma were more likely to miss work and lose their jobs
[388].
With the above links between asthma and the Health, Education, and Employ-
ment domains of the overall WIMD index, using the latter as a predictor of asthma
outcomes is challenging, and caution should be exercised in the interpretation of
results. However, the eﬀect of such circular relationship could be limited. A study
In England found that removing the health domain from the Index of Multiple De-
privation had small, practically unimportant eﬀect on themeasured socioeconomic
disparities in census measures of health [389].
5.5.5 Implications for health policy
Health inequalities are of paramount importance to health policy. The work pre-
sented in this chapter is an example of the utility of routinely collected, linked data
from EHRs and the WIMD in Wales in assessing health inequalities, namely those
in asthma outcomes, and in informing health policy.
The presented findings could improve our understanding of the social gradient in
asthma in Wales and inform the development and redesign of policies to reduce
inequalities in asthma outcomes. These findings suggest that several aspects of
health care services for asthma patients in the most deprived areas in Wales could
be targeted for improvement. These aspects may include quality of primary care
services, including early diagnosis and optimal prescribing, the lack of which could
lead to poor disease control.
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To reduce health literacy gap and the associated gaps in asthma outcomes, the
most deprived asthma population requires active eﬀorts and further resources
to ensure eﬀective education on asthma and asthma self-management. This in-
cludes training in proper inhaler technique, adequate adherence to medications,
and avoiding exacerbation triggers. The variation in quality of secondary care for
asthma patients across the socioeconomic spectrum could also identify further
potential to reduce the gap in asthma outcomes.
Avoidable health inequalities at any level create concerns and are socially and
politically unacceptable. They may also result in wasted resources. With the high
prevalence of asthma in Wales, even modest inequalities in asthma outcomes are
likely to result in likely avoidable, significant disease costs at the country level.
The overall cost of asthma in Wales in the fiscal year 2011-2012 was estimated as
£74.7 million pounds (approximately US$104.7 million) [43]. An IRR of 2.23 for
asthma hospitalisations between the extreme WIMD quintiles means that there
were 1,340 hospitalisations4 in the most deprived areas that would have not hap-
pened if the hospitalisation rate there was equal to that in the most aﬄuent ar-
eas. Assuming a conservatively estimated average of £1,000 for the cost of an
asthma hospital episode (approximated from cost data presented by Mukherjee
et al. [43]), those extra 1,340 asthma hospitalisations in the most deprived areas
costed NHS Wales at least £1,340,000 over the five-year follow-up. This calcu-
lation demonstrates the potential for avoiding significant, unnecessary costs of
asthma healthcare utilisation in themost deprived areas. However, it does not take
into consideration the costs of increased asthma prescriptions, A&E visits, and GP
visits in the more deprived areas. In fact, while hospital admissions accounted for
13.1% of asthma-related costs to the NHS in Wales in 2011-2012, prescriptions
accounted for two third and asthma-related GP visits, ambulance trips, and A&E
visits together accounted for around 16% [43]. A comprehensive cost analysis is
therefore needed to estimate the variations in the overall asthma financial burden
across deprivation levels in Wales and the potential savings by reducing these
variations. Such an analysis should include the costs of asthma-related visits to
GPs, A&E and outpatient departments, ambulance trips, and prescriptions and
hospital admissions as well as other wider societal costs such as Disability Living
Allowance and costs resulting from school and work absenteeism.
4(2.23 − 1) × 0.022 × 49, 597; where 0.022 is the hospitalisation rate in WIMD 5, and 49,597 is the
number of patients in WIMD 1 areas based on Cohort 1 characteristics (Table 5.2).
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Identifying inequalities in asthma outcomes and identifying potential targets to
reduce them aligns with the Welsh Respiratory Health Implementation Group’s
vision towards reducing inappropriate variations in respiratory outcomes across
Wales [390]. Reducing health inequalities is also a key objective of the Welsh
Government. The use of routinely collected data in this exercise to explore asthma
outcomes aligns with political landscape inWales tomaximise the use of these data
to support respiratory health policy and care delivery [96, 391].
5.5.6 Future work
The limitations and methodological challenges encountered in this study warrant
further work. For example, algorithms to identify asthma-related A&E visits and
hospital admissions in the SAIL databank need to be externally validated. If avail-
able in high quality, measures of potential confounders such as smoking status
and health literacy could be added to the statistical model.
Further analysis would be needed to improve the understanding of the asthma
social gradient in Wales and explore possible explanations to the observed in-
equalities, taking into account the complex inter-relationships between the rel-
evant variables. Including additional data on healthcare utilisation and asthma
outcomes across the deprivation levels would provide additional insights into the
diﬀerential severity of asthma exacerbations and the associated cost of avoidable
outcomes. Such data may include detailed hospitalisation data, such as LOS and
HRG, as well as death due to asthma.
Further work on associations between asthma outcomes and each of the eight
domains of the overall WIMD index would be useful to understand the individual
contribution of each deprivation domain to asthma inequalities.
Asthma is associated with a wide range of comorbidities such as rhinitis, sinusitis,
obstructive sleep apnoea, gastroesophageal reflux disease, obesity, anxiety, and
depression [392–394]. More comorbidities are in general associated with lower
socioeconomic status [395]. Therefore, the impact of comorbidities on asthma
inequalities and the associated avoidable cost and burden of these comorbidities
is worth exploring.
Ethnicity may in general influence both socioeconomic status and health outcomes
[396–398]. Wales is generally a homogeneous country with about 5% of the pop-
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ulation identified themselves as being from non-white background [399]. How-
ever, the percentages of non-white people are higher in large urban areas such as
Cardiﬀ (17.2%), Swansea (10.6%), and Newport (7.7%) [400]. In these areas, the
individual role of ethnicity in the social gradient of asthma is worth investigating.
Finally, future work will explore the trends and costs of asthma inequalities over
the last two decades to see whether they are changing over time.
5.6 Conclusion
This chapter demonstrated an important application of the Wales Asthma Ob-
servatory in supporting health policy regarding equality in health care. I found
wide inequality gaps in asthma outcomes between the extremes of socioeconomic
deprivation spectrum in Wales and showed a social gradient in asthma-related
hospital admissions. Compared to the least deprived areas, the most deprived
areas had slightly more primary care contacts, including annual asthma reviews,
per asthma patient. However, asthma patients in the most deprived areas were
37% more likely to have asthma-related ED visits and more than twice as likely
to be admitted to hospitals due to asthma than those in the least deprived areas,
although those gaps decreased slightly among patients with continuous asthma
prescriptions throughout the study period.
These wide gaps in asthma healthcare utilisation were possibly due to higher
severity and poorer control of the disease in the least deprived areas. Possible
underlying factors such as suboptimal asthma prescribing, inadequate health lit-
eracy, poor asthma self-management, and wider non-health related socioeconomic
determinants, such as income, employment, education, air pollution, might be
contributing to the observed gaps and require further investigation.
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Reflection and future directions
In this chapter, I summarise the work I performed in this thesis about the devel-
opment and utilisation of the Wales Asthma Observatory, highlighting my original
contributions. I critically review the strengths and limitations of the Observatory
as a platform for asthma research and surveillance, and as a tool to improve our
understanding of asthma in Wales and to inform health policy, service planning
and delivery. I then compare my findings with related works and studies. I then
discuss the opportunities and challenges encountered during the Observatory de-
velopment and utilisation. I reassert the high potential of using asthma-related
routinely collected data to improve asthma patients’ lives, and the pressing need
to reduce avoidable harm and waste from the suboptimal re-use of these data.
I discuss the potential role of the Observatory in the national eﬀorts to improve
asthma outcomes. I then propose a future research agenda to improve the Obser-
vatory’s methodology and to answer further questions about the social gradient
of asthma in Wales, I also propose further technical and content developments to
the Observatory.
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6.1 Summary of findings
In this doctoral project, I demonstrated how routinely collected electronic health
record (EHR) data can be used to develop a data-intensive platform for asthma
research and surveillance–the Wales Asthma Observatory. The Observatory aims
to maximise the benefit of these data and is based on a regularly updated, national
cohort for asthma.
Due to the inherent limitations of routinely collected data (RCD) [88–93], special
attention should be paid to methods of defining diseases and health outcomes us-
ing these data. Therefore, to inform the Observatory development, I systematically
reviewed the contemporary methods to define and assess asthma using routinely
collected data and the ways these methods have been described (Chapter 2). I
found a wide variation in these methods and suboptimal reporting on their imple-
mentation and validity. I highlighted the challenges of standardising methods to
define and assess asthma, and the need to develop and validate database-specific
methods.
In Chapter 3, in the light of the literature review findings, and considering asthma
heterogeneity, data limitations, and the absence of a gold standard to define asthma,
I justified the use of data-driven approaches to identify people with asthma. I
demonstrated the appropriateness and benefits of using latent class analysis (LCA)
on recorded asthma-related primary care data to identify clusters of asthma pa-
tients, including those with current asthma. My latent class modelling was based
on healthcare utilisation data related to asthma and chronic obstructive pulmonary
disease (COPD) for a large, random sample of the population of Wales. I chose
the eight-class model as the best-fit model based on its model diagnostics and
clinical interpretability. I assigned clinical labels to the latent classes. I then
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reduced the model complexity by merging the ‘asthma’ classes into two classes
representing ‘ever diagnosed asthma without current treatment’ and ‘currently
treated asthma’. I then applied recursive partitioning (a supervisedmachine learn-
ing technique) to derive a decision tree which could identify patients with asthma,
including whether they were currently treated, as well as those with COPD and
asthma-COPD overlap syndrome (ACOS) in primary care data.
I used this case identification algorithm, in addition to several other case defini-
tions for asthma, in the development of the Observatory, described in Chapter 4. I
included in the Observatory a number of essential disease outcomes and variables
such as disease severity, treatment step, and asthma exacerbations. I also devel-
oped and described a technical platform to improve the eﬃciency, reporting, and
reproducibility of data extraction of studies that use the Observatory.
I investigated the quality of selected asthma-related event groups, and described
variable patterns and levels of data missingness. Notably, many lung function tests
were recorded without their measurements. When recorded, measurements were
inconsistent for many of the lung function event codes. To improve the capture of
asthma data, I recommended improved data entry quality checks by EHR systems,
data-quality awareness training for clinicians, and the inclusion of data quality to
receive a greater focus in payment-for-performance schemes.
In Chapter 5, to demonstrate the Observatory’s utility for health policy, I inves-
tigated the inequalities of asthma outcomes across the socioeconomic spectrum
in Wales. I used count regression models to compare asthma-related primary and
secondary care events between asthma patients living in areas with diﬀerent de-
privation levels. I found that, compared to asthma patients who lived in the least
deprived areas, those in the most deprived areas had slightly more primary care
contact (7.8% more general practitioner (GP) visits per patient), yet they had sig-
nificantly more asthma-related emergency department visits (31.1%) and hospi-
talisations (123.2%). There was a clear gradient of more asthma-related hospital
admissions in the more deprived areas in Wales. The inequality gaps were slightly
smaller among patients who continuously received asthma prescriptions over the
five-year follow-up period. I discussed the implications of these inequality gaps,
and outlined future research directions to improve the modelling and account for
possible confounders. I then proposed potential measures to reduce and bridge
the inequality gaps in asthma outcomes.
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6.2 Original contributions
I summarise the original contributions in this thesis as follows:
Chapter 2
1. I found a wide variation in the contemporary methods to define asthma and
assess asthma outcomes in observational studies conducted using routinely
collected EHR data.
2. I found that reporting on the implementation and validity of these methods
was poor overall.
3. I identified 10 practices of reporting or justifying the validity of these meth-
ods (Table 2.1). These practices varied widely from performing validity as-
sessment in the same study, to relying on clinical guidelines or the validity
of database coding. The majority of EHR-based asthma studies reported no
information on the methods’ validity.
Chapter 3
4. I described a probabilistic approach, using LCA of primary care data of a
large population sample, to identify groups of people with asthma (including
those with current asthma), distinguish them from those with COPD, and to
identify people with asthma-COPD overlap.
5. I described the groups of people with asthma based on their asthma-related
health care utilization.
Chapter 4
6. To identify people with asthma in the Wales Asthma Observatory, I used the
above-mentioned data-driven probabilistic model as well as commonly used
deterministic case definitions.
7. I described diﬀerent levels and patterns of missingness and inconsistencies
in asthma-recorded data, apparently due to diﬀerent approaches used by GPs
to record similar data items and using the same clinical codes for diﬀerent
purposes.
Chapter 5
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8. I demonstrated the extent of inequality gaps in asthma health care utilisation
in Wales: Compared to the least deprived areas, the most deprived areas had
8% more asthma related GP contact, but 123.3% more asthma hospitalisa-
tions; the inequality gaps were slightly smaller among patients who contin-
uously received asthma prescriptions over the five-year follow-up period. I
also found wide variations in these outcomes across age and gender groups.
6.3 Strengths and limitations
The Wales Asthma Observatory is the first of its kind in Wales as a platform for
asthma research and surveillance using routinely collected data. The work pre-
sented in this thesis has a number of strengths and limitations related to the data
used in the Observatory, the methods used to identify asthma patients and assess
disease outcomes, and the Observatory design and structure.
6.3.1 Data sources: pros and cons
The type and sources of data used in the Observatory are one of its major strengths.
The Observatory currently utilises key nationwide clinical datasets in Wales, in-
cluding data on primary care, secondary care, area-based deprivation as well as
causes of death. These data are already collected from EHRs, anonymised, and
linked in the Secure Anonymised Information Linkage (SAIL) Databank. This of-
fers a unique opportunity to answer a wide range of research questions that is not
feasible with de novo data collection.
Throughout the previous chapters, I highlighted the advantages of EHR-based rou-
tinely collected data over purpose-specific data collection. Briefly, RCD are inex-
pensive, person-level streams of data that reflect the real-world picture of people’
health status and clinical care. They are mainly recorded from the perspective of
healthcare professionals rather than patients. Thus, their validity does not rely
on patients’ memory or health literacy. These data are routinely collected in huge
volumes across Wales. This allows obtaining nationally representative epidemi-
ological estimates, and enables conducting high-power studies and investigating
rare outcomes. These opportunities are usually not present with small-sized pri-
mary data collected first hand by investigators.
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However, RCD suﬀer from a wide range of problems such as missingness, miscod-
ing, under-recording, and linkage errors. There was no information about the ver-
sion of coding system used to codify primary care data. Primary care events in the
United Kingdom (UK) are usually coded with the Read code vocabulary, namely the
second and third versions. The second version is a hierarchical vocabulary, while
the third version is a radically developed version which, for example, supports
poly-hierarchy (i.e., a code can have multiple parent codes), includes additional
concepts, and has the codes changed for some of the existing concepts. It was
diﬃcult within the SAIL Databank to ascertain the vocabulary version in which
a GP event was coded. The vast majority of GP practices in Wales, however, use
the second version of Read Code vocabulary [401]. Therefore, in the Observatory
development, I used only the second version for data extraction. However, this
might have introduced a misclassification bias. This may happen, for example, if
the GP practices that used Read Code version 3 diﬀered from the rest of practices
in their population characteristics or in the quality of care. Nonetheless, given the
small number of those GP practices, this limitation is unlikely to undermine the
national representativeness of the Observatory.
6.3.2 Case definitions: Flexibility and data driven approach
The Observatory is empowered by the availability of multiple case dentitions of
asthma. Thereby, it allows capturing most cases of asthma including those with
uncertain diagnosis. At the same time, it includes more strict case definitions such
as currently treated asthma. This flexible approach facilitates studying diverse
groups of asthma patients. It also allows researchers to choose, for their studies,
the appropriate case definitions that are comparable with other particular studies.
Those case definitions, whether they are based on a single diagnosis code or more
complex deterministic algorithms, are based on clinical guidelines, clinical knowl-
edge, or epidemiological judgement. Each of those case definitions has a specific
meaning and is intended to be used to identify a specific group of people with
‘asthma’. In particular, the case definition of ever-diagnosed currently-treated
asthma is the most useful one as it allows selecting people with active asthma at a
certain point in time. This case definition has been commonly used as an essential
eligibility criterion in the contemporary EHR-based asthma studies [102] and is
also the basis of the main asthma indicator in the Quality of Outcomes Frame-
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work (QOF). Therefore, the Observatory will commit to use the ever-diagnosed
currently-treated asthma as the main case definition of asthma for surveillance
and research.
The Observatory also benefits from a latent class model which can be used as an
‘internal’ data-driven reference to identify asthma patients. Unlike cluster analy-
sis, which uses distances between individuals, LCA uses a top-down approach to
understand the population structure: it utilises the distributions of the observed
data to identify the likely population latent classes. By computationally uncovering
the population structure, LCA identifies all the likely patient groups, some of which
could be overlooked in the manual researcher-led development of case definitions.
LCA probabilistically determines to which latent class each person belongs. This
probabilistic approach fits well with the nature of asthma as a heterogeneous
condition represented by a continuous spectrum of various pathogeneses, over-
lapping phenotypes, and variable severity and natural history, which may coexist
with other conditions (COPD, for example). This approach to patient identification
allows researchers to select patients, not only based on their most likely classes,
but also by preferred probability thresholds, or based on overlap patterns of in-
terest (e.g., asthma-COPD overlap). The decision tree that I derived from the LCA
model allows researchers to use this model to identify asthma patients in the SAIL
Databank and similar databases.
However, unsupervised approaches such as LCA has limitations. The output of
LCA depends on the quality of the input data and their relevance to the desired
classification. It also involves a level of subjectivity in the model specification
(i.e. choosing features), selection of the best-fit model, and interpretation of the
latent classes. Therefore, while data-driven approaches can be useful to under-
stand the population structure, they need to be coupled by knowledge about the
disease pathophysiology, clinical course, and epidemiology as well as about data
provenance and quality [142].
6.3.3 Longitudinally assessed disease outcomes
The Observatory includes longitudinally calculated key disease outcomes. For
each patient in the Observatory, key disease states and outcomes such as treat-
ment step and disease severity and exacerbations are ascertained longitudinally
as state variables along the patient’s follow-up period. This allows both cross-
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sectional and longitudinal analysis of these variables. The definition of these vari-
ables was informed by the algorithms to assess asthma outcomes that I found in
the systematic scoping review in Chapter 2. While the validity of those algorithms
was assessed elsewhere, it should not be assumed to hold in the SAIL Databank.
However, assessing the validity of these definitions was not feasible within the
time-frame of this doctoral project.
6.3.4 Supporting research reproducibility
In the Observatory’s design and implementation, I took into consideration the chal-
lenges of data extraction reproducibility. Therefore, I equipped the Observatory
with a clinical code set library and data extraction platform, with an easy-to-use
graphical interface, which allows researchers with no programming skills to inter-
rogate the Observatory and the SAIL’s primary care dataset. This platform is also
intended to save time for experienced analysts by reducing unnecessarily repeti-
tive programming code writing and database query development. This platform is
aimed to support and promote research transparency and reproducibility as well
as sharing and re-use of clinical code sets and data extraction procedures.
I designed the Observatory data structure in such a way that it can be seamlessly
updated when the source datasets in the SAIL Databank are updated, using a
programming script I built for this purpose. Since updated data may include his-
torical changes, versioning of the Observatory data allows reproducing studies
performed on historical versions.
6.4 Interpretation of findings in the light of related
literature
6.4.1 Methods to define complex disease entities using rou-
tinely collected data
The findings in the Chapter 2 were in line with previous studies. A related system-
atic review identified wide variation in the categorisation of asthma severity using
health insurance claim data [222]. Similar variations in case definitions and the
need for standardisation have been recognised in other conditions such as heart
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diseases [402], osteoarthritis [403], and immune thrombocytopenic purpura (ITP)
[404, 405].
Standardisation of methods to define and assess asthma from RCD has been faced
with a number of challenges including the disease heterogeneity, lack of consen-
sus on its clinical definitions, variations in populations’ characteristics, and cross-
country diﬀerences and limitations of RCD resources.
Clinical coding systems help standardise the documentation of health and health
care concepts in EHRs. However, the clinical meaning of those concepts should
be standardised in the first place. Standardisation of asthma terminology requires
clear understanding of the disease’s aetiology, genetic and molecular pathogene-
sis including gene-environment interaction, and how the underlying disease mech-
anisms manifest in diﬀerent pathophysiological and clinical phenotypes. However,
from a precision medicine perspective, a fixed terminology to describe a heteroge-
neous continuum of diseases may be insuﬃcient to provide personalised diagno-
sis and management. Instead, Agusti et al. have suggested a label-free precision
medicine strategy for chronic lung diseases in which treatable traits, rather than
encompassing labels such as asthma and COPD, form the basis for diagnosis and
management [406]. This contemporary clinical perspective has been epitomised
in a recent editorial with Oscar Wilde’s quote “to define is to limit” [208].
Wherever the debate on clinical definitions of asthma and asthma outcomes might
move, standardisation and harmonisation of the corresponding operationalised
RCD-based definitions are needed. Algorithms to define particular clinical con-
cepts (e.g., ‘asthma’, asthma endotypes or phenotypes, or treatable traits) should
be ideally validated wherever they are used. Subsequently, the optimal method to
measure the same clinical concept may diﬀer across databases and populations.
6.4.2 Various approaches to asthma registries, surveillance
systems, and research platforms
Asthma surveillance systems and registries around the world have various pur-
poses. They have been also established using diﬀerent approaches to defining
source populations and cases of interest. They also diﬀer in their data sources,
content, and usability, and data security models.
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6.4.2.1 Asthma surveillance systems used routinely collected and/or self-
reported data
To be used for surveillance, data sources should have high geographical coverage
and representation, suﬃcient data quality, and sustainability. RCD usually satisfy
these requirements and are widely used for asthma surveillance. These include
data on asthma-related accident and emergency (A&E) visits, urgent care, and
hospital admissions, medication dispensing, and health insurance claims [134,
407–409].
The Ontario Asthma Surveillance Information System (OASIS) is closely related
to the Observatory in terms of the purpose and the use of RCD [134, 242, 410].
It was established as a platform for asthma surveillance and epidemiological re-
search in the Canadian province of Ontario. OASIS uses administrative and health
insurance data about out-of-hospital, emergency, and inpatient asthma care. The
Observatory, however, use EHR data which are richer and more comprehensive
than administrative and health insurance data.
Self-reported data are commonly used in the United States (US) asthma surveil-
lance systems to estimate the disease prevalence [407–409]. These data are col-
lected as part of the Behavioral Risk Factor Surveillance System (BRFSS) [411]
telephone survey. The BRFSS survey contains questions about whether the re-
spondent ever had and still has asthma, the age at diagnosis, symptoms frequency,
exacerbation history, routine asthma check-up, number of preventer and rescuer
asthma medications used, and the impact of asthma on the quality of life [412].
People who report having asthma are invited to the Asthma Call-back Survey
(ACBS) [413]. The ACBS collects more detailed information on the disease history,
healthcare utilisation, knowledge of asthma and management plan, patient’s be-
haviour towards environmental risk factors, medication use, medical self-management,
personal cost of asthma, asthma eﬀects on work and/or school attendance, work-
related asthma, asthma comorbidities, and use of complementary and alternative
therapy [414, 415].
Compared to the rich asthma-related self-reported data collected in theUS, asthma-
related self-reported data in the UK nations’ annual health surveys are much more
limited. In particular, the Welsh Health Survey (WHS) only asked whether the re-
spondent (or their child) was currently being treated for asthma or wheezing or
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had recent shortness of breath, tightness of chest, or wheezing [416]. In addi-
tion to their scarce asthma-related details, the WHS data had small sample sizes
and suboptimal geographical representation, let alone the biases of self-report.
Therefore, their role in the Observatory development was limited to being used
as an external data source for the evaluation of the RCD-based case identification
model.
6.4.2.2 Asthma registries generally target the problematic cases
Unlike asthma surveillance systems which generally target the whole asthma pop-
ulation, asthma registries are mainly dedicated to the more severe or complicated
cases. One example is the British Thoracic Society (BTS) Diﬃcult AsthmaNetwork
(DAN) registry [126], which was succeeded by the UK Severe Asthma Registry.1
The DAN registry included people who fulfilled the American Thoracic Society
(ATS) definition of refractory asthma [417]. The UK Paediatric Diﬃcult Asthma
Network Registry2 comprises four specialist asthma specialist centres in the UK
and aligns with eﬀorts to incentivise the appropriate identification and manage-
ment of problematic asthma cases. Both registries receive data entered by health
professionals into secure portals as well as routinely collected data.
The Belgian Severe Asthma Registry (BSAR) is dedicated to diﬃcult asthma cases
[418]. It collects data on asthma diagnostics, such as lung functions, fractional ex-
haled nitric oxide (FeNO), blood eosinophil count, serum immunoglobulin E (IgE),
sputum inflammatory cell profile, skin prick test, medication use, comorbidities,
as well as smoking status. It also collects asthma-related patient reported out-
come measures (PROMs) including Asthma Quality of Life Questionnaire (AQLQ),
Asthma Control Questionnaire (ACQ), and Asthma Control Test (ACT).
The Italian Registry of Severe and Uncontrolled Asthma (abbreviated in Italian
as RItA) oﬀers secure web-based access to a database of asthma-related clinical
data, risk factors, and exacerbations for patient with severe and/or uncontrolled
asthma [419].
In comparison to those asthma registries, the Observatory is designed to be both a
surveillance and research platform and a disease registry. Thanks to its nationwide
1https://cl2.n3-dendrite.com/csp/asthma/frontpages/index.html
2http://rs2.e-dendrite.com/csp/paedasthma/frontpages/index.html
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data sources, the Observatory is a comprehensive disease registry that targets the
whole asthma population across Wales, regardless of disease severity.
Algorithms based on domain expert knowledge (e.g., researcher’s clinico-epidemiological
judgement and/or clinical guidelines) to identify eligible cases have been the con-
ventional approach in asthma registries. Those algorithms are often validated
against clinical reassessment or review of the full medical record, neither of which
is a universal gold standard for asthma diagnosis.
The Observatory’s multi-approach to case identification, based on domain expert
knowledge and data-driven methods, oﬀers the flexibility needed to study diﬀer-
ent asthma populations. LCA helped see the likely population structure behind
the recorded data, while recursive partitioning produced a corresponding trans-
ferable algorithm to identify patients with asthma and/or COPD. Deriving a simple
classification algorithm from a complex clustering model was previously described
by Moore et al. [273]. They identified asthma phenotypes from cluster analysis of
34 variables, and derived a simpler three-variable classification tree which later
identified similar clusters in a diﬀerent population [420].
6.4.2.3 Routinely collected data (RCD) for disease registries
For disease registries, the approach of using RCD to develop a disease registry is
relatively new. Instead, traditional disease registries are set up to include cases of
interest that are managed in health care facilities within particular geographical
areas. Cases are usually included in a registry by healthcare professionals based
on defined criteria which are assessed on a case by case basis. Inclusion of cases
in the registry is often carried out using detailed clinical information available in
the doctor-patient encounter and the full patient record. However, there are a
number of disadvantages of the traditional approach of asthma registries:
• the denominator is often not defined [124];
• the number of patients in the registry is relatively small due to the often-
limited geographical coverage and the strict case definitions;
• case ascertainment is labour-intensive (which makes traditional disease reg-
istries more suitable for rare conditions);
• the inclusion in the registry often require the patient’s consent; and,
• data collection is subject to the experimenter bias.
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For a prevalent condition such as asthma, individual case identification at a na-
tional scale would consume significant time and resources.
RCD oﬀer inexpensive, accessible, wide-coverage, and rich alternative data sources
for disease registry development. In this approach, cases of interest are automat-
ically identified and characterised en masse from large datasets [127]. Larger
numbers of cases can be identified. RCD usually have defined denominators, al-
lowing estimation of the condition’s epidemiology and burden. RCD are usually
de-identified, and therefore no individual patient consents are needed [421]. How-
ever, misclassification of cases andmissing variables are among the disadvantages
of using RCD to create a disease registry.
6.4.2.4 Data acquisition, management, and quality
Sariyar et al. proposed a framework to evaluate medical registries purposes, data
acquisition and management processes, and data quality [422]. The framework
included assessment of data accuracy, trustworthiness, consistency, granularity,
timeliness, completeness, security, and privacy. These criteria should be assessed
along the flow of data in the registry: from acquisition, through storage, to presen-
tation [422]. The authors argued that a registry should only include high quality
variables that fit with its purpose(s). The Observatory, however, is built for generic
purposes of asthma research and surveillance. This requires continuously expand-
ing sets of case definitions and research-ready variables to satisfy the growing
surveillance needs and the emerging research questions. However, RCD used
in the Observatory inherently suﬀer from accuracy, trustworthiness, consistency,
and completeness issues (see Section 4.5). Therefore, further assessment of case
definitions validity and variables quality should be high priority in the future de-
velopments of the Observatory.
Modern implementations of registries for asthma and other conditions are increas-
ingly web-based, where data are entered by patients and/or healthcare profes-
sionals through secure online user interfaces [126, 130, 418]. Patient consent is
normally needed before their data are included in a registry. The stored data
are usually de-identified. In contrast, the Observatory uses already-linked de-
identified data from the SAIL Databank. The Observatory’s person-level data are
maintained within the secure environment of the SAIL Gateway. In the future,
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however, secure online or mobile-based data collection could be implemented to
capture asthma-related PROMs and link them to RCD in the Observatory.
6.4.2.5 Facilitating data interrogation is an increasingly recognised need
I designed the Observatory’s user interface so that it improves the workflow of
data interrogation including automation, reproducibility, reusability, and share-
ability. With the growing use of EHR-derived data for research elsewhere, the
need for data extraction automation and code set engineering has been recognised
in many EHR-derived data resources [301]. Facilitating data interrogation from
EHR data resources can be achieved by variety of approaches such as providing
‘research-ready’ variables, developing tools to automate common data extraction
tasks, and maintaining clinical code set libraries.
The Observatory provides essential asthma-related ‘research-ready’ variables in-
cluding disease state (i.e. current case defintion) and key outcomes and variables
such as treatment steps, asthma severity, and exacerbations. ‘Research-ready’
variables have been provided in EHR-derived data resources elsewhere. An ex-
ample is the Clinical research using LInked Bespoke studies and Electronic health
Records (CALIBER), a UK-based platform that provides access to ‘research-ready’
variables derived from data linked across EHRs, disease registries, bespoke cohort
studies, and other routine data sources through a common data model [129].
The Observatory also provides an easy-to-use platform to design, share, and reuse
complex data extraction procedures as well as manage clinical code sets. With this
platform, researchers can create additional study-specific Read code sets and com-
plex variables derived from the SAIL’s GP dataset. The graphical interface mimics
the process of creating a data table and populating its fields in the Structured
Query Language (SQL). It can be used by users with no programming skills. In
addition, the visual interface accepts inserting SQL pieces of codes so that users
with programming skills can design more advanced data extraction procedures. A
related tool is rEHR, an R package which provides functions for advanced data in-
terrogation from the Clinical Practice Research Datalink (CPRD) [423]. However,
as a programming library, rEHR can only be used by members of a research team
who have programming skills. In contrast, the Observatory interface allows col-
laborative development of code sets and data extraction procedures by anyone in
a multidisciplinary research team. Another diﬀerence is that rEHR works on data
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files exported from the CPRD, whereas data extraction procedures designed with
the Observatory’s platform can be exported to be run on a database connection,
such as the case in the SAIL Gateway. Lastly, an rEHR-based data extraction code
can be shared and published as a computer file. By contrast, a data extraction
procedure designed in the Observatory is maintained centrally on a web address
where it can be (re)used, shared, cited, and exported as an SQL or an interoperable
JavaScript Object Notation (JSON) file.3
The need for supporting the collaboration in data interrogation has been pre-
viously recognised. eLab is a web-based environment which allows multidisci-
plinary research teams including researchers and healthcare professionals to ac-
cess health dataset and collaboratively develop methods to analyse and visualise
the results [424].
eLab is based on the concept of Research Objects. Research Objects have been
proposed as a generic, comprehensive approach to representing the research pro-
cess and outcomes as semantically linked, reusable, shareable, entities [425, 426].
eLab has been used as ‘Asthma eLab’ in the Study Team for Early Life Asthma Re-
search (STELAR) consortium [427]. Asthma eLab provides web-based platform
for collaborative management and analysis of asthma-related data from five birth
cohorts in the UK. It allows research teams to model relationships between patho-
logical and physiological processes in graphical and computable forms.
The Observatory’s approach of using simpler variable types to specify complex
data extraction procedures (‘building blocks’ approach) that are reusable, exten-
sible, and shareable roughly corresponds to the concept of Research Objects.
ClinicalCodes.org is another related tool which provides repository for clinical
codes used in EHR studies [216]. This public web-based repository is similar to
the code set library provided in the Observatory. Whereas it only archives already
used code sets, the Observatory’s platform allows users to collaboratively create,
edit, and revise code sets and then easily use them in data extraction procedures
hosted in the same platform.
In summary, an eﬃcient and eﬀective user interface for an EHR-based data re-
source such as the Observatory should ideally satisfy a number of principles [426]
includingmethods versioning, repeatability, auditability, reusability, repurposeabil-
3JSON is an open-standard file format to exchange human-readable data in the form of arrays and
attribute–value pairs.
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ity, shareability, referenceability, and interoperability, as well as results repro-
ducibility.
6.4.3 Social gradient of asthma: consistent findings
and methodological challenges
The findings in Chapter 5 were consistent with local and international studies.
While some studies found that societal aﬄuence was associate with higher asthma
prevalence, others found the disease more severe in poorer areas [428]. Low so-
cioeconomic status was associated with less treatment in wheezy children [325],
poorer asthma control and persistent airway obstruction in adults [326], and higher
asthma hospitalisation rates [323, 324]. Watson et al. found that higher asthma
hospitalisation rates among the most deprived could not be explained solely by
readmissions; instead, more asthma patients from the poorer areas were hospi-
talised [323]. The route of admission to hospitals for asthma was not considered
in my study, but were previously found to diﬀer by deprivation level. In the West
Midland, England, the proportion of asthma admissions through A&E departments
was higher in the poorest than in the richest areas [323], but rates of GP re-
ferrals for asthma were not associated with deprivation level. The environment
plays a role in inequalities. Air pollution induces asthma exacerbations [318, 319],
whereas persistent asthma was associated with poor housing [326, 429–431].
Health inequalities including those in asthma outcomes has been traditionally eco-
logically assessed. For example, Watson et al. assessed the association between
asthma age-standardised admission rate in the whole population of a geographical
area with the area’s Townsend Deprivation Index [323]. Theoretically, an ecologi-
cal variable such as asthma prevalence in an area might have aﬀected the admis-
sion rate in that area. Yet, the authors ruled out an increased asthma prevalence
in poorer communities based on previous surveys. In my study, I assessed the
person-level association between area-based deprivation level and asthma hos-
pitalisations, among other outcomes. Therefore, my findings were independent
from asthma prevalence. That study used the deprivation level of the hospital
area rather than that of the person’s address. In my analysis, I used the depri-
vation index associated with the patient address, which eliminated the bias from
admissions in hospitals located in areas with diﬀerent deprivation levels.
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When both the explanatory and outcome variables being measured at the group
or area levels, associations are threatened by ecological fallacy. Replacing aggre-
gated data, person-level RCD are increasingly used to measure health outcomes
in health inequality studies [432]. In this thesis, the availability of nation-wide
person-level data on asthma outcomes in the SAIL Databank reduced the risk of
ecological bias. This bias was further reduced by using a deprivation index, the
Welsh Index of Multiple Deprivation (WIMD), that was calculated for relatively
small areas (average population ≈ 1,600).
Researching health inequalities is challenging. It is important to calculate the pure
eﬀects of socioeconomic factors on health outcomes and to determine causality
direction [433]. However, these are not straightforward exercises in an indeter-
minate space of complexly interrelated factors. Important social determinants of
health as well as confounders are often missing or indirectly assessed. RCD often
lack these variables; EHRs usually do not capture suﬃcient data on health liter-
acy, disease self-management, and wider social determinants of health. In order to
advance health inequality research, those vital data need to be routinely collected
[434].
6.5 Challenges
I identified several challenges towards the development of the Observatory. These
were mainly related to the complex nature of asthma, data limitations, lack of
locally validated methods to assess asthma outcomes, and the public’s attitudes
to reusing health data.
6.5.1 Asthma heterogeneity complicates case identification
and comparability of studies
There is an increasing recognition that asthma is a heterogeneous condition, com-
prising distinct phenotypes and endotypes [4, 5]. In addition, there is no consensus
on the clinical definitions of asthma and its key outcomes such as disease severity,
control, exacerbations [147, 148]. This is probably reflected in the wide hetero-
geneity in the methods in which asthma and asthma outcomes have been defined
from routinely collected data, as I found in Chapter 2. The lack of standardisation
of methods to define and assess asthma hinders the comparability of studies and
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evidence of synthesis. For flexibility, however, the Observatory users can choose
from several case definitions of asthma, in addition to the one I developed locally
using LCA and recursive partitioning. This enable researchers who use the Obser-
vatory to choose a method to identify people with asthma so that their study can
be compared to studies that used the same case definition.
6.5.2 Data from important care domains are still missing
Despite the availability of various datasets in the SAIL Databank, data from impor-
tant healthcare domains are still not available. Dispensing data contain informa-
tion needed to assess medication adherence. However, they are yet to be linked
into the SAIL Databank. In addition, treatments and prescriptions given to asthma
patients during hospital episodes are not collected into the SAIL Databank. These
data can be potentially useful to improve the sensitivity and specificity of methods
to identify asthma-related hospitalisations. These data, especially pathology test
results, could also improve methods of asthma phenotyping in the Observatory.
In Chapter 5, I demonstrated the utility of the Observatory to support health pol-
icy by investigating inequalities in asthma outcomes across the socioeconomic
groups. The study had high statistical power and provided useful insights into the
magnitude of the asthma social gradient in Wales. However, as with all observa-
tional studies, there were limitations with potentially residual confounders, many
of which were not readily available or directly measurable in the SAIL Databank.
An example of such confounders was health literacy which has significant eﬀects
on health status, disease prevention, early diagnosis, adherence to treatment, and
disease self-management. Direct, patient-level data on health literacy was not
available in the SAIL Databank. Instead, possible proxies include individual or
area-based data on education attainment.
6.5.3 Quality of routinely collected data is imperfect
Data quality has implications in almost all uses of data. Quality of RCD can sig-
nificantly influence the internal validity of studies using these data. Data quality
is potentially compromised by a variety of factors at diﬀerent stages of their flow
from points of care to data safe havens. These factors include, for example, poor
capture and record linkage errors.
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At the point of care, recording and coding of clinical data is often incentivised by
payment-for-performance schemes such as the UK’s QOF. This means that only
a small set of essential health events are well recorded. I showed in Section 4.5
examples of data quality issues where many asthma related data were missing
from the SAIL’s GP dataset, including lung functions recordings, disease severity
stratification, and measures to manage disease control.
Practices of data recording and coding into EHRs diﬀer between health organisa-
tions and potentially between healthcare professionals in the same organisation.
These practices have been influenced by the type of EHR systems used [435, 436].
They may also change over time due to administrative requirements (e.g., intro-
duction and changes in the QOF indicators) and in response to changes in clinical
guidelines and practice protocols.
Record linkage errors also compromise quality of linked data. Despite the high
matching rate in the SAIL Databank [140], linkage error may still happen if iden-
tifiers are incorrectly recorded or missing [234]. Record linkage errors have been
associated with several individual and population factors such as gender, race, ge-
ographical location, health status, and socioeconomic status [437]. If not properly
addressed, record linkage errors may introduce random and/or systematic errors
to study findings [234, 438].
6.5.4 Routinely collected data suﬀer from time lags
Many routinely collected data are not available for secondary uses in real-time [80,
439, 440]. Rather, considerable lead time is usually needed before they are made
available in usable form [80]. This time, ranging from weeks to several months
or years [441], is needed for preparation, transfer, anonymisation, record linkage
and encryption as well as quality checks of data [141]. This time lag limits the
usability of routinely collected data for applications that require timely data such
as producing real-time epidemiological estimates and follow-up of outcomes in
prospective studies and clinical trials [442]. Therefore, advances in data collection
and transfer operations as well as in infrastructures are needed for seamless and
faster production of usable RCD in order to facilitate applications that need timely
access to data [440].
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6.5.5 Routinely collected data does not reflect precise dis-
ease timeline
Data derived from EHRs often do not reflect precise timeline of chronic disease
development. For example, it is practically impossible to accurately determine
the date on which a disease starts to develop without intensive follow-up [443, p.
11]. Instead, EHRs usually record the dates at which patients report symptoms to
their physicians and when physicians make and record the diagnosis. This leaves
implications on epidemiological studies and timely surveillance of asthma. For
instance, asthma prevalence at a certain date or during a certain period, may be
underestimated unless future data for the denominator population are considered
in the estimation.
6.5.6 Lack of valid methods to assess outcomes
There were no standardised operational definitions for asthma outcomes in the
SAIL Databank. For example, to my knowledge, there were no validated and
standardised methods to identify asthma-related emergency and secondary care
use. Using diﬀerent diagnosis positions in hospital admission records to ascer-
tain asthma-related hospitalisation may have significant impact on sensitivity and
specificity. Lack of standardisation hinders comparability of studies and evidence
synthesis.
6.5.7 Public attitudes to data re-use are mixed
The Wales Asthma Observatory is based on linked, anonymised routinely collected
data held in the SAIL Databank. The public’s awareness of secondary use, anonymi-
sation, and linkage of person level health data is currently limited [444]. In addi-
tion, attitudes towards these important concepts are mixed, although a minority
of people in the United Kingdom are thought to have concerns about them [444,
445]. Public and patient involvement and partnership, strict information security
and governance, and transparency [446] are all needed to win and maintain the
trust of data safe haven stakeholders including the public, patients, and data pro-
viding organisations. Data safe havens should satisfy high level of competency in
safe-guarding data and must have strict protocols to ensure the use of data for the
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public’s good [447]. These requirements are fulfilled in the operation model of the
SAIL Databank [295]. The mixed public’s attitudes toward reusing health data for
research may have implications on the plan to collect PROMs into the Observatory
from the asthma population in Wales.
6.6 Implications and potential uses of the Obser-
vatory
The Observatory can be utilised for asthma research as well as to support asthma
care in Wales at national, organisational, and patient levels. The design of the Ob-
servatory facilitates answering a wide range of questions about asthma in Wales,
ranging from prevalence studies to incidence and retrospective longitudinal stud-
ies as well as assessment of quality and equality of care.
6.6.1 Implications on health policy and wider societal impact
With near complete geographical coverage, the Observatory can support health
policy and service planning across Wales. For example, the Observatory can be
used to identify variations in the asthma outcomes between patient groups diﬀer-
ing by socioeconomic status or age as demonstrated in Chapter 5. The Observatory
can also be used to analyse the trends of these variations and their implication on
the disease burden. Linking the Observatory to data on air pollution and housing
quality would allow generating insights about the eﬀects of environmental factors
data on asthma outcomes. These insights could be used to support healthy urban
planning and assess housing regeneration interventions [312, 448, 449].
6.6.2 Implications on service planning and delivery
The Observatory can be used to monitor the trends of asthma incidence, preva-
lence, and estimating the disease burden on the National Health Services (NHS)
at regional and national levels and across patient groups on a regular basis. By
including linked data on asthma management and disease outcomes across the
levels of care, the Observatory provides an ideal platform for Health Boards to
assess their performance in asthma care and evaluate the impact of asthma ser-
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vice level interventions. The quality of primary care services, including asthma
prescribing and reviews, can be assessed against national guidelines.
6.6.3 Implications on clinical practice and patient outcomes
The Observatory has potential applications in clinical practice to improve the out-
comes of patients with asthma. The availability of longitudinally assessed asthma
outcomes, which are linkable to person level EHR-derived data in the SAIL Data-
bank, facilitates research aiming to improve patient outcomes.
The Observatory can be used in the identification of risk factors, including modi-
fiable ones, of asthma and asthma adverse outcomes. This allows development of
algorithms to predict the risk of asthma exacerbations and assess asthma progno-
sis [70]. I used the Observatory data and its technical platform in the validation of
the asthma risk prediction algorithm that has been developed in the “At-Risk Reg-
isters Integrated into primary care to Stop Asthma crises in the United Kingdom”
(ARRISA-UK) study [450].
The Observatory can also facilitate pharmacovigilance research and studies on
how the eﬀectiveness of diﬀerent interventions diﬀers based on patient charac-
teristics. Such interventions include therapeutic regimens; primary care inter-
ventions such as routine and proactive review of asthma status, medications, and
action plans; asthma self-management approaches.
The outputs of asthma studies that will use the Observatory can be translated
into clinical decision support tools that can be used by healthcare professionals to
improve patient care. For example, the ARRISA-UK risk-finding algorithm will be
used in GP practice EHR systems to flag records of high-risk asthma patients so
that they receive the appropriate attention, disease management, and prevention
[451]. In addition, comparative eﬀectiveness studies can be used to develop EHR-
tools that provide clinicians with patient-tailored asthma prescribing recommen-
dations. The development and validation of such clinical decision support tools is
an important potential application of the Observatory in providing stratified and
personalised care.
The Observatory can also contribute to improvement of patient outcomes by facil-
itating implementation research and informing care pathway development. Link-
ing the Observatory data to asthma-related healthcare utilisation from primary
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and secondary care in the SAIL Databank can be useful for the assessment and
auditing of guideline implementation and in the improvement of asthma care path-
ways in primary and secondary care settings.
6.6.4 Implications on asthma research
The Observatory can be used as a platform to conduct various types of person-
level observational studies including cross-sectional and longitudinal studies. By
linking the Observatory to other data sources in the SAIL Databank, such as ed-
ucation or pollution data, using the linking field, many more research questions
about patients in the Observatory can be answered. The Observatory facilitates in-
terrogation of data on asthma patients in a way that increases research eﬃciency
and reproducibility.
6.7 Towards maximising benefits from population-
based data to improve asthma outcomes
6.7.1 Improving data capture
In Chapter 4, I proposed recommendations to improve the capture of asthma data
in routine health care. These data should not only include clinical data but also
wider societal determinants of health. It has been argued that “every doctor writ-
ing in the medical record is an information designer and is responsible for making
the data recorded easy to find and interpret” [452]. There are increasing calls
to include health informatics education in medical curricula [453], which could
improve data quality awareness among health professionals. However, with short
clinical encounters, doctors have limited time to spend on data recording. Facili-
tating valid, accessible, and timely recording of data is one of the core functions
of EHR systems. Informatics approaches including natural language processing
(NLP), machine learning, and medical knowledge engineering promise automated
capture of data that are locked in narrative clinical documentation [454]. EHR de-
sign should consider secondary uses of data such as research, service planning,
and health policy [455, 456].
6.7. Towards maximising population data benefits to improve asthma outcomes215
6.7.2 Reducing waste from underuse of data
Huge volumes of asthma-related RCD are collected every day across Wales. How-
ever, a small amount of these data is actually utilised to advance medical knowl-
edge and improve health care delivery and patient outcomes. It has been argued
that “the biggest waste in the healthcare system is not unnecessary treatment or
duplicated test results; it is that we collect data and never use it again.”4 Subopti-
mal utilisation of these data can arguably lead to unnecessary waste in resources,
repeated care mistakes and, most importantly, avoidable adverse outcomes for
patients [457].
Despite being a preventable disease, asthma adverse outcomes such as exacer-
bations and deaths still unnecessarily happen. The National Review of Asthma
Deaths (NRAD) report “Why asthma still kills” which was published in 2014, found
that over two-thirds of asthma deaths were potentially avoidable by better health
care and adoption of clinical guidelines as well as better patient adherence to med-
ical advice and treatment [51]. Among its recommendations, the report called for a
national audit of asthma. It recommended that asthma audits should be performed
on an ongoing basis with involvement and collaboration of patient organisations
and commissioners as well as clinicians. A national audit for asthma for Wales
and England is currently being scoped and developed in a project led by the Royal
College of Physicians [458]. It will focus on helping clinicians improve the docu-
mentation of asthma reviews in order to improve patient outcomes. It may also
cover several aspects of asthma care such as diagnosis, prescribing, personalised
action plan, disease triggers, emergency and secondary care, patient monitor-
ing [459]. Many of these care events can be assessed through the Wales Asthma
Observatory on an ongoing basis. Therefore, with its aforementioned strengths,
the Observatory is well positioned to play a vital role to support this forthcoming
audit programme [458]. Bringing additional asthma-related data such as commu-
nity prescribing and pathology data to the Observatory will further augment its
capability for regularly performed asthma audit and surveillance.
The NRAD was a crucial inquiry into reasons of asthma deaths, which received
publicity and attention among respiratory health professional societies and patient
organisations. Nonetheless, it is important to evaluate the report’s impact since
4Chris Lehmann, MD, Vanderbilt University Medical Center.
https://www.healthcare-informatics.com/blogs/david-raths/promise-structured-data-capture
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its publication in 2014. Asthma continues to kill and exacerbate. Similar repeated
inquiries are therefore likely to be needed in order to explore the avoidable factors.
The NRAD was based mainly on manual review of clinical records from health
care providers—a burdensome, expensive and time-consuming process. Such an
inquiry can potentially be instead performed using routinely collected data. This
will allow rapid and timely investigation into asthma adverse outcomes, which can
be regularly repeated, possibly as a part of the forthcoming national asthma audit.
The overriding and growing need to bridge the gap between research and care has
led to developing the concept of learning health systems (LHS). An LHS aims to
maximise learning from delivered care on an ongoing basis which can seamlessly
inform future care delivery [291]. Ideally, in a cyclical process, data is converted
into knowledge, which in turn informs performance, fromwhich new data is gener-
ated and feedback to create new knowledge [292]. The opposite case of a learning
health system has been dubbed as a ‘forgetting health system’ in which “today’s
mistakes are forgotten quickly and are repeated tomorrow” [460]. In the UK, an
initiative to develop a learning health system for asthma has started in Scotland
[461]. In Wales, theWales Asthma Observatory is well-suited to be a building block
in a future LHS for asthma.
6.7.3 Supportive data-intensive research environment
The Observatory benefits from a supportive, unique research environment and
atmosphere in Wales. This doctoral project was funded by Welsh Government’s
Health and Care ResearchWales (HCRW)5 and the Abertawe Bro Morgannwg Uni-
versity Health Board. This funding came in line with the Welsh Government’s vi-
sion to extend the investment in novel research applications of routinely collected
data [462]. The Government’s report titled “Maximising the Use of Routine Data
for Research in Wales” described its plans to support research based on routinely
collected data that can be translated into actionable knowledge and direct benefits
to the residents of Wales [96].
Partnerships involving government bodies, healthcare providers, research com-
munity, and funders are vital to maximise benefits from routinely collected data
[77]. The SAIL Databank is funded mainly by the Welsh Government’s Health and
Care Research Wales and receives support from Farr Institute of Health Infor-
5Previously named as the National Institute for Social Care and Health Research (NISCHR).
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matics Research which is in turn funded by the Medical Research Council (MRC).
Governmental and political support and the cooperation of data providing organ-
isations are all crucial for sustainable routine data collection [77]. This facilitates
disease surveillance and enables undertaking up-to-date studies. Continuous col-
lection of evidence is also a core requirement of a successful learning health sys-
tem [289, 291].
In the SAIL Databank, anonymisation and record linkage of routine health data are
performed with support of the National Health Services Wales Informatics Service
(NWIS) [140, 141]. The SAIL Databank regularly seeks to link new datasets to the
existing ones. For example, the Welsh Result Report Service dataset, which in-
cludes pathology data, is expected to be available in the SAIL Databank in 2018.
Medication dispensing data is another vital dataset which are expected to be
linked to the SAIL Databank. Linked data from various domains of health care
in the SAIL Databank are key to study and monitor a chronic condition that is
managed at various levels of care such as asthma. The prospect of the Observa-
tory, including further developments and wider utilisation, is highly contingent on
the continuous support of routinely collected data research in Wales.
6.7.4 Potentials of asthma big data
Successful experiences of learning from big data to oﬀer personalised services
and insights for organisations have been already happening in non-health care
sectors. These sectors include, for example, personal banking, marketing, retail-
ing, social networking, and digital personal assistants. Health care is already in
a significant lag behind other industries towards unlocking the full potentials of
linkable big data [463]. Utilisation of asthma big data is still at a nascent stage.
Patient data are scattered across multiple healthcare providers (e.g., GP prac-
tices, hospitals, and pharmacies). While medical record linkage in the UK is more
than half a century old, not all patient data are currently linked together. Despite
being a single organisation, the UK National Health Services eﬀectively has been
acting as disconnected providers. Experience of US healthcare providers such as
Kaiser Permanente demonstrates promising case of rapid learning from patient
data [288].
Asthma data are rapidly expanding in volumes and complexity including data from
emerging and non-clinical paradigms. Advanced biomedical technologies such as
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smart inhalers, wearable sensors, and internet-enabled devices, and gene analysis
enable the collection of rich, granular information about symptoms, breathomics,
disease self-management, medication use and adherence, environmental factors,
and PROMs [464–468]. Large volume of these data could enable better under-
standing of the disease aetiology and mechanism, and developing precise risk
prediction and decision support tools. Publicly available data on people’s inter-
net information seeking behaviour and online behaviour can be used to forecast
asthma epidemiology and health care resource utilisation [469–472]. Ubiquitous
collection, linkage, analysis of asthma-related big data can unlock substantial ad-
vantages for individuals and populations.
6.8 Future work
6.8.1 Improving methods to define asthma patients and as-
sess disease outcomes
The latent class model to identify asthma patients from the GP data, described
in Chapter 3, was based on a single calendar year (2014). However, due to the
change in data capture practices over time, this model may not be valid for dif-
ferent years. It is therefore important to compare this model with similar models
developed in diﬀerent years.
The change in disease status (e.g., new diagnosis, change in severity, and de-
velopment of comorbidities) can be tracked over time. Latent transition analysis
(LTA) can be used for this purpose. It aims to identify latent statuses of individ-
uals, defined over multiple time points or intervals, which explain the changes in
the observed characteristics in the population. LTA can be thought of as an LCA
repeated for the same cohort of patients over several intervals. LTA will allow ex-
ploration of common disease trajectories of asthma patients and their transition,
if any, between diﬀerent disease subgroups.
In Chapter 2, I found that, in the contemporary asthma literature, asthma severity
and control were most often assessed over a 12-month interval. An expert report
proposed that asthma control should be assessed over an interval of 2 to 4 weeks
for adults and at least 4 weeks for children [2]. A 12-month interval for assessing
a disease state is arguably a traditional artefact that makes assessment easier for
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investigators. However, this interval may not be the optimal one for assessment
of asthma severity and control. For example, a high disease severity inferred from
the number of high-dose prescriptions over 12 months does not necessarily mean
the disease was ‘severe’ all over the year. An unjustified interval may lead to mis-
classification of disease statuses and may undermine the study validity. Therefore,
it is important to explore the optimal intervals for disease statuses, possibly using
event sequence analysis and related visualisation techniques [473, 474].
6.8.2 Understanding inequalities in asthma outcomes
The analysis of inequalities of asthma outcomes, presented in Chapter 5, revealed
a wide gradient in asthma outcomes over five-year follow-up across the socioeco-
nomic groups in Wales. In that analysis, I used the WIMD index quintiles as an
explanatory variable. However, it is important to investigate the distribution of
asthma outcomes across each of the individual domains that make up the overall
deprivation index.
An extension of the study should also investigate whether the inequality gaps can
be partly explained by the individual deprivation domains and a number of po-
tential factors. These include patient’s health literacy, education attainment, self-
management, inhaler technique, environmental smoke exposure, housing condi-
tions, air pollution, comorbidities, ethnicity, as well as quality of primary care and
prescribing and proximity to GP practices and emergency departments. The time
trends of the social gradient of asthma should be also assessed at national and
regional levels.
6.8.3 Monitoring and forecasting asthma trends
The availability of longitudinal data from about two decades in the SAIL Databank
allows understanding and forecasting the seasonal and annual trends of asthma.
This can be performed by time series analysis and forecasting techniques such
as the autoregressive integrated moving average (ARIMA) of counts of healthcare
events over time intervals.
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6.8.4 Linking additional data sources
Linking additional healthcare datasets to the Observatory will allow answering
more research questions. Among such person-level datasets is the Welsh Results
Reports Service (WRRS) dataset [475]. This dataset includes laboratory test re-
sults across all Wales, and is currently in the process of being transferred into
the SAIL Databank. While laboratory test results can be recorded in the general
practice EHR system, they suﬀer from missingness and inconsistency across gen-
eral practices. Linking the WRRS data to the Observatory will potentially allow
improvement in the identification and phenotyping of asthma patients. For exam-
ple, more accurate data on peripheral eosinophil counts, total and specific IgE can
help in the identification of patients with eosinophilic and atopic asthma.
Person-level medication dispensing data are also available in Wales, but are not
currently available in the SAIL Databank. These data can be used to comple-
ment and crosscheck prescription data in the General Practice (GP) dataset. Pre-
scription data in the GP dataset currently do not include the quantity of the total
prescribed dose prescribed to the patient. Dispensing data ideally contain these
pieces of information, which can be used, for example, to assess asthma severity
and control (e.g., using a more accurate number of actually used short-acting beta
agonist inhalers) and identify exacerbations (e.g., by calculating the total supplied
dose and duration of administration of oral corticosteroids). Dispensing data also
contain the evidence that prescriptions issued by GPs are taken by patients to
pharmacies where they are dispensed. This information would provide an indica-
tive picture, although not certain, about patient’s adherence to medications. It is
not currently known, however, when dispensing data will be available in the SAIL
Databank.
Collecting asthma-related PROMs is important to understand patient’s perspec-
tive about the disease, treatment, disease control, and quality of life. These data
include standardised tools such as the AQLQ, ACQ, and ACT, which can be col-
lected during the clinical encounter or at patients’ home. The incentives and
barriers towards collecting such data need to be explored. Linking those data
to RCD in the SAIL Databank will enable identifying healthcare interventions that
are most important from patients’ perspectives. It will also allow the assessment
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of the concurrent validity of objective measures of asthma outcomes against the
correspondent PROMs (e.g., RCD-based asthma control definition vs. ACQ).
6.8.5 Improving the Observatory’s technical platform
The Observatory’s data interrogation interface needs further work to improve the
workflow of users. Planned improvements include support to additional data ex-
traction methods, and better documentation of data extraction. I also work with
the SAIL technical team towards making this interface available to the public.6
This will promote transparency, sharing, and reproducibility of studies that use
the Observatory.
6.8.6 Data quality reports
The Observatory could provide reports for the quality of its data. Examples of
these reports are those on the quality of recorded lung function data presented in
Chapter 4. It is important for users of the Observatory to be aware of data quality
issues beforehand. This will inform their study design and analysis, and makes it
easier for them to communicate data quality issues in their reports [157].
6.8.7 Getting ready for SNOMED-CT
In 2018, the Systematized Nomenclature of Medicine–Clinical Terms (SNOMED-
CT) will replace Read code vocabulary as the terminology of primary care in the
UK [311]. This transition is intended to support standardisation of clinical data
capture across the National Health Service. It is unclear how long this transi-
tion will take across Wales. However, it will be crucial to ensure compatibility
of the Observatory with the new data that will feed into the SAIL Databank from
general practices. This requires updating the methods used to identify asthma
patients and assess disease outcomes to capture data coded in SNOMED-CT. This
can be performed with the help of the Data Migration package, originally provided
by the NHS’s Health and Social Care Information Centre (NHS Digital) to guide
the transition. In addition to recognising the new data coded with SNOMED-CT,
the Observatory will still support backward compatibility with the historical Read
Code data held in the SAIL Databank.
6The interrogation interface outside the SAIL Gateway does not allow access to patient data.
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6.9 Conclusions
In this thesis, I described the establishment of the Wales Asthma Observatory us-
ing routinely collected data inWales. The Observatory represents a non-traditional,
cost-eﬀective approach to a patient registry and a platform for asthma surveillance
and research.
RCD oﬀer unique opportunities to understand asthma, inform health policy and
service planning, and improve patient outcomes. However, the inherent limita-
tions of these data impose challenges on those endeavours.
Among these challenges, defining a heterogeneous disease such as asthma using
RCD is fraught with pitfalls. In a systematic scoping review of the contemporary
literature, I found wide variation in methods to define asthma and its key outcomes
using RCD, let alone suboptimal reporting on implementation and validity of those
methods. These findings reflected the lack of consensus on the clinical definitions
of asthma and its outcomes as well as the wide diﬀerences in data resources. The
findings highlight the need to reach a consensus on clinical definition of asthma
and its outcomes and to harmonise operational definitions in RCD studies.
With the absence of a gold standard for asthma definition, unsupervised analysis of
asthma-related RCD coupled with clinico-epidemiological knowledge can identify
likely asthma patients. Clustering methods seek to identify the most likely popu-
lation structure behind the recorded data. Using latent class analysis, I identified
fuzzy clusters of asthma and COPD patients, based on which I derived a classifi-
cation algorithm to identify patients with any or both diseases. The probabilistic
case definition of asthma using RCD fits with the probabilistic approach to diag-
nose asthma in clinical practice. In addition to the LCA-based case definition, the
Observatory oﬀers other commonly used asthma case definitions.
Quality of asthma-related RCD inWales is suboptimal. I described various patterns
of missingness and inconsistencies in the recorded asthma data. I recommended
measures to improve the capture of asthma data including data quality awareness
training of healthcare professionals, improved data entry checks, and data quality-
based incentives. NLP promises to capture clinical data that are otherwise locked
in narrative documentations.
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Facilitating data interrogation is a growing requirement in RCD resources. The
Observatory supports shareable, reusable, and scalable data extraction, which
promotes research eﬃciency and reproducibility.
Health inequalities indicate unjust outcome variations within the population and
lead to wasted resources. They are a key challenge to health policy. I demon-
strated the Observatory’s value to health policy by exploring the social gradient
of asthma in Wales. I described a wide social gradient in asthma outcomes; de-
spite an excess in asthma-related primary care contact in the most deprived areas,
asthma patients there were more than twice likely to be hospitalised for asthma
than those in the least deprived areas. This suggested a wide gap in asthma con-
trol, that should be further investigated to identify avoidable contributing factors.
There is a growing attention to the waste and harm caused by the underuse of
health data. The Observatory is a promising endeavour to maximise the use of
asthma data in Wales in research and surveillance. It is well-positioned to play
a vital role in the upcoming national asthma audit programme in Wales. Learn-
ing health systems eﬀectively learn from experience in order to improve services.
The Observatory could be a building block in a future learning health system for
asthma in Wales.
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Table A.1.1: Search query used in the systematic scoping review.
Search
ID
Query Number of
matching
articles
#1 Search (”humans”[mh] AND English[lang] AND (”2012/11/19”[PDat] : ”2015/11/18”[PDat]) AND ”loattrfull text”[sb] AND ( Asthma[mh] OR ”Anti-Asthmatic Agents”[mh] ) AND ( Asthma[tiab] OR
Asthmatic[tiab] OR Asthmatics[tiab] ) NOT ”Comment” [pt] NOT ”Editorial”[pt] NOT ”Letter” [pt] NOT ”review”[pt] NOT ”Meta-Analysis” [pt] NOT ”clinical trial”[pt] NOT ”Randomized Controlled Trial”
[pt] NOT ”Clinical Trial, Phase I” [pt] NOT ”Clinical Trial, Phase II” [pt] NOT ”Clinical Trial, Phase III” [pt] NOT ”Clinical Trial, Phase IV” [pt] NOT ”Controlled Clinical Trial” [pt] NOT ”Clinical Trials as
Topic” [Mesh] NOT ”double-blind” [All] NOT ”placebo-controlled” [All] NOT ”case reports” [pt] NOT ”pilot study” [All] NOT ”pilot projects” [Mesh] NOT ”Prospective Studies” [Mesh])
3164
#2 ”GPRD” OR ”CPRD” OR ”Clinical Practice Research Datalink” OR ”General Practice Research Database” OR ”SAIL databank” OR ”Secure Anonymised Information Linkage Databank” OR ”Hospital
Episode Statistics” OR (”HES” AND ”England”) OR ”Mediplus” OR ”DIN-LINK” OR ”QResearch” OR ”RiRL” OR ”Research in Real Life” OR ”Paediatric Intensive Care Audit Network” OR ”PICANet” OR
”Scottish Drug Misuse Database” OR ”Prescribing Information System” OR ”Maternity and Neonatal Linked Database” OR ”Office for National Statistics” OR (”ONS” AND (”UK” OR ”United Kingdom”))
OR ”Primary Care Mortality Database” OR ”PCMD” OR ”Emergency department Data Set” OR ”National Community Child Health Database” OR ”Outpatient Dataset” OR ”Patient Episode Database for
Wales” OR ”PEDW” OR ”Primary Care dataset” OR OR ”Primary Care GP dataset” OR ”Maternity and Neonatal Linked Database” OR ”Prescribing Information System” OR ”Scottish Birth Record” OR
”Scottish Drug Misuse Database” OR ”Scottish Morbidity Records” OR ”Scottish morbidity” OR ”SMR01” OR ”SMR00” OR ”Outpatient Attendance dataset” OR ”SMR01” OR ”General / Acute Inpatient
and Day Case dataset” OR ”Department of Health Victoria Australia” OR ”Clalit Health Service computerized databases” OR ”National Health Insurance Research Database” OR ”NHIRD” OR
”Portuguese Anti-Doping authority database” OR ”Children’s Hospital Srebrnjak Database” OR ”CHSD” OR ”Practice Team Information” OR ”Norwegian Prescription Database” OR ”NorPD” OR ”National
Health Insurance Claims Database” OR ”Longitudinal Health Insurance Database” OR ”LHID” OR ”Medical Birth Registry” OR ”Medical Birth Register” OR ”Statistics Norway” OR ”National Insurance
Scheme” OR ”Medco Health Solutions administrative database” OR ”Discharge Abstract Database”) OR ”Ontario Asthma Database” OR ”Ontario COPD Database” OR ”Ontario Hypertension Database”
OR ”Ontario Diabetes Database” OR ”Surveillance, Epidemiology and End Results” OR ”SEER” OR ”National Board of Health and Welfare and Statistics” OR ”Prescribed Drug Register” OR ”National
Patient Registry” OR ”Optimum Patient Care Research Database” OR ”OPCRD” OR ”Hospital Discharge Register” OR ”Cause of Death Register” OR ”Register of Population and Population Changes” OR
”British Thoracic Society Difficult Asthma Registry” OR ”InterAction Database” OR ”IADB” OR ”Total Population Register” OR ”Multi-Generation Register” OR ”Prescribed Drug Register” OR ”PDR” OR
”National Patient Register” OR ”NPR” OR ”Statistics Denmark” OR ”Odense Pharmaco-Epidemiological Database” OR ”Register of Medicinal Product Statistics” OR ”RMPS” OR ”Register of Medical
Product Statistics” OR ”RMPS” OR ”National Hospital Register” OR ”Hospital In-Patient Enquiry” OR ”HIPE” OR ”Utrecht General Practitioner Research Network” OR ”Christelijke Mutualiteiten health
insurance” OR ”MigMed2” OR ”Hospital Discharge Registers” OR ”Ambulatory Care Classification System” OR ”ACCS” OR ”Physician Claims Database” OR ”Medical Services Plan” OR ”Discharge
Abstracts Database” OR ”Régie de l’Assurance Maladie du Quebec” OR ”RAMQ” OR ”MED-ECHO” OR ”Fichier des événements démographiques” OR ”The Health Improvement Network” OR ”Oxford
Record Linkage” OR ”PharMetrics” OR ”National Inpatient Sample” OR ”Mutuelle Générale de l’Education Nationale” OR ”INSS Unified Benefit System”
36991
#3 (”Premier” [All] OR ”Solucient” [All] OR ”Cerner” [All] OR ”Ingenix” [All] OR ”LabRx” [All] OR ”IHCIS” [All] OR ”marketscan” [All] OR ”market scan” [All] OR ”Medstat” [All] OR ”Thomson” [All] OR
”pharmetrics” [All] OR ”healthcore” [All] OR ”united healthcare” [All] OR ”UnitedHealthcare” [All] OR ”UHC” [All] OR ”Research Database” [All] OR ”Group Health” [All] OR ”HCUP” [All] OR (”Healthcare
Cost” [All] AND ”Utilization Project” [All]) OR (”Health Care Cost” [All] AND ”Utilization Project” [All]) OR ”MEPS” [All] OR ”Medical Expenditure Panel Survey” [All] OR ”NAMCS” [All] OR ”National
Hospital Ambulatory Medical Care Survey” [All] OR ”National Ambulatory Medical Care Survey” [All] OR ”NHIS” [All] OR ”National Health Interview Survey” [All] OR ”Kaiser” [All] OR
”Kaiser-Permanente” [All] OR ”Kaiser Permanente” [All] OR ”HMO Research” [All] OR ”Health Maintenance Organization” [All] OR ”HMO” [All] OR ”Cleveland Clinic” [All] OR ”Lovelace” [All] OR
”Department of Defense” [All] OR ”Henry Ford” [All] OR ”i3 Drug Safety” [All] OR ”i3” [All] OR ”Aetna” [All] OR ”Humana” [All] OR ”Wellpoint” [All] OR ”IMS” [All] OR ”Intercontinental Marketing
Services” [All] OR ”IMS Health” [All] OR ”Geisinger” [All] OR ”GE Healthcare” [All] OR ”MQIC” [All] OR ”PHARMO” [All] OR ”Institute for Drug Outcome Research” [All] OR ”Pilgrim” [All] OR ”Puget
Sound” [All] OR ”Regenstrief” [All] OR ”Saskatchewan” [All] OR ”Tayside” [All] OR ”MEMO” [All] OR ”Veterans Affairs” [All] OR ”Partners Healthcare” [All] OR ”Mayo Clinic” [All] OR ”Rochester
Epidemiology” [All] OR ”Indiana Health Information Exchange” [All] OR ”Indiana Health” [All] OR ”Intermountain” [All] OR ”blue cross” [All] OR ”health partners” [All] OR ”health plan” [All] OR ”health
services” [All] OR ”Nationwide Inpatient Sample” [All] OR ”National Inpatient Sample” [All] OR ”medicaid” [All] OR ”medicare” [All] OR ”MediPlus” [All] OR ”Outcome Assessment” [All] OR (TennCare
[tiab]) OR (RAMQ [tiab]) OR (Cigna [tiab]) OR ((british columbia [tiab]) AND ((health [tiab]) OR (data [tiab]) OR (database [tiab]) OR (population [tiab]))) OR (CIHI [All Fields]) OR ((manitoba [tiab]) AND
((center for health policy [all fields]) OR (population [tiab]) OR (health insurance [tiab]))) OR ((ontario [tiab]) AND ((population [tiab]) OR (OHIP [tiab]) OR (registered persons database [tiab]) OR (health
insurance [tiab]) OR (ICES [All Fields]) OR (Institute for Clinical Evaluative Sciences [All Fields]))) OR ((Alberta [tiab]) AND ((health [tiab]) OR (data [tiab]) OR (database [tiab]) OR (population [tiab]) OR
(Alberta Health and Wellness [All Fields]))) OR ”ICD-9-CM” [All Fields] OR ”ICD-10-CM” [All Fields] OR ”ICD-9” [All] OR ”ICD-10” [All] OR ”international statistical classification” [All] OR ”international
classification of diseases” [All] OR ”Database Management Systems” [Mesh] OR ”Medical Records Systems, Computerized” [Mesh] OR ”CPT” [All] OR ”Current procedural terminology” [All] OR ”OPCS4”
OR ”OPCS-4” OR ”Read code*” OR ”SNOMED-CT” OR ”J45*” OR ”H33*” OR ”insurance database” [All] OR ”insurance databases” [All] OR ”health insurance claim*” OR ”health insurance data*” OR
”claim data” OR ”claims data” OR (”claims” [tw] AND ”administrative” [tw]) OR ”Insurance Claim Review”[mh] OR ((medical OR pharmacy) AND claim) OR ((medical OR pharmacy) AND claims) OR
”Insurance Claim Reporting”[mh] OR ”routine data” OR ”routine health data” OR ”routine clinical data” OR ”routine electronic data” OR ”routinely collected data” OR ”routinely-collected data” OR
”routinely-collected health data” OR ”drug surveillance” [All] OR ”pharmacy data” OR ”dispensing data” OR ”administrative data” OR ”administrative health data” OR ”health administrative data” OR
(”data” [tw] AND ”administrative” [tw]) OR ”database analysis” OR ”register” OR ”registry” OR ”Databases, Factual” [Mesh] OR ”Databases as topic” [Mesh] OR ”Data Warehouse” [All] OR ”Medical
Record Linkage” [Mesh] OR ”record-linkage” OR ”record linkage”)
996792
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Table A.1.2: Charting table showing the data extracted from the reviewed articles.
Variable Notes
General
Title/Year
Country
Study design
Routine data sources used We extracted the names and types of the
routine datasets from which asthma variables
are measured or derived.
Algorithms and case definitions
Asthma Includes asthma labels, case definitions,
comorbidity and age exclusions, as well as
validity reporting. We distinguished in each
study between the criteria for defining ‘asthma’
and the study-specific criteria for subject
selection which can be more specific.
Asthma severity Also includes validity reporting.
Asthma control Also includes validity reporting.
Asthma exacerbation Also includes validity reporting.
Clarity of reporting routine data-related methods
Title and abstract
RECORD 1.1: Types or names of routine data sources used are mentioned
RECORD 1.2: Geographical regions covered by the routine data sources used are mentioned
RECORD 1.2: Study-time frame is mentioned
RECORD 1.3: Record linkage is mentioned (if used)
Methods
RECORD 6.1: Selection process of study population ismentioned in detail; clinical codes for asthma case
definitions are reported
Clinical codes could be either in the Methods
section or in supplementary documents.
RECORD 6.2: Validation for case definitions
RECORD 6.3 and 12.3: Record-linkage, if used, is sufficiently explained
RECORD 7.1: List of codes used in study variables
RECORD 12.1: Authors explained their level of access to database population
RECORD 12.2: Data cleaning is explained
Results
RECORD 13.1: Details of study population selection
Discussion
RECORD 19.1: Implications of using routine data for asthma research (e.g. misclassification bias, un-
measured confounding, missing data, and changing eligibility over time)
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Variable Notes
RECORD 22.1: Information on how to access study protocol, raw data, and programming code is men-
tioned
A.1. Additional results for Chapter 2 259
Table A.1.3: Geographical distribution of the reviewed studies.
Country Number of studies
US 52
Taiwan 20
Canada 12
Sweden 4
Denmark 4
UK 3
Republic of Korea 2
Israel 2
France 2
Finland 2
Europe 2
USA, UK 1
Spain 1
Singapore 1
Portugal 1
Netherlands 1
Korea 1
Italy 1
Iran 1
Australia 1
Table A.1.4: Study designs of the reviewed studies.
Study design Number of studies
cohort study, retrospective, using routine database(s) 62
cross-sectional / prevalence study 27
nested case-control 5
cohort study, prospective, using routine database(s) 5
validation study 3
time series analysis 3
population based cross-sectional ecological study 2
cohort study, retrospective, linked to self-reported data 1
cohort study, retrospective, linked to medical charts 1
cohort study, retrospective, linked to death registry 1
case-crossover study 1
case-control study 1
case-control 1
Table A.1.5: Types of EHR-derived data sources used in the reviewed articles.
Type Number of studies
health insurance claim 72
medical records or medical administrative data 39
dispensing 13
mortality with causes of death 2
public health surveillance database 1
medical birth register 1
health insurance claim + medical records 1
drug adverse effect surveillance 1
disease register 1
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Table A.1.6: Algorithms used to identify asthma patients.
Label Algorithm Number of
studies
asthma asthma encounter (position = unspecified)≥ 1 22
IP (position = unspecified)≥ 1 7
Rx≥ 1 5
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 1 OR ED (position = unspecified)≥ 1 3
asthma encounter (position = 1)≥ 1 3
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 2 2
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 2 2
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 1 2
IP (position = 1)≥ 1 2
ED (position≤ 3)≥ 1 2
asthma encounter (position = unspecified)≥ 1 OR Rx≥ 1 2
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 2 within 12 months 2
SABA≥ 1 AND (ICS, inhaled anticholinergics, Theo, LTRA, OCS, Combo)≥ 2 OR LABA-ICS≥1 1
Rx≥ 1 within 12 months 1
Rx > 1 OR omalizumab≥ 1 within 12 months 1
OP (position = unspecified)≥ 3 OR IP (position = unspecified)≥ 1 1
OP (position = unspecified)≥ 2 OR IP (position = unspecified)≥ 2 1
OP (position = unspecified)≥ 2 OR IP (position = 1)≥ 1 within 12 months 1
OP (position≤ 2)≥ 2 OR IP (position = unspecified)≥ 1 OR ED (position = unspecified)≥ 1 1
OP (position≤ 2)≥ 2 OR ED (position = 1)≥ 1 OR IP (position = 1)≥ 1 1
IP OR ED (position = 1 or second to a respiratory diagnosis)≥ 1 1
IP (position≥ 1)≥ 1 OR OP (position≥ 1)≥ 2 within 2 years 1
IP (position≥ 1)≥ 1 OR OP (position≥ 1)≥ 2 1
IP (position≥ 1)≥ 1 OR OP (position≥ 1)≥ 1 1
ED = emergency department visit; GP = general practitioner visit; ICS = inhaled corticosteroid; IP = inpatient hospitalisation; LABA = long-acting beta agonist; LTRA = leukotriene receptor antagonist; OCS =
oral corticosteroids; OP = outpatient visit; RSV = respiratory syncytial virus; SABA = short-acting beta-2 agonists
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Table A.1.6: Algorithms used to identify asthma patients.(cont’d)
Label Algorithm Number of
studies
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 3 within 36 months 1
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 2 within 12 months 1
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 2 OR ED (position = unspecified)≥ 2 OR within 24 months 1
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 1 OR ED (position = unspecified)≥ 1 1
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 1 within 1 year 1
IP (position = unspecified)≥ 1 OR OP (position = unspecified)≥ 1 OR Rx≥ 4 within 12 months 1
IP (position = unspecified)≥ 1 OR (OP (position = unspecified) + ED (position = unspecified))≥ 2 1
IP (position = unspecified)≥ 1 AND Rx≥ 1 1
IP (position = 1) OR OP (position = 1) ever 1
IP (position = 1)≥ 1 OR IP (position = 2 or 3, following pneumonia/influenza, respiratory failure, RSV/bronchiolitis) 1
IP (position≤ 2)≥ 1 1
GP (position≤ 2)≥ 1 OR IP (position≤ 2)≥ 1 OR ED (position≤ 2)≥ 1 OR asthma urgent care visit (position≤ 2)≥ 1 OR Rx≥ 1 1
ED (position = any)≥ 1 OR wheeze≥ 1 1
ED (position = 1)≥ 1 1
ED (position = 1 to 11)≥ 1 1
based on ICS 1
based on asthma medications 1
asthma encounter (position = unspecified)≥ 2 within 12 months 1
asthma encounter (position = unspecified)≥ 2 ever 1
asthma encounter (position = unspecified)≥ 2 1
asthma encounter (position = unspecified)≥ 1 within 12 months 1
asthma encounter (position = unspecified)≥ 1 OR Rx within 6 months 1
asthma encounter (position = unspecified)≥ 1 OR Rx≥ 2 ever 1
asthma encounter (position = unspecified)≥ 1 OR Rx≥ 1 ever 1
asthma encounter (position = unspecified)≥ 1 OR ICS≥ 1 within 12 months 1
asthma encounter (position = unspecified)≥ 1 OR asthma medications≥2 1
asthma encounter (position = unspecified)≥ 1 ever 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 2 within 24 months 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 2 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 1 within 12 months 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 1 1
asthma encounter (position = unspecified)≥ 1 AND current Rx≥ 2 1
asthma encounter (position = unspecified)≥ 1 AND current Rx≥ 1 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 2 1
asthma encounter (position = unspecified)≥ 1 AND Rx≥ 1 1
ED = emergency department visit; GP = general practitioner visit; ICS = inhaled corticosteroid; IP = inpatient hospitalisation; LABA = long-acting beta agonist; LTRA = leukotriene receptor antagonist; OCS =
oral corticosteroids; OP = outpatient visit; RSV = respiratory syncytial virus; SABA = short-acting beta-2 agonists
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Table A.1.6: Algorithms used to identify asthma patients.(cont’d)
Label Algorithm Number of
studies
(asthma encounter (position = 1)≥ 1 OR asthma encounter (position≥ 1)≥ 4) AND (asthma prescriptions≥1 OR asthma tests≥ 1)
within 5 years
1
current asthma asthma encounter (position = unspecified)≥ 1 1
current GP-reported
asthma
asthma encounter (position = unspecified)≥ 1 within 12 months 1
current treated asthma asthma encounter (position = unspecified)≥ 1 AND Rx≥ 1 within 12 months 1
treated asthma Rx > = 3 within 12 months 1
persistent asthma Rx≥ 4 OR IP≥ 1 OR ED (position = 1)≥ 1 OR (OP (position = any)≥ 1 AND Rx≥ 2) within 12 months 2
Rx≥ 4 OR IP≥ 1 OR ED (position = 1)≥ 1 OR (OP (position = any)≥ 1 AND Rx≥ 2) within 24 months 1
Rx≥ 4 OR IP≥ 1 OR ED (position = 1)≥ 1 OR (OP (position = any)≥ 1 AND Rx≥ 2) within 12 months 1
Rx≥ 4 OR IP≥ 1 OR ED (position = 1)≥ 1 OR (OP (position = any)≥ 1 AND Rx≥ 2) 1
IP (position = unspecified)≥ 1 OR ED (position = unspecified)≥ 1 OR OCS≥ 3) within 12 months 1
ED = emergency department visit; GP = general practitioner visit; ICS = inhaled corticosteroid; IP = inpatient hospitalisation; LABA = long-acting beta agonist; LTRA = leukotriene receptor antagonist; OCS =
oral corticosteroids; OP = outpatient visit; RSV = respiratory syncytial virus; SABA = short-acting beta-2 agonists
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Table A.1.7: Approaches used in identifying asthma patients.
Criteria base on Diagnostic label
used
Number of studies
Asthma diagnostic/management codes
‘asthma’ 68
persistent asthma 1
acute asthma 1
current asthma 1
current GP-reported
and diagnosed
asthma
1
Asthma diagnostic/management codes
AND asthma prescription codes
‘asthma’ 11
current treated
asthma
1
persistent asthma 2
Asthma prescription codes
asthma 22
treated asthma 1
persistent asthma 4
Table A.1.8: Age restriction approaches used in asthma patient identification.
Age limits Studies Number of studies
Minimum age limits
6 months A1 1
2 years A2–A7 6
3 years A8–A10 3
5 years A11–A13 3
Maximum age limits
44 years A14 1
55 years A15 1
60 years A16 1
64 years A17 1
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Table A.1.9: Co-morbidities and conditions based on which asthma patients were excluded.
Condition Number of studies
COPD 11
Cystic fibrosis 13
Pulmonary embolism 3
Bronchiectasis 4
Pulmonary hypertension 4
Congestive heart failure 3
Emphysema 3
Chronic bronchitis 2
Immunodeficiency 2
Churg Strauss syndrome 1
Wegener syndrome 1
Sarcoidosis 1
Smoker over age of 60 1
Pneumonia 1
Anti-cholinergic prescription as a proxy of COPD 1
Chronic respiratory failure 1
Achondroplasia 1
Bronchopulmonary dysplasia 1
Respiratory cancer 1
Active or past tobacco use 1
Primary ciliary dyskinesia 1
Tracheomalacia 1
Bronchiolitis/RSV infection 2
Pneumoconiosis 1
Other lung diseases due to external agents 1
Psychosis 1
“Perinatal respiratory condition” 1
Tracheostomy 1
Gastrostomy 1
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Table A.1.10: Algorithms used to ascertain asthma severity using EHR data.
Variable Algorithm Interval
(months)
Appears in Validated by
Mild asthma either
500 mg/day of ICS monotherapy (in beclomethasone
chlorofluorocarbon equivalents)
OR
250 mg/day of ICS + additional controller
AND
either
≤ 3 SABA doses per week on average (each = 2
salbutamol 100mg puffs)
OR
both
4−10 doses of SABA per week on average
AND
no moderate to severe asthma exacerbation (defined
as asthma ED visit OR asthma hospitalisation OR
short−course OCS)
12 [A18] previous study(-ies) on same
database(s)
Moderate asthma NOTmild asthma NOR severe asthma as defined in the
same study
12 [A18] previous study(-ies) on same
database(s)
Severe asthma > 1000 mg/day of ICS
AND
one of
> 3 SABA per week on average
OR
≥ 1 moderate to severe asthma exacerbation
OR
both
lower doses of ICS with >10 SABA doses per week on
average
AND
1 moderate to severe asthma exacerbation
12 [A18] previous study(-ies) on same
database(s)
> 6 albuterol refills per year 12 [A2] not justified
GINA step 4 or higher unclear [A19] Based on GINA guidelines
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral
corticosteroids; OP = outpatient; SABA = short-acting β2 agonists.
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Table A.1.10: Algorithms used to ascertain asthma severity using EHR data. (cont’d).
Variable Algorithm Interval
(months)
Appears in Validated by
continuous treatment with ICS (at least 800 mg
budesonide daily or equivalent [500 mg fluticasone])
and (LABA)
12 [A20] not justified
presence of persistent asthma according to the HEDIS
criteria associated with readmission
OR
presence of complex chronic condition within the prior
year associated with readmission
12 [A4] previous study(-ies) on
different database(s)
based on number of ICS, LABA, and OCS prescriptions 24 [A21] not justified
based on number of asthma prescriptions (including
OCS)
12 [A22] not justified
based on asthma hospitalisation, asthma Ed visits,
outpatient visits for asthma exacerbation, number of
SABA dispensings, number of OCS dispensings
12 [A23] previous study(-ies) on
different database(s)
based on number of asthma hospitalisations, asthma
ED visits, SABA prescriptions, OCS prescriptions, and
asthma exacerbations over 6 months
6 [A13] previous study(-ies) on
different database(s)
based on acute OCS course, mean daily SABA dose,
number of asthma consultations with no acute OCS
12 [A16] not justified
ICS (>800 mg
budesonide daily) AND second controller
OR
ICS−LABA
OR
omalizumab
12 [A14] Based on clinical guidelines
According to GINA 2006 classification of severity unclear [A24] Based on clinical guidelines
Based on OCS prescriptions unclear [A25] not justified
Number of OP over variable follow−up periods variable [A26] not justified
‘More severe asthma’ ≥ 2 SABA prescriptions within 90 days of ICS
prescriptions
3 [A27] previous study(-ies) on
different database(s)
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral
corticosteroids; OP = outpatient; SABA = short-acting β2 agonists.
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Table A.1.10: Algorithms used to ascertain asthma severity using EHR data. (cont’d).
Variable Algorithm Interval
(months)
Appears in Validated by
HEDIS criteria for persistent asthma:
≥ 1 asthma hospitalisation
OR
≥ 1 asthma ED visit
OR
≥ 4 asthma prescriptions
OR
both
≥ 4 asthma outpatient visits
AND
≥ 2 asthma prescriptions
24 [A6] previous study(-ies) on
different database(s)
≥ 1 asthma hospitalisations or ED visits 12 [A28] not justified
Low-risk asthma no asthma ED visits
AND
no asthma hospitalisations
AND
< 15 β−agonist canisters dispensed
AND
no OCS dispensed
12 [A9] previous study(-ies) on
different database(s)
Moderate-risk
asthma
no asthma ED visits
AND
no asthma hospitalisations
AND
only one of:
≥ 15 β−agonist canisters dispensed
OR
≥ 1 OCS dispensings
12 [A9] previous study(-ies) on
different database(s)
High-risk asthma ≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalisations
OR
both:
≥ 15 β−agonist canisters dispensed
AND
≥ 1 OCS dispensings
12 [A9] previous study(-ies) on
different database(s)
ED = emergency department; GINA = Global Initiative for Asthma; HEDIS = Healthcare Effectiveness Data and Information Set; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral
corticosteroids; OP = outpatient; SABA = short-acting β2 agonists.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data.
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
Exacerba-
tion
[A29] ≥ 1 OCS prescription for < 21 days
OR
≥ 4 asthma GP visits per year
OR
≥ 5 SABA prescriptions per year
< 21
days
≥
4/yr
> 5/yr based on
a
national
expert
review
[A30]
[A14] ≥ 1 OCS prescription
OR
Hospitalisation or ED visit for asthma,
status asthmaticus, pneumonia,
dyspnoea, or respiratory insufficiency
≥ 1 p p previous
study(-
ies) on
differ-
ent
database(s)
[A31] asthma hospitalisation
OR
asthma ED visit
OR
OCS pharmacy claim
p p p not
justified
[A19] OCS prescription within 7 days of any
asthma encounter (which may
include hospitalisation, ED,
outpatient, or GP visit, ascertained
with the ICD−9 code 493 as a
primary diagnosis or as a secondary
diagnosis provided the primary
diagnosis is another respiratory
condition)
Variation: asthma encounter = asthma
hospitalisation or ED visit only
within
7 days
within
7 days
not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d).
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
[A21] OCS with asthma as indication
OR
asthma ED visit
OR
asthma hospitalisation
indica-
tion is
asthma
p p not
justified
[A22] OCS prescription
OR
number of asthma GP visits
OR
hospitalisation for asthma (as a
primary diagnosis; variation: as a
primary or secondary diagnosis)
p p p not
justified
[A32] Occurrence, after 3 months from
previous asthma hospitalisation, if
any, of:
OCS short−course
OR
asthma ED visit (ICD−9−CM =
493)
OR
asthma hospitalisation
(ICD−9−CM = 493)
p p p not
justified
[A33] Primary hospital discharge diagnosis of
asthma exacerbation
p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d).
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
[A34] ED visit with primary diagnosis of
asthma
OR
outpatient visit with
diagnosis of asthma exacerbation
OR
diagnosis of asthma with OCS
prescription (< 14−day supply)
within 5 days
OR
hospitalisation with diagnosis of
asthma (primary) or asthma
exacerbation (any position)
< 14-
day
sup-
ply;
within
5 days
p p Dx is
AE
not
justified
[A35] OCS use
OR
asthma ED visit
OR
asthma hospitalisation
p p p not
justified
[A23] outpatient visit with primary diagnosis
of asthma (ICD−9−CM = 493) and
OCS dispensing within 5 days
OR
asthma ED visit (ICD−9−CM = 493.xx)
OR
asthma hospitalisation (ICD−9−CM =
493.xx)
within
5 days
p p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d).
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
[A36] ED visit with any asthma diagnosis
OR
hospitalisation with primary diagnosis
asthma
OR
OCS with asthma claim within 7 days
within
7 days
p p not
justified
[A37] one−off OCS prescription
(short−course)
p not
justified
[A38] OCS within 7 days of an encounter with
diagnosis of exacerbation or
uncontrolled asthma
P
[A39] ≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalisations
OR
OCS prescriptions
p p p not
justified
[A40] asthma ED visit (ICD−9−CM = 493)
AND/OR
asthma hospitalisation (ICD−9−CM =
493)
p p not
justified
[A8] Encounter with asthma exacerbation
code
not
justified
[A16] acute OCS
OR
unscheduled asthma hospitalisation
OR
ED visit
p p p not
justified
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d).
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
[A17] new occurrence (after >= 8−day
wash−up period) of:
Both
Asthma outpatient visit (with a
code for acute exacerbation,
status asthmaticus, acute
asthma attack, uncontrolled
asthma, asthmatic bronchitis)
AND
OCS dispensing within 7 days
OR
Asthma ED visit or hospitalisation
(asthma diagnosis position = 1
OR position = 2 following a
primary respiratory diagnosis)
p p p being
based
on na-
tionally
devel-
oped
algo-
rithm(s)
[A41] Asthma hospitalisation
OR
Asthma ED visit
OR
Asthma OP visit with OCS prescription
p p p not
justified
[A24] Based on rescue medications not
justified
Moderate-
to-severe
exacerba-
tion
[A18] OCS short−course
OR
asthma ED visit
OR
asthma hospitalisation
p p p previous
study(-
ies) on
same
database(s)
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.11: Algorithms used to ascertain asthma exacerbation using EHR data. (cont’d).
Variable Study Algorithm OCS IP ED OP GP SABA Validity
reportingalone + OP + IP,
ED, OP
or GP
+ IP or
ED
[A13] OCS within 7 days of asthma
outpatient visit
OR
Asthma ED visit
within
7 days
p not
justified
Moderate
exacerba-
tion
[A42] ≥ 1 ED visits for asthma
AND
no hospitalisation for asthma
a p being
consis-
tent
with
algo-
rithms
used in
previ-
ous
similar
studies
on dif-
ferent
database(s)
Severe ex-
acerbation
[A42] ≥ 1 hospitalisation for asthma as a
primary or admission diagnosis
p being
consis-
tent
with
algo-
rithms
used in
previ-
ous
similar
studies
on dif-
ferent
database(s)
p = present; a = absent; OCS = oral corticosteroids; AE = asthma exacerbation; SABA = short-acting β2 agonists; ED = emergency department; ICD = International Classification of Diseases; IP = inpatient hospitalisation; OP =
outpatient; GP = general practitioner.
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Table A.1.12: Algorithms used to assess asthma control using EHR data
Variable Algorithm Interval Appears in Validated by
Low control/
uncontrolled asthma
≥ 600 doses (1 dose = 1 puff) of SABA in the recent year
OR
≥ 1 exacerbation in the recent year, defined as:
≥ 1 hospitalisation or ED visit associated with ICD−10 code for asthma,
status asthmaticus, pneumonia, dyspnoea, or respiratory insufficiency
OR
≥ 1 OCS prescription
12 months [A14] previous
study(-ies) on
different
database(s)
≥ 1 hospitalisation or ED visit
OR
dispensing of OCS for≥ 3 days
12 months [A39] not justified
≥ 1 ED or OP visit for asthma
OR
≥ 1 antibiotic prescriptions
unclear [A43] previous
study(-ies) on
same database(s)
≥ 1 moderate to severe asthma exacerbation
AND
> 3 and 10 SABA doses per week on average for mild and moderate/severe
asthma, respectively
12 months [A18] previous
study(-ies) on
same database(s)
≥ 2 acute care contact within 1 month
OR
≥ 3 reliever inhaler uses per week
OR
severe exacerbation requiring ICU/intubation in the last 3 months
OR
asthma hospitalisation in the last 3 months
1-3 months [A24] previous
study(-ies) on
same database(s)
LRTI = lower respiratory tract infection; SABA = short-acting β agonists; OCS = oral corticosteroids; GP = general practitioner; ED = emergency department; ICD = International Classification of Diseases
A.1.
Additionalresults
for
C
hapter
2
275
Table A.1.12: Algorithms used to assess asthma control using EHR data (cont’d)
Variable Algorithm Interval Appears in Validated by
at the assessment date
> 2 asthma drug classes
OR
≥ 1 SABA
OR
in 12 months
≥ 1 OCS
OR
≥ 6 SABA
OR
≥ 1 asthma ED visits
OR
≥ 1 asthma hospitalisations
12 months [A37] being consistent
with algorithms
used in previous
similar studies on
the same
database
Low-risk asthma
control
Absence of all the following:
hospitalisation, ED, and unscheduled outpatient visits for asthma
(ascertained by any asthma or LRTI codes)
GP consultation for LRTI requiring antibiotics
acute course of OCS
12 months [A16] previous
study(-ies) on
different
database(s)
based on number of OCS prescriptions per year 12 months [A44] previous
study(-ies) on
different
database(s)
Impairment-domain
asthma control
based on number of β−agonists prescriptions per year 12 months [A44] previous
study(-ies) on
different
database(s)
> 2 salbutamol puffs per day (> 200µg in the UK and > 180µg in the US) 12 months [A16] previous
study(-ies) on
different
database(s)
LRTI = lower respiratory tract infection; SABA = short-acting β agonists; OCS = oral corticosteroids; GP = general practitioner; ED = emergency department; ICD = International Classification of Diseases
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Table A.1.12: Algorithms used to assess asthma control using EHR data (cont’d)
Variable Algorithm Interval Appears in Validated by
Overall asthma control based on impairment−domain and risk−domain asthma control algorithms
used by the same study
12 months [A16] previous
study(-ies) on
different
database(s)
LRTI = lower respiratory tract infection; SABA = short-acting β agonists; OCS = oral corticosteroids; GP = general practitioner; ED = emergency department; ICD = International Classification of Diseases
References for Chapter 2
appendix
[A1] Parikh K, Davis AB, and Pavuluri P. Dowe need this blood culture? Hosp Pediatr 4.2 (2014), 78–
84.
[A2] Wu CL, Andrews AL, Teufel RJ, and Basco WT. Demographic predictors of leukotriene antag-
onist monotherapy among children with persistent asthma. J. Pediatr. 164.4 (2014), 827–
831.e1.
[A3] Kaiser SV, Bakel LA, Okumura MJ, Auerbach AD, Rosenthal J, et al. Risk Factors for Prolonged
Length of Stay or Complications During Pediatric Respiratory Hospitalizations. Hosp Pediatr
5.9 (2015), 461–73.
[A4] Kenyon CC, Rubin DM, Zorc JJ, Mohamad Z, Faerber JA, et al. Childhood Asthma Hospital Dis-
chargeMedication Fills and Risk of Subsequent Readmission. J. Pediatr. 166.5 (2015), 1121–
7.
[A5] Parikh K, Hall M, Mittal V, Montalbano A, Mussman GM, et al. Establishing benchmarks for
the hospitalized care of children with asthma, bronchiolitis, and pneumonia. Pediatrics 134.3
(2014), 555–62.
[A6] Capo-Ramos DE, Duran C, Simon AE, Akinbami LJ, and Schoendorf KC. Preventive asthma
medication discontinuation among children enrolled in fee-for-serviceMedicaid. J Asthma 51.6
(2014), 618–26.
[A7] Lachance L, Benedict MB, Doctor LJ, Gilmore LA, Kelly C, et al. Asthma coalition eﬀects on
vulnerable sub groups of children: the most frequent users of health care and the youngest. J
Asthma 51.5 (2014), 474–9.
[A8] Bhattacharjee R, Choi BH, Gozal D, and Mokhlesi B. Association of adenotonsillectomy with
asthma outcomes in children: a longitudinal database analysis. PLoS Med. 11.11 (2014), e1001753.
[A9] Chang J, Freed GL, Prosser LA, Patel I, Erickson SR, et al. Comparisons of health care utiliza-
tion outcomes in children with asthma enrolled in private insurance plans versus medicaid. J
Pediatr Health Care 28.1 (2014), 71–9.
277
278 References for Chapter 2 appendix
[A10] Liu X, Olsen J, Pedersen LH, Agerbo E, Yuan W, et al. Antidepressant use during pregnancy and
asthma in the oﬀspring. Pediatrics 135.4 (2015), e911–7.
[A11] Jena AB, Ho O, Goldman DP, and Karaca-Mandic P. The Impact of the US Food and Drug Admin-
istration Chlorofluorocarbon Ban on Out-of-pocket Costs and Use of Albuterol Inhalers Among
Individuals With Asthma. JAMA Intern Med 175.7 (2015), 1171–9.
[A12] Malhotra K, Baltrus P, Zhang S, McRoy L, Immergluck LC, et al. Geographic and racial variation
in asthma prevalence and emergency department use among Medicaid-enrolled children in 14
southern states. J Asthma 51.9 (2014), 913–21.
[A13] Adimadhyam S, Schumock GT, Walton S, Joo M, McKell J, et al. Risk of arrhythmias associated
with ipratropium bromide in children, adolescents, and young adults with asthma: a nested
case-control study. Pharmacotherapy 34.4 (2014), 315–23.
[A14] Bülow A von, Kriegbaum M, Backer V, and Porsbjerg C. The prevalence of severe asthma and
low asthma control among Danish adults. J Allergy Clin Immunol Pract 2.6 (2014), 759–67.
[A15] Hasegawa K, Tsugawa Y, Brown DFM, and Camargo CA. A population-based study of adults
who frequently visit the emergency department for acute asthma. California and Florida, 2009-
2010. Ann Am Thorac Soc 11.2 (2014), 158–66.
[A16] Martin RJ, Price D, Roche N, Israel E, Aalderen WMC van, et al. Cost-eﬀectiveness of initiat-
ing extrafine- or standard size-particle inhaled corticosteroid for asthma in two health-care
systems: a retrospective matched cohort study. NPJ Prim Care Respir Med 24 (2014), 14081.
[A17] Zeiger RS, Schatz M, Li Q, ChenW, Khatry DB, et al. High blood eosinophil count is a risk factor
for future asthma exacerbations in adult persistent asthma. J Allergy Clin Immunol Pract
2.6 (2014), 741–50.
[A18] Blais L, Kettani FZ, and Forget A. Associations of maternal asthma severity and control with
pregnancy complications. J Asthma 51.4 (2014), 391–8.
[A19] Schatz M, Meckley LM, Kim M, Stockwell BT, and Castro M. Asthma exacerbation rates in
adults are unchanged over a 5-year period despite high-intensity therapy. J Allergy Clin
Immunol Pract 2.5 (2014), 570–4.e1.
[A20] Nordlund B, Melén E, Schultz ES, Grönlund H, Hedlin G, et al. Prevalence of severe childhood
asthma according to the WHO. Respir Med 108.8 (2014), 1234–7.
[A21] Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Stanford R, et al. Impact of adherence to
treatment with fluticasone propionate/salmeterol in asthma patients. Curr Med Res Opin 30.7
(2014), 1417–25.
[A22] Laforest L, Licaj I, Devouassoux G, Chatte G, Martin J, et al. Asthma drug ratios and exacerba-
tions: claims data from universal health coverage systems. Eur. Respir. J. 43.5 (2014), 1378–
86.
[A23] Dilokthornsakul P, ChaiyakunaprukN, SchumockGT, and Lee TA. Calendar time-specific propen-
sity score analysis for observational data: a case study estimating the eﬀectiveness of in-
haled long-acting beta-agonist on asthma exacerbations. Pharmacoepidemiol Drug Saf 23.2
(2014), 152–64.
[A24] Tan NC, Nadkarni NV, Lye WK, Sankari U, et al. Ten-year longitudinal study of factors influenc-
ing nocturnal asthma symptoms among Asian patients in primary care. NPJ Prim Care Respir
Med 25 (2015), 15064.
[A25] Garne E, Hansen AV, Morris J, Zaupper L, Addor MC, et al. Use of asthma medication during
pregnancy and risk of specific congenital anomalies: A European case-malformed control study.
J Allergy Clin Immunol 136 (6 2015), 1496–502.e1-7.
[A26] Jian ZH, Huang JY, Lin FCF, Nfor ON, Jhang KM, et al. The use of corticosteroids in patients
with COPD or asthma does not decrease lung squamous cell carcinoma. BMC Pulm Med 15
(2015), 154.
[A27] Rust G, Zhang S, Holloway K, and Tyler-Hill Y. Timing of emergency department visits for
childhood asthma after initial inhaled corticosteroid use. Popul Health Manag 18.1 (2015), 54–
60.
[A28] Fung V, Graetz I, Galbraith A, Hamity C, Huang J, et al. Financial barriers to care among low-
income childrenwith asthma: health care reform implications. JAMA Pediatr 168.7 (2014), 649–
56.
[A29] Confino-Cohen R, Brufman I, Goldberg A, and Feldman BS. Vitamin D, asthma prevalence and
asthma exacerbations: a large adult population-based study. Allergy 69.12 (2014), 1673–80.
[A30] Fuhlbrigge A, Peden D, Apter AJ, Boushey HA, Camargo CA, et al. Asthma outcomes: Exacer-
bations. J Allergy Clin Immunol 129.3 (2012), S34–S48.
[A31] Tunceli O, Williams SA, Kern DM, Elhefni H, Pethick N, et al. Comparative eﬀectiveness of
budesonide-formoterol combination and fluticasone-salmeterol combination for asthma man-
agement: a United States retrospective database analysis. J Allergy Clin Immunol Pract
2.6 (2014), 719–26.
[A32] Tan CC, McDowell KM, Fenchel M, Szczesniak R, and Kercsmar CM. Spirometry use in children
hospitalized with asthma. Pediatr. Pulmonol. 49.5 (2014), 451–7.
[A33] Nanchal R, Kumar G, Majumdar T, Taneja A, Patel J, et al. Utilization of mechanical ventilation
for asthma exacerbations: analysis of a national database. Respir Care 59.5 (2014), 644–53.
[A34] Sumino K, O’Brian K, Bartle B, Au DH, CastroM, et al. Coexisting chronic conditions associated
with mortality and morbidity in adult patients with asthma. J Asthma 51.3 (2014), 306–14.
[A35] Li L, Vollmer WM, Butler MG, Wu P, Kharbanda EO, et al. A comparison of confounding ad-
justment methods for assessment of asthma controller medication eﬀectiveness. Am. J. Epi-
demiol. 179.5 (2014), 648–59.
[A36] Hagiwara M, Delea TE, and Stanford RH. Health-care utilization and costs with fluticasone
propionate and fluticasone propionate/salmeterol in asthma patients at risk for exacerbations.
Allergy Asthma Proc 35.1 (2014), 54–62.
References for Chapter 2 appendix 279
[A37] Ali AK, Hartzema AG, Winterstein AG, Segal R, Lu X, et al. Application of multicategory ex-
posure marginal structural models to investigate the association between long-acting beta-
agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Prac-
tice Research Datalink. Value Health 18.2 (2015), 260–70.
[A38] Schatz M, Zeiger RS, Yang SJ, Chen W, Crawford W, et al. Change in asthma control over time:
predictors and outcomes. J Allergy Clin Immunol Pract 2.1 (), 59–64.
[A39] Wu AC, Li L, Fung V, Kharbanda EO, Larkin EK, et al. Use of leukotriene receptor antago-
nists are associated with a similar risk of asthma exacerbations as inhaled corticosteroids. J
Allergy Clin Immunol Pract 2.5 (), 607–13.
[A40] Tse SM, Charland SL, Stanek E, Herrera V, Goldfarb S, et al. Statin use in asthmatics on inhaled
corticosteroids is associated with decreased risk of emergency department visits. Curr Med
Res Opin 30.4 (2014), 685–93.
[A41] Kim S, Kim J, Park SY, Um HY, Kim K, et al. Eﬀect of pregnancy in asthma on health care use
and perinatal outcomes. J Allergy Clin Immunol 136 (5 2015), 1215–23.e1-6.
[A42] Blais L, Kettani FZ, Forget A, Beauchesne MF, and Lemière C. Asthma exacerbations during
the first trimester of pregnancy and congenital malformations: revisiting the association in a
large representative cohort. Thorax 70.7 (2015), 647–52.
[A43] Keast SL, Thompson D, Farmer K, Smith M, Nesser N, et al. Impact of a prior authorization
policy for montelukast on clinical outcomes for asthma and allergic rhinitis among children and
adolescents in a state Medicaid program. J Manag Care Spec Pharm 20.6 (2014), 612–21.
[A44] Sullivan PW, Campbell JD, Ghushchyan VH, and Globe G. Outcomes before and after treatment
escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma. Ann. Allergy Asthma
Immunol. 114.6 (2015), 462–9.
280 References for Chapter 2 appendix
A.2 Published paper related to Chapter 2
Defining asthma and assessing asthma outcomes
using electronic health record data: a systematic
scoping review
Mohammad A Al Sallakh, MD B1,a, Eleftheria Vasileiou, MPH2,a, Sarah E
Rodgers, PhD1,b, Ronan A Lyons, MD1,b, Aziz Sheikh, MD2,a,b and Gwyneth A
Davies, MD1,a
1Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, UK
2Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Teviot Place,
Edinburgh, EH8 9AG, Scotland, UK
aAsthma UK Centre for Applied Research
bThe Farr Institute of Health Informatics Research
Short Title
Defining and assessing asthma using EHR data
Correspondence
Mohammad A Al Sallakh, MD, MSc
Data Science Building, Swansea University, Singleton Park, Swansea, SA2 8PP, United Kingdom
Phone: +
Email: M.A.AlSallakh@swansea.ac.uk
This is an author-submitted, peer-reviewed version of an article that has been accepted for
publication in the European Respiratory Journal, prior to copy-editing, formatting and typesetting.
This version of the article may not be duplicated or reproduced without prior permission from
the copyright owner, the European Respiratory Society. The publisher is not responsible or
liable for any errors or omissions in this version of the article or in any version derived from it
by any other parties. The final, copy-edited, published article, which is the version of record, is
available online (https://doi.org/10.1183/13993003.00204-2017) from the European Respiratory
Journal without a subscription 18 months after the date of issue publication.
1
A.2. Published paper related to Chapter 2 281
Abstract
There is currently no consensus on approaches to defining asthma or assessing asthma outcomes
using electronic health record (EHR)-derived data. We explored these approaches in the recent
literature, and examined the clarity of reporting.
We systematically searched for asthma-related articles published between 1-1-2014 and 31-12-
2015, extracted the algorithms used to identify asthma patients and assess severity, control and
exacerbations, and examined how the validity of these outcomes was justified.
From 113 eligible articles, we found significant heterogeneity in the algorithms used to define
asthma (n=66 different algorithms), severity (n=18), control (n=9), and exacerbations (n=24).
For the majority of algorithms (n=106), validity was not justified. In the remaining cases,
approaches ranged from using algorithms validated in the same databases, to using non-validated
algorithms that were based on clinical judgement or clinical guidelines. The implementation of
these algorithms was sub-optimally described overall.
Although EHR-derived data are now widely used to study asthma, the approaches being used
are significantly varied and are often underdescribed, rendering it difficult to assess the validity
of studies and compare their findings. Given the substantial growth in this body of literature, it
is crucial that scientific consensus is reached on the underlying definitions and algorithms.
Keywords: Algorithms; asthma; electronic health records; quality of reporting; reproducibility.
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Introduction
Asthma is in clinical practice a diagnosis based on the patient history, examination and objective
tests [1]. It is however increasingly considered to represent a heterogeneous group of disorders
with different phenotypes and endotypes [2]. The clinical definitions of asthma and its key
outcomes, including disease severity, control, and attacks/exacerbations have been the subject of
vigorous debate [3–8].
Particular challenges arise in the context of epidemiologic studies where validated operational
definitions are needed [9, 10]. These studies are, increasingly, being undertaken using electronic
health record (EHR)-derived data, which adds a further layer of complexity as the use of valid
and reliable approaches is essential in order to ensure the reproducibility of research findings
[11].
In order to assess current approaches, we systematically interrogated the recent EHR-based
asthma literature. Our specific objectives were to: i) describe the different methods of defining
asthma and assessing disease severity, control and exacerbations in EHR-based studies; ii)
investigate whether authors reported on the validity of those methods; and iii) assess their
reporting practices.
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Methods
We conducted a systematic scoping review based on Arksey and O’Malley’s five-stage frame-
work, including identifying the research question, identifying relevant studies, study selection,
data charting and collating, summarising and reporting the results [12]. The research questions
were: (1) How were asthma and its key outcomes defined using EHR data in the recent literature?
(2) How did authors report on the validity of their EHR-based algorithms? (3) How clearly were
the EHR-related methods reported?
Eligibility criteria and search strategy
We searched PubMed using a broad query (Table E1) to retrieve asthma studies that used EHR-
derived data and were published between January 1, 2014 and December 31, 2015. The search
query was iteratively improved by adding many variations and equivalents of the keywords
“EHR” and “routinely collected data” as well as named data sources found in the literature. Only
articles written in English were included.
Study selection
We excluded non-relevant articles by reviewing titles and abstracts, referring to the full-text
when needed. We included only articles where asthma was a main finding. For the purpose of
this review, we limited the concept of EHR-derived data to coded, objective, individual-level
data that were generated as a by-product of routine health care.
Data extraction and synthesis
From each of the eligible articles, we extracted and summarised information from the full text
and online supplements, including basic bibliography, setting (country) and design; names
and types of EHR-derived data sources used; algorithms to identify asthma patients, assess
disease severity, control, exacerbation; and how authors reported on algorithm validity. In
this context, we referred to ‘validation’ as any attempt to assess the algorithm’s concurrent or
construct validity. We used the RECORD Statement’s 13-items checklist to assess the clarity
of reporting of other EHR-related aspects such as clinical code lists used in the algorithms,
and the implications of using EHR data in asthma research. The RECORD Statement is a
recently introduced extension to the STROBE Statement which helps improve the reporting of
observational studies conducted using routinely collected data [13]. Table E2 describes the data
extraction and charting tool. Article screening and data extraction were performed independently
by two authors (MAS and EV) with a third author arbitrating (GAD).
Role of the funding sources
The funding sources had no role in study design; in the collection, analysis, and interpretation of
data; in the writing of the report; or in the decision to submit the paper for publication.
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Results
We included 113 articles in the review. Figure 1 shows the study selection process. Most studies
were conducted in the United States (US), Taiwan, and Canada (Table E3), and employed
longitudinal designs (Table E4). The most commonly used data types were health insurance
claims followed by medical record repositories and dispensing databases (Table E5).
307 articles identified
through database searching
307 articles screened
155 full-text articles
assessed for eligibility
113 studies included in
qualitative synthesis
152 records excluded
42 full-text articles excluded
Figure 1: Flowchart for study selection in this scoping review.
Defining asthma
We identified 66 different algorithms to define asthma under seven diagnostic labels (Table E6).
‘Persistent asthma’ was defined over 12 and 24 months using the US Healthcare Effectiveness
Data and Information Set (HEDIS) criteria [14], which involved assessing for any of the
following asthma-related events: (1) emergency department (ED) visit, (2) hospitalisation,
(3) outpatient visit and two asthma prescriptions, or (4) four asthma prescriptions [15–18];
by HEDIS criteria except “four asthma prescriptions” [19]; and by any asthma encounter
(hospitalisation or ED visit) or using oral corticosteroids (OCS) for three or more days [20].
‘Current asthma’ was defined by any asthma encounter in the last three years [21].
‘Current general practitioner (GP)-reported and diagnosed asthma’ was defined as any asthma
encounter in the last 12 months, and ‘current GP-reported, diagnosed and treated asthma’ as
the same plus any asthma prescription in the same period [22].
Patients with treated asthma were otherwise required to have at least three dispensing events of
asthma treatments in three different quarters of the year [23].
‘Acute asthma’ was defined using any asthma diagnosis codes in ED or inpatient data [24].
In the remaining studies, the label ‘asthma’ was defined using various algorithms, some of
which were similar to those of the aforementioned more specific labels.
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The intervals over which asthma diagnostic/management and prescription codes where queried
were specified in 31 and 8 studies, respectively. The positions of diagnostic codes in the
encounter (i.e. primary or secondary) were specified in 37 studies.
We identified five approaches in these algorithms: requiring diagnostic/management events,
prescription events, or both (Table E7). In addition, to exclude likely non-asthma patients, some
studies applied additional non-asthma criteria to restrict the study population based on age
(Table E8) and/or comorbidities (Table E9).
Assessing asthma severity
Eighteen studies used 20 different algorithms to assess asthma severity (Table E10), as binary
(i.e. severe vs. non-severe asthma) [15, 23, 25–38] or ordinal variables (mild, moderate,
and severe asthma [39]; or low, moderate, and high-risk asthma [40]). The algorithms were
based on one or more of the following asthma-related variables: number and/or dosage of
prescriptions—namely SABA, inhaled corticosteroids (ICS), OCS, and leukotriene receptor
antagonist (LTRA)—and number of hospitalisations, ED and outpatient visits. Almost all
algorithms (17) used prescriptions (either alone or with other variables), while one algorithm
was based only on hospitalisations and ED visits [36]. The intervals over which asthma severity
was assessed were three [29], six [38], 12 [15, 23, 28, 30–32, 34, 36, 37, 39, 40], 24 months [33,
35], or unclear [26, 27].
Assessing asthma control
Nine studies assessed asthma control using 11 algorithms, in 9 of which the interval was
12 months, in one 1-3 months, and in the remaining study this was unclear (Table E12).
Uncontrolled asthma was defined by a minimum number/dose of SABA prescriptions [30,
31, 39, 41, 42]; any or short-course OCS prescriptions [30, 31, 41–44]; any hospitalisation or ED
visit with either diagnosis of asthma [27, 30, 31, 41–43, 45] or — in already diagnosed asthma
patients — diagnosis of status asthmaticus, pneumonia, dyspnoea, or respiratory insufficiency
[30]; unscheduled outpatient visits for asthma or lower respiratory tract infections (LRTI) [31];
and GP consultations for LRTI requiring antibiotics in asthma patients [31]. Asthma impairment
was defined based on the required SABA use, namely an average of more than two salbutamol
puffs per day [31]. One study assessed asthma control based on number of OCS and SABA
prescriptions per year (without giving any further details about the actual algorithm) [41].
Defining exacerbations
Twenty-four studies defined exacerbations using EHR-derived data (Table E11), as a dichoto-
mous variable (absent vs. present) [16, 17, 23, 27, 30–32, 35, 37–39, 42–44, 46–54], or stratified
into absent, moderate and severe [55]. Oral corticosteroid prescriptions were used as a marker for
exacerbations in 17 studies, either alone [23, 30, 31, 35, 39, 42, 47, 48, 53] or with a concurrent
asthma encounter (e.g., a GP, outpatient, or ED visit, or hospitalisation within five or seven days)
[16, 17, 32, 37, 38, 46, 52, 54]. In one study, exacerbations were defined by a minimum of six
short-acting beta-2 agonist (SABA) prescriptions per year [47]. Other definitions included an
outpatient code of ‘asthma exacerbation’ [52], asthma hospitalisation [23, 30, 32, 35, 37, 39, 43,
6
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Table 1: Practices of reporting or justifying the validity of algorithms to define and assess asthma
using EHR-derived data.
Algorithm validity was justified by Number of algorithms
Identifying
asthma
pa-
tients
Assessing
sever-
ity
Assessing
control
Defining
exacer-
bation
Total
per
cate-
gory
Validation of the same algorithm in the same database 14 1 1 1 17
Validation of the same algorithm in different database(s) 2 6 3 2 13
Validation of other diseases’ algorithms in the same database 2 0 0 0 2
Validation of other diseases’ algorithms in different database(s) 1 0 0 0 1
Being consistent with similar studies in the same database 1 0 1 0 2
Being consistent with similar studies in different database(s) 1 0 0 1 2
Validation or concordance analysis in the same study 4 0 0 0 4
Being based on nationally developed algorithms 3 0 0 2 5
Relying on the validity of database coding 5 0 0 0 5
Being based on clinical guidelines 0 3 0 0 3
Not justified 76 8 4 18 106
44, 46, 48, 50, 51, 53–55], asthma ED visit [16, 30–32, 35, 37, 38, 43, 44, 46, 48, 51–54], or
hospitalisation with diagnosis of status asthmaticus, or — in already diagnosed asthma patients
— diagnosis of pneumonia, dyspnoea, or respiratory insufficiency [30].
Clarity of reporting
Overall, the reporting of methodological aspects of using EHR-derived data was suboptimal.
The majority of studies presented no information on the algorithms’ validity. Among studies
that reported on the validity, we identified 10 practices of reporting or justifying on the validity
of algorithms (Table 1): (1) performing validation or concordance analysis in the same study
against other measures based on different data sources (e.g., medical record review or patient-
reported measures); (2) referring to previous validation of similar algorithms in the same or
(3) different databases; (4) referring to previous validation of similar algorithms for different
diseases in the same or (5) different database (6); using algorithms ‘consistent’ with previous
studies in the same or (7) different databases; (8) using nationally developed algorithms; (9)
using algorithms based on clinical guidelines; (10) and relying on previous validation of the
database content. Some studies did not provide clear algorithms for asthma severity or control,
but only referred to their components [23, 35, 37, 38, 41].
Of the 113 reviewed studies, 40 studies used record-linkage, of which 17 mentioned it in the
abstract, and 28 provided at least some explanation in the full text. The geographical region,
time frame of data, and types or names of the data sources were mentioned in 83, 91, and 104
abstracts, respectively. Eighty-three studies reported their extent of access to the data sources.
The intervals over which the algorithms were applied were often not reported. One hundred and
eleven studies touched on the implications of using EHR data to study asthma. Of these, 64 and
63 studies discussed the risk of misclassification bias and unmeasured confounding, respectively.
Six studies acknowledged the possible changes over time in data quality and coding practices
and the entailing changes in case definition eligibility and accuracy. Five studies explained their
data cleansing procedures. Finally, no study shared the programming codes of data preparation
and analysis.
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Discussion
Statement of principal findings
This systematic analysis of the contemporaneous asthma literature has found evidence of
considerable international activity in using EHR-derived data to study a variety of asthma
populations and outcomes. Importantly, we also found wide variations in the approaches used
with limited attention being paid to the validity of the underlying algorithms used and suboptimal
reporting of studies. This poses a major challenge to the interpretation and reproducibility of
this important, emerging body of research inquiry.
Strengths and limitations
To our knowledge, this is the first systematic exercise to investigate the quality of reporting on
EHR-based studies, especially the validity of measures, in the context of asthma. In undertaking
this work, we used robust approaches which involved two people independently selecting
studies and undertaking data extraction. The findings may also apply to other chronic diseases.
This review had no geographic limits, but it was confined to assessing the recent literature.
Examining the most recent asthma literature is most likely to provide meaningful insights on
current practices. A limitation is that we did not systematically check whether the references
provided to support the claimed validity of algorithms in question actually provided sufficient
evidence of validity. For example, differences might exist between the algorithms used in a
given study and those previously validated.
Interpretation in the light of previous studies
Although EHR-derived data are convenient resources for research, they are originally collected
for other purposes, and usually suffer from missing or incorrect data and potential biases [56–58].
In addition, EHR systems usually fail to capture complete and accurate clinical information at
the point of care due to design limitations and inefficient use of these systems by clinicians to
document clinical data [59, 60].
These issues impose challenges on their use to assess a complex and heterogeneous condition
such as asthma. For example, asthma diagnosis codes, which are commonly used solely for
patient identification, may be recorded after a trial or wrong diagnosis, and do not capture
undiagnosed patients [61]. In addition, many EHR-derived databases often lack important
variables, such as lung function, indication of dispensed medications, adherence to treatment,
and lifestyle, which are vital for identifying and assessing asthma patients. These challenges are
however not insurmountable. In this review, we found several techniques intended to improve
algorithm accuracy such as age limitation, comorbidity exclusion, and diagnosis position
restriction.
Ideally, algorithms should be validated in the databases in which they are used. However, this
was often not the case. Instead, using algorithms with only reasonable face validity based
on clinical guidelines or clinical judgement is a very common practice in EHR-based studies
8
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[62, 63]. These approaches assume that clinical codes in the database accurately represent the
patient’s actual health care events [62].
Under-reporting on implementation details and methods’ validity compromises transparency
and reproducibility, a crucial issue in medical research. It has been previously found that in
EHR-based studies, full lists of clinical codes were often not reported [64]. A recent, large-scale
reproducibility exercise identified similar challenges due to suboptimal reporting of EHR-based
studies, particularly sharing code lists and algorithms [65].
The significant methodological heterogeneity we found in EHR-based asthma assessment
algorithms reflects, in addition to the content differences between the databases used, the lack
of consensus on the clinical definitions in the first place despite continuous standardisation
efforts [5, 6, 66, 67]. The focus of our work was to examine asthma definitions and their validity
specifically in the context of EHR, but this highlights the fundamental need to reach consensus
on clinical asthma definitions and the appropriate validation of asthma diagnosis. For example,
there is still an active debate on whether lung function is essential to establish asthma diagnosis
[7, 8]. A recent study also found significant variation in algorithms to assess asthma severity
from health insurance data [68]. Unjustified inter-study variation in the operational definitions
of the same clinical concepts creates challenges for comparability, meta-analysis and evidence
synthesis. These issues have been raised for asthma [69] and other allergic conditions such as
peanut allergy [70, 71] and anaphylaxis [72], where wide variations in findings were potentially
attributed to inconsistent case definitions.
Implications for policy, practice and research
This review sheds light on the opportunities offered by the increasingly ubiquitous EHRs, but also
highlights considerable heterogeneity and suboptimal reporting of EHR-based asthma assessment
algorithms and the implications of these practices on comparability and reproducibility of studies.
Developing reliable algorithms to assess asthma outcomes using EHR data is a non-trivial
challenge. In addition, standardising such algorithms across different populations may be
impractical since databases differ in content, validity may not hold across different populations,
and no best practice currently exists [68]. Similar challenges arise when comparing asthma
epidemiology between multiple populations [73]. These methodologic issues, in addition to
suboptimal reporting, should be considered when interpreting and synthesising evidence from
geographically dispersed studies.
With the accelerating availability of EHR-derived data and their use to study asthma, we believe
that consideration needs to be given to convening an international task force to work on the
harmonisation of those algorithms under uniform and consistent clinical labels, while considering
the differences between populations and databases. In addition, validation of these algorithms in
the respective populations should be given a high priority. Furthermore, to allow more accurate
assessment of asthma from EHR data, efforts are needed to improve the capture and coding of
asthma-related data at the point of care [74] which requires more efficient EHR systems [59,
60]. In addition, emerging data sources such as patient-generated data and wearables need to
be harnessed [75]. Finally, to improve the clarity of reporting on EHR-related methodological
aspects, we strongly advocate the adoption of the RECORD Statement as an extension of the
STROBE Statement by both authors and journal editors [13]. Optimal reporting should include
complete code lists, detailed algorithms and validity assessment. Implications of using EHR-
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derived data to study a complex condition such as asthma should be clearly communicated to
enable judgement of internal and external validity.
In summary, we have found that there is considerable international interest in exploiting EHR-
derived data to study asthma, but that there are considerable variations in the approaches used.
These variations are compounded by sub-optimal reporting of methods, which makes it difficult
to assess the reproducibility of research. Given the substantial investments taking place in EHRs
globally, this body of work is likely to grow significantly in the coming years. It is therefore
important that the asthma-interested research community works to place it on a solid footing in
order to ensure the quality and reproducibility of this work.
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Chapter 3 Appendix
B.1 Making sense of patient-reported currently treated
asthma using routinely collected data
Mohammad Al Sallakh,1 Sarah Rodgers,1 Ronan Lyons,1 Aziz Sheikh,2 Gwyneth
Davies.1 P148 Making sense of patient-reported currently treated asthma using
routinely collected data. Thorax 2016;71:A163-A164.
1Medical School, Swansea University, Swansea, UK; 2Usher Institute of Population
Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
An abstract presented at British Thoracic Society Winter Meeting 2016.
Background: Currently treated asthma (CTA) is commonly assessed in epidemi-
ological studies and is typically self-reported.
Aims: To investigate how patient understanding of this label compared with ob-
jective measures from routinely collected data.
Methods: We obtained the valid CTA responses of individuals aged 16+ from the
Welsh Health Survey 2014, who also had linked records in the GP dataset of the
Secure Anonymised Information Linkage databank and complete GP registrations
between 2009-2014. We queried their recent prescriptions and whether they had
ever asthma diagnosis. We examined the concordance between self-reported CTA
and each of ’ever prescriptions’, ’ever diagnosis’, and ’prescriptions in varying
backward intervals from mid-2014’, with the latter repeated by adding ’ever diag-
nosis’.
Results: Of 4,291 eligible people, 10.2% self-reported CTA, of these 11.2% and
22.4% had no prescriptions in the past 12 months and no recorded asthma diagno-
sis ever. For concordance between self-reported CTA and each of ’ever prescrip-
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tions’ and ’ever diagnosis’, Cohen’s kappa was 0.42 and 0.68. For concordance
between self-reported CTA and ’prescriptions in backward intervals’, kappa was
0.76 for the 12-month interval but peaked to 0.77 at 9-months. After adding ’ever
diagnosis’, the kappa became 0.78 for the 12-month measure (which represents
the treated asthma criteria of the Quality of Outcomes Framework, QOF), and
peaked to 0.79 at 18-months.
Conclusions: InWales, self-reported CTA agreedwell with the QOF treated asthma
criteria, but slightly better with ’any prescriptions in last 18 months and ever
diagnosis’. However, the concordance remains suboptimal, demonstrating that
objective measures from routinely collected data are preferred over self-reported
CTA.
Funding: Health and Care Research Wales and ABMU Health Board. Supported
by Asthma UK Centre for Applied Research (AUK-AC-2012-01) and the Farr Insti-
tute @ CIPHER.
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B.2 Read Codes sets used to define the observed
variables in the latent class analysis
Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3.
Read code Description
Asthma Diagnosis
Codes
173A Exercise induced asthma
1O2.. Asthma confirmed
663V. Asthma severity
663V0 Occasional asthma
663V1 Mild asthma
663V2 Moderate asthma
663V3 Severe asthma
9Q21. Patient in asthma study
H3120 Chronic asthmatic bronchitis
H33%% Asthma
Asthma GP Visits
173A. Exercise induced asthma
173c. Occupational asthma
173d. Work aggravated asthma
178 Asthma trigger
1780. Aspirin induced asthma
1781. Asthma trigger - pollen
1782. Asthma trigger - tobacco smoke
1783. Asthma trigger - warm air
1784. Asthma trigger - emotion
1785. Asthma trigger - damp
1786. Asthma trigger - animals
1787. Asthma trigger - seasonal
1788. Asthma trigger - cold air
1789. Asthma trigger - respiratory infection
178A. Asthma trigger - airborne dust
178B. Asthma trigger - exercise
1O2.. Asthma confirmed
388t Royal College of Physicians asthma assessment
388t. Royal College of Physicians asthma assessment
38DL. Asthma control test
38DV. Mini asthma quality of life questionnaire
38QM. Childhood Asthma Control Test
661M1 Asthma self-management plan agreed
661N1 Asthma self-management plan review
663N. Asthma disturbing sleep
663N0 Asthma causing night waking
663N1 Asthma disturbs sleep weekly
663N2 Asthma disturbs sleep frequently
663O. Asthma not disturbing sleep
663O0 Asthma never disturbs sleep
663P. Asthma limiting activities
663P0 Asthma limits activities 1 to 2 times per month
663P1 Asthma limits activities 1 to 2 times per week
663P2 Asthma limits activities most days
663Q. Asthma not limiting activities
663U. Asthma management plan given
663V. Asthma severity
663V0 Occasional asthma
663V1 Mild asthma
663V2 Moderate asthma
663V3 Severe asthma
663W. Asthma prophylactic medication used
663d. Emergency asthma admission since last appointment
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
663e. Asthma restricts exercise
663e0 Asthma sometimes restricts exercise
663e1 Asthma severely restricts exercise
663f. Asthma never restricts exercise
663h. Asthma - currently dormant
663j. Asthma - currently active
663m. Asthma accident and emergency attendance since last visit
663n. Asthma treatment compliance satisfactory
663p. Asthma treatment compliance unsatisfactory
663q. Asthma daytime symptoms
663r. Asthma causes night symptoms 1 to 2 times per month
663s. Asthma never causes daytime symptoms
663t. Asthma causes daytime symptoms 1 to 2 times per month
663u. Asthma causes daytime symptoms 1 to 2 times per week
663v. Asthma causes daytime symptoms most days
663w. Asthma limits walking up hills or stairs
663x. Asthma limits walking on the flat
663y. Number of asthma exacerbations in past year
66Y5. Change in asthma management plan
66Y9. Step up change in asthma management plan
66YA. Step down change in asthma management plan
66YC. Absent from work or school due to asthma
66YE. Asthma monitoring due
66YJ. Asthma annual review
66YK. Asthma follow-up
66YP. Asthma night-time symptoms
66YQ. Asthma monitoring by nurse
66YR. Asthma monitoring by doctor
66YZ. Does not have asthma management plan
66Yp. Asthma review using Royal College of Physicians three questions
66Yq. Asthma causes night time symptoms 1 to 2 times per week
66Yr. Asthma causes symptoms most nights
66Ys. Asthma never causes night symptoms
66Yu. Number of days absent from school due to asthma in past 6 months
679J. Health education - asthma
679J0 Health education - asthma self management
679J1 Health education - structured asthma discussion
679J2 Health education - structured patient focused asthma discussion
8791. Further asthma - drug prevent.
8793. Asthma control step 0
8794. Asthma control step 1
8795. Asthma control step 2
8796. Asthma control step 3
8797. Asthma control step 4
8798. Asthma control step 5
8B3j. Asthma medication review
8CMA0 Patient has a written asthma personal action plan
8CR0. Asthma clinical management plan
8H2P. Emergency admission, asthma
8HTT. Referral to asthma clinic
9N1d. Seen in asthma clinic
9N1d0 Seen in school asthma clinic
9NI8. Asthma outreach clinic
9NNX. Under care of asthma specialist nurse
9OJ.. Asthma monitoring admin.
9OJ1. Attends asthma monitoring
9OJ2. Refuses asthma monitoring
9OJ3. Asthma monitor offer default
9OJ4. Asthma monitor 1st letter
9OJ5. Asthma monitor 2nd letter
9OJ6. Asthma monitor 3rd letter
9OJ7. Asthma monitor verbal invite
9OJ8. Asthma monitor phone invite
9OJ9. Asthma monitoring deleted
9OJA. Asthma monitoring check done
9OJB. Asthma monitoring invitation SMS (short message service) text message
9OJC. Asthma monitoring invitation email
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
9OJZ. Asthma monitoring admin.NOS
9Q21. Patient in asthma study
9hA.. Exception reporting: asthma quality indicators
9hA1. Excepted from asthma quality indicators: Patient unsuitable
SLF7. Antiasthmatic poisoning
SLF7z Antiasthmatic poisoning NOS
COPD Diagnosis Codes
H3... Chronic obstructive pulmonary disease
H31 Chronic bronchitis
H32 Emphysema
H36 Mild chronic obstructive pulmonary disease
H37 Moderate chronic obstructive pulmonary disease
H38 Severe chronic obstructive pulmonary disease
H39 Very severe chronic obstructive pulmonary disease
H3A End stage chronic obstructive airways disease
H3y Other specified chronic obstructive airways disease
H3z Chronic obstructive airways disease NOS
H4640 Chronic emphysema due to chemical fumes
H4641 Obliterative bronchiolitis due to chemical fumes
H5832 Eosinophilic bronchitis
Hyu30 [X]Other emphysema
Hyu31 [X]Other specified chronic obstructive pulmonary disease
H3101 Smokers’ cough
H31y0 Chronic tracheitis
COPD GP Visits
66YL. Chronic obstructive pulmonary disease follow-up
66YS. Chronic obstructive pulmonary disease monitoring by nurse
66YT. Chronic obstructive pulmonary disease monitoring by doctor
66YB Chronic obstructive pulmonary disease monitoring
66YM Chronic obstructive pulmonary disease annual review
9Oi Chronic obstructive pulmonary disease monitoring administration
SABA Inhalers
c11 SALBUTAMOL [ORAL PREPARATIONS]
c12 SALBUTAMOL [PARENTERAL PREPARATIONS]
c13 SALBUTAMOL [INHALATION PREPRATIONS]
c14 TERBUTALINE SULPHATE [RESPIRATORY USE]
c15 FENOTEROL HYDROBROMIDE
c1E SALBUTAMOL [INHALATION PREPRATIONS 2]
OCS
fe6 PREDNISOLONE [ENDOCRINE]
fe61. PREDNISOLONE 1mg tablets
fe62. PREDNISOLONE 5mg tablets
fe64. *DELTA-PHORICOL 5mg tablets
fe65. DELTACORTRIL ENTERIC 2.5mg tablets
fe66. DELTACORTRIL ENTERIC 5mg tablets
fe67. *DELTALONE 1mg tablets
fe68. *DELTALONE 5mg tablets
fe69. *DELTASTAB 1mg tablets
fe6a. *DELTASTAB 5mg tablets
fe6c. *PRECORTISYL 1mg tablets
fe6d. *PRECORTISYL 5mg tablets
fe6e. PRECORTISYL FORTE 25mg tablets
fe6f. *PREDNESOL 5mg tablets
fe6g. *SINTISONE 5mg tablets
fe6h. PREDNISOLONE 2.5mg e/c tablets
fe6i. PREDNISOLONE 5mg e/c tablets
fe6j. PREDNISOLONE 5mg soluble tablets
fe6k. PREDNISOLONE 50mg tablets
fe6l. DILACORT 5mg gastro-resistant tablets
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
fe6m. DILACORT 2.5mg gastro-resistant tablets
fe6n. PEVANTI 2.5mg tablets
fe6o. PEVANTI 25mg tablets
fe6p. PEVANTI 5mg tablets
fe6q. PEVANTI 10mg tablets
fe6r. PEVANTI 20mg tablets
fe6s. PREDNISOLONE 20mg tablets
fe6t. PREDNISOLONE 10mg tablets
fe6v. *PREDNISOLONE 2.5mg tablets
fe6w. *PREDNISOLONE 2.5mg tablets
fe6z. PREDNISOLONE 25mg tablets
fe63 *CODELSOL 32mg/2mL injection
fe6b DELTASTAB 25mg/1mL injection
fe6u PREDNISOLONE 32mg/2mL injection
fe6y PREDNISOLONE 125mg/5mL injection
LABA Inhalers
c19.. SALMETEROL XINAFOATE
c191. SALMETEROL 25microgram inhaler
c192. *SEREVENT 25microgram inhaler
c193. SEREVENT 50microgram diskhaler
c194. SEREVENT 50micrograms disk refill
c195. SALMETEROL 50micrograms disks+disk inhaler
c196. SALMETEROL 50micrograms disk refill
c197. SALMETEROL 50micrograms breath-actuated dry powder inhaler
c198. SEREVENT 50micrograms Accuhaler
c199. SEREVENT 25micrograms Evohaler
c19z. SALMETEROL 25micrograms CFC-free inhaler
c1B.. BAMBUTEROL HYDROCHLORIDE
c1B1. BAMBEC 10mg tablets
c1B2. BAMBEC 20mg tablets
c1B3. BAMBUTEROL HYDROCHLORIDE 10mg tablets
c1B4. BAMBUTEROL HYDROCHLORIDE 20mg tablets
c1C.. FORMOTEROL
c1C1. FORMOTEROL FUMARATE 12micrograms inhalation capsules+inhaler
c1C2. FORADIL 12micrograms inhalation capsules+inhaler
c1C3. FORMOTEROL FUMARATE DIHYDRATE 6micrograms breath-act dry powder
inhaler
c1C4. FORMOTEROL FUMARATE DIHYDRATE 12micrograms breath-act dry powder
inhaler
c1C5. OXIS 6micrograms Turbohaler
c1C6. OXIS 12micrograms Turbohaler
c1C7. ATIMOS MODULITE 12micrograms metered dose inhaler
c1C8 FORMOTEROL EASYHALER 12micrograms breath-act dry powder inhaler
c1Cy FORMOTEROL FUMARATE DIHYDRATE 12micrograms breath-act dry powder
inhaler
c1Cz. FORMOTEROL FUMARATE DIHYDRATE 12micrograms metered dose inhaler
c1a.. TULOBUTEROL HYDROCHLORIDE
c1a1. *TULOBUTEROL 2mg tablets
c1a2. *BRELOMAX 2mg tablets
c1a3. *RESPACAL 2mg tablets
c1a4. TULOBUTEROL 1mg/5mL sugar free liquid
c1a5. RESPACAL 1mg/5mL sugar free liquid
ICS-LABA Combination
Inhalers
c1D SALMETEROL+FLUTICASONE PROPIONATE
c1c FLUTICASONE PROPIONATE+FORMOTEROL FUMARATE
c67 BUDESONIDE+FORMOTEROL
c6A BECLOMETASONE+FORMOTEROL
c6B FLUTICASONE+VILANTEROL
ICS Inhalers
c6... CORTICOSTEROIDS [RESPIRATORY USE]
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
c61.. BECLOMETASONE DIPROPIONATE [RESPIRATORY USE]
c611. BECLOFORTE 250microgram inhaler
c612. BECOTIDE-50 50microgram inhaler
c613. BECOTIDE 100micrograms rotacaps
c614. BECOTIDE 200micrograms rotacaps
c615. *BECOTIDE rotahaler device
c616. BECOTIDE 50micrograms/mL nebuliser solution
c617. BECOTIDE-100 100microgram inhaler
c618. *VOLUMATIC spacer device
c619. BECODISK 100micrograms diskhaler 14x8
c61A. BECLOMETASONE DIPROPIONATE 400micrograms disks+disk inhaler
c61B. BECLOMETASONE DIPROPIONATE 400micrograms disk refill
c61C. BECLOMETHASONE DIPROPIONATE 250micrograms inhaler+spacer device
c61E. BECLOMETASONE DIPROPIONATE 250micrograms breath-actuated aerosol
inhaler
c61F. BECLOMETASONE DIPROPIONATE 100micrograms breath-actuated aerosol
inhaler
c61G. *FILAIR 50micrograms inhaler
c61H. *FILAIR 100micrograms inhaler
c61J. FILAIR FORTE 250micrograms inhaler
c61K. BECLAZONE 50micrograms inhaler
c61L. BECLAZONE 100micrograms inhaler
c61M. BECLAZONE 250micrograms inhaler
c61N. BECLAZONE 50 EASI-BREATHE inhaler
c61O. BECLAZONE 100 EASI-BREATHE inhaler
c61P. BECLAZONE 250 EASI-BREATHE inhaler
c61Q. BECLOFORTE INTEGRA 250micrograms inhaler+compact spacer
c61R. BECLOFORTE INTEGRA 250micrograms refill
c61S. BECLOMETHASONE DIPROPIONATE 250micrograms inhaler+compact spacer
c61T. BECLOMETHASONE DIPROPIONATE 250micrograms compact spacer refill
c61U. BECLOMETHASONE rotahaler device
c61V. BECLOMETHASONE DIPROPIONATE 50micrograms vortex metered dose
inhaler
c61W. *BDP 50micrograms Spacehaler
c61X. BECLOMETHASONE DIPROPIONATE 100micrograms vortex metered dose
inhaler
c61Y. *BDP 100micrograms Spacehaler
c61Z. BECLOMETHASONE DIPROPIONATE 250micrograms vortex metered dose
inhaler
c61a. BECODISK 200micrograms diskhaler 14x8
c61b. BECOTIDE 400micrograms rotacaps
c61c. BECODISK 100micrograms disk refill 14x8
c61d. BECODISK 200micrograms disk refill 14x8
c61e. BECODISK 400micrograms diskhaler 7x8
c61f. BECODISK 400micrograms disk refill 7x8
c61g. BECLOFORTE VM 250micrograms inhaler+volumatic
c61h. BECLOMETASONE DIPROPIONATE 400micrograms inhalation capsules
c61i. BECOTIDE-200 200microgram inhaler
c61j. *AEROBEC 50microgram Autohaler
c61k. AEROBEC FORTE 250micrograms Autohaler
c61l. AEROBEC 100microgram Autohaler
c61m. BECLOFORTE DISKHALER 400micrograms 14x8
c61n. BECLOFORTE DISKS 400micrograms disk refill 14x8
c61p. BECLOMETASONE DIPROPIONATE 100micrograms disks+disk inhaler
c61q. BECLOMETASONE DIPROPIONATE 200micrograms disks+disk inhaler
c61r. BECLOMETASONE DIPROPIONATE 100micrograms disk refill
c61s. BECLOMETASONE DIPROPIONATE 200micrograms disk refill
c61u. BECLOMETASONE DIPROPIONATE 200micrograms inhaler
c61v. BECLOMETASONE DIPROPIONATE 50micrograms inhaler
c61w. BECLOMETASONE DIPROPIONATE 100micrograms inhalation capsules
c61x. BECLOMETASONE DIPROPIONATE 200micrograms inhalation capsules
c61y. BECLOMETHASONE DIPROPIONATE 50micrograms/mL nebuliser solution
c61z. BECLOMETASONE DIPROPIONATE 100micrograms inhaler
c62.. BECLOMETASONE COMPOUNDS
c621. *VENTIDE inhaler
c622. *VENTIDE Rotacaps
c623. *VENTIDE paediatric Rotacaps
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
c624. *VENTIDE Rotahaler device
c63.. *BETAMETHASONE VALERATE
c631. *BEXTASOL 100microgram inhaler
c63z. BETAMETHASONE 100micrograms inhaler
c64.. BUDESONIDE [RESPIRATORY USE]
c641. PULMICORT 200micrograms inhaler 200dose
c642. PULMICORT 200micrograms refill 100dose
c643. PULMICORT 200micrograms refill 200dose
c644. PULMICORT LS 50micrograms inhaler
c645. PULMICORT LS 50micrograms refill
c646. *NEBUHALER spacer device
c647. PULMICORT 200microgram inhaler 100dose
c649. PULMICORT 400microgram Turbohaler 50dose
c64A. BUDESONIDE 200micrograms refill cannister
c64B. BUDESONIDE 50micrograms spacer inhaler
c64C. PULMICORT 200micrograms spacer inhaler
c64D. PULMICORT LS 50micrograms spacer inhaler
c64E. PULMICORT 200micrograms inhaler with NebuChamber
c64F. BUDESONIDE 200micrograms/dose dry powder cartridge refill
c64G. NOVOLIZER BUDESONIDE 200micrograms/dose dry powder cartridge refill
c64H. EASYHALER BUDESONIDE 100micrograms breath-actuated dry powder inhaler
c64I. EASYHALER BUDESONIDE 200micrograms breath-actuated dry powder inhaler
c64J. EASYHALER BUDESONIDE 400micrograms breath-actuated dry powder inhaler
c64K. PULMICORT 100micrograms CFC-free inhaler
c64a. PULMICORT 500micrograms Respules 2mL unit
c64b. PULMICORT 1mg Respules 2mL unit
c64c. PULMICORT 100microgram Turbohaler 200dose
c64d. BUDESONIDE 100micrograms breath-actuated dry powder inhaler
c64e. BUDESONIDE 50micrograms refill cannister
c64g. BUDESONIDE 200micrograms breath-actuated dry powder inhaler
c64h. BUDESONIDE 400micrograms breath-actuated dry powder inhaler
c64i. BUDESONIDE 500micrograms/2mL nebuliser solution
c64j. BUDESONIDE 1mg/2mL nebuliser solution
c64k. *BUDESONIDE 200 Cyclocaps
c64l. *BUDESONIDE 400 Cyclocaps
c64m. BUDESONIDE 200micrograms inhalation capsules
c64n. BUDESONIDE 400micrograms inhalation capsules
c64o. BUDESONIDE 200micrograms inhaler with spacer device
c64p. NOVOLIZER BUDESONIDE 200micrograms/dose dry powder cartridge and
refillable inhaler device
c64u. BUDESONIDE 200micrograms/dose dry powder cartridge and refillable inhaler
device
c64v. BUDESONIDE 200micrograms inhaler
c64x. *BUDESONIDE refill 200dose
c64y. BUDESONIDE 50micrograms inhaler
c64z. BUDESONIDE 200micrograms spacer inhaler
c65.. FLUTICASONE PROPIONATE [RESPIRATORY USE]
c651. FLIXOTIDE 50micrograms diskhaler
c652. FLIXOTIDE 100micrograms diskhaler
c653. FLIXOTIDE 250micrograms diskhaler
c654. FLUTICASONE PROPIONATE 50micrograms disks+disk inhaler
c655. FLUTICASONE PROPIONATE 100micrograms disks+disk inhaler
c656. FLUTICASONE PROPIONATE 250micrograms disks+disk inhaler
c657. FLIXOTIDE 50micrograms disk refill
c658. FLIXOTIDE 100micrograms disk refill
c659. FLIXOTIDE 250micrograms disk refill
c65A. FLUTICASONE PROPIONATE 50micrograms disk refill
c65B. FLUTICASONE PROPIONATE 100micrograms disk refill
c65C. FLUTICASONE PROPIONATE 250micrograms disk refill
c65D. FLIXOTIDE 25micrograms inhaler
c65E. FLIXOTIDE 50micrograms inhaler
c65F. FLIXOTIDE 125micrograms inhaler
c65G. FLUTICASONE PROPIONATE 25micrograms inhaler
c65H. FLUTICASONE PROPIONATE 50micrograms inhaler
c65I. FLUTICASONE PROPIONATE 125micrograms inhaler
c65K. FLIXOTIDE 250micrograms inhaler
c65L. FLIXOTIDE 500micrograms diskhaler
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
c65M. FLIXOTIDE 500micrograms disk refill
c65N. FLUTICASONE PROPIONATE 500micrograms disks+disk inhaler
c65O. FLUTICASONE PROPIONATE 500micrograms disk refill
c65P. FLUTICASONE PROPIONATE 50micrograms breath-actuated dry powder
inhaler
c65Q. FLUTICASONE PROPIONATE 100micrograms breath-actuated dry powder
inhaler
c65R. FLUTICASONE PROPIONATE 250micrograms breath-actuated dry powder
inhaler
c65S. FLUTICASONE PROPIONATE 500micrograms breath-actuated dry powder
inhaler
c65T. FLIXOTIDE 50micrograms Accuhaler
c65U. FLIXOTIDE 100micrograms Accuhaler
c65V. FLIXOTIDE 250micrograms Accuhaler
c65W. FLIXOTIDE 500micrograms Accuhaler
c65X. FLUTICASONE PROPIONATE 0.5mg/2mL nebulisation units
c65Y. FLUTICASONE PROPIONATE 2mg/2mL nebulisation units
c65Z. FLIXOTIDE 0.5mg/2mL Nebules
c65a. FLIXOTIDE 2mg/2mL Nebules
c65b. FLUTICASONE PROPIONATE 125micrograms CFC-free inhaler
c65c. FLUTICASONE PROPIONATE 250micrograms CFC-free inhaler
c65d. FLIXOTIDE 125micrograms Evohaler
c65e. FLIXOTIDE 250micrograms Evohaler
c65f. FLUTICASONE PROPIONATE 50micrograms CFC-free inhaler
c65g. FLIXOTIDE 50micrograms Evohaler
c66.. BECLOMETASONE DIPROPIONATE [RESPIRATORY USE 2]
c661. *BDP 250micrograms Spacehaler
c662. BECOTIDE 50 EASI-BREATHE inhaler
c663. BECOTIDE 100 EASI-BREATHE inhaler
c664. BECLOFORTE EASI-BREATHE 250micrograms inhaler
c665. QVAR 50 inhaler
c666. QVAR 100 inhaler
c667. QVAR 50 Autohaler
c668. QVAR 100 Autohaler
c669. *BECLAZONE 200 inhaler
c66A. BECLOMETASONE DIPROPIONATE 50micrograms breath-actuated dry powder
inhaler
c66B. BECLOMETASONE DIPROPIONATE 100micrograms breath-actuated dry
powder inhaler
c66C. BECLOMETASONE DIPROPIONATE 250micrograms breath-actuated dry
powder inhaler
c66D. ASMABEC 50micrograms Clickhaler
c66E. ASMABEC 100micrograms Clickhaler
c66F. ASMABEC 250micrograms Clickhaler
c66G. BECLOMETASONE DIPROPIONATE 400micrograms breath-actuated dry
powder inhaler
c66H. BECLOMETASONE DIPROPIONATE 200micrograms breath-actuated dry
powder inhaler
c66I. PULVINAL BECLOMETHASONE DIPROPIONATE 100micrograms
breath-actuated dry powder inhaler
c66J. PULVINAL BECLOMETHASONE DIPROPIONATE 200micrograms
breath-actuated dry powder inhaler
c66K. PULVINAL BECLOMETHASONE DIPROPIONATE 400micrograms
breath-actuated dry powder inhaler
c66L. *BECLOMETASONE 100 cyclocaps
c66M. *BECLOMETASONE 200 cyclocaps
c66N. *BECLOMETASONE 400 cyclocaps
c66P. BECODISK 100micrograms diskhaler 15x8
c66Q. BECODISK 200micrograms diskhaler 15x8
c66R. BECODISK 400micrograms diskhaler 15x8
c66S. BECODISK 100micrograms disk refill 15x8
c66T. BECODISK 200micrograms disk refill 15x8
c66U. BECODISK 400micrograms disk refill 15x8
c66V. BECLOMETASONE DIPROPIONATE 50micrograms CFC-free inhaler
c66W. BECLOMETASONE DIPROPIONATE 100micrograms CFC-free inhaler
c66X. BECLOMETASONE DIPROPIONATE 50micrograms CFC-free breath-actuated
aerosol inhaler
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
c66Y. BECLOMETASONE DIPROPIONATE 100micrograms CFC-free breath-actuated
aerosol inhaler
c66Z. QVAR EASI-BREATHE 50micrograms CFC-free breath-actuated dry powder
inhaler
c66a. QVAR EASI-BREATHE 100micrograms CFC-free breath-actuated dry powder
inhaler
c66c. CLENIL MODULITE 50micrograms CFC-free inhaler
c66d. CLENIL MODULITE 100micrograms CFC-free inhaler
c66e. CLENIL MODULITE 200micrograms CFC-free inhaler
c66f. CLENIL MODULITE 250micrograms CFC-free inhaler
c66g. BECLOMETASONE DIPROPIONATE 200micrograms CFC-free inhaler
c66h. BECLOMETASONE DIPROPIONATE 250micrograms CFC-free inhaler
c68.. MOMETASONE [RESPIRATORY USE]
c681. MOMETASONE FUROATE 200micrograms breath-actuated dry powder inhaler
c682. MOMETASONE FUROATE 400micrograms breath-actuated dry powder inhaler
c683. ASMANEX TWISTHALER 200micrograms breath-actuated dry powder inhaler
c684. ASMANEX TWISTHALER 400micrograms breath-actuated dry powder inhaler
c69.. CICLESONIDE
c691. ALVESCO 160micrograms inhaler
c692. ALVESCO 80micrograms inhaler
c69y. CICLESONIDE 80micrograms inhaler
c69z. CICLESONIDE 160micrograms inhaler
COPD-specific
Prescriptions
8BMW. Issue of chronic obstructive pulmonary disease rescue pack
8I610 Chronic obstructive pulmonary disease rescue pack not indicated
8IEZ. Chronic obstructive pulmonary disease rescue pack declined
a46.. GLYCOPYRRONIUM BROMIDE [ANTISPASMODIC]
a46z. *GLYCOPYRRONIUM 2mg tablets
c1b.. INDACATEROL
c1b1. ONBREZ BREEZHALER 150micrograms inhalation capsules+inhaler
c1b2. INDACATEROL 150micrograms inhalation capsules+inhaler
c1b3. ONBREZ BREEZHALER 300micrograms inhalation capsules+inhaler
c1b4. INDACATEROL 300micrograms inhalation capsules+inhaler
c1d.. OLODATEROL
c1d1. STRIVERDI RESPIMAT 2.5micrograms inhaler
c1d2 OLODATEROL 2.5micrograms inhaler
c1e.. INDACATEROL+GLYCOPYRRONIUM
c1e2. INDACATEROL+GLYCOPYRRONIUM 85mcg/43mcg inh powder caps+inh
c3... ANTICHOLINERGIC BRONCHODILATORS
c31.. IPRATROPIUM BROMIDE [1]
c311. *ATROVENT 20micrograms inhaler
c312. ATROVENT 500microgram/2mL nebuliser solution
c313. ATROVENT FORTE 40microgram inhaler
c314. ATROVENT 250microgram/1mL nebuliser solution
c315. ATROVENT 20micrograms Autohaler
c316. STERI-NEB IPRATROPIUM 250micrograms/1mL nebulisation units
c317. STERI-NEB IPRATROPIUM 500micrograms/2mL nebulisation units
c318. ATROVENT 40micrograms Aerocaps refill pack
c319. ATROVENT 40micrograms Aerocaps+Aerohaler device
c31A. IPRATROPIUM BROMIDE 40mcg inhalation capsules
c31B. IPRATROPIUM BROMIDE 40mcg inhalation capsules+inhaler device
c31C. RESPONTIN 250micrograms/1mL Nebules
c31D. RESPONTIN 500micrograms/2mL Nebules
c31E. TROPIOVENT 250micrograms/1mL Steripoules
c31F. TROPIOVENT 500micrograms/2mL Steripoules
c31G. ATROVENT 20micrograms CFC-free inhaler
c31t. IPRATROPIUM BROMIDE 20micrograms CFC-free inhaler
c31u. IPRATROPIUM 20micrograms breath-actuated aerosol inhaler
c31v. IPRATROPIUM 250micrograms/1mL nebuliser solution
c31w. IPRATROPIUM 500micrograms/2mL nebuliser solution
c31x. IPRATROPIUM 20micrograms inhaler
c31y. IPRATROPIUM 250micrograms/mL nebuliser solution
c31z. IPRATROPIUM 40microgram inhaler
c32.. OXITROPIUM BROMIDE
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
c321. OXITROPIUM 100micrograms/dose inhaler 200dose
c322. OXIVENT 100micrograms/dose inhaler 200dose
c323. OXIVENT 100micrograms Autohaler
c324. OXITROPIUM 100micrograms breath-actuated aerosol inhaler
c33.. TIOTROPIUM
c331. TIOTROPIUM 18micrograms inhalation capsules
c332. TIOTROPIUM 18micrograms capsules with inhaler device
c333. TIOTROPIUM 2.5micrograms inhalation cartridges with inhaler device
c33x. SPIRIVA RESPIMAT 2.5micrograms inhalation cartridges with Respimat inhaler
device
c33y. SPIRIVA COMBOPACK 18micrograms capsules with HandiHaler inhaler device
c33z. SPIRIVA 18micrograms inhalation capsules
c34.. ACLIDINIUM
c341. EKLIRA GENUAIR 322micrograms/dose dry powder inhaler
c342. ACLIDINIUM 322micrograms/dose dry powder inhaler
c35.. UMECLIDINIUM
c351. INCRUSE ELLIPTA 55micrograms/dose dry powder inhaler
c352. UMECLIDINIUM 55micrograms/dose dry powder inhaler
c51J UMECLIDINIUM+VILANTEROL 55mcg/22mcg dry powder inhaler
c51L. ACLIDINIUM+FORMOTEROL FUMARATE DIHYD 340mcg/12mcg pdr inh
c51N TIOTROPIUM+OLODATEROL 2.5micrograms/2.5micrograms inhaler
cl1.. ROFLUMILAST
cl11. DAXAS 500micrograms tablets
cl1z. ROFLUMILAST 500micrograms tablets
pc3.. OXYGEN CYLINDERS
pc31. OXYGEN BP 1360litres cylinder
pc32. OXYGEN GAS cylinder AD
pc33. OXYGEN GAS cylinder AF 1360L
pc34. OXYGEN GAS cylinder C
pc35. OXYGEN GAS cylinder D
pc36. OXYGEN GAS cylinder E
pc37. OXYGEN GAS cylinder F 1360L
pc38. OXYGEN GAS cylinder G
pc39. OXYGEN GAS cylinder J
pc3A. OXYGEN GAS cylinder PD
pc3B. OXYGEN GAS cylinder SD
pc3C. OXYGEN gas cylinder DD
pc3D. OXYGEN gas cylinder HD
pc3E. OXYGEN gas cylinder RD
pc3F. OXYGEN gas cylinder DF
pc3G. OXYGEN gas cylinder HX
pc3H. OXYGEN GAS cylinder FC
Current Smoking
1373. Light smoker - 1-9 cigs/day
1374. Moderate smoker - 10-19 cigs/d
1375. Heavy smoker - 20-39 cigs/day
1376. Very heavy smoker - 40+cigs/d
137C. Keeps trying to stop smoking
137G. Trying to give up smoking
137H. Pipe smoker
137J. Cigar smoker
137M. Rolls own cigarettes
137P. Cigarette smoker
137R. Current smoker
137V. Smoking reduced
137X. Cigarette consumption
137Y. Cigar consumption
137Z. Tobacco consumption NOS
137a. Pipe tobacco consumption
137b. Ready to stop smoking
137c. Thinking about stopping smoking
137d. Not interested in stopping smoking
137e. Smoking restarted
137f. Reason for restarting smoking
137h. Minutes from waking to first tobacco consumption
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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Table B.2.1: Read Codes sets used to define the observed variables in the latent class modelling in
Chapter 3. (cont’d).
Read code Description
137m. Failed attempt to stop smoking
137o. Waterpipe tobacco consumption
Ex-smoking
1378. Ex-light smoker (1-9/day)
1379. Ex-moderate smoker (10-19/day)
137A. Ex-heavy smoker (20-39/day)
137B. Ex-very heavy smoker (40+/day)
137F. Ex-smoker - amount unknown
137K. Stopped smoking
137N. Ex pipe smoker
137O. Ex cigar smoker
137S. Ex smoker
137T. Date ceased smoking
137j. Ex-cigarette smoker
137l. Ex roll-up cigarette smoker
COPD = chronic obstructive pulmonary disease; ICS = inhaled corticosteroids; LABA = long-acting β2 agonists; OCS = oral corticos-
teroids; SABA = short-acting β2 agonists.
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B.3 Item-response probabilities for the competing
latent class models
The following diagrams shows item-response probabilities in the classes of each of
the competing models. The names and levels of the observed variables are shown
on the left-most column in each diagram. Model diagnostics are shown below each
diagram and includes Akaike Information Criterion (AIC), Bayesian Information
Criterion (BIC), likelihood ratio chi-squared statistic (Gsq), Pearson’s Chi-square
goodness of fit statistic (Chisq), maximum log-likelihood value (llik), number of
iterations needed (numiter), number of individuals included in the modelling (N),
and number of estimated parameters (i.e. the number of degrees of freedom used;
npar).
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B.4 Related study protocol: identifying patients with
asthma-COPD overlap syndrome using latent
class analysis of electronic health record data
The following study protocol is related to the work presented in Chapter 3 and is
focused on identifying people with asthma-COPD overlap syndrome using latent
class analysis of electronic health record data. It has been published in npj Primary
Care RespiratoryMedicine (DOI: 10.1038/s41533-018-0088-4, https://www.nature.com/ar-
ticles/s41533-018-0088-4).
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Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are two common different 
clinical diagnoses with overlapping clinical features. Global Initiative for Asthma (GINA) 
defined asthma based on variable respiratory symptoms and expiratory airflow limitation.1 
On the other hand, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) defined 
COPD based on persistent respiratory symptoms and airflow limitations.2 While asthma 
affects people from the early school age, COPD mainly affects those aged over 40 years with 
a smoking history. Clinically, the differentiation between the two diseases and identifying 
their overlap in those older people can be challenging.1 Co-existence of clinical features of 
both conditions along with persistent airflow limitation has been recently recognized by a 
joint committee publication between GOLD and GINA as the asthma–COPD overlap 
syndrome (ACOS).3 
However, there are currently no universally agreed consensus clinical definitions for the 
diagnosis of asthma,4–9 COPD,10,11 and ACOS.12–15 Subsequently, the prevalence of these 
three conditions is highly dependent on the different available case definitions and data 
sources.16–20 
In studies conducted using electronic health records (EHR), identifying patient groups is 
further complicated by the limitations of these data, such as missing data and coding 
errors.21–23 Despite the lack of consensus clinical definitions, we expect EHR data of people 
with “ACOS” to be systematically different from those with “asthma only” or “COPD only”. 
Case definitions aiming to differentiate between those patient groups based solely on clinical 
knowledge or face validity may be inaccurate, and validating them with traditional methods, 
e.g., review of full patient records, is time-consuming and labour-intensive. Clustering 
methods overcome these challenges by automatically identifying subgroups in the 
population that best explain the patterns in high-dimensional EHR data, without an a priori 
hypothesis about those subgroups and their labels.24 Latent class analysis (LCA) is such a 
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method that can probabilistically identify patients with asthma and/or COPD using the 
available recorded data. 
Aims 
We plan to develop an LCA model to identify and characterise patients with asthma, COPD 
and ACOS in Wales. Based on this LCA model, we will derive a classification algorithm, and 
compare its performance with commonly used objective and self-reported case definitions 
for asthma and COPD. 
Methods 
We will use primary care data on asthma and COPD recorded in or before 2014 for a sample 
of the Welsh population to find, using LCA, clinically meaningful classes (i.e. clusters) related 
to the two conditions in that year. We will follow the STROBE25 and RECORD Statements26 in 
reporting the full study. 
Data sources 
We will use the following two de-identified datasets from the Secure Anonymised 
Information 
Linkage (SAIL) Databank in Wales:27,28 
• The Welsh Demographic Service (WDS) which contains demographic and 
administrative information for the National Health Services (NHS) patient in Wales. 
• The General Practitioner (GP) dataset which contains primary care events, such as 
diagnoses, clinical findings, prescriptions codified in Read codes by general 
practitioners. 
At the time of writing of this protocol, the most recent extract of the GP dataset was in 
March 2017, covering about 80% of GP surgeries in Wales. 
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Patient population 
The study sample will be randomly selected from the total population of Wales within the 
SAIL Databank in 2014. The sampling will be stratified by general practices to improve their 
representativeness. We will determine the sample size based on the computational capacity 
in the SAIL Databank which will be available for this study. The sampling frame will include 
all individuals who were aged at least 40 years on 1-1-2014. 
Latent class modelling 
LCA is a finite mixture modelling method that aims to divide a sample into classes or clusters 
related to a set of observed variables.24,29 LCA assumes that the patterns in these observed 
variables can be explained by, in addition to measurement errors, a hidden categorical 
variable that divides the sample into a pre-defined number of distinct classes. 
In our study, we will construct observed variables from asthma- and COPD-related events 
recorded in the GP Dataset. The construction of observed variables will be based on their 
usefulness, from a clinical perspective, for identifying and distinguishing between patients 
with asthma and/or COPD. These variables will include diagnosis, GP visits, and prescriptions 
related to asthma and COPD, as well as history of allergy (including atopic 
eczema/dermatitis, food allergy, allergic rhinitis, and anaphylaxis) and smoking history (see 
Table 1). GP visits and prescriptions will be queried during 2014, while the other events will 
be queried in or any time before 2014. 
Model parameters include proportions of the latent classes, and probabilities of observing 
the levels of observed variables in each latent class, a.k.a item–response probabilities. 
Parameters are estimated by the expectation–maximisation (EM) algorithm, which 
iteratively searches for maximum–likelihood parameter values for which the data are more 
likely to be observed.30 Based on observed characteristics, each individual is assigned 
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membership probability in each latent class,29 and is finally assigned to the latent class of 
maximum membership probability.31 
We will begin the modelling for two latent classes and will then iteratively increase the 
numbers of latent classes. Model selection will be based on model diagnostics and 
interpretability. 
We will look for a model for which the Bayesian Information Criterion (BIC)32,33 is ideally 
minimum, or becomes ‘stabilised’, indicating no significant improvement in information gain 
beyond a certain number of classes. In addition, the selected model should be clinically 
relevant; we will use the estimated item–response probabilities to assign labels consistent 
with “asthma”, “COPD”, “both” (ACOS), and “none” to the latent classes. We will use class 
shares as prevalence estimates for these clinical labels among the age groups of 40 and over 
in 2014. 
LCA modelling will be performed using the R package poLCA (version 1.4.1, 2014).34 
Derivation of a classification algorithm 
Based on the LCA model, we will derive a classification algorithm to identify patients with 
asthma, COPD and ACOS according to their characteristics. To do so, we will perform 
recursive partitioning35 using the assigned latent classes as labels and the aforementioned 
observed variables as predictors. We will use the R package rpart (version 4.1-11, 2017)36 for 
this purpose. 
Comparison with other case definitions 
We will compare the LCA model and the derived classification algorithm with other objective 
and self-reported measures. As objective measures, we will use definitions used in the 
Quality of Outcomes Framework (QOF) 2014–2015 indicators for ‘treated asthma’ (AST001) 
and ‘COPD’ (COPD001).37 From the Welsh Health Survey (WHS) 2014,38 we will use self-
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reported responses on current treatment of ‘asthma’, ‘emphysema’, and ‘spells of bronchitis 
that have lasted over 3 years’, with any of the latter two representing currently-treated 
COPD. We will treat invalid and missing responses as negative responses. We will perform 
the comparisons in the group of the WHS 2014 participants who were aged 40 years or over 
on 1-1-2014, and whose responses where successfully linked to the SAIL Databank. We will 
calculate diagnostic accuracy measures of the LCA model and the classification algorithm 
against each of the above case definitions and vice versa. 
Ethics, timeline and dissemination 
We obtained an approval to use the SAIL Databank from the Information Governance 
Review Panel. NHS Research Ethics Committee approval for this study is not required 
because we will only use anonymised data. The data extraction and statistical analysis will be 
performed between March and May 2018. The full paper will be submitted for publication in 
a respiratory care-related peer-reviewed journal in due course. 
Discussion 
While the interest in ACOS is growing, there is no consensus definition for this emerging and 
debated concept,39 leading to wide variations in prevalence and impaired comparability 
between studies. With the increasing use of EHR data to study asthma and COPD, it is 
important to develop operational definitions for ACOS based on such data. In this study, we 
will perform LCA on recorded events of diagnosis, prescriptions, and healthcare utilisation 
for asthma and COPD in routinely collected primary care data. By including observed 
variables for asthma and COPD in the same model, we will be able to identify patients with 
either or both conditions (i.e. ACOS). 
An inherent limitation of routinely collected EHR data is the lack of vital pieces of 
information that are often used to make diagnoses at the point of care. Unlike diagnosis and 
prescriptions which are generally well coded, important diagnostic tests such as lung 
B.4. Study protocol: identifying patients with ACOS using LCA 327
7 
function and peripheral eosinophil count are often poorly and inconsistently recorded in 
primary care datasets. These missing data would have been potentially useful for improving 
the accuracy of our model. However, it is often difficult to assess data missingness in event-
based databases. The GP Dataset in the SAIL Databank is a long-format dataset, in which 
each row contains a dated code representing a single primary care event. The presence of a 
code usually indicates that the corresponding event occurred. However, when a code is 
absent, it is often impossible to ascertain whether the event did not occur or whether it was 
simply not recorded or coded. This is a particular challenge for events that are known to be 
poorly recorded. Therefore, since the quality of observed variables is essential in LCA, we will 
only include variables that are thought to be of reasonable quality in the SAIL Databank. In 
interpreting the results, we will consider the limitations of EHR-derived data such as the 
possibility of missing or incorrect codes and the changes in coding practices over time. 
LCA itself has limitations. The construction of observed variables, model selection and 
interpretation involves a level of subjectivity. The model’s interpretation and usefulness 
depends largely on the choice and structure of observed variables. In our LCA modelling, the 
clinical meaning of the latent classes will be based on surrogate variables, such as diagnosis, 
GP visits, and prescriptions, rather than on more direct disease markers such as clinical and 
laboratory findings. Nevertheless, we hypothesise that LCA of these surrogate variables can 
reasonably distinguish between patients with asthma, COPD, and ACOS. This will also 
provide an opportunity to assess how clustering based on these surrogate variables will 
perform compared with that based on disease markers.40–47 Comparing our LCA model and 
classification algorithm against other objective and self-reported measures will provide 
useful information about their validity and performance. 
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Table C.1.1: Data fields of the datasets that were used for the development of the Wales Asthma Observatory. These metadata and data quality statistics were produced by
the SAIL Databank in 2018.
Column Name
Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
Welsh Demographic Service (WDS) - AR_PERS (Administrative Register - Persons)
pers_id_e Encrypted Person Id integer 0 0 5218464 An encrypted unique identifier for each person registered on the Welsh
Demographic Service.
alf_e Encrypted Anonymised
Linking Field
bigint 0 0 5218464 The Anonymised Linking Field, which has been Encrypted for its use within the
database, is derived from the persons NHS number by double encryption (first
encryption occurs in NWIS and the second in SAIL). If the NHS number is not
supplied in the data extract then matching methods are applied.
wob Week of Birth date 0 0 6880 The date of the Monday that occurs prior, or on, the actual date of birth. Access
to this data item is limited, however, it can be used to calculate age at specific
events.
dod Date of Death date 4394400 84.21 10079 The date of death for the individual (if known).
gndr_cd Gender code (also
known as sex)
character 0 0 3 This is the sex (gender) of person, employee or patient.
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
Welsh Demographic Service (WDS) - AR_PERS_ADD (Administrative Register - Addresses)
pers_id_e Encrypted Person Id integer 0 0 5240178 An encrypted unique identifier for each person registered on the Welsh
Demographic Service.
ralf_e Encrypted Residential
Anonymous Linking
Field
bigint 1242454 8.79 1332673 The encrypted Residential Anonymous Linking Field (RALF) is a number
derived from the persons postal address. The matching methods applied are
described in the paper "Residential Anonymous Linking Fields (RALFs): a
novel information infrastructure to study the interaction between the
environment and individuals health".
ralf_sts_cd Residential Anonymous
Linking
Field_status_code
character 0 0 3 The status code generated when deriving the RALF field.
uprn_qas_match_cd UPRN quality match
code
character 134288 0.95 1260 The UPRN (Unique Property Reference Number) quality match code.
lsoa_cd Local Super Output
Area code
character 1228010 8.69 1896 The Local Super Output Area of residence.
row_sts Row status character 0 0 2 Row status code.
from_dt From date date 0 0 28413 From date.
to_dt To date date 0 0 10428 To date.
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
Welsh Demographic Service (WDS) - AR_PERS_GP (Administrative Register - GP registrations)
pers_id_e Encrypted Person Id integer 0 0 5240179 An encrypted unique identifier for each person registered on the Welsh
Demographic Service.
prac_cd_e Encrypted GP practice
code
integer 177360 1.25 663 The encrypted GP practice code where the patient is registered.
row_sts Row status character 0 0 2 Row status code.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
from_dt From date date 0 0 30723 From date.
to_dt To date date 0 0 12754 To date.
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
Welsh Longitudinal General Practice (WLGP)
alf_e Encrypted Anonymised
Linking Field
bigint 3462255 0.15 4016617 The Anonymised Linking Field, which has been Encrypted for its use within the
database, is derived from the persons NHS number by double encryption (first
encryption occurs in NWIS and the second in SAIL). If the NHS number is not
supplied in the data extract then matching methods are applied.
alf_sts_cd ALF status code character 0 0 5 Status code assigned when deriving the Encrypted Anonymised Linking Field.
alf_mtch_pct ALF match percentage decimal 2367210983 99.68 90859 Match percentage assigned when deriving the Encrypted Anonymised Linking
Field.
prac_cd_e Encrypted GP practice
code
integer 0 0 340 The encrypted GP practice code where the patient is registered.
local_num_e NA bigint 0 0 274452 NA
gndr_cd Gender code (also
known as sex)
character 0 0 3 This is the sex (gender) of person, employee or patient.
wob Week of Birth date 0 0 6857 The date of the Monday that occurs prior, or on, the actual date of birth. Access
to this data item is limited, however, it can be used to calculate age at specific
events.
lsoa_cd Local Super Output
Area code
character 18212565 0.77 6606 The Local Super Output Area of residence.
reg_cat_cd Registration category
code
character 0 0 36 This denotes the registration status for the individual.
event_dt Event date date 0 0 52003 The date the event occurred.
event_yr Event year smallint 0 0 273 The year the event occurred.
event_cd_vrs Event code version character 0 0 2 This denotes the coding classification used for this record. Since the data is
collated from diﬀerent GP practices which use diﬀerent clinical systems there
are a variety of coding classifications used. However, the majority of practices
use Read Code version 2.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
event_cd Event code character 0 0 267925 This code documents clinical information recorded during the event. In the
majority of practices this will be a read code which can be linked to text
description denoting a sign, symptom, diagnosis, prescription, referral etc.
event_val Event value decimal 1048003348 44.13 118407 This value is associated to the EVENT_CD, e.g. the value of diastolic blood
pressure or the number of tablets prescribed.
episode Episode character 0 0 6 This denotes the type of episode.
sequence Sequence integer 0 0 108853875 This numeric sequence denotes the order of multiple records for a specific
event. For example if a blood pressure reading was taken more than once
within an appointment.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
Patient Episode Database for Wales (PEDW) - SPELL
prov_unit_cd Provider unit code character 0 0 662 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
spell_num_e Encrypted spell number integer <5 0 18555146 A number (alphanumeric) to provide a unique identifier for each hospital
provider spell for a health care provider.
gndr_cd Gender code (also
known as sex)
character 0 0 7 This is the sex (gender) of person, employee or patient.
res_dha_cd District health
authority of residence
code
character 30526 0.16 1276 The District Health Authority in which the patient is resident.
admis_yr Admission year character 72 0 104 The year of the beginning of a hospital provider spell, or the year of admission.
admis_dt Admission date date 72 0 10242 This is the beginning of a hospital provider spell, or the date of admission. The
consultant has assumed responsibility for care following the decision to admit
the patient. This may be before formal admission procedures have been
completed and the patient is transferred to a ward.
fin_admis_yr Financial admission
year
character 72 0 102 The financial year of the beginning of a hospital provider spell, or the year of
admission.
admis_mthd_cd Admission method code character 974 0.01 21 This is the method of admission to a hospital provider spell.
admis_source_cd Admission source code character 8550 0.04 49 This is the source of admission to a hospital.
intended_manage-
ment_cd
Intended management
code
character 1930 0.01 8 The intended pattern of bed use for a patient, decided when the decision is
made to admit, and only applies to patients on the Elective Admission List.
This categorization describes what is intended to happen to the patient.
Occasionally the patients treatment does not go exactly to plan.For example, a
patient admitted as a day case may develop complications and have to be kept
in overnight. Therefore another data item, patient classification, is used to
describe what actually happens to the patient.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
disch_yr Discharge year character 21984 0.11 31 The year of discharge from the Hospital Provider Spell. The year in which a
patient dies or is discharged from a continuous spell of care using the hospital
bed(s) within a single hospital provider. Identical to the end year of the last
consultant episode of care and ward stay within a hospital provider spell.
disch_dt Discharge date date 21983 0.11 9481 Date of discharge from the Hospital Provider Spell. The date on which a patient
dies or is discharged from a continuous spell of care using the hospital bed(s)
within a single hospital provider. Identical to the end date of the last
consultant episode of care and ward stay within a hospital provider spell.
fin_disch_yr Financial discharge
year
character 21984 0.11 30 The financial year of the end of a hospital provider spell, or the year of
discharge.
disch_mthd_cd Discharge method code character 0 0 8 This is the method of discharge from a hospital provider spell.
disch_destination_cd Discharge destination
code
character 30548 0.16 75 The classification of where a patient is sent on completion of a hospital provider
spell, or a note that the patient died or was a still birth.
dur_elect_wait Duration of elective
wait
decimal 9064942 46.83 3271 This is the waiting time from the date of the decision to admit to the provider
where the treatment actually takes place, to the date of admission.
pat_class_cd Patient classification
code
character 5833 0.03 9 A coded classification of Patients who have been admitted to a Hospital
Provider Spell.
spell_dur Spell duration integer 22093 0.11 3163 The period of time in days between the start date of the provider spell and the
discharge date of the provider spell.
admis_spec_cd Admission speciality
code
character 0 0 145 This is the specialty under which the patient will be or is treated. This may
either be the same as the specialty function recorded as the consultants main
specialty or a diﬀerent specialty function which will be the consultants interest
specialty function. Note that both the main specialty function and the interest
specialty function should be based on one of the Royal College specialties.
disch_spec_cd Discharge speciality
code
character 0 0 146 This is the specialty under which the patient will be or is treated. This may
either be the same as the specialty function recorded as the consultants main
specialty or a diﬀerent specialty function which will be the consultants interest
specialty function. Note that both the main specialty function and the interest
specialty function should be based on one of the Royal College specialties.
ua_cd Unitary Authority code character 62105 0.32 196 The unitary authority in which the patient is resident.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
res_ward_cd Ward code of residence character 86052 0.44 320 The electoral ward in which the patient is resident.
reg_gp_cd_e Encrypted registered
GP code
integer 22083 0.11 42463 The encrypted unique GP Practice code to which the patient is registered.
reg_gp_prac_cd_e Encrypted registered
GP practice code
integer 1239686 6.4 10192 The encrypted unique GP Practice code to which the patient is registered.
ref_cd_e Encrypted referrer
code
integer 897630 4.64 47174 This is the nationally recognized code of the person making the referral.This
may be a General Medical Practitioner (GMP), General Dental Practitioner
(GDP), Consultant or Independent Nurse. If the referral is not from a GMP,
GDP, Consultant or Independent Nurse one of the default codes used.
ref_org_cd Referring organisation
code
character 1054418 5.45 11670 The code of the referring organisation.
admis_dec_dt Admission decision
date
date 4919073 25.41 10071 This is the date upon which the clinician makes the decision to admit the patient
local_health_grp_cd Local health group code integer 19357775 100 0 The local health group associated with the hospital admission.
curr_prov_unit_cd Current provider unit
code
character 0 0 333 The current organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient. To enable longtiduninal analysis over a period of
years, a current field can be used to map previously used codes to current
version/name.
curr_res_dha_cd Current district health
authority of residence
code
character 199 0 312 The current District Health Authority in which the patient is resident. To enable
longtiduninal analysis over a period of years, a current field can be used to
map previously used codes to current version/name.
curr_lo-
cal_health_grp_cd
Current local health
group code
integer 19357775 100 0 The current local health group associated with the hospital admission. To
enable longtiduninal analysis over a period of years, a current field can be
used to map previously used codes to current version/name.
curr_ua_cd Current Unitary
Authority code
character 62105 0.32 196 The current unitary authority in which the patient is resident. To enable
longtiduninal analysis over a period of years, a current field can be used to
map previously used codes to current version/name.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
curr_res_ward_cd Current ward residence
code
character 86052 0.44 320 The current electoral ward in which the patient is resident. To enable
longtiduninal analysis over a period of years, a current field can be used to
map previously used codes to current version/name.
pat_id_e Encrypted patient
identifier
integer 0 0 3923115 An encrypted unique Patient Identifier
alf_e Encrypted Anonymised
Linking Field
bigint 1026066 5.3 3228910 The Anonymised Linking Field, which has been Encrypted for its use within the
database, is derived from the persons NHS number by double encryption (first
encryption occurs in NWIS and the second in SAIL). If the NHS number is not
supplied in the data extract then matching methods are applied.
case_rec_num_e Encrypted casenote
record number
integer 3211 0.02 4964329 This is the case record number. It is a unique identifier for a patient within a
health care provider.
alf_sts_cd ALF status code character 0 0 5 Status code assigned when deriving the Encrypted Anonymised Linking Field.
alf_mtch_pct ALF match percentage decimal 19057851 98.45 36332 Match percentage assigned when deriving the Encrypted Anonymised Linking
Field.
hrg_localpayment_cd HRG local payment
code
varchar 11598773 59.92 1918 The Healthcare Resource Group Local Payment Code for the overall spell.
hrg_localpayment_desc HRG local payment
description
varchar 0 0 3079 The Healthcare Resource Group Local Payment Code description for the overall
spell.
hrg_referencecost_cd HRG reference cost
code
varchar 11601219 59.93 4439 The Healthcare Resource Group Reference Cost Code for the overall spell.
hrg_referencecost_desc HRG reference cost
description
varchar 0 0 6152 The Healthcare Resource Group Reference Cost Code description for the
overall spell
hrg_v31_cd HRG version 31 code varchar 5887305 30.41 572 Healthcare Resource Group code for a previous version of HRG codes (v3.1).
hrg_v31_desc HRG version 31
description
varchar 0 0 572 Healthcare Resource Group code description for a previous version of HRG
codes (v3.1)
hrg_v35_cd HRG version 35 code varchar 5886058 30.41 610 Healthcare Resource Group code for a previous version of HRG codes (v3.5).
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
hrg_v35_desc HRG version 31
description
varchar 0 0 609 Healthcare Resource Group code description for a previous version of HRG
codes (v3.5)
lsoa_cd_2001 Local Super Output
Area code 2001
character 92527 0.48 34261 The Local Super Output Area of residence (based on 2001 census LSOA codes).
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
Patient Episode Database for Wales (PEDW) - EPISODE
prov_unit_cd Provider unit code character 0 0 663 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
spell_num_e Encrypted spell number integer <5 0 18555146 A number (alphanumeric) to provide a unique identifier for each hospital
provider spell for a health care provider.
epi_num Episode number character 0 0 99 A number used to identify episodes uniquely, and is a sequence number for
each consultant episode in a hospital provider spell.
epi_str_yr Episode start year character 573 0 101 The year of the start of a stay, an episode, period covered by a plan, or other
period of time.
epi_str_dt Episode start date date 573 0 10084 This is the start date of a stay, an episode, period covered by a plan, or other
period of time.
epi_end_yr Episode end year character 0 0 29 The year of the end of a stay, an episode, period covered by a plan, or other
period of time.
epi_end_dt Episode end date date 0 0 9477 This is the end of a stay, an episode, period covered by a plan, or other period of
time.
prov_site_cd Provider site code character 0 0 1949 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
age_epi_str_yr Age at start of episode integer 3198 0.01 196 The age of patient at start date of episode or at date of admission if first episode.
age_epi_str_under1 Age at start of episode
for under 1s
integer 21632323 99.3 182 Is the age of patient at start date of episode or at date of admission if first
episode.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
con_spec_main_cd Consultant main
speciality code
character 7507 0.03 162 A unique code identifying each Main Specialty designated by Royal
Colleges.Specialties are divisions of clinical work which may be defined by
body systems (dermatology), age (paediatrics), clinical technology (nuclear
medicine), clinical function (rheumatology), group of diseases (oncology) or
combinations of these factors.Only Specialty titles recognised by the Royal
Colleges and Faculties should be used. This list is maintained by the General
and Specialist Medical Practice (Education, Training and Qualifications) Order
2003 and European Primary and Specialist Dental Qualifications Regulations
1998.
con_spec_cd_of_treat Consultant treatment
speciality code
character 0 0 148 This is the specialty under which the patient will be or is treated. This may
either be the same as the specialty function recorded as the consultants main
specialty or a diﬀerent specialty function which will be the consultants interest
specialty function. Note that both the main specialty function and the interest
specialty function should be based on one of the Royal College specialties.
epi_dur Episode duration decimal 645 0 2879 The period of time in days between the Start Date of Consultant Episode and
the End Date of Consultant Episode for finished episodes, or the period of time
in days between the Start Date of Episode and the end date of the current
period for unfinished episodes.
diag_cd_123 Diagnosis code (3
digits)
varchar 689333 3.16 2415 The first 3 digits of the Diagnostic code available (ICD 10)
diag_cd_4 Diagnosis code (4th
digit)
varchar 693337 3.18 13 The 4th digit of the Diagnostic code available (ICD 10)
diag_cd_1234 Diagnosis code (4
digits)
varchar 693337 3.18 10963 The first 4 digits of the Diagnostic code available (ICD 10)
oper_cd_123 Operation code (3
digits)
varchar 9834137 45.14 1449 The first 3 digits of the Procedure code available (OPCS4)
oper_cd_4 Operation code (4th
digits)
varchar 9847548 45.21 17 The 4th digit of the Procedure code available (OPCS4)
oper_cd Operation code varchar 9847548 45.21 7869 The full Procedure code available (OPCS4)
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
curr_prov_unit_cd Current provider unit
code
varchar 0 0 333 The current organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient. To enable longtiduninal analysis over a period of
years, a current field can be used to map previously used codes to current
version/name.
curr_prov_site_cd Current provider site
code
varchar 0 0 1291 The current organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient. To enable longtiduninal analysis over a period of
years, a current field can be used to map previously used codes to current
version/name.
fin_epi_end_yr Financial episode end
year
character 0 0 28 The financial year of the end of a hospital episode.
hsw_first_epi_in_spell HSW first episode in
spell
integer 21784142 100 0 Flag to show if an episode is first in the spell
site_cd_of_treat Site code of treatment character 3348076 15.37 1885
gmc_con_cd_e Encrypted GMC
consultant code
integer 519033 2.38 36175 Nationally agreed form for consultant code or Independent Nurse. It is the
General Medical Council (GMC) code for the Consultant or the GP acting as a
Consultant or locum Consultant, which is the unique identifier. The nurses
Registration Number will be used to identify the Independent Nurse.
ua_cd Unitary Authority code character 70916 0.33 196 The unitary authority in which the patient is resident.
hrg_localpayment_cd HRG local payment
code
varchar 12752672 58.54 4441 The Healthcare Resource Group Local Payment Code for the overall spell.
hrg_localpayment_desc HRG local payment
description
varchar 0 0 6155 The Healthcare Resource Group Local Payment Code description for the overall
spell.
hrg_referencecost_cd HRG reference cost
code
varchar 12702016 58.31 1920 The Healthcare Resource Group Reference Cost Code for the overall spell.
hrg_referencecost_desc HRG reference cost
description
varchar 0 0 3083 The Healthcare Resource Group Reference Cost Code description for the
overall spell
hrg_v31_cd HRG version 31 code varchar 6604546 30.32 572 Healthcare Resource Group code for a previous version of HRG codes (v3.1).
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
hrg_v31_desc HRG version 31
description
varchar 0 0 572 Healthcare Resource Group code description for a previous version of HRG
codes (v3.1)
hrg_v35_cd HRG version 35 code varchar 6603156 30.31 610 Healthcare Resource Group code for a previous version of HRG codes (v3.5).
hrg_v35_desc HRG version 31
description
varchar 0 0 609 Healthcare Resource Group code description for a previous version of HRG
codes (v3.5)
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
Patient Episode Database for Wales (PEDW) - DIAG
prov_unit_cd Provider unit code character 0 0 642 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
spell_num_e Encrypted spell number integer <5 0 18129197 A number (alphanumeric) to provide a unique identifier for each hospital
provider spell for a health care provider.
epi_num Episode number character 0 0 99 A number used to identify episodes uniquely, and is a sequence number for
each consultant episode in a hospital provider spell.
diag_num Diagnosis number integer 0 0 14 A number used to identify the position of diagnosis assigned to a patient. Value
1 relates to the primary ICD Diagnostic Code. Values > 1 relate to secondary
ICD diagnositic codes.
diag_cd_123 Diagnosis code (3
digits)
character 0 0 2668 The first 3 digits of the Diagnostic code available (ICD 10)
diag_cd_4 Diagnosis code (4th
digit)
character 81534 0.11 33 The 4th digit of the Diagnostic code available (ICD 10)
diag_cd_56 Diagnosis code (5th
and 6th digits)
character 65323041 91.52 262 The 5th and 6th digit of the Diagnostic code available (ICD 10)
diag_cd_1234 Diagnosis code (4
digits)
character 0 0 15420 The first 4 digits of the Diagnostic code available (ICD 10)
diag_cd Diagnosis code character 0 0 40086 The full Diagnostic code available (ICD 10)
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
Emergency Department Data Set (EDDS)
record_id Record ID character 8506326 100 0 This is the field to identify the type of record being submitted.
prov_unit_cd Provider unit code character 0 0 14 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
prov_site_cd Provider site code character 0 0 23 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
admin_arr_dt Administrative arrival
date
date 0 0 3327 Accident and Emergency Attendance Administrative Arrival Date is the date the
Accident and Emergency reception staﬀ are notified in person that a patient
has arrived and needs to be seen within the Accident and Emergency
Department.Notification could be by the Ambulance Crew, the patient
themselves, or a person accompanying the patient e.g. relative / friend.
admin_arr_tm Administrative arrival
time
time 0 0 1440 Accident and Emergency Attendance Administrative Arrival Time is when the
Accident and Emergency reception staﬀ are notified in person that a patient
has arrived and needs to be seen within the Accident and Emergency
Department.Notification could be by the Ambulance Crew, the patient
themselves, or a person accompanying the patient e.g. relative / friend.
alf_e Encrypted Anonymised
Linking Field
bigint 272963 3.21 2537941 The Anonymised Linking Field, which has been Encrypted for its use within the
database, is derived from the persons NHS number by double encryption (first
encryption occurs in NWIS and the second in SAIL). If the NHS number is not
supplied in the data extract then matching methods are applied.
nhs_no_ind NA character 636636 7.48 30 NA
prac_cd_e Encrypted GP practice
code
integer 189972 2.23 12840 The encrypted GP practice code where the patient is registered.
dob_year Year of Date of Birth character 1168 0.01 128 The year of the Date of birth of patient / client.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
age Age at start of
admission
smallint 1168 0.01 143 The age of patient at start date of admission.
sex Sex (also known as
gender code)
character 414 0 7 This is the sex (gender) of person, employee or patient.
lsoa_cd Local Super Output
Area code
character 211271 2.48 35994 The Local Super Output Area of residence.
ref_cd_e NA bigint 472888 5.56 23123 NA
arrival_mode Mode of arrival character 101884 1.2 18 The principal means by which a patient arrives at an Accident and Emergency
department.
amb_incid_no_e Encrypted ambulance
incident number
integer 7357724 86.5 1059762 When a patient arrives by ambulance, this is the incident number for that
journey, allocated by the Ambulance Control.
site_cd_of_treat Site code of treatment character 0 0 51
health_event_dt Health event date date 1784422 20.98 4266 Date of the incident / acute medical episode that led to the Accident and
Emergency Department Attendance.
health_event_tm Health event time time 2909289 34.2 1440 This is the time of the incident / acute medical episode that led to the Accident
and Emergency Department Attendance.
attend_group Attendance group character 218653 2.57 25 A general reason for an Accident and Emergency Department Attendance.
attend_category Attendance Category character 6751 0.08 6 Accident and Emergency Attendance Category is an indication of whether a
patient is making a first or follow-up attendance at the Accident and
Emergency Department.
diag_cd_1 Diagnosis Type code 1 character 943809 11.1 756 A broad list of diagnosis types, which may be identified during an Accident and
Emergency Department Attendance.
diag_cd_2 Diagnosis Type code 2 character 6706626 78.84 670 A broad list of diagnosis types, which may be identified during an Accident and
Emergency Department Attendance.
diag_cd_3 Diagnosis Type code 3 character 6987207 82.14 459 A broad list of diagnosis types, which may be identified during an Accident and
Emergency Department Attendance.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
diag_cd_4 Diagnosis Type code 4 character 7022431 82.56 270 The 4th digit of the Diagnostic code available (ICD 10)
diag_cd_5 Diagnosis Type code 5 character 7027918 82.62 151 A broad list of diagnosis types, which may be identified during an Accident and
Emergency Department Attendance.
diag_cd_6 Diagnosis Type code 6 character 7029211 82.64 98 A broad list of diagnosis types, which may be identified during an Accident and
Emergency Department Attendance.
anat_area_cd_1 Anatomical area code 1 character 1125400 13.23 39 A list of parts of the human body
anat_area_cd_2 Anatomical area code 2 character 6884335 80.93 40 A list of parts of the human body
anat_area_cd_3 Anatomical area code 3 character 7005530 82.36 39 A list of parts of the human body
anat_area_cd_4 Anatomical area code 4 character 7024604 82.58 39 A list of parts of the human body
anat_area_cd_5 Anatomical area code 5 character 7028269 82.62 36 A list of parts of the human body
anat_area_cd_6 Anatomical area code 6 character 7029132 82.63 34 A list of parts of the human body
side_cd_1 Anatomical side code 1 character 3067296 36.06 9 An indication of the side of the human body
side_cd_2 Anatomical side code 2 character 8149792 95.81 9 An indication of the side of the human body
side_cd_3 Anatomical side code 3 character 8269796 97.22 10 An indication of the side of the human body
side_cd_4 Anatomical side code 4 character 8290114 97.46 9 An indication of the side of the human body
side_cd_5 Anatomical side code 5 character 8294677 97.51 8 An indication of the side of the human body
side_cd_6 Anatomical side code 6 character 8295877 97.53 6 An indication of the side of the human body
treat_cd_1 Treatment code 1 character 1383221 16.26 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
treat_cd_2 Treatment code 2 character 6609855 77.71 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
treat_cd_3 Treatment code 3 character 7008801 82.4 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
treat_cd_4 Treatment code 4 character 7164431 84.22 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
treat_cd_5 Treatment code 5 character 7222299 84.91 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
treat_cd_6 Treatment code 6 character 7238663 85.1 17 A broad list of types of treatment or guidance which may be provided to a
patient as a result of an Accident and Emergency Attendance.
invest_cd_1 Investigation code 1 character 1561708 18.36 14 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
invest_cd_2 Investigation code 2 character 6873257 80.8 11 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
invest_cd_3 Investigation code 3 character 7161646 84.19 11 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
invest_cd_4 Investigation code 4 character 7373525 86.68 11 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
invest_cd_5 Investigation code 5 character 7501448 88.19 11 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
invest_cd_6 Investigation code 6 character 7518976 88.39 10 A broad list of types of investigation which may be requested to assist with
diagnosis during and Accident and Emergency Department Attendance.
admin_end_dt Administrative end date date 61624 0.72 3329 This is the date that the patients Accident and Emergency Attendance Ends.
admin_end_tm Administrative end time time 82466 0.97 1440 This is the time that the patients Accident and Emergency Attendance Ends.
add_details Additional incident
details
varchar 8506326 100 0 A record of any additional details of the incident that led to the Accident &
Emergency Department Attendance that cannot be recorded elsewhere within
the dataset.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
discharge Outcome of attendance character 161927 1.9 27 This records the outcome of the Accident and Emergency Department
Attendance.
location_type Location place type character 338871 3.98 69 The type of place where the physical or chemical injury occurred which led to
the Accident and Emergency Department Attendance.
road_user Road user character 767921 9.03 15 This is the nature of the patients road use at the time of the road traﬃc collision.
presenting_complaint Presenting complaint varchar 8506326 100 0 This is the presenting complaint with which the patient attended the Accident
and Emergency Department.
mech_of_inj Mechanism of injury character 564890 6.64 180 The mechanics of how the physical or chemical injury was sustained.
activity Activity at time of injury character 666342 7.83 18 What the patient was doing at the time of injury. This item helps establish a
picture of how the physical or chemical injury occurred.
sport Sporting activity character 1088994 12.8 37 The sport in which the patient was participating at the time of injury that led to
the Accident and Emergency Department attendance.
crn_pseud_e Encrypted
Pseudonimised Case
Record Number
integer 0 0 3221753 This is the case record number. It is a unique identifier for a patient within a
health care provider.
alf_sts_cd ALF status code character 0 0 5 Status code assigned when deriving the Encrypted Anonymised Linking Field.
alf_mtch_pct ALF match percentage decimal 8399224 98.74 27110 Match percentage assigned when deriving the Encrypted Anonymised Linking
Field.
alcohol_ind Alcohol indicator character 405798 4.77 29 In the clinical opinion of the Emergency Department, has the presence of
alcohol in the presenting patient contributed to this attendance?
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
batch_num Batch number smallint 0 0 1 The batch number is a sequential number allocated when data is loaded into
SAIL.
triage_cat Triage category character 371878 4.37 16 The triage category is assigned to a patient as a result of an initial assessment
by medical or nursing staﬀ in an Accident and Emergency Department.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
Outpatient Dataset (OPD) - OUTPATIENTS
prov_unit_cd Provider unit code character 0 0 237 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
prov_site_cd Provider site code character 0 0 679 This is the organisation code of the health care provider. The provider code
identifies the health care provider who is responsible for managing the
treatment of the patient.
alf_e Encrypted Anonymised
Linking Field
bigint 484178 0.93 3187662 The Anonymised Linking Field, which has been Encrypted for its use within the
database, is derived from the persons NHS number by double encryption (first
encryption occurs in NWIS and the second in SAIL). If the NHS number is not
supplied in the data extract then matching methods are applied.
gndr_cd Gender code (also
known as sex)
character 3400 0.01 7 This is the sex (gender) of person, employee or patient.
age_at_appt Age at appointment integer 22742 0.04 156 The age of the individual at the time of the appointment.
reg_prac_cd_e Encrypted registered
GP practice code
integer 49357 0.09 9026 The encrypted unique GP Practice code to which the patient is registered.
ref_cd_e Encrypted referrer
code
integer 2713322 5.19 42737 This is the nationally recognized code of the person making the referral.This
may be a General Medical Practitioner (GMP), General Dental Practitioner
(GDP), Consultant or Independent Nurse. If the referral is not from a GMP,
GDP, Consultant or Independent Nurse one of the default codes used.
case_rec_num_e Encrypted casenote
record number
integer 0 0 4796488 This is the case record number. It is a unique identifier for a patient within a
health care provider.
ref_dt Date of patient referral date 10036898 19.19 10093 This is the date on which the patient was told about the referral. The starting
point should be the date of referral given on the referral notification (not the
date the letter was received in hospital).In cases where the referrer fails to
specify a date of referral, the date the referral notification was received should
be used.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
clinical_ref_dt Clinical referral date date 9377699 17.93 9864 The Clinical Referral Date (CRD) is the clinically significant date marking the
start of a period of waiting either for an initial outpatient consultation or for an
episode of treatment such as elective surgery. The CRD is used to order pick
lists used for booking patients, and it does not change under any
circumstances. It is not used to calculate performance waiting times statistics.
waiting_list_dt Waiting list date date 24015264 45.92 8635 The Waiting List Date is set initially as the same date as the Clinical Referral
Date. It is used to calculate waiting times for the purpose of measuring Local
Health Board/Trust performance against Welsh Assembly Government
performance targets. It is not used to order outpatient waiting lists for partial
booking or to order inpatient or daycase lists for selection of patients
surgery.There are a number of situations where the WLD may be changed.
These include rescheduling an appointment at the patients request,
reinstatement to a waiting list following removal, or where a patient has
chosen to remain with a consultant when oﬀered an earlier appointment with a
diﬀerent consultant.
priority_type_cd Priority type new
patients
character 31340596 59.92 5 This is the priority of a request for services and is to be recorded for new
attendances only, that is, where Attendance Category = 1.In the case of
services to be provided by a Consultant, it is as assessed by or on behalf of the
Consultant.For a Follow Up Attendance or a Pre-Operative Assessment
Attendance, Priority Type must be blank.
source_of_ref_cd Source of referal
outpatients code
character 326558 0.62 35 This is a classification which is used to identify the source of referral of each
Outpatient Episode or Outpatient Referral.
con_spec_main_cd Consultant main
speciality code
character 41308 0.08 163 A unique code identifying each Main Specialty designated by Royal
Colleges.Specialties are divisions of clinical work which may be defined by
body systems (dermatology), age (paediatrics), clinical technology (nuclear
medicine), clinical function (rheumatology), group of diseases (oncology) or
combinations of these factors.Only Specialty titles recognised by the Royal
Colleges and Faculties should be used. This list is maintained by the General
and Specialist Medical Practice (Education, Training and Qualifications) Order
2003 and European Primary and Specialist Dental Qualifications Regulations
1998.
con_spec_cd_of_treat Consultant treatment
speciality code
character 19168 0.04 186 This is the specialty under which the patient will be or is treated. This may
either be the same as the specialty function recorded as the consultants main
specialty or a diﬀerent specialty function which will be the consultants interest
specialty function. Note that both the main specialty function and the interest
specialty function should be based on one of the Royal College specialties.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
local_spec_cd Local sub specialty character 8737323 16.71 358 This is a locally or nationally defined division of clinical work which may cross
specialty boundaries.
clinic_purpose_cd Clinic Purpose code character 7355159 14.06 46859 This is the function of an outpatient clinic e.g. psychogeriatric, obstetric. No
national classification of functions for outpatient clinics has been developed, so
function titles must be decided locally.Certain specialty sub-divisions must be
shown, such as: a. Obstetric antenatal, b. Obstetric postnatal, c. Gynaecology.
gmc_con_cd_e Encrypted GMC
consultant code
integer 225378 0.43 24479 Nationally agreed form for consultant code or Independent Nurse. It is the
General Medical Council (GMC) code for the Consultant or the GP acting as a
Consultant or locum Consultant, which is the unique identifier. The nurses
Registration Number will be used to identify the Independent Nurse.
att_id_e Encrypted attendance
identifier
integer 0 0 43721493 A sequential number or time of day used to enable an attendance or
appointment to be uniquely identified.
admin_cat_cd Administrative
category code
character 1859 0 17 This is to indicate whether the patient is treated as an NHS, private or amenity
patient etc.
loc_type_cd Location type code character 1464101 2.8 26 This is a classification of location type.
site_cd_of_treat Site code of treatment character 21452 0.04 1928
med_staﬀ_type_cd Medical staﬀ type
seeing patient code
character 1531441 2.93 11 A classification of the type of medical staﬀ seeing the patient during an
Outpatient attendance.
attend_dt Attendance date date 0 0 5230 This is the date of an attendance or appointment to attend.
first_attend_cd First Attendance
Category
character 8262 0.02 5 The first attendance is the start of the Outpatient episode and is the first
attendance in a series with the same Consultant or Independent Nurse
following a referral.
attend_cd Attendance code character 61143 0.12 13 This indicates whether a person or patient attended for an appointment. If the
patient did not attend, it also indicates whether or not advanced warning was
given.
outcome_cd Outcome of attendance character 3388267 6.48 14 This records the outcome of the Outpatient Attendance.
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
last_dna_cancel_dt Last DNA or patient
cancelled date
date 48882640 93.46 7572 This derived item should only be recorded for the first attendance for outpatient
treatment
oper_sts_flg Operation status flag character 1704072 3.26 11 Operation status should be used once for each record to record states of
knowledge regarding the operative procedure.
oper_cd_123 Operation code (3
digits)
character 49048246 93.78 943 The first 3 digits of the Procedure code available (OPCS4)
oper_cd_4 Operation code (4th
digits)
character 49150721 93.97 34 The 4th digit of the Procedure code available (OPCS4)
lsoa_cd Local Super Output
Area code
character 231313 0.44 25100 The Local Super Output Area of residence.
alf_sts_cd ALF status code character 0 0 5 Status code assigned when deriving the Encrypted Anonymised Linking Field.
alf_mtch_pct ALF match percentage decimal 52135801 99.68 33811 Match percentage assigned when deriving the Encrypted Anonymised Linking
Field.
avail_from_dt Available from date date 0 0 1 Date when the data made available i.e. date of loading
Annual District Death Extract (ADDE)
alf_e bigint 35345 5.12 655547
alf_sts_cd character 0 0 2
death_annual-
record_ind_cd
character 37857 5.48 1
count_death integer 0 0 1
death_dt date 14 0 7949
death_dt_valid varchar 0 0 2
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
death_reg_dt timestamp 0 0 5706
death_reg_dt_valid varchar 0 0 1
neonatal_ind_flg integer 0 0 3
dec_urbanrural_cd character <5 0 8
dec_stats_curr_cen-
sus_lsoa_cd
varchar 18 0 1909
dec_stats_curr_cen-
sus_la_cd
varchar 18 0 22
dec_stats_curr_cen-
sus_la_previous_cd
varchar 18 0 22
dec_stats_curr_cen-
sus_country_cd
varchar 18 0 1
dec_stats_curr_cen-
sus_health_org_cd
varchar 18 0 7
dec_stats_curr_cen-
sus_health_org_previ-
ous_cd
varchar 18 0 7
dec_stats_prev_cen-
sus_lsoa_cd
varchar 76 0.01 1896
dec_stats_prev_cen-
sus_la_cd
varchar 76 0.01 22
dec_stats_prev_cen-
sus_la_prev_cd
varchar 76 0.01 7
dec_stats_prev_cen-
sus_country_cd
varchar 76 0.01 1
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
dec_stats_prev_cen-
sus_health_org_cd
varchar 76 0.01 22
dec_stats_prev_cen-
sus_health_org_prev_cd
character 76 0.01 7
dec_sha_cd varchar 0 0 1
dec_health_org_cd varchar 0 0 7
dec_sex_cd character 0 0 2
deathcause_diag_un-
derlying_cd
varchar 2160 0.31 4205
deathcause_diag_1_cd varchar <5 0 2997
deathcause_diag_2_cd varchar 167660 24.27 4714
deathcause_diag_3_cd varchar 416684 60.31 4292
deathcause_diag_4_cd varchar 567539 82.15 3623
deathcause_diag_5_cd varchar 640374 92.69 2683
deathcause_diag_6_cd varchar 671192 97.15 1879
deathcause_diag_7_cd varchar 683353 98.91 1245
deathcause_diag_8_cd varchar 687856 99.56 750
death_communal_es-
tablishment_cd_e
bigint 0 0 2663
death_urbanrural_cd character 145133 21.01 8
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
deathstats_curr_cen-
sus_lsoa_cd
varchar 145135 21.01 4215
deathstats_curr_cen-
sus_la_cd
varchar 145135 21.01 340
deathstats_curr_cen-
sus_la_prev_cd
varchar 145270 21.03 333
deathstats_curr_cen-
sus_country_cd
varchar 145135 21.01 2
deathstats_curr_cen-
sus_health_org_cd
varchar 145135 21.01 157
deathstats_curr_cen-
sus_health_org_prev_cd
character 165362 23.93 7
deathstats_prev_cen-
sus_lsoa_cd
varchar 145137 21.01 4198
deathstats_prev_cen-
sus_la_cd
varchar 145137 21.01 340
deathstats_prev_cen-
sus_la_prev_cd
varchar 145137 21.01 157
deathstats_prev_cen-
sus_country_cd
varchar 145137 21.01 2
deathstats_prev_cen-
sus_health_org_cd
varchar 145137 21.01 340
deathstats_prev_cen-
sus_health_org_prev_cd
varchar 165362 23.93 7
death_ccg_cd varchar 670674 97.07 209
death_countyanddis-
trict_cd
varchar 145156 21.01 172
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
death_health_org_cd varchar 145156 21.01 157
death_nhs_establish-
ment_ind_cd
varchar 160663 23.25 2
death_establish-
ment_type_cd
varchar 160663 23.25 49
death_postcode_impu-
tation_ind_cd
varchar 690891 100 1
dec_age varchar 0 0 204
dec_age_unit_cd varchar 0 0 4
dec_occ_type_cd varchar 6 0 5
dec_or_mother_socioe-
conomic_class_cd
varchar 447238 64.73 49
dec_husband_or_fa-
ther_socioeco-
nomic_class_cd
varchar 578935 83.8 48
dec_or_mother_occ_class_cd varchar 447220 64.73 944
dec_husband_or_fa-
ther_occ_class_cd
varchar 578930 83.79 904
dec_or_mother_re-
tired_ind_cd
varchar 618493 89.52 1
dec_husband_or_fa-
ther_retired_ind_cd
varchar 663323 96.01 1
dec_birthcountry_cd varchar 21 0 330
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
dec_governmentof-
fice_region_cd
varchar 0 0 1
dec_countyanddis-
trict_cd
varchar 0 0 22
dec_county_cd varchar 0 0 2
dec_countydistrict_cd varchar 0 0 22
dec_ccg_cd varchar 690892 100 0
dec_lsoa_cd varchar 0 0 1909
dec_ward_cd varchar 0 0 148
death-
cause_diag_sec_cause_cd
varchar 665526 96.33 658
deathcause_row-
pos_1_cd
varchar 95743 13.86 8
deathcause_row-
pos_2_cd
varchar 253788 36.73 10
deathcause_row-
pos_3_cd
varchar 479168 69.35 10
deathcause_row-
pos_4_cd
varchar 609554 88.23 10
deathcause_row-
pos_5_cd
varchar 663883 96.09 8
deathcause_row-
pos_6_cd
varchar 682433 98.78 9
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Table C.1.1: SAIL Databank Datasets used in the Observatory (cont’d).
Column Name Friendly Name Type NULL
Count
NULL % Distinct
Values
Description
deathcause_row-
pos_7_cd
varchar 688336 99.63 9
deathcause_row-
pos_8_cd
varchar 690079 99.88 7
avail_from_dt date 0 0 1
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Table C.1.2: Frequency of events and number of patients in calendar year for each of the SAIL datasets
used in the Wales Asthma Observatory.
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FigureC.1.1: Frequencyof events andnumber of patients in calendar years for eachof theSAILdatasets
used in the Wales Asthma Observatory.
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C.2 SAIL IGRP approval letter
     
  10 April 2015 
  
Dr Gwyneth Davies 
 
College of Medicine 
ILS1 
Swansea University 
Singleton Park,  
Swansea, SA2 8PP 
 
Dear Gwyneth 
Re: Wales Asthma Observatory 
Your proposal to use the SAIL databank has been assessed by the SAIL 
Collaboration Review System (CRS).  The CRS consists of the SAIL 
Management Team and the Information Governance Review Panel (IGRP).  
The membership of the IGRP is comprised of senior representatives from: 
 British Medical Association (BMA) 
 National Research Ethics Service (NRES) 
 Public Health Wales  
 NHS Wales Informatics Service (NWIS) 
 Involving People 
 
After careful consideration the proposal has been given approval to 
commence with analysis. 
 
The project has been given a SAIL project number of 0317. 
 
Creation of project specific data view 
Work will now commence on the creation of the project specific data 
view.  The analyst working on this will be Mohammad Al Sallakh                  
and they will be in contact with you to confirm your data specification. 
 
 
Publication statement 
All publications must acknowledge the use of SAIL data. 
 
 
Yours sincerely 
 
Cynthia McNerney 
Information Governance Coordinator 
 
 
 
Institute of Life Science 2 
College of Medicine  
Swansea University 
Singleton Park 
Swansea 
SA2 8PP 
 
 
SAILDatabank@swansea.ac.uk 
 
www.SAILDatabank.com 
Figure C.2.1: Approval letter by the SAIL Databank IGRP panel for using SAIL data in the development
of the Wales Asthma Observatory.
.
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C.3 A tool for automatic characterisation of cohorts
using primary care data.
The following abstract has been presented at the Informatics for Health 2017
congress, 24-26 April 2017 in Manchester, UK [476, page 164].
Abstract no. 594 A tool to improve the eﬃciency and reproducibility of
research using electronic health record databases
Mohammad Al Sallakh and Gwyneth Davies, Swansea University Medical School,
Swansea
Sarah Rodgers, Farr Institute, CIPHER, Swansea
Ronan Lyons, Farr Institute, CIPHER, Swansea
Aziz Sheikh, Usher Institute of Population Health Sciences and Informatics, Uni-
versity of Edinburgh, Edinburgh
Introduction: Interrogation of routine electronic health record (EHR) databases
often involves repetitive programming tasks, such as manually constructing and
modifying complex database queries, requiring significant time from an experi-
enced data analyst. The objective was to develop a tool to automate the selection
and characterisation of cohorts from primary care databases to be used by data
analysts and researchers.
Methods: We identified a set of common elementary approaches to query clinical
variables from the primary care database of the Secure Anonymised Information
Linkage databank. We then designed an easy-to-use web-based user interface to
allow using combinations of these approaches as ‘building blocks’ for querying
more complex variables. We created an R programme to automatically generate
and execute the corresponding Structured Query Language (SQL) queries.
Results: The developed prototype allows researchers to query clinical informa-
tion from primary care databases based on the following elementary variable
types: (1) count of events of interest (e.g. asthma prescriptions) or their distinct
dates (2) the code or date of the earliest or latest event of interest (e.g. type of
the earliest smoking cessation prescription) (3) the code or date of the event of
maximum or minimum value (e.g., maximum BMI recording ever) and (4) count
of events of interest having complex temporal constraints with other events (e.g.,
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count of asthma doctor visits with oral steroid prescriptions within one week).
Researchers may choose fixed, dynamic, or individualised query intervals. Algo-
rithms are saved on a web server as versioned and shareable objects. The proto-
type integrates with a Read Codes dictionary and a shareable codeset repository
allowing researchers to keep a record of codes used for reporting transparency.
Discussion: The developed prototype provides a scalable, versatile solution for
the implementation of complex cohort selection and characterisation algorithms
using primary care databases. The automatic generation of SQL queries reduces
human errors and should enable rapid and scalable implementation of these algo-
rithms, which has the potential to improve research eﬃciency and reproducibility.
In addition, the graphical user interface allows researchers with no programming
skills to interrogate the data. The tool is under active development to improve the
functionality and usability, and we look forward to testing it in other databases
and assessing its suitability in diﬀerent research contexts. We plan to make this
tool available under an open source licence.
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Manual writing of 
programming scripts 
increases the risk of 
unnoticed human errors.
GP-ACT
Funded by Supported by
2
Interrogation of EHR databases for research is often an unstreamlined, poorly 
documented process that hinders transparency and reproducibility.
A tool for automatic characterisation
of cohorts using primary care data
1
#$%^@
Life is shorter than
writing the same SQL
query twice!
Oops!
I mean H33
h33 is for "mercaptopurine!"
What does this have to
do with asthma?
Inefficient sharing/reuse 
of programming scripts 
and clinical codes, 
wastes time and effort.
My pleasure
This time we need
to just add few
more 27 variables
with some few hundreds
of Read codes and
we will also remove som-
Mohammad, may I ask
you to modify 
your SQL slightly?
for the
fourth time?! !
I wish I do it myself
but I don't know SQL
Non-technical members of 
the research team cannot 
directly interrogate the 
data.
Analysts spend significant 
time on repetitive work, 
which could be otherwise 
automated.
17981   FROM SAILDATABANK.GPDATASET
17982   WHERE LEFT(EVENT_CD, 3) = 'h33'
17983   AND EVENT_DT BETWEEN '2005-01-01' AND 
Hi Mohammad,
could you please send 
me the Read codes you 
used in your analysis?
Sure
cc' me 
please 
We now need
to review the
whole SQL file!! 
Mohammad Al Sallakh 1 *     Sarah Rodgers 1    Ronan Lyons 1    Aziz Sheikh 2    Gwyneth Davies 1
* 594803@swansea.ac.uk      01792 60 2349
comics modified from xkcd.com (CC BY-NC 2.5); comic font: github.com/ipython/xkcd-font
Earliest
event date
Method
Latest
event date
Count of
events
Computed
from 
other
variables
GP-ACT provides a scalable, versatile solution for implementing cohort characterisation 
algorithms.
Automatic SQL queries generation -> less human errors, rapid implementation, improved 
research efficiency, and direct involvement of non-technical researchers
Sharable code sets and algorithms -> better research transparency and reproducibility
-- So, what is GP-ACT? ---------------------------------
-- How does it help? -----------------------------------
--------------------------------------------------------
Web Server
Algorithm 
Specifications
Read Codes
Dictionary
Read Codes Sets
Existing
cohort 
Final Table
for analysis
Elementary
Variables
Types
SQL
Queries
GP
Dataset
Web Interface
asthma_dx_
earliest_date
asthma_
resolved_
latest_date
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----------------------------------------------------------------------------------------------------------------
It is a platform that allows researchers and analysts to query complex clinical information from primary 
care databases based on common elementary variable types. Users can maintain and share clinical codes 
and phenotyping algorithms as versioned and cite-able objects on a web server, and can run 
automatically-generated SQL queries against the database.
Currently supported variable types:
(1) Count of events of interest or their distinct dates
(2) Code or date of the earliest or latest event of interest
(3) Code or date of the event of maximum or minimum value
(4) Count of events of interest having temporal constraints with other events
Figure C.3.1: A poster presented at the Informatics for Health 2017 congress in Manchester, United
Kingdom.
.
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C.4 Read codes used in the assessment of data qual-
ity in Chapter 4
Table C.4.1: Asthma diagnosis Read codes.
Read code Description
Asthma diagnosis codes
173A. Exercise induced asthma
H3120 Chronic asthmatic bronchitis
H33.. Asthma
H330. Extrinsic (atopic) asthma
H3300 Extrinsic asthma without status asthmaticus
H3301 Extrinsic asthma with status asthmaticus
H330z Extrinsic asthma NOS
H331. Intrinsic asthma
H3310 Intrinsic asthma without status asthmaticus
H3311 Intrinsic asthma with status asthmaticus
H331z Intrinsic asthma NOS
H332. Mixed asthma
H333. Acute exacerbation of asthma
H334. Brittle asthma
H335. Chronic asthma with fixed airflow obstruction
H33z. Asthma unspecified
H33z0 Status asthmaticus NOS
H33z1 Asthma attack
H33z2 Late-onset asthma
H33zz Asthma NOS
H3B.. Asthma-chronic obstructive pulmonary disease overlap syndrome
Asthma resolved codes
21262 Asthma resolved
212G. Asthma resolved
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Table C.4.3: Asthma-related event groups chosen for the coding quality analysis.
Read code Description
Asthma triggers
178.. Asthma trigger
1780. Aspirin inducted asthma
1781. Asthma trigger - pollen
1782. Asthma trigger - tobacco smoke
1783. Asthma trigger - warm air
1784. Asthma trigger - emotion
1785. Asthma trigger - damp
1786. Asthma trigger - animals
1787. Asthma trigger - seasonal
1788. Asthma trigger - cold air
1789. Asthma trigger - respiratory infections
178A. Asthma trigger - airborne dust
178B. Asthma trigger - exercise
Asthma severity
663V1 Mild asthma
663V2 Moderator asthma
663V3 Severe asthma
Asthma control steps
8793. Asthma control step 0
8793. Asthma control step 1
8793. Asthma control step 2
8793. Asthma control step 3
8793. Asthma control step 4
8793. Asthma control step 5
Spirometry
33G1. Spirometry reversibility positive
33H1. Positive reversibility test to salbutamol
33I1. Positive reversibility test to ipratropium bromide
33J1. Positive reversibility test to a combination of salbutamol and
ipratropium bromide
33K1. Positive reversibility test to corticosteroids
663J. Airways obstruction reversible
745D4 Post bronchodilator spirometry
8HRC. Referral for spirometry
Serum eosinophil count
42K.. Eosinophil count
42K1. Eosinophil count normal
42K3. Eosinophil count raised
42KZ. Eosinophil count NOS (not otherwise specified)
42b9. Percentage eosinophil
Serum total IgE
43J7. IgE
43Jw. Total immunoglobulin E level
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C.5 Density distributions of lung function test val-
ues
Figure C.5.1: Beanplots showing density distributions for lung function event values.
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D.1 Meeting abstract
I presented the following abstract about the findings in Chapter 5 at The Lancet’s
Public Health Science Conference 2017 in London and the European Respiratory
Society International Congress 2017 in Milan.
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www.thelancet.com    19
Socioeconomic deprivation and inequalities in asthma care 
in Wales
Mohammad A Al Sallakh, Sarah E Rodgers, Ronan A Lyons, Aziz Sheikh, Gwyneth A Davies
Abstract 
Background Area-based deprivation indices are widely used to study health inequalities. We explored whether 
inequality exists for asthma care across socioeconomic deprivation levels in Wales.
  
 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Appendix E
Clinical codes
These codes were used in asthma case definitions and outcome variables in Chap-
ter 4 and Chapter 5.
Code Description
Asthma GP Visits (Read codes)
173c. Occupational asthma
173d. Work aggravated asthma
178.. Asthma trigger
1780. Aspirin induced asthma
1781. Asthma trigger - pollen
1782. Asthma trigger - tobacco smoke
1783. Asthma trigger - warm air
1784. Asthma trigger - emotion
1785. Asthma trigger - damp
1786. Asthma trigger - animals
1787. Asthma trigger - seasonal
1788. Asthma trigger - cold air
1789. Asthma trigger - respiratory infection
178A. Asthma trigger - airborne dust
178B. Asthma trigger - exercise
1O2.. Asthma confirmed
388t. Royal College of Physicians asthma assessment
38DL. Asthma control test
38DV. Mini asthma quality of life questionnaire
38QM. Childhood Asthma Control Test
661M1 Asthma self-management plan agreed
661N1 Asthma self-management plan review
663d. Emergency asthma admission since last appointment
663e. Asthma restricts exercise
663e0 Asthma sometimes restricts exercise
663e1 Asthma severely restricts exercise
663f. Asthma never restricts exercise
663h. Asthma - currently dormant
663j. Asthma - currently active
663m. Asthma accident and emergency attendance since last visit
663n. Asthma treatment compliance satisfactory
663N. Asthma disturbing sleep
663N0 Asthma causing night waking
663N1 Asthma disturbs sleep weekly
663N2 Asthma disturbs sleep frequently
663O. Asthma not disturbing sleep
663O0 Asthma never disturbs sleep
663p. Asthma treatment compliance unsatisfactory
663P. Asthma limiting activities
663P0 Asthma limits activities 1 to 2 times per month
663P1 Asthma limits activities 1 to 2 times per week
663P2 Asthma limits activities most days
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Table E.1: (cont’d).
Code Description
663q. Asthma daytime symptoms
663Q. Asthma not limiting activities
663r. Asthma causes night symptoms 1 to 2 times per month
663s. Asthma never causes daytime symptoms
663t. Asthma causes daytime symptoms 1 to 2 times per month
663u. Asthma causes daytime symptoms 1 to 2 times per week
663U. Asthma management plan given
663v. Asthma causes daytime symptoms most days
663V. Asthma severity
663V0 Occasional asthma
663V1 Mild asthma
663V2 Moderate asthma
663V3 Severe asthma
663w. Asthma limits walking up hills or stairs
663W. Asthma prophylactic medication used
663x. Asthma limits walking on the flat
663y. Number of asthma exacerbations in past year
66Y5. Change in asthma management plan
66Y9. Step up change in asthma management plan
66YA. Step down change in asthma management plan
66YC. Absent from work or school due to asthma
66YE. Asthma monitoring due
66YJ. Asthma annual review
66YK. Asthma follow-up
66Yp. Asthma review using Royal College of Physicians three questions
66YP. Asthma night-time symptoms
66YQ. Asthma monitoring by nurse
66Yq.. Asthma causes night time symptoms 1 to 2 times per week
66Yr. Asthma causes symptoms most nights
66YR. Asthma monitoring by doctor
66Ys. Asthma never causes night symptoms
66Yu. Number of days absent from school due to asthma in past 6 months
66YZ. Does not have asthma management plan
679J. Health education - asthma
679J0 Health education - asthma self management
679J1 Health education - structured asthma discussion
679J2 Health education - structured patient focused asthma discussion
8791. Further asthma - drug prevent.
8793. Asthma control step 0
8794. Asthma control step 1
8795. Asthma control step 2
8796. Asthma control step 3
8797. Asthma control step 4
8798. Asthma control step 5
8B3j. Asthma medication review
8CMA0 Patient has a written asthma personal action plan
8CR0. Asthma clinical management plan
8H2P. Emergency admission, asthma
8HTT. Referral to asthma clinic
9hA.. Exception reporting: asthma quality indicators
9hA1. Excepted from asthma quality indicators: Patient unsuitable
9N1d. Seen in asthma clinic
9N1d0 Seen in school asthma clinic
9NI8. Asthma outreach clinic
9NNX. Under care of asthma specialist nurse
9OJ.. Asthma monitoring admin.
9OJ1. Attends asthma monitoring
9OJ2. Refuses asthma monitoring
9OJ3. Asthma monitor offer default
9OJ4. Asthma monitor 1st letter
9OJ5. Asthma monitor 2nd letter
9OJ6. Asthma monitor 3rd letter
9OJ7. Asthma monitor verbal invite
9OJ8. Asthma monitor phone invite
9OJ9. Asthma monitoring deleted
9OJA. Asthma monitoring check done
9OJB. Asthma monitoring invitation SMS (short message service) text message
9OJC. Asthma monitoring invitation email
9OJZ. Asthma monitoring admin.NOS
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Table E.1: (cont’d).
Code Description
9Q21. Patient in asthma study
SLF7. Antiasthmatic poisoning
SLF7z Antiasthmatic poisoning NOS
Asthma Reviews
66YJ. Asthma annual review
66YK. Asthma follow-up
66Yp. Asthma review using Royal College of Physicians three questions
66YQ. Asthma monitoring by nurse
8B3j. Asthma medication review
9OJA. Asthma monitoring check done
Asthma Emergency Department Visits (A&E code)
14A Asthma
Asthma Hospitalisations (ICD-10 codes)
J45 Asthma
J45.0 Predominantly allergic asthma
J45.1 Nonallergic asthma
J45.8 Mixed asthma
J45.9 Asthma, unspecified
J46 Status asthmaticus
Asthma Prescriptions (Read codes)
SABA
c11%% SALBUTAMOL [ORAL PREPARATIONS]
c12%% SALBUTAMOL [PARENTERAL PREPARATIONS]
c13%% SALBUTAMOL [INHALATION PREPRATIONS]
c14%% TERBUTALINE SULPHATE [RESPIRATORY USE]
c15%% FENOTEROL HYDROBROMIDE
c1E%% SALBUTAMOL [INHALATION PREPRATIONS 2]
ICS
c615. *BECOTIDE rotahaler device
c616. BECOTIDE 50micrograms/mL nebuliser solution
c617. BECOTIDE-100 100microgram inhaler
c618. *VOLUMATIC spacer device
c619. BECODISK 100micrograms diskhaler 14x8
c61A. BECLOMETASONE DIPROPIONATE 400micrograms disks+disk inhaler
c61B. BECLOMETASONE DIPROPIONATE 400micrograms disk refill
c61C. BECLOMETHASONE DIPROPIONATE 250micrograms inhaler+spacer device
c61E. BECLOMETASONE DIPROPIONATE 250micrograms breath-actuated aerosol
inhaler
c61F. BECLOMETASONE DIPROPIONATE 100micrograms breath-actuated aerosol
inhaler
c61G. *FILAIR 50micrograms inhaler
c61H. *FILAIR 100micrograms inhaler
c61J. FILAIR FORTE 250micrograms inhaler
c61K. BECLAZONE 50micrograms inhaler
c61L. BECLAZONE 100micrograms inhaler
c61M. BECLAZONE 250micrograms inhaler
c61N. BECLAZONE 50 EASI-BREATHE inhaler
c61O. BECLAZONE 100 EASI-BREATHE inhaler
c61P. BECLAZONE 250 EASI-BREATHE inhaler
c61Q. BECLOFORTE INTEGRA 250micrograms inhaler+compact spacer
c61R. BECLOFORTE INTEGRA 250micrograms refill
c61S. BECLOMETHASONE DIPROPIONATE 250micrograms inhaler+compact spacer
c61T. BECLOMETHASONE DIPROPIONATE 250micrograms compact spacer refill
c61U. BECLOMETHASONE rotahaler device
c61V. BECLOMETHASONE DIPROPIONATE 50micrograms vortex metered dose
inhaler
c61W. *BDP 50micrograms Spacehaler
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Table E.1: (cont’d).
Code Description
c61X. BECLOMETHASONE DIPROPIONATE 100micrograms vortex metered dose
inhaler
c61Y. *BDP 100micrograms Spacehaler
c61Z. BECLOMETHASONE DIPROPIONATE 250micrograms vortex metered dose
inhaler
c61a. BECODISK 200micrograms diskhaler 14x8
c61b. BECOTIDE 400micrograms rotacaps
c61c. BECODISK 100micrograms disk refill 14x8
c61d. BECODISK 200micrograms disk refill 14x8
c61e. BECODISK 400micrograms diskhaler 7x8
c61f. BECODISK 400micrograms disk refill 7x8
c61g. BECLOFORTE VM 250micrograms inhaler+volumatic
c61h. BECLOMETASONE DIPROPIONATE 400micrograms inhalation capsules
c61i. BECOTIDE-200 200microgram inhaler
c61j. *AEROBEC 50microgram Autohaler
c61k. AEROBEC FORTE 250micrograms Autohaler
c61l. AEROBEC 100microgram Autohaler
c61m. BECLOFORTE DISKHALER 400micrograms 14x8
c61n. BECLOFORTE DISKS 400micrograms disk refill 14x8
c61p. BECLOMETASONE DIPROPIONATE 100micrograms disks+disk inhaler
c61q. BECLOMETASONE DIPROPIONATE 200micrograms disks+disk inhaler
c61r. BECLOMETASONE DIPROPIONATE 100micrograms disk refill
c61s. BECLOMETASONE DIPROPIONATE 200micrograms disk refill
c61u. BECLOMETASONE DIPROPIONATE 200micrograms inhaler
c61v. BECLOMETASONE DIPROPIONATE 50micrograms inhaler
c61w. BECLOMETASONE DIPROPIONATE 100micrograms inhalation capsules
c61x. BECLOMETASONE DIPROPIONATE 200micrograms inhalation capsules
c61y. BECLOMETHASONE DIPROPIONATE 50micrograms/mL nebuliser solution
c61z. BECLOMETASONE DIPROPIONATE 100micrograms inhaler
c62.. BECLOMETASONE COMPOUNDS
c621. *VENTIDE inhaler
c622. *VENTIDE Rotacaps
c623. *VENTIDE paediatric Rotacaps
c624. *VENTIDE Rotahaler device
c63.. *BETAMETHASONE VALERATE
c631. *BEXTASOL 100microgram inhaler
c63z. BETAMETHASONE 100micrograms inhaler
c64.. BUDESONIDE [RESPIRATORY USE]
c641. PULMICORT 200micrograms inhaler 200dose
c642. PULMICORT 200micrograms refill 100dose
c643. PULMICORT 200micrograms refill 200dose
c644. PULMICORT LS 50micrograms inhaler
c645. PULMICORT LS 50micrograms refill
c646. *NEBUHALER spacer device
c647. PULMICORT 200microgram inhaler 100dose
c649. PULMICORT 400microgram Turbohaler 50dose
c64A. BUDESONIDE 200micrograms refill cannister
c64B. BUDESONIDE 50micrograms spacer inhaler
c64C. PULMICORT 200micrograms spacer inhaler
c64D. PULMICORT LS 50micrograms spacer inhaler
c64E. PULMICORT 200micrograms inhaler with NebuChamber
c64F. BUDESONIDE 200micrograms/dose dry powder cartridge refill
c64G. NOVOLIZER BUDESONIDE 200micrograms/dose dry powder cartridge refill
c64H. EASYHALER BUDESONIDE 100micrograms breath-actuated dry powder inhaler
c64I. EASYHALER BUDESONIDE 200micrograms breath-actuated dry powder inhaler
c64J. EASYHALER BUDESONIDE 400micrograms breath-actuated dry powder inhaler
c64K. PULMICORT 100micrograms CFC-free inhaler
c64a. PULMICORT 500micrograms Respules 2mL unit
c64b. PULMICORT 1mg Respules 2mL unit
c64c. PULMICORT 100microgram Turbohaler 200dose
c64d. BUDESONIDE 100micrograms breath-actuated dry powder inhaler
c64e. BUDESONIDE 50micrograms refill cannister
c64g. BUDESONIDE 200micrograms breath-actuated dry powder inhaler
c64h. BUDESONIDE 400micrograms breath-actuated dry powder inhaler
c64i. BUDESONIDE 500micrograms/2mL nebuliser solution
c64j. BUDESONIDE 1mg/2mL nebuliser solution
c64k. *BUDESONIDE 200 Cyclocaps
c64l. *BUDESONIDE 400 Cyclocaps
c64m. BUDESONIDE 200micrograms inhalation capsules
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Table E.1: (cont’d).
Code Description
c64n. BUDESONIDE 400micrograms inhalation capsules
c64o. BUDESONIDE 200micrograms inhaler with spacer device
c64p. NOVOLIZER BUDESONIDE 200micrograms/dose dry powder cartridge and
refillable inhaler device
c64u. BUDESONIDE 200micrograms/dose dry powder cartridge and refillable inhaler
device
c64v. BUDESONIDE 200micrograms inhaler
c64x. *BUDESONIDE refill 200dose
c64y. BUDESONIDE 50micrograms inhaler
c64z. BUDESONIDE 200micrograms spacer inhaler
c65.. FLUTICASONE PROPIONATE [RESPIRATORY USE]
c651. FLIXOTIDE 50micrograms diskhaler
c652. FLIXOTIDE 100micrograms diskhaler
c653. FLIXOTIDE 250micrograms diskhaler
c654. FLUTICASONE PROPIONATE 50micrograms disks+disk inhaler
c655. FLUTICASONE PROPIONATE 100micrograms disks+disk inhaler
c656. FLUTICASONE PROPIONATE 250micrograms disks+disk inhaler
c657. FLIXOTIDE 50micrograms disk refill
c658. FLIXOTIDE 100micrograms disk refill
c659. FLIXOTIDE 250micrograms disk refill
c65A. FLUTICASONE PROPIONATE 50micrograms disk refill
c65B. FLUTICASONE PROPIONATE 100micrograms disk refill
c65C. FLUTICASONE PROPIONATE 250micrograms disk refill
c65D. FLIXOTIDE 25micrograms inhaler
c65E. FLIXOTIDE 50micrograms inhaler
c65F. FLIXOTIDE 125micrograms inhaler
c65G. FLUTICASONE PROPIONATE 25micrograms inhaler
c65H. FLUTICASONE PROPIONATE 50micrograms inhaler
c65I. FLUTICASONE PROPIONATE 125micrograms inhaler
c65K. FLIXOTIDE 250micrograms inhaler
c65L. FLIXOTIDE 500micrograms diskhaler
c65M. FLIXOTIDE 500micrograms disk refill
c65N. FLUTICASONE PROPIONATE 500micrograms disks+disk inhaler
c65O. FLUTICASONE PROPIONATE 500micrograms disk refill
c65P. FLUTICASONE PROPIONATE 50micrograms breath-actuated dry powder
inhaler
c65Q. FLUTICASONE PROPIONATE 100micrograms breath-actuated dry powder
inhaler
c65R. FLUTICASONE PROPIONATE 250micrograms breath-actuated dry powder
inhaler
c65S. FLUTICASONE PROPIONATE 500micrograms breath-actuated dry powder
inhaler
c65T. FLIXOTIDE 50micrograms Accuhaler
c65U. FLIXOTIDE 100micrograms Accuhaler
c65V. FLIXOTIDE 250micrograms Accuhaler
c65W. FLIXOTIDE 500micrograms Accuhaler
c65X. FLUTICASONE PROPIONATE 0.5mg/2mL nebulisation units
c65Y. FLUTICASONE PROPIONATE 2mg/2mL nebulisation units
c65Z. FLIXOTIDE 0.5mg/2mL Nebules
c65a. FLIXOTIDE 2mg/2mL Nebules
c65b. FLUTICASONE PROPIONATE 125micrograms CFC-free inhaler
c65c. FLUTICASONE PROPIONATE 250micrograms CFC-free inhaler
c65d. FLIXOTIDE 125micrograms Evohaler
c65e. FLIXOTIDE 250micrograms Evohaler
c65f. FLUTICASONE PROPIONATE 50micrograms CFC-free inhaler
c65g. FLIXOTIDE 50micrograms Evohaler
c66.. BECLOMETASONE DIPROPIONATE [RESPIRATORY USE 2]
c661. *BDP 250micrograms Spacehaler
c662. BECOTIDE 50 EASI-BREATHE inhaler
c663. BECOTIDE 100 EASI-BREATHE inhaler
c664. BECLOFORTE EASI-BREATHE 250micrograms inhaler
c665. QVAR 50 inhaler
c666. QVAR 100 inhaler
c667. QVAR 50 Autohaler
c668. QVAR 100 Autohaler
c669. *BECLAZONE 200 inhaler
c66A. BECLOMETASONE DIPROPIONATE 50micrograms breath-actuated dry powder
inhaler
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Table E.1: (cont’d).
Code Description
c66B. BECLOMETASONE DIPROPIONATE 100micrograms breath-actuated dry
powder inhaler
c66C. BECLOMETASONE DIPROPIONATE 250micrograms breath-actuated dry
powder inhaler
c66D. ASMABEC 50micrograms Clickhaler
c66E. ASMABEC 100micrograms Clickhaler
c66F. ASMABEC 250micrograms Clickhaler
c66G. BECLOMETASONE DIPROPIONATE 400micrograms breath-actuated dry
powder inhaler
c66H. BECLOMETASONE DIPROPIONATE 200micrograms breath-actuated dry
powder inhaler
c66I. PULVINAL BECLOMETHASONE DIPROPIONATE 100micrograms
breath-actuated dry powder inhaler
c66J. PULVINAL BECLOMETHASONE DIPROPIONATE 200micrograms
breath-actuated dry powder inhaler
c66K. PULVINAL BECLOMETHASONE DIPROPIONATE 400micrograms
breath-actuated dry powder inhaler
c66L. *BECLOMETASONE 100 cyclocaps
c66M. *BECLOMETASONE 200 cyclocaps
c66N. *BECLOMETASONE 400 cyclocaps
c66P. BECODISK 100micrograms diskhaler 15x8
c66Q. BECODISK 200micrograms diskhaler 15x8
c66R. BECODISK 400micrograms diskhaler 15x8
c66S. BECODISK 100micrograms disk refill 15x8
c66T. BECODISK 200micrograms disk refill 15x8
c66U. BECODISK 400micrograms disk refill 15x8
c66V. BECLOMETASONE DIPROPIONATE 50micrograms CFC-free inhaler
c66W. BECLOMETASONE DIPROPIONATE 100micrograms CFC-free inhaler
c66X. BECLOMETASONE DIPROPIONATE 50micrograms CFC-free breath-actuated
aerosol inhaler
c66Y. BECLOMETASONE DIPROPIONATE 100micrograms CFC-free breath-actuated
aerosol inhaler
c66Z. QVAR EASI-BREATHE 50micrograms CFC-free breath-actuated dry powder
inhaler
c66a. QVAR EASI-BREATHE 100micrograms CFC-free breath-actuated dry powder
inhaler
c66c. CLENIL MODULITE 50micrograms CFC-free inhaler
c66d. CLENIL MODULITE 100micrograms CFC-free inhaler
c66e. CLENIL MODULITE 200micrograms CFC-free inhaler
c66f. CLENIL MODULITE 250micrograms CFC-free inhaler
c66g. BECLOMETASONE DIPROPIONATE 200micrograms CFC-free inhaler
c66h. BECLOMETASONE DIPROPIONATE 250micrograms CFC-free inhaler
c68.. MOMETASONE [RESPIRATORY USE]
c681. MOMETASONE FUROATE 200micrograms breath-actuated dry powder inhaler
c682. MOMETASONE FUROATE 400micrograms breath-actuated dry powder inhaler
c683. ASMANEX TWISTHALER 200micrograms breath-actuated dry powder inhaler
c684. ASMANEX TWISTHALER 400micrograms breath-actuated dry powder inhaler
c69.. CICLESONIDE
c691. ALVESCO 160micrograms inhaler
c692. ALVESCO 80micrograms inhaler
c69y. CICLESONIDE 80micrograms inhaler
c69z. CICLESONIDE 160micrograms inhaler
ICS-LABA
c1D.. SALMETEROL+FLUTICASONE PROPIONATE
c1D1. SERETIDE 100 Accuhaler
c1D2. SERETIDE 250 Accuhaler
c1D3. SERETIDE 500 Accuhaler
c1D4. SERETIDE 50 Evohaler
c1D5. SERETIDE 125 Evohaler
c1D6. SERETIDE 250 Evohaler
c1D7. SIRDUPLA 25micrograms/125micrograms inhaler
c1D8. SIRDUPLA 25micrograms/250micrograms inhaler
c1Du. SALMETEROL+FLUTICASONE PROPIONATE 25micrograms/50micrograms
CFC-free inhaler
c1Dv. SALMETEROL+FLUTICASONE PROPIONATE 25micrograms/125micrograms
CFC-free inhaler
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Code Description
c1Dw. SALMETEROL+FLUTICASONE PROPIONATE 25micrograms/250micrograms
CFC-free inhaler
c1Dx. SALMETEROL+FLUTICASONE PROPIONATE 50micrograms/100micrograms
breath-actuated dry powder inhaler
c1Dy. SALMETEROL+FLUTICASONE PROPIONATE 50micrograms/250micrograms
breath-actuated dry powder inhaler
c1Dz. SALMETEROL+FLUTICASONE PROPIONATE 50micrograms/500micrograms
breath-actuated dry powder inhaler
c1c.. FLUTICASONE PROPIONATE+FORMOTEROL FUMARATE
c1c1. FLUTIFORM 50micrograms/5micrograms inhaler
c1c2. FLUTIFORM 125micrograms/5micrograms inhaler
c1c3. FLUTIFORM 250micrograms/10micrograms inhaler
c1cx. FLUTICASONE PROPIONATE+FORMOTEROL FUMARATE 250mcg/10mcg inh
c1cy. FLUTICASONE PROPIONATE+FORMOTEROL FUMARATE 125mcg/5mcg inh
c1cz. FLUTICASONE PROPIONATE+FORMOTEROL FUMARATE 50mcg/5mcg inh
c67.. BUDESONIDE+FORMOTEROL
c671. SYMBICORT 100/6 Turbohaler
c672. SYMBICORT 200/6 Turbohaler
c673. SYMBICORT 400/12 Turbohaler
c674. DUORESP SPIROMAX 160mcg/4.5mcg breath-act dry powder inhaler
c675. DUORESP SPIROMAX 320mcg/9mcg breath-act dry powder inhaler
c67x. BUDESONIDE+FORMOTEROL FUMARATE DIHYDRATE
400micrograms/12micrograms breath-actuated dry powder inhaler
c67y. BUDESONIDE+FORMOTEROL FUMARATE DIHYDRATE
200micrograms/6micrograms breath-actuated dry powder inhaler
c67z. BUDESONIDE+FORMOTEROL FUMARATE DIHYDRATE
100micrograms/6micrograms breath-actuated dry powder inhaler
c6A.. BECLOMETASONE+FORMOTEROL
c6A1. FOSTAIR 100micrograms/6micrograms inhaler
c6A2. FOSTAIR NEXTHALER 100micrograms/6micrograms powder inhaler
c6Ay. BECLOMET DIPROP+FORMOTERL FUMARATE DIHYD 100mcg/6mcg pdr inh
c6Az. BECLOMETASONE DIPROPIONATE+FORMETEROL FUMARATE DIHYDRATE
100micrograms/6micrograms inhaler
c6B.. FLUTICASONE+VILANTEROL
c6B1. RELVAR ELLIPTA 184micrograms/22micrograms inhaler
c6B2. FLUTICASONE FUROATE+VILANTEROL 184mcg/22mcg dry pdr inhaler
c6B3. RELVAR ELLIPTA 92micrograms/22micrograms inhaler
c6B4. FLUTICASONE FUROATE+VILANTEROL 92mcg/22mcg dry pdr inhaler
Theophyllines
c41.. AMINOPHYLLINE
c411. AMINOPHYLLINE 100mg tablets
c412. AMINOPHYLLINE 250mg/10mL injection
c413. AMINOPHYLLINE 500mg/2mL injection
c414. AMINOPHYLLINE 50mg suppositories
c415. AMINOPHYLLINE 100mg suppositories
c416. AMINOPHYLLINE 150mg suppositories
c417. AMINOPHYLLINE 180mg suppositories
c418. AMINOPHYLLINE 360mg suppositories
c419. *THEODROX tablets
c41A. *NORPHYLLIN 100mg tablets
c41B. NORPHYLLIN SR 225mg m/r tablets
c41C. NORPHYLLIN SR 350mg m/r tablets
c41a. PHYLLOCONTIN CONTINUS 225mg m/r tablets
c41b. PHYLLOCONTIN FORTE 350mg m/r tablets
c41c. PHYLLOCONTIN PAEDIATRIC 100mg m/r tablets
c41d. AMINOPHYLLINE 225mg m/r tablets
c41e. *PECRAM 225mg m/r tablets
c41f. AMINOPHYLLINE 350mg m/r tablets
c41g. AMINOPHYLLINE 100mg m/r tablets
c41h. *AMNIVENT 225mg m/r tablets
c41i. *AMNIVENT 350mg m/r tablets
c41j. MIN-I-JET AMINOPHYLLINE 250mg/10mL injection
c41k. AMINOPHYLLINE 250mg/10mL prefilled syringe
c41m. AMINOPHYLLINE HYDRATE 225mg m/r tablets
c43.. THEOPHYLLINE
c431. *BIOPHYLLINE 125mg/5mL syrup
c432. *NUELIN 125mg tablets
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c433. *NUELIN 60mg/5mL liquid
c434. *LASMA 300mg m/r tablets
c435. NUELIN SA 175mg m/r tablets
c436. NUELIN SA-250 250mg m/r tablets
c437. *PRO-VENT 300mg m/r capsules
c438. SLO-PHYLLIN 60mg m/r capsules
c439. SLO-PHYLLIN 125mg m/r capsules
c43A. THEOPHYLLINE 200mg/10mL injection
c43B. THEOPHYLLINE 10mg/5mL sugar free solution
c43a. SLO-PHYLLIN 250mg m/r capsules
c43b. *THEO-DUR 200mg m/r tablets
c43c. *THEO-DUR 300mg m/r tablets
c43d. *THEOGRAD 350mg m/r tablets
c43e. UNIPHYLLIN CONTINUS 400mg m/r tablets
c43f. UNIPHYLLIN CONTINUS 200mg m/r tablets
c43g. LABOPHYLLINE 200mg/10mL injection
c43h. UNIPHYLLIN CONTINUS 300mg m/r tablets
c43i. *BIOPHYLLINE 350mg m/r tablets
c43j. *BIOPHYLLINE 500mg m/r tablets
c43k. THEOPHYLLINE 500mg m/r tablets
c43m. *THEOPHYLLINE 125mg/5mL syrup
c43n. *THEOPHYLLINE 125mg tablets
c43o. *THEOPHYLLINE 60mg/5mL liquid
c43p. THEOPHYLLINE 175mg m/r tablets
c43q. THEOPHYLLINE 250mg m/r tablets
c43r. THEOPHYLLINE 300mg m/r capsules
c43s. THEOPHYLLINE 60mg m/r capsules
c43t. THEOPHYLLINE 125mg m/r capsules
c43u. THEOPHYLLINE 250mg m/r capsules
c43v. THEOPHYLLINE 200mg m/r tablets
c43w. THEOPHYLLINE 300mg m/r tablets
c43x. THEOPHYLLINE 350mg m/r tablets
c43y. THEOPHYLLINE 400mg m/r tablets
c43z. *THEOPHYLLINE 200mg tablets
LTRA
cA... LEUKOTRIENE RECEPTOR ANTAGONIST
cA1.. MONTELUKAST
cA11. MONTELUKAST 10mg tablets
cA12. MONTELUKAST 5mg chewable tablets
cA13. SINGULAIR 10mg tablets
cA14. SINGULAIR PAEDIATRIC 5mg chewable tablets
cA15. SINGULAIR PAEDIATRIC 4mg chewable tablets
cA16. SINGULAIR PAEDIATRIC 4mg/sachet granules
cA1y. MONTELUKAST 4mg/sachet granules
cA1z. MONTELUKAST 4mg chewable tablets
cA2.. ZAFIRLUKAST
cA21. ZAFIRLUKAST 20mg tablets
cA22. ACCOLATE 20mg tablets
OCS
fe61 PREDNISOLONE 1mg tablets
fe62 PREDNISOLONE 5mg tablets
fe66 DELTACORTRIL ENTERIC 5mg tablets
fe6i PREDNISOLONE 5mg e/c tablets
fe6j PREDNISOLONE 5mg soluble tablets
fe6k PREDNISOLONE 50mg tablets
fe6z PREDNISOLONE 25mg tablets
